<SEC-DOCUMENT>0001171843-20-005753.txt : 20200826
<SEC-HEADER>0001171843-20-005753.hdr.sgml : 20200826
<ACCEPTANCE-DATETIME>20200807185247
ACCESSION NUMBER:		0001171843-20-005753
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200807
DATE AS OF CHANGE:		20200807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		201085971

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bcrx20200630_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:bcrx="http://www.biocryst.com/20200630" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31"> <head>
  <title>bcrx20200630_10q.htm</title>
  <!-- Generated by ThunderDome Portal - 8/7/2020 8:06:29 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000882796</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">BIOCRYST PHARMACEUTICALS INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
<ix:nonFraction id="c63926980" contextRef="i_2020-06-30" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c63926981" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c63926982" contextRef="i_2020-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction>
<ix:nonFraction id="c63926983" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction>
<ix:nonFraction id="c63926984" contextRef="i_2020-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c63926985" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c63926987" contextRef="i_2020-06-30" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c63926988" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c63926992" contextRef="i_2020-06-30" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c63926993" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c63926994" contextRef="i_2020-06-30" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-7">450,000</ix:nonFraction>
<ix:nonFraction id="c63926995" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-7">450,000</ix:nonFraction>
<ix:nonFraction id="c63926996" contextRef="i_2020-06-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">176,429</ix:nonFraction>
<ix:nonFraction id="c63926998" contextRef="i_2020-06-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">176,429</ix:nonFraction>
<ix:nonFraction id="c63926997" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">154,082</ix:nonFraction>
<ix:nonFraction id="c63926999" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">154,082</ix:nonFraction>
<ix:nonFraction id="c63927165" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-4">110</ix:nonFraction>
<ix:nonFraction id="c63927195" contextRef="d_2020-04-01_2020-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">193</ix:nonFraction>
<ix:nonFraction id="c63927205" contextRef="d_2020-04-01_2020-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">22,044</ix:nonFraction>
<ix:nonFraction id="c63927215" contextRef="d_2020-04-01_2020-06-30" unitRef="Share" name="bcrx:ClassOfWarrantOrRightIssuedDuringPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">3,511</ix:nonFraction>
<ix:nonFraction id="c63927255" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-4">160</ix:nonFraction>
<ix:nonFraction id="c63927265" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">47</ix:nonFraction>
<ix:nonFraction id="c63927295" contextRef="d_2019-04-01_2019-06-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-5">100</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember" name="bcrx:MaturityPeriodOfHighQualityMarketablesecurities" id="c63927396" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c63927423" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c63927425" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c63927426" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonFraction id="c63927438" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c63927479" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">341</ix:nonFraction>
<ix:nonFraction id="c63927506" contextRef="i_2020-06-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" unitRef="USD" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c63927507" contextRef="i_2019-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" unitRef="USD" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c63927695" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c63927701" contextRef="d_2020-01-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c63927723" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" name="bcrx:ContractTerm" id="c63927844" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" name="bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" id="c63927862" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="c63927876" format="ixt-sec:duryear">0.5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" name="bcrx:RenewablePeriodOfAgreement" id="c63927906" format="ixt-sec:duryear">5</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcrx-20200630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2020-01-01_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-07-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2020-04-01_2020-06-30_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-06-30_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-08-01</xbrli:startDate><xbrli:endDate>2013-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-09-01</xbrli:startDate><xbrli:endDate>2013-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-04-01_2020-06-30_TypeOfArrangementAxis-ASPRBARDAContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_StatementScenarioAxis-ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-11-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-16</xbrli:startDate><xbrli:endDate>2015-06-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-16_2020-06-30_CounterpartyNameAxis-CSLLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-16</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-04</xbrli:startDate><xbrli:endDate>2020-03-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-06-01</xbrli:startDate><xbrli:endDate>2006-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2006-02-28_2006-02-28_TypeOfArrangementAxis-MundipharmaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-02-28</xbrli:startDate><xbrli:endDate>2006-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-11-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2000-06-01</xbrli:startDate><xbrli:endDate>2000-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2000-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-03-01</xbrli:startDate><xbrli:endDate>2011-03-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-03-01</xbrli:startDate><xbrli:endDate>2011-03-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="JPYPerUSD"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-05</xbrli:startDate><xbrli:endDate>2019-02-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilitySecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-05</xbrli:startDate><xbrli:endDate>2019-02-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-05</xbrli:startDate><xbrli:endDate>2019-02-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-01_2020-06-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<div style="display: none;">
 <b>&#xa0;</b>
</div>
<p style="text-align: center;"><b>UNITED STATES<br /> SECURITIES AND EXCHANGE COMMISSION<br /> Washington, D.C. 20549</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2020-01-01_2020-06-30">10-Q</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table style="width: 100%; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top;"><td style="width: 5%;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-06-30">&#x2612;</ix:nonNumeric> </b></p> </td><td style="width: 95%;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> </td></tr>
<tr><td style="width: 5%;">&#xa0;</td><td style="width: 95%;font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the quarterly period ended </b><ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2020-01-01_2020-06-30"><b>June 30</b><b>, 2020</b></ix:nonNumeric><b></b></td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table style="width: 100%; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top;"><td style="width: 5%;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-06-30">&#x2610;</ix:nonNumeric></b></p> </td><td style="width: 95%;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> </td></tr>
</tbody></table>
<table style="width: 100%; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top;"><td style="width: 5%;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> </td><td style="width: 95%;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the transition period from __________ to __________.</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Commission File Number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2020-01-01_2020-06-30">000-23186</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Exact name of registrant as specified in its charter)</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table style="margin-left:11.7%;width:69.6%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:60.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:81.5pt;margin-top:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2020-01-01_2020-06-30">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 39.9%; background-color: rgb(255, 255, 255);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; vertical-align: top; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2020-01-01_2020-06-30">62-1413174</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:60.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:80.5pt;margin-top:0pt;text-align:center;"><b>(State o</b><b>r</b><b> other jurisdiction of</b></p> </td><td style="vertical-align: bottom; width: 39.9%; background-color: rgb(255, 255, 255);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; vertical-align: top; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>(I.R.S. Employer</b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:60.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:80.5pt;margin-top:0pt;text-align:center;"><b>incorporation or organization)</b></p> </td><td style="vertical-align: bottom; width: 39.9%; background-color: rgb(255, 255, 255);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; vertical-align: top; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Identification No.)</b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:60.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:81.5pt;margin-top:0pt;text-align:center;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:81.5pt;margin-top:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2020-01-01_2020-06-30">4505 Emperor Blvd., Suite 200</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 39.9%; background-color: rgb(255, 255, 255);">&#xa0;</td></tr>
<tr><td style="vertical-align:bottom;width:60.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:80.5pt;margin-top:0pt;text-align:center;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2020-01-01_2020-06-30">Durham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2020-01-01_2020-06-30">North Carolina</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 39.9%; background-color: rgb(255, 255, 255);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; vertical-align: top; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2020-01-01_2020-06-30">27703</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:60.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:81.5pt;margin-top:0pt;text-align:center;"><b>(Address of principal executive offices)</b></p> </td><td style="vertical-align: bottom; width: 39.9%; background-color: rgb(255, 255, 255);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; vertical-align: top; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>(Zip Code)</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2020-01-01_2020-06-30">919</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2020-01-01_2020-06-30">859-1302</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(Registrant&#x2019;s telephone number, including area code</b><b>)</b></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: bottom; border: thin solid rgb(0, 0, 0); width: 23.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Title of each class</p> </td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 22.9%; border-right: thin solid rgb(0, 0, 0); border-top: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trading Symbol(s)</p> </td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 53.7%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name of each exchange on which registered</p> </td></tr>
<tr><td style="vertical-align: bottom; border-bottom: thin solid rgb(0, 0, 0); width: 23.3%; border-right: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: none 100% / 1 / 0 stretch;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2020-01-01_2020-06-30">Common Stock</ix:nonNumeric></p> </td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 22.9%; border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2020-01-01_2020-06-30">BCRX</ix:nonNumeric></p> </td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 53.7%; border-right: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2020-01-01_2020-06-30">Nasdaq Global Select Market</ix:nonNumeric></p> </td></tr></tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2020-01-01_2020-06-30">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:18pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2020-01-01_2020-06-30">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table style="width:95.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:21.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Large accelerated filer</p> </td><td style="vertical-align:bottom;width:26.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#x2610;</p> </td><td style="vertical-align:bottom;width:45.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:117pt;margin-right:0pt;margin-top:0pt;text-align:left;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2020-01-01_2020-06-30">Accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:6.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#x2612;</p> </td></tr><tr><td style="vertical-align:bottom;width:21.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-accelerated filer</p> </td><td style="vertical-align:bottom;width:26.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#x2610;</p> </td><td style="vertical-align:bottom;width:45.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:117pt;margin-right:0pt;margin-top:0pt;text-align:left;">Smaller reporting company</p> </td><td style="vertical-align:bottom;width:6.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-06-30">&#x2610;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:bottom;width:21.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emerging growth company</p> </td><td style="vertical-align:bottom;width:26.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-06-30">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:45.1%;">&#xa0;</td><td style="vertical-align:bottom;width:6.5%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-06-30">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;No &#x2612;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding as of July 31, 2020 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2020-07-31">176,565,622</ix:nonFraction>.</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p> </td>
      <td style="vertical-align:bottom;width:8.9%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>INDEX</b></p> </td>
      <td style="vertical-align:bottom;width:8.9%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Part I. Financial Information</span></a></p> </td>
      <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:8pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>Page No.</b></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:8.9%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i1" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Item 1. Financial Statements:</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i1" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">1</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22pt;margin-right:0pt;margin-top:0pt;text-align:left;"><a href="#balance_sheets" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Balance Sheets - </span><span style="text-decoration: underline; ">June 30</span><span style="text-decoration: underline; ">, 2020 and December 31, 2019</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#balance_sheets" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">1</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22pt;margin-right:0pt;margin-top:0pt;text-align:left;"><a href="#comprehensive_loss" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Statements of Comprehensive Loss - Three </span><span style="text-decoration: underline; ">and Six </span><span style="text-decoration: underline; ">Months Ended </span><span style="text-decoration: underline; ">June 30</span><span style="text-decoration: underline; ">, 2020 and 2019</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#comprehensive_loss" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22pt;margin-right:0pt;margin-top:0pt;text-align:left;"><a href="#cash_flows" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Statements of Cash Flows - </span><span style="text-decoration: underline; ">Six </span><span style="text-decoration: underline; ">Months Ended</span><span style="text-decoration: underline; "> June 30</span><span style="text-decoration: underline; ">, 2020 and 2019</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#cash_flows" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22pt;margin-right:0pt;margin-top:0pt;text-align:left;"><a href="#stockholders_equity" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consolidated Statements of Stockholders&#x2019; Equity - Three </span><span style="text-decoration: underline; ">and Six </span><span style="text-decoration: underline; ">Months Ended </span><span style="text-decoration: underline; ">June 30</span><span style="text-decoration: underline; ">, 2020 and 2019</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#stockholders_equity" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:22pt;margin-right:0pt;margin-top:0pt;text-align:left;"><a href="#financial_notes" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Notes to Consolidated Financial Statements</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#financial_notes" style="-sec-extract:exhibit;">6</a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i2" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i2" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">21</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i3" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i3" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">34</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i4" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Item 4. Controls and Procedures</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1i4" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">34</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p2" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Part II. Other Information</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p2i1a" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Item 1A. Risk Factors</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p2i1a" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">34</span></a></p> </td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p2i6" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Item 6. Exhibits</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"><a href="#p2i6" style="-sec-extract:exhibit;">58</a></td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#signatures" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Signatures</span></a></p> </td>
      <td style="vertical-align:bottom;width:8.9%;"><a href="#signatures" style="-sec-extract:exhibit;">59</a></td>
      <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196806.htm" style="-sec-extract:exhibit;">EX-10.3</a></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196626.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">EX-31.1</span></a></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196627.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">EX-31.2</span></a></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196628.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">EX-32.1</span></a></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196629.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">EX-32.2</span></a></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM">
        &#xa0;
      </div>
     </div>
    </div>
    <hr />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="margin: 0pt;">&#xa0;</p>
  </div>
  <div>
    &#xa0;
  </div>
  <table cellpadding="0" cellspacing="0" style="margin-left: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 72.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:158.25pt;margin-right:0pt;margin-top:0pt;text-align:center;"><b><a id="p1" title="p1" href="#"></a>PART I. FINANCIAL INFORMATION</b></p> </td>
     <td style="vertical-align: bottom; width: 1.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 11.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 72.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="p1i1" title="p1i1" href="#"></a>Item 1.&#xa0; Financial Statements</b></p> </td>
     <td style="vertical-align: bottom; width: 1.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 11.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 72.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:158.25pt;margin-right:0pt;margin-top:0pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p> </td>
     <td style="vertical-align: bottom; width: 1.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 11.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 72.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:157.5pt;margin-right:0pt;margin-top:0pt;text-align:center;"><b><a id="balance_sheets" title="balance sheets" href="#"></a>CONSOLIDATED BALANCE SHEETS</b></p> </td>
     <td style="vertical-align: bottom; width: 1.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 11.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 72.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:158.25pt;margin-right:0pt;margin-top:0pt;text-align:center;"><b>June 30, 2020 and December 31, 2019</b></p> </td>
     <td style="vertical-align: bottom; width: 1.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 11.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 72.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:157.5pt;margin-right:0pt;margin-top:0pt;text-align:center;"><b>(In thousands, except per share data)</b></p> </td>
     <td style="vertical-align: bottom; width: 1.7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 11.6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 2.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 0.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b><b><em style="font: inherit;">2020</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b><b><em style="font: inherit;">2019</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b><b><em style="font: inherit;">(Unaudited)</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b><b><em style="font: inherit;">(Note 1)</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926934" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">173,468</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926935" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">114,172</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926936" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,188</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926937" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,551</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926938" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">15,935</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926939" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">22,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Receivables from collaborations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926940" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,997</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926941" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">22,146</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926942" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">5,233</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926943" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63926944" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,016</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63926945" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4,422</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total current assets</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926946" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">203,837</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926947" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">164,345</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926948" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,149</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926949" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,347</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63926950" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">3,720</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63926951" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">3,590</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63926952" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">214,706</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63926953" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">175,282</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and Stockholders&#x2019; Equity</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926955" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">9,354</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926956" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">13,988</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926957" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">24,843</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926959" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">21,365</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926960" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:InterestPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">17,806</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926962" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:InterestPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">14,904</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred collaboration revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926963" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">715</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926964" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">2,120</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Lease financing obligation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926965" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,096</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926966" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,377</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Senior credit facility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926967" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LinesOfCreditCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">19,056</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926968" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LinesOfCreditCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">9,020</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-recourse notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63926969" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">29,780</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63926970" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">29,561</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total current liabilities</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926971" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">102,650</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926972" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">92,335</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Lease financing obligation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926973" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926974" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,406</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Senior credit facility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926975" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LineOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">31,715</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926976" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LineOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">41,289</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#x2019; equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Preferred stock, <span style="-sec-ix-hidden:c63926980"><span style="-sec-ix-hidden:c63926981">$0.001</span></span> par value; shares authorized - <span style="-sec-ix-hidden:c63926982"><span style="-sec-ix-hidden:c63926983">5,000</span></span>; <span style="-sec-ix-hidden:c63926984"><span style="-sec-ix-hidden:c63926985"><span style="-sec-ix-hidden:c63926987"><span style="-sec-ix-hidden:c63926988">no</span></span></span></span> shares issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926978" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926979" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Common stock, <span style="-sec-ix-hidden:c63926992"><span style="-sec-ix-hidden:c63926993">$0.01</span></span> par value: shares authorized - <span style="-sec-ix-hidden:c63926994"><span style="-sec-ix-hidden:c63926995">450,000</span></span>; shares issued and outstanding &#x2013; <span style="-sec-ix-hidden:c63926996"><span style="-sec-ix-hidden:c63926998">176,429</span></span> in 2020 and <span style="-sec-ix-hidden:c63926997"><span style="-sec-ix-hidden:c63926999">154,082</span></span> in 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926989" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,764</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63926991" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,541</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927000" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">991,574</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927001" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-5">877,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927002" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927003" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927004" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">916,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927005" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">840,628</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927006" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">76,507</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927007" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">38,252</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total liabilities and stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927008" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">214,706</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927009" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">175,282</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td></tr></tbody></table>
  </div>
  <p style="margin: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="margin: 0pt; text-align: center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       1
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="comprehensive_loss" title="comprehensive loss" href="#"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Three </b><b>and Six </b><b>Months Ended </b><b>June 30</b><b>, 2020 and 2019</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>(In thousands, except per share data-Unaudited)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom;">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom;">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>20</b><b>20</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>20</b><b>19</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>20</b><b>20</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>20</b><b>19</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Revenues</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927011" contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927012" contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927013" contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">218</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927014" contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,679</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927015" contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">44</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927016" contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">696</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927017" contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,989</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927018" contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3,018</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927019" contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,827</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927020" contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">752</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927021" contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">5,487</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927022" contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,638</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total revenues</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927023" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,871</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927024" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,448</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927025" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7,694</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927026" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7,335</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Expenses</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of product sales</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927028" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927029" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927030" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927031" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-3">1,399</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927032" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">27,498</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927033" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">27,681</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927034" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">57,365</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927035" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">55,174</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927036" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">13,883</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927037" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,659</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927038" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">29,748</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927039" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">14,897</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927040" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927041" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">26</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927042" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">69</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927043" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">113</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927044" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">41,381</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927045" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">36,366</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927046" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">87,182</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927047" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">71,583</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927048" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">38,510</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927049" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">34,918</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927050" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">79,488</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927051" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,248</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest and other income</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927052" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:InterestAndOtherIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">2,758</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927053" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:InterestAndOtherIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">547</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927054" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:InterestAndOtherIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">9,204</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927055" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:InterestAndOtherIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">1,143</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927056" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,918</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927057" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,035</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927058" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,965</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927059" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,761</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gain (loss) on foreign currency derivative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927060" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3">63</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927061" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">223</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927062" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3">43</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927063" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3">183</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927064" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,607</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927065" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,629</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927066" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">76,206</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927067" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">68,683</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unrealized (loss)&#xa0;gain on available for sale investments</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927068" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">11</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927069" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4">130</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927070" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">36</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927071" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">338</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Comprehensive loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c63927072" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,618</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c63927073" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,499</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c63927074" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">76,242</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c63927075" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">68,345</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per common share</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927076" contextRef="d_2020-04-01_2020-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.24</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927077" contextRef="d_2019-04-01_2019-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.34</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927078" contextRef="d_2020-01-01_2020-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.48</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927079" contextRef="d_2019-01-01_2019-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.62</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#xa0;</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927080" contextRef="d_2020-04-01_2020-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">161,569</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#xa0;</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927081" contextRef="d_2019-04-01_2019-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">110,338</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#xa0;</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927082" contextRef="d_2020-01-01_2020-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">157,862</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#xa0;</b></td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927083" contextRef="d_2019-01-01_2019-06-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">110,253</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><a id="cash_flows" title="cash flows" href="#"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Six </b><b>Months Ended </b><b>June 30</b><b>, 2020 and 2019</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands-Unaudited)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom;">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>20</b><b>20</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>201</b><b>9</b></b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Operating activities</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927085" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">76,206</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927086" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">68,683</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Depreciation and amortization</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927088" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">401</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927089" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">357</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927090" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">6,034</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927091" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">8,702</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Amortization of debt issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927092" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">681</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927093" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">596</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Amortization of premium/discount on investments</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927094" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">104</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927095" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">17</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Change in fair value of foreign currency derivative</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927096" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">590</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927097" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">646</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Receivables</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927099" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">18,149</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927100" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">691</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Inventory</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927101" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3">5,233</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927102" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">649</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Prepaid expenses and other assets</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927103" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">817</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927104" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">84</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Accounts payable and accrued expenses</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927106" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,156</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927108" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">2,579</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Interest payable</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927109" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">2,902</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927110" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">2,897</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Deferred revenue</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927111" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,405</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927112" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><b>Net cash used in operating activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927113" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54,322</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927114" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">51,499</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Investing activities</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions of property and equipment</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927116" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">187</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927117" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-4">180</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Purchases of investments</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927118" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">15,438</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927119" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">3,018</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales and maturities of investments</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927120" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">21,417</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927121" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">41,357</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><b>Net cash provided by investing activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927122" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">5,792</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927123" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">38,159</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Financing activities</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sale of common stock, net</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927125" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">92,848</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927126" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sale of pre-funded warrants</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927127" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">14,817</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927128" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Proceeds from senior credit facility</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927129" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927130" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">19,477</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net proceeds from common stock issued under stock-based compensation plans</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927131" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">798</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927132" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">977</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><b>Net cash provided by (used in) financing activities</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c63927133" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">108,463</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><ix:nonFraction id="c63927134" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">20,454</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Increase in cash, cash equivalents and restricted cash</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927135" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">59,933</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927136" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">7,114</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash, cash equivalents and restricted cash at beginning of period</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927137" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">115,723</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927138" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">28,275</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash, cash equivalents and restricted cash at end of period</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927139" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">175,656</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
      <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927140" contextRef="i_2019-06-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">35,389</ix:nonFraction></b></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:17pt;margin-right:4.05pt;margin-top:0pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:17pt;margin-right:4.05pt;margin-top:0pt;text-align:center;"><b><a id="stockholders_equity" title="stockholders' equity" href="#"></a>CONSOLIDATED STATEMENTS </b><b>OF </b><b>STOCKHOLDERS&#x2019; EQUITY (DEFICIT)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:17pt;margin-right:4.05pt;margin-top:0pt;text-align:center;"><b>Three </b><b>and Six </b><b>Months Ended </b><b>June 30</b><b>, 20</b><b>20</b><b> and 201</b><b>9</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>(In thousands, except per share amounts-Unaudited)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Common</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Additional</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Paid-In</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Capital</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accumulated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Other</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Comprehensive</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(Loss) Income</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accumulated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Deficit</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Total</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Stockholders&#x2019;</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Equity (Deficit)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2019</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927141" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,541</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927142" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-5">877,300</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927143" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927144" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">840,628</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927145" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">38,252</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927146" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927147" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927148" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927149" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,599</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927150" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,599</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927151" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927152" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927153" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">25</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927154" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927155" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">25</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c63927165">110</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927156" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927157" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">265</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927158" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927159" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927160" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">266</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927166" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927167" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,754</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927168" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927169" contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927170" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,754</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at March 31, 2020</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927171" contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,542</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927172" contextRef="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">880,319</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927173" contextRef="i_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">14</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927174" contextRef="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">878,227</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927175" contextRef="i_2020-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">3,648</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927176" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927177" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927178" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927179" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,607</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927180" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,607</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927181" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927182" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927183" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">11</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927184" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927185" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">11</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Exercise of stock options, <span style="-sec-ix-hidden:c63927195">193</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927186" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927187" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-4">530</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927188" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927189" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927190" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">532</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Issuance of common stock, <span style="-sec-ix-hidden:c63927205">22,044</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927196" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927197" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">92,628</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927198" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927199" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927200" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">92,848</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Issuance of pre-funded, <span style="-sec-ix-hidden:c63927215">3,511</span> warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927206" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927207" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">14,817</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927208" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927209" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927210" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">14,817</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927216" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927217" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-4">3,280</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927218" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927219" contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927220" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-4">3,280</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at June 30, 2020</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927221" contextRef="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,764</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927222" contextRef="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">991,574</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927223" contextRef="i_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927224" contextRef="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">916,834</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927225" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">76,507</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr></tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Common</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Stock</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Additional</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Paid-In</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Capital</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accumulated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Other</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Comprehensive</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>(Loss) Income</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accumulated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Deficit</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Total</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Stockholders&#x2019;</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Equity (Deficit)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2018</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927226" contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,101</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927227" contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-5">780,400</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927228" contextRef="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">297</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927229" contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">731,969</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927230" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">49,235</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Impact to retained earnings from adoption of ASC 842</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927231" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927232" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927233" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927234" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">238</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927235" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">238</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927236" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927237" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927238" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927239" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">31,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927240" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">31,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927241" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927242" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927243" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">208</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927244" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927245" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">208</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Exercise of stock options, <span style="-sec-ix-hidden:c63927255">160</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927246" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927247" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">341</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927248" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927249" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927250" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">343</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c63927265">47</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927256" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927257" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927258" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927259" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927260" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927266" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927267" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927268" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927269" contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927270" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at March 31, 2019</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927271" contextRef="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,103</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927272" contextRef="i_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">784,278</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927273" contextRef="i_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">89</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c63927274" contextRef="i_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">762,785</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c63927275" contextRef="i_2019-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">22,507</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927276" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927277" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927278" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927279" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,629</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927280" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,629</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927281" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927282" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927283" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4">130</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927284" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927285" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4">130</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Exercise of stock options, <span style="-sec-ix-hidden:c63927295">100</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927286" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927287" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">413</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927288" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927289" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927290" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">414</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927296" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927297" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,385</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927298" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927299" contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927300" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,385</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at June 30, 2019</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927301" contextRef="i_2019-06-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,104</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927302" contextRef="i_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">790,076</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c63927303" contextRef="i_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">41</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927304" contextRef="i_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">800,414</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c63927305" contextRef="i_2019-06-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">9,193</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><b>)</b></b></p> </td></tr></tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b><a id="financial_notes" title="financial notes" href="#"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>(In thousands, except per share amounts)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c1621663" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">1</em> - Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:DescriptionOfCompanyPolicyTextBlock" id="c63928935" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>The Company</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in <em style="font: inherit;">1986,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">With the funds available at <em style="font: inherit;"> June 30, 2020, </em>the Company believes these resources will be sufficient to fund its operations through the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2021.</em> The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2020</em> expenses will exceed its <em style="font: inherit;">2020</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern through <em style="font: inherit;">2021.</em> The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the progression of its product candidates in the future. The Company also <em style="font: inherit;"> may </em>consider other plans to fund operations through <em style="font: inherit;">2021</em> including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"></p>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c63928938" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Basis of Presentation</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $<ix:nonFraction id="c63927359" contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> financing transaction the Company completed on <em style="font: inherit;"> March 9, 2011. </em>See Note <em style="font: inherit;">4,</em> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a $<ix:nonFraction id="c63927365" contextRef="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:LineOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-6">23,000</ix:nonFraction> senior credit facility that the Company closed on <em style="font: inherit;"> September 23, 2016 </em>and subsequently amended and restated on each of <em style="font: inherit;"> July 20, 2018 </em>and <em style="font: inherit;"> February 5, 2019. </em>See Note <em style="font: inherit;">5</em> for a further description of these transactions. All intercompany transactions and balances have been eliminated.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form <em style="font: inherit;">10</em>-Q and do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">These financial statements should be read in conjunction with the financial statements for the year ended <em style="font: inherit;"> December 31, 2019 </em>and the notes thereto included in the Company&#x2019;s <em style="font: inherit;">2019</em> Annual Report on Form <em style="font: inherit;">10</em>-K. Interim operating results are <em style="font: inherit;">not</em> necessarily indicative of operating results for the full year. The balance sheet as of <em style="font: inherit;"> December 31, 2019 </em>has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c63929022" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Cash and Cash Equivalents</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="c63929023" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Restricted Cash</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Restricted cash as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019 </em>reflects $<ix:nonFraction id="c63927388" contextRef="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">766</ix:nonFraction> and $<ix:nonFraction id="c63927389" contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">134</ix:nonFraction>, respectively, in royalty revenue paid by Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">4</em>) and $<ix:nonFraction id="c63927392" contextRef="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,422</ix:nonFraction> and $<ix:nonFraction id="c63927393" contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,417</ix:nonFraction>, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">6</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:InvestmentPolicyTextBlock" id="c63929060" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Investments</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c63927396">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember" name="bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities" id="c63927399" format="ixt-sec:durmonth">18</ix:nonNumeric> months. Some of the securities the Company invests in <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember" name="bcrx:MaturityperiodOfShortTermInvestment" id="c63927407" format="ixt-sec:durmonth">12</ix:nonNumeric> months from the balance sheet date are classified as current. Investments with a maturity beyond <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_RangeAxis-MinimumMember" name="bcrx:LongtermInvestmentMaturityMinimum" id="c63927409" format="ixt-sec:durmonth">12</ix:nonNumeric> months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> June 30, 2020, </em>the Company believes that the cost of its investments is recoverable in all material respects.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="c6040A63A-B15A-4988-8636-B6988314190C" escape="true" continuedAt="B898924E-353D-49E0-AB1B-142BA0BC6B46">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of the U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927573" contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">14,991</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927574" contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927575" contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927576" contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927577" contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">14,991</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927578" contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">938</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927579" contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927580" contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927581" contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927582" contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">944</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927583" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">15,929</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927584" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927585" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927586" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927587" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">15,935</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr></tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:continuation id="B898924E-353D-49E0-AB1B-142BA0BC6B46">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927588" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">10,488</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927589" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927590" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">23</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927591" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927592" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">10,561</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927593" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">9,742</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927594" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">59</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927595" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-4">10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927596" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927597" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-4">9,810</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927598" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">1,669</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927599" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927600" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927601" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927602" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,683</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927603" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">21,899</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927604" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">116</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927605" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-4">40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c63927606" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927607" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">22,054</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr></tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ReceivablesPolicyTextBlock" id="c63929083" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Receivables from Collaborations</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">At <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the Company had the following receivables.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock" id="c36E0A6AB-F144-45E2-AF5F-E385202D3C7F" escape="true" continuedAt="B01DD773-3074-4D67-AACC-7E27D994A215">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927608" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927609" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,253</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927610" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,272</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927611" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,683</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927612" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927613" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,683</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927614" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">35</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927615" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927616" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">35</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927617" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927618" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927619" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927620" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927621" contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,253</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927622" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,997</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td></tr></tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="margin: 0pt;">&#xa0;</p>
   <ix:continuation id="B01DD773-3074-4D67-AACC-7E27D994A215">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927623" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,353</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927624" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">15,023</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927625" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">16,376</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927626" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,336</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927627" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927628" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,340</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Green Cross Corporation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927629" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,924</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927630" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927631" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,932</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927632" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927633" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927634" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927635" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,091</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927636" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">351</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927637" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,442</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927638" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">6,760</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927639" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">15,386</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927640" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">22,146</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td></tr></tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Receivables from Product Sales</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:InventoryPolicyTextBlock" id="c63929068" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Inventory</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Inventory is stated at the lower of cost and net realizable value, determined under the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&#xa0; At <em style="font: inherit;"> June 30, 2020, </em>the Company&#x2019;s inventory consisted of $<ix:nonFraction id="c63927421" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">1,723</ix:nonFraction> of peramivir raw materials and $<ix:nonFraction id="c63927422" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-4">3,510</ix:nonFraction> of peramivir work-in-process.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"></p>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c63929069" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Property and Equipment</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c63927423">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c63927425">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c63927426">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c63929070" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Patents and Licenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">8</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:AccruedExpensesPolicyTextBlock" id="c63929071" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accrued Expenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <table style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="width:12pt;">&#xa0;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <table style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="width:12pt;">&#xa0;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to investigative sites in connection with clinical trials;</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <table style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="width:12pt;">&#xa0;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <table style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="width:12pt;">&#xa0;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x2022;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">professional fees.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c63929072" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Income Taxes</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="c63929073" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accumulated Other Comprehensive Loss</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>realized gains of $<ix:nonFraction id="c63927437" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction> were reclassified out of accumulated other comprehensive loss. <span style="-sec-ix-hidden:c63927438">No</span> reclassifications out of accumulated other comprehensive loss were recorded during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2019.</em></p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><em style="font: inherit;"></em></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c63929074" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Revenue Recognition</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Product Sales</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">The Company&#x2019;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#x2019;s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">The Company recorded the following revenues for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c1621668" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927641" contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927642" contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927643" contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">218</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927644" contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,679</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927645" contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927646" contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">696</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927647" contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927648" contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3,018</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927650" contextRef="d_2020-04-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,545</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927651" contextRef="d_2019-04-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">752</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927652" contextRef="d_2020-01-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">4,152</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927653" contextRef="d_2019-01-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,638</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Torii Pharmaceutical Co., Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927654" contextRef="d_2020-04-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">282</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927655" contextRef="d_2019-04-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927656" contextRef="d_2020-01-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,335</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927657" contextRef="d_2019-01-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927658" contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,827</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927659" contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">752</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927660" contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">5,487</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927661" contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,638</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927662" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,871</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927663" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,448</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927664" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7,694</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63927665" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7,335</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr></tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Balances</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="text-decoration: underline; "><i>Contract assets</i></span><i> </i>- The Company&#x2019;s long-term contracts, typically the government research and development contracts, are billed as work progresses<i> </i>in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheet.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="text-decoration: underline; "><i>Contract liabilities</i></span><i> </i>- The Company often receives cash payments from customers in advance of the Company&#x2019;s performance resulting in contract<i> </i>liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize the revenue.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Costs</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company <em style="font: inherit;"> may </em>incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that the Company expects to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that the Company does expect to recover are expensed as incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Advertising</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c63929075" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Research and Development Expenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c63929076" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Stock-Based Compensation</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" id="c63929077" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Interest Expense and Deferred Financing Costs</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Interest expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June&#xa0;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c63927467" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">2,918</ix:nonFraction> and $<ix:nonFraction id="c63927469" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">3,035</ix:nonFraction>, respectively, and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c63927472" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">5,965</ix:nonFraction> and $<ix:nonFraction id="c63927474" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">5,761</ix:nonFraction>, respectively, related to the issuance of the PhaRMA Notes (defined in Note <em style="font: inherit;">4</em>) and the Second Amended and Restated Senior Credit Facility (defined in Note <em style="font: inherit;">5</em>). Costs directly associated with the issuance of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was $<ix:nonFraction id="c63927477" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">341</ix:nonFraction> for each of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and $<ix:nonFraction id="c63927482" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">681</ix:nonFraction> and $<ix:nonFraction id="c63927484" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">596</ix:nonFraction> for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;">2019,</em> respectively.</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:CurrencyHedgeAgreementPolicyTextBlock" id="c63929078" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Currency Hedge Agreement</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> resulted in losses of $<ix:nonFraction id="c63927492" contextRef="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-4">590</ix:nonFraction> and $<ix:nonFraction id="c63927494" contextRef="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">646</ix:nonFraction>, respectively. Mark to market adjustments are determined by a <em style="font: inherit;">third</em>-party pricing model that uses quoted prices in markets that are <em style="font: inherit;">not</em> actively traded and for which significant inputs are observable directly or indirectly, representing Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of $<ix:nonFraction id="c63927499" contextRef="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">632</ix:nonFraction> and $<ix:nonFraction id="c63927500" contextRef="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-4">830</ix:nonFraction> during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em><span style="-sec-ix-hidden:c63927506"><span style="-sec-ix-hidden:c63927507">no</span></span> hedge collateral was posted under the agreement.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c63929079" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Net Loss Per Share</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> does <em style="font: inherit;">not</em> include <ix:nonFraction id="c63927512" contextRef="d_2020-04-01_2020-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">14,007</ix:nonFraction> and <ix:nonFraction id="c63927513" contextRef="d_2019-04-01_2019-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,927</ix:nonFraction>, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> does <em style="font: inherit;">not</em> include <ix:nonFraction id="c63927518" contextRef="d_2020-01-01_2020-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">12,963</ix:nonFraction> and <ix:nonFraction id="c63927519" contextRef="d_2019-01-01_2019-06-30" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">2,528</ix:nonFraction>, respectively, of such potential common shares, as their impact would be anti-dilutive.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:UseOfEstimates" id="c63929080" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Use of Estimates</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:ConcentrationOfMarketRiskPolicyTextBlock" id="c63929081" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Significant Customers and Other Risks</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Significant Customers</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Other than royalty revenues, the Company&#x2019;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Centers for Disease Control and Prevention. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:28pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company <em style="font: inherit;"> may </em>rely on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Credit Risk</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember" name="bcrx:AverageMaturityForPortfolioInvestments" id="c63927524" format="ixt-sec:durmonth">18</ix:nonNumeric> months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b></b></i></p><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c63929082" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Recent Accounting Pronouncements</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:33.65pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of</i> <i>Credit Losses on Financial Instruments </i>(&#x201c;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#x201d;</em>)<i>.</i><i> </i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires a financial asset (or a group of financial assets) measured at amortized<i> </i>cost basis to be presented at the net amount expected to be collected. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:33.65pt;">The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> as of <em style="font: inherit;"> January 1, 2020. </em>Given the nature of the Company&#x2019;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic</i> <i><em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>) </i>(&#x201c;ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15&#x201d;</em>). ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service<i> </i>contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2019, </em>with early adoption permitted. The Company elected to adopt this standard early, beginning <em style="font: inherit;"> October 1, 2019 </em>on a prospective basis. Adoption did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</p></ix:nonNumeric><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;"></p>  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c1621669" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">2</em> - Stock-Based Compensation</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.55pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the Company had <em style="font: inherit;">three</em> stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the Amended and Restated Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Amended and Restated Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated on <em style="font: inherit;"> March 19, 2020 </em>and approved by the Company&#x2019;s stockholders on <em style="font: inherit;"> May 12, 2020. </em>The Inducement Plan was adopted by the Board of Directors on <em style="font: inherit;"> April 24, 2019 </em>and amended and restated by the Board of Directors in <em style="font: inherit;"> February 2020 </em>and in <em style="font: inherit;"> July 2020. </em>The ESPP was amended and restated in <em style="font: inherit;"> March 2020 </em>and approved by the Company&#x2019;s stockholders in <em style="font: inherit;"> May 2020. </em>Stock-based compensation expense of $<ix:nonFraction id="c63927668" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">6,034</ix:nonFraction> ($<ix:nonFraction id="c63927669" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,205</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c63927670" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">710</ix:nonFraction> of expense related to the Inducement Plan, and $<ix:nonFraction id="c63927671" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">119</ix:nonFraction> of expense related to the ESPP) was recognized during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020,</em> while $<ix:nonFraction id="c63927675" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,702</ix:nonFraction> ($<ix:nonFraction id="c63927676" contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,535</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c63927677" contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction> of expense related to the Inducement Plan and $<ix:nonFraction id="c63927678" contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">151</ix:nonFraction> of expense related to the ESPP) was recognized during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2019.</em></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">There was approximately $<ix:nonFraction id="c63927682" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">22,873</ix:nonFraction> of total unrecognized compensation cost related to non-vested stock option awards granted by the Company as of <em style="font: inherit;"> June 30, 2020. </em>That cost is expected to be recognized as follows: $<ix:nonFraction id="c63927683" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-3">5,251</ix:nonFraction> during the remainder of <em style="font: inherit;">2020,</em> $<ix:nonFraction id="c63927685" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">8,086</ix:nonFraction> in <em style="font: inherit;">2021,</em> $<ix:nonFraction id="c63927687" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">6,604</ix:nonFraction> in <em style="font: inherit;">2022,</em> $<ix:nonFraction id="c63927689" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">2,668</ix:nonFraction> in <em style="font: inherit;">2023</em> and $<ix:nonFraction id="c63927691" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" scale="3" format="ixt:numdotdecimal" decimals="-3">264</ix:nonFraction> in <em style="font: inherit;">2024.</em> In addition, the Company has outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Stock Incentive Plan</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 10pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Stock option awards and restricted stock units granted to employees generally vest <ix:nonFraction id="c63927694" contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% each year until fully vested after <span style="-sec-ix-hidden:c63927695">four</span> years. In <em style="font: inherit;"> August 2013, </em><em style="font: inherit;"> December 2014 </em>and <em style="font: inherit;"> December 2019, </em>the Company issued <ix:nonFraction id="c63927696" contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,032</ix:nonFraction>, <ix:nonFraction id="c63927697" contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-4">1,250</ix:nonFraction> and <ix:nonFraction id="c63927698" contextRef="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-3">315</ix:nonFraction> performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of <em style="font: inherit;"> June 30, 2020, </em><ix:nonFraction id="c63927699" contextRef="d_2020-01-01_2020-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">75</ix:nonFraction>% of the <em style="font: inherit;"> August 2013 </em>grants have vested. As of <em style="font: inherit;"> June 30, 2020, </em><ix:nonFraction id="c63927700" contextRef="d_2020-01-01_2020-06-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the <em style="font: inherit;"> December 2014 </em>grants have vested. As of <em style="font: inherit;"> June 30, 2020, </em><span style="-sec-ix-hidden:c63927701">none</span> of the <em style="font: inherit;"> December 2019 </em>grants have vested. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020, </em>the Company recognized $<ix:nonFraction id="c63927703" contextRef="d_2020-04-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">86</ix:nonFraction> of compensation expense related to <em style="font: inherit;">one</em> milestone within the <em style="font: inherit;"> December 2019 </em>grants for which achievement became probable. During <em style="font: inherit;">2019,</em> the Company recognized $<ix:nonFraction id="c63927706" contextRef="d_2019-01-01_2019-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,998</ix:nonFraction> of stock compensation expense related to <em style="font: inherit;">two</em> milestones within the <em style="font: inherit;"> December 2014 </em>grants for which achievement became probable. Stock option awards granted to non-employee directors of the Company generally vest over <em style="font: inherit;">one</em> year. All stock option awards have contractual terms of <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c63927709" format="ixt-sec:duryear">10</ix:nonNumeric> years. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</p>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:56.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">Related activity under the Incentive Plan is as follows:</p> </td><td style="vertical-align:bottom;width:14%;">&#xa0;</td><td style="vertical-align:bottom;width:13.9%;">&#xa0;</td><td style="vertical-align:bottom;width:2.1%;">&#xa0;</td><td style="vertical-align:bottom;width:11.7%;">&#xa0;</td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="ACCEC004-2B9B-4339-987E-002BE916D98C" escape="true" continuedAt="c7950D4E6-FDD4-4640-9D18-6373E7B74D74">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2019</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927776" contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">968</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927777" contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-4">21,050</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927778" contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.96</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Plan amendment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927779" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">8,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927782" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">22</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Restricted stock unit awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927785" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927788" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">547</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927789" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">547</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927790" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.87</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927792" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">193</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927793" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.76</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927794" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">2,495</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927795" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">2,495</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927796" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.66</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927797" contextRef="i_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">10,894</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927798" contextRef="i_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">18,909</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927799" contextRef="i_2020-06-30_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr></tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 18pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">For stock option awards granted under the Incentive Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c63927719" contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3.35</ix:nonFraction> and $<ix:nonFraction id="c63927720" contextRef="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4.69</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</p>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Inducement Equity Incentive Plan</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:18pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant and generally vest <ix:nonFraction id="c63927722" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% each year until fully vested after <span style="-sec-ix-hidden:c63927723">four</span> years. Each stock option has a term of <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c63927725" format="ixt-sec:duryear">10</ix:nonNumeric> years and is subject to the terms and conditions of the Inducement Plan. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <table style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:56.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">Related activity under the Inducement Plan is as follows:</p> </td><td style="vertical-align:bottom;width:14%;">&#xa0;</td><td style="vertical-align:bottom;width:1.1%;">&#xa0;</td><td style="vertical-align:bottom;width:13.9%;">&#xa0;</td><td style="vertical-align:bottom;width:0.9%;">&#xa0;</td><td style="vertical-align:bottom;width:2.1%;">&#xa0;</td><td style="vertical-align:bottom;width:11.7%;">&#xa0;</td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#xa0;</p>
   <ix:continuation id="c7950D4E6-FDD4-4640-9D18-6373E7B74D74">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2019</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927806" contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">171</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927807" contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">1,329</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927808" contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.60</ix:nonFraction></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Plan amendment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927809" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-5">1,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63927812" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">1,502</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927813" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">1,502</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927814" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.34</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927816" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927817" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927818" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">145</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c63927819" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">145</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927820" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.28</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927821" contextRef="i_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">514</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927822" contextRef="i_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">2,686</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927823" contextRef="i_2020-06-30_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr></tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">For stock option awards granted under the Inducement Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c63927738" contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3.67</ix:nonFraction> and $<ix:nonFraction id="c63927740" contextRef="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3.94</ix:nonFraction>, respectively.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan and the Inducement Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <em style="font: inherit;">not</em> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed <ix:nonFraction id="c63927747" contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> expected dividend yield, as dividends have never been paid to stock or option holders and will <em style="font: inherit;">not</em> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <em style="font: inherit;">zero</em>-coupon government issues with a remaining term equal to the expected term.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><b>&#xa0;</b></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>Weighted Average Assumptions for Stock Option Awards Granted to</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>Employees and Directors under the Plans</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c1621672" escape="true">
    <table class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td colspan="2" style="text-align: center; border-bottom: 1px solid black;"><b><b>2020</b></b></td><td style="border-bottom: 1px solid black;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Life in Years</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c63927824" format="ixt-sec:duryear">5.5</ix:nonNumeric></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c63927825" format="ixt-sec:duryear">5.5</ix:nonNumeric></td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927826" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">83.7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927827" contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">81.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Dividend Yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927828" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927829" contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free Interest Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927830" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">0.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927831" contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">2.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr></tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company has reserved a total of <ix:nonFraction id="c63927751" contextRef="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-3">4,475</ix:nonFraction> shares of common stock to be purchased under the ESPP, of which <ix:nonFraction id="c63927752" contextRef="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">3,009</ix:nonFraction> shares remain available for purchase at <em style="font: inherit;"> June 30, 2020. </em>Eligible employees <em style="font: inherit;"> may </em>authorize up to <ix:nonFraction id="c63927753" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum" scale="-2" format="ixt:numdotdecimal" decimals="2">15</ix:nonFraction>% of their salary to purchase common stock at the lower of <ix:nonFraction id="c63927754" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfCommonStockSharesBeginning" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the beginning or <ix:nonFraction id="c63927755" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfCommonStockSharesEnding" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the ending price during <em style="font: inherit;">six</em>-month purchase intervals. <em style="font: inherit;">No</em> more than <ix:nonFraction id="c63927758" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction> shares <em style="font: inherit;"> may </em>be purchased by any <em style="font: inherit;">one</em> employee at the <em style="font: inherit;">six</em>-month purchase dates, and <em style="font: inherit;">no</em> employee <em style="font: inherit;"> may </em>purchase stock having a fair market value at the commencement date of $<ix:nonFraction id="c63927762" contextRef="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">25</ix:nonFraction> or more in any <em style="font: inherit;">one</em> calendar year. The Company issued <ix:nonFraction id="c63927764" contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-4">110</ix:nonFraction> shares during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.</p>  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c1621673" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">3</em> - Collaborative and Other Research and Development Contracts</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;). </i>In <em style="font: inherit;"> September 2013, </em>NIAID/HHS contracted with the Company for the<i> </i>development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $<ix:nonFraction id="c63927833" contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractValue" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction> to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&#x201c;i.v.&#x201d;) and intramuscular (&#x201c;i.m.&#x201d;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Yellow Fever and Ebola virus disease, and to conduct an initial Phase <em style="font: inherit;">1</em> human clinical trial. In <em style="font: inherit;"> April 2020, </em>the Company and NIAID/HHS agreed to add a group of COVID-<em style="font: inherit;">19</em> patients to the ongoing clinical trial in Yellow Fever. On <em style="font: inherit;"> April 9, 2020, </em>the Company announced it had opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-<em style="font: inherit;">19.</em> As of <em style="font: inherit;"> June 30, 2020, </em>the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program is $<ix:nonFraction id="c63927837" contextRef="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">43,035</ix:nonFraction>. As of <em style="font: inherit;"> June 30, 2020, </em>all options have been exercised under this contract.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>U.S. Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;). </i>On <em style="font: inherit;"> March 31, 2015, </em>the Company announced that BARDA/HHS had awarded<i> </i>the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $<ix:nonFraction id="c63927838" contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">16,265</ix:nonFraction> to support galidesivir drug manufacturing, as well as $<ix:nonFraction id="c63927839" contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">22,855</ix:nonFraction> in additional development options that can be exercised by the government, bringing the potential value of the contract to $<ix:nonFraction id="c63927840" contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-4">39,120</ix:nonFraction>. As of <em style="font: inherit;"> June 30, 2020, </em>a total of $<ix:nonFraction id="c63927841" contextRef="d_2015-04-01_2020-06-30_TypeOfArrangementAxis-ASPRBARDAContractMember" unitRef="USD" name="bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">20,574</ix:nonFraction> has been awarded under exercised options within this contract.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;)</i>. On <em style="font: inherit;"> September 6, 2018, </em>the Company announced that HHS had awarded the Company a<i> </i>$<ix:nonFraction id="c63927842" contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractValue" scale="3" format="ixt:numdotdecimal" decimals="-4">34,660</ix:nonFraction> contract for the procurement of up to <em style="font: inherit;">50,000</em> doses of RAPIVAB (peramivir injection) over a <span style="-sec-ix-hidden:c63927844">five</span>-year period. HHS&#x2019;s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation&#x2019;s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. The Company delivered <em style="font: inherit;">two</em> shipments under this contract in <em style="font: inherit;">2019</em> for a total price of approximately $<ix:nonFraction id="c63927847" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ProceedsFromCollaborators" scale="3" format="ixt:numdotdecimal" decimals="-3">13,864</ix:nonFraction>, and expects to deliver at least <em style="font: inherit;">one</em> shipment within the award in <em style="font: inherit;">2020,</em> totaling approximately $<ix:nonFraction id="c63927850" contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_StatementScenarioAxis-ScenarioForecastMember" unitRef="USD" name="us-gaap:ProceedsFromCollaborators" scale="3" format="ixt:numdotdecimal" decimals="-3">6,932</ix:nonFraction>.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;). </i>On <em style="font: inherit;"> November 5, 2019, </em>the Company announced that it had entered into the Torii Agreement, granting<i> </i>Torii the exclusive right to commercialize ORLADEYO&#x2122; (berotralstat) for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks in Japan.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction id="c63927851" contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="bcrx:UpfrontPaymentsReceivableAmount" scale="3" format="ixt:numdotdecimal" decimals="-6">22,000</ix:nonFraction> and <em style="font: inherit;"> may </em>be eligible to receive an additional milestone payment of either $<ix:nonFraction id="c63927852" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction> if the Japanese Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;) grants regulatory approval on or before <em style="font: inherit;"> December 31, 2020, </em>or $<ix:nonFraction id="c63927853" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> if regulatory approval is granted on or before <em style="font: inherit;"> December 31, 2021. </em>In either case, the regulatory milestone payment is contingent upon receipt of a reimbursement price approval from Japan&#x2019;s National Health Insurance system in excess of the threshold specified in the Torii Agreement.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In addition, the Company will be entitled under the Torii Agreement to receive tiered royalty payments based on the amount of annual net sales of ORLADEYO in Japan during each calendar year. If ORLADEYO maintains its Sakigake designation during the PMDA review, the tiered royalty rate will range from <ix:nonFraction id="c63927855" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember" unitRef="Pure" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% to <ix:nonFraction id="c63927856" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember" unitRef="Pure" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" format="ixt:numdotdecimal" decimals="1">40</ix:nonFraction>% of net sales; otherwise, the tiered royalty rate will range from <ix:nonFraction id="c63927857" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember" unitRef="Pure" name="bcrx:RoyaltyRateOtherwise" scale="-2" format="ixt:numdotdecimal" decimals="2">15</ix:nonFraction>% to <ix:nonFraction id="c63927858" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember" unitRef="Pure" name="bcrx:RoyaltyRateOtherwise" scale="-2" format="ixt:numdotdecimal" decimals="2">35</ix:nonFraction>% of net sales. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be reduced by more than <ix:nonFraction id="c63927860" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="Pure" name="bcrx:MaximumCustomaryReductionOnRoyaltyRate" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commence upon the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:c63927862">tenth</span> anniversary of the date of <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan, (ii) the expiration of our patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the Torii Agreement, the Company has granted Torii a right of <em style="font: inherit;">first</em> negotiation (&#x201c;ROFN&#x201d;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if the Company develops ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that the Company <em style="font: inherit;"> may </em>develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do <em style="font: inherit;">not</em> agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a <em style="font: inherit;">third</em>-party arbitrator.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the <em style="font: inherit;">$22,000</em> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC <em style="font: inherit;">606.</em> Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used and an expected cost plus margin approach was utilized for the other performance obligations. The Company recognized $<ix:nonFraction id="c63927869" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">20,101</ix:nonFraction> in revenue in <em style="font: inherit;">2019</em> including $<ix:nonFraction id="c63927871" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">19,344</ix:nonFraction> associated with the license which was transferred to Torii at the execution of the Agreement and $<ix:nonFraction id="c63927872" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">757</ix:nonFraction> related to the year to date services provided in the performance of the <em style="font: inherit;">two</em> approvals. The remaining $<ix:nonFraction id="c63927874" contextRef="i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01" unitRef="USD" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">1,899</ix:nonFraction> of the <em style="font: inherit;">$22,000</em> upfront payment is expected to be recognized as revenue in <span style="-sec-ix-hidden:c63927876">2020</span> as the services are delivered.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Seqirus UK Limited (&#x201c;SUL&#x201d;). </i>On <em style="font: inherit;"> June 16, 2015, </em>the Company and SUL, a limited company organized under the laws of the United Kingdom and a<i> </i>subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#x201c;Territory&#x201d;).</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA. Pursuant to rights to sell ALPIVAB in the EU, the Company was also responsible for regulatory filings and interactions with the European Medicines Agency (&#x201c;EMA&#x201d;). In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development. In <em style="font: inherit;"> October 2017, </em>SUL transferred Canadian registration rights for RAPIVAB to the Company.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the terms of the SUL Agreement, the Company has received an upfront payment of $<ix:nonFraction id="c63927877" contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" unitRef="USD" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="3" format="ixt:numdotdecimal" decimals="-4">33,740</ix:nonFraction> and has achieved all development milestones under the contract totaling $<ix:nonFraction id="c63927878" contextRef="d_2015-06-16_2020-06-30_CounterpartyNameAxis-CSLLimitedMember" unitRef="USD" name="bcrx:MilestonePaymentReceived" scale="3" format="ixt:numdotdecimal" decimals="-6">12,000</ix:nonFraction>. The Company is entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as <em style="font: inherit;"> July 1 - </em><em style="font: inherit;"> June 30) </em>and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstances or events impacting the overall market opportunity. SUL's royalty payment obligations commenced on the date of the SUL Agreement. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company and SUL entered arbitration proceedings that involved many items under the SUL Agreement including, but <em style="font: inherit;">not</em> limited to, the EMA approval milestone, which BioCryst maintains is due under the contract as well as appropriately commercializing peramivir in the Territory. On <em style="font: inherit;"> March 4, 2020, </em>the International Court of Arbitration of the International Chamber of Commerce (&#x201c;ICC Tribunal&#x201d;) delivered a Partial Arbitration Award (the &#x201c;Partial Arbitration Award&#x201d;) in the arbitration matter between the Company and SUL with respect to the SUL Agreement.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties have agreed on a transition process for the product, including a full transition of commercialization of the product in the U.S. to the Company as of <em style="font: inherit;"> August 1, 2020 </em>and a full transition of commercialization of the product in Australia as of <em style="font: inherit;"> November 1, 2020. </em>The ICC Tribunal also awarded the Company its attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to the Company within <em style="font: inherit;">30</em> days of the approval of peramivir for adult use in the European Union and awarded the Company $<ix:nonFraction id="c63927882" contextRef="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember" unitRef="USD" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction> (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#x2019; fees and for any dispute relating to the return to the Company of all rights to peramivir in the Territory. The Company recorded the settlement gain of $<ix:nonFraction id="c63927883" contextRef="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember" unitRef="USD" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" format="ixt:numdotdecimal" decimals="-3">8,893</ix:nonFraction> in other income and legal fees and other expenses of $<ix:nonFraction id="c63927884" contextRef="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember" unitRef="USD" name="us-gaap:LegalFees" scale="3" format="ixt:numdotdecimal" decimals="-3">5,026</ix:nonFraction> in selling, general and administrative expenses for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020.</em></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><i>Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). </i>In <em style="font: inherit;"> February 2007, </em>the Company entered into an exclusive license agreement with Shionogi to develop and<i> </i>commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In <em style="font: inherit;"> October 2008, </em>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In <em style="font: inherit;"> December 2017, </em>the Company, on behalf of Royalty Sub, instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings have concluded, with the decision that <em style="font: inherit;">no</em> sales milestones have been achieved and that the royalties will remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Green Cross Corporation (&#x201c;Green Cross&#x201d;). </i>In <em style="font: inherit;"> June 2006, </em>the Company entered into an agreement with Green Cross to develop and commercialize<i> </i>peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a <em style="font: inherit;">one</em>-time license fee of $<ix:nonFraction id="c63927888" contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="3" format="ixt:numdotdecimal" decimals="-4">250</ix:nonFraction>. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;). </i>In <em style="font: inherit;"> February 2006, </em>the Company entered into an exclusive, royalty bearing right<i> </i>and license agreement with Mundipharma for the development and commercialization of Mundesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology (the &#x201c;Original Agreement&#x201d;). Under the terms of the Original Agreement, Mundipharma obtained rights to Mundesine in markets across Europe, Asia, and Australasia in exchange for a $<ix:nonFraction id="c63927889" contextRef="d_2006-02-28_2006-02-28_TypeOfArrangementAxis-MundipharmaMember" unitRef="USD" name="bcrx:UpfrontPaymentsReceivableAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">10,000</ix:nonFraction> up-front payment.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> November 11, 2011, </em>the Company entered into the Amended and Restated License and Development Agreement (the &#x201c;Amended and Restated Agreement&#x201d;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to Mundesine. Commencing on <em style="font: inherit;"> November 11, 2011, </em>Mundipharma controls the development and commercialization of Mundesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling $<ix:nonFraction id="c63927890" contextRef="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember" unitRef="USD" name="bcrx:PotentialMilestonePaymentsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.35pt;"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively). </i>In <em style="font: inherit;"> June 2000, </em>the<i> </i>Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $<ix:nonFraction id="c63927891" contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:MilestonePaymentMinimum" scale="3" format="ixt:numdotdecimal" decimals="-5">1,400</ix:nonFraction> to almost $<ix:nonFraction id="c63927892" contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:MilestonePaymentMaximum" scale="3" format="ixt:numdotdecimal" decimals="-6">4,000</ix:nonFraction> per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately <em style="font: inherit;">one</em> quarter of future payments received from other <em style="font: inherit;">third</em>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $<ix:nonFraction id="c63927895" contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:AnnualLicenseFeeMinimum" scale="3" format="ixt:numdotdecimal" decimals="-4">150</ix:nonFraction> to $<ix:nonFraction id="c63927896" contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:AnnualLicenseFeeMaximum" scale="3" format="ixt:numdotdecimal" decimals="-5">500</ix:nonFraction>, that are creditable against actual royalties and other payments due to the Licensors. This agreement <em style="font: inherit;"> may </em>be terminated by the Company at any time by giving <ix:nonNumeric contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" name="bcrx:AdvanceNoticePeriodForTerminationOfAgreement" id="c63927897" format="ixt-sec:durday">60</ix:nonNumeric> days advance notice or in the event of material uncured breach by the Licensors.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">In <em style="font: inherit;"> May 2010, </em>the Company amended the license agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of <em style="font: inherit;">one</em>-half in the percentage of future payments received from <em style="font: inherit;">third</em>-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does <em style="font: inherit;">not</em> apply to (i) any milestone payments the Company <em style="font: inherit;"> may </em>receive in the future under its license agreement dated <em style="font: inherit;"> February 1, 2006 </em>with Mundipharma and (ii) royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> November 17, 2011, </em>the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of <em style="font: inherit;">one</em>-half in the percentage of Net Proceeds (as defined in the license agreement) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> June 19, 2012, </em>the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement <em style="font: inherit;"> may </em>be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> January 6, 2014, </em>the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><i>The University of Alabama at Birmingham (&#x201c;UAB&#x201d;). </i>The Company currently has agreements with UAB for influenza neuraminidase and<i> </i>complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <em style="font: inherit;">third</em>-party partners. The Company has completed the research under the UAB agreements. These <em style="font: inherit;">two</em> agreements each have an initial <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" name="bcrx:PeriodOfAgreement" id="c63927905" format="ixt-sec:duryear">25</ix:nonNumeric>-year term, are automatically renewable for <span style="-sec-ix-hidden:c63927906">five</span>-year terms throughout the life of the last patent and are terminable by the Company upon <em style="font: inherit;">three</em> months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <em style="font: inherit;">no</em> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><ix:exclude>&#xa0;</ix:exclude></b></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:RoyaltyMonetizationTextBlock" id="c1621674" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">4</em> - Royalty Monetization</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Overview</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">On <em style="font: inherit;"> March 9, 2011, </em>the Company completed a $<ix:nonFraction id="c63927912" contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $<ix:nonFraction id="c63927913" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">22,691</ix:nonFraction> from the transaction after transaction costs of $<ix:nonFraction id="c63927914" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="bcrx:TransactionCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">4,309</ix:nonFraction> and the establishment of a $<ix:nonFraction id="c63927915" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="bcrx:InterestReserve" scale="3" format="ixt:numdotdecimal" decimals="-6">3,000</ix:nonFraction> interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <em style="font: inherit;"> September 2012 </em>interest payment.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">As part of the transaction, the Company entered into a purchase and sale agreement dated as of <em style="font: inherit;"> March 9, 2011 </em>with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen, and milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was <em style="font: inherit;">not</em> impacted as a result of this transaction.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Non-Recourse Notes Payable</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">On <em style="font: inherit;"> March 9, 2011, </em>Royalty Sub completed a private placement to institutional investors of $<ix:nonFraction id="c63927917" contextRef="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="bcrx:PrivatePlacementOfSeniorSecuredNotes" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> in aggregate principal amount of its PhaRMA Senior Secured <ix:nonFraction id="c63927918" contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">14.0</ix:nonFraction>% Notes due <em style="font: inherit;">2020</em> (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <em style="font: inherit;"> March 9, 2011 (</em>the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at <ix:nonFraction id="c63927920" contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">14</ix:nonFraction>% per annum, payable annually in arrears on <em style="font: inherit;"> September </em><em style="font: inherit;">1st</em> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, make capital contributions to a capital account that <em style="font: inherit;"> may </em>be used to redeem, or on up to <em style="font: inherit;">one</em> occasion pay any interest shortfall on, the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:30.7pt;">In <em style="font: inherit;"> September 2014, </em>Royalty Sub was unable to pay the accrued interest obligation due <em style="font: inherit;"> September 3, 2013. </em>Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in <em style="font: inherit;"> September 2013 </em>by the next succeeding Payment Date for the PhaRMA Notes, which was <em style="font: inherit;"> September 1, 2014, </em>constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <em style="font: inherit;"> December 31, 2014 </em>balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <em style="font: inherit;"> may </em>pursue acceleration of the PhaRMA Notes, <em style="font: inherit;"> may </em>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company <em style="font: inherit;"> may </em>incur costs associated with liquidating the related Currency Hedge Agreement, which would <em style="font: inherit;">no</em> longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is <em style="font: inherit;">not</em> expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of <em style="font: inherit;"> June 30, 2020, </em>the PhaRMA Notes remain in default.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:36pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Indenture does <em style="font: inherit;">not</em> contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the aggregate fair value of the PhaRMA Notes was estimated to be approximately <ix:nonFraction id="c63927929" contextRef="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="bcrx:PercentageOfCarryingAmountInExcessOfFairValue1" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>% of the PhaRMA Notes carrying value of $<ix:nonFraction id="c63927930" contextRef="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>. The estimated fair value of the PhaRMA Notes is classified as Level <em style="font: inherit;">3</em> in the fair value hierarchy as defined in U.S. GAAP.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Currency Hedge Agreement</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of <ix:nonFraction id="c63927932" contextRef="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" unitRef="JPYPerUSD" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction> yen per dollar.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Currency Hedge Agreement does <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> resulted in losses of $<ix:nonFraction id="c63927936" contextRef="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-4">590</ix:nonFraction> and $<ix:nonFraction id="c63927937" contextRef="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">646</ix:nonFraction> respectively.</p>  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:DebtDisclosureTextBlock" id="c1621675" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">5</em> - Senior Credit Facility</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> February 5, 2019, </em>the Company entered into a $<ix:nonFraction id="c63927942" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-8">100,000</ix:nonFraction> Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#x201c;Second Amended and Restated Senior Credit Facility&#x201d;). Borrowings under the Second Amended and Restated Senior Credit Facility will be available in <em style="font: inherit;">three</em> tranches, with (i) the <em style="font: inherit;">first</em> tranche comprised of $<ix:nonFraction id="c63927945" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction> funded at closing, which included $<ix:nonFraction id="c63927946" contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#x2019;s prior credit agreement, (ii) the <em style="font: inherit;">second</em> tranche to be comprised of $<ix:nonFraction id="c63927948" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>, and (iii) the <em style="font: inherit;">third</em> tranche to be comprised of $<ix:nonFraction id="c63927950" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction>, with the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> tranches to be funded upon the completion of certain contingencies related to the Company&#x2019;s development activities of its product candidates and the establishment of certain financial covenants. On <em style="font: inherit;"> September 10, 2019 </em>the Company executed the <em style="font: inherit;">first</em> amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the <em style="font: inherit;">second</em> tranche to <em style="font: inherit;"> November 30, 2019. </em>On <em style="font: inherit;"> November 30, 2019, </em>the Company&#x2019;s access to the <em style="font: inherit;">second</em> tranche expired.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of <em style="font: inherit;"> July 20, 2018 (</em>the &#x201c;Amended and Restated Senior Credit Facility&#x201d;). The Second Amended and Restated Senior Credit Facility bears a variable interest rate of LIBOR (which shall <em style="font: inherit;">not</em> be less than <ix:nonFraction id="c63927957" contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="Pure" name="bcrx:DebtInstrumentMinimumLibor" scale="-2" format="ixt:numdotdecimal" decimals="3">0.5</ix:nonFraction>%) plus <ix:nonFraction id="c63927958" contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="2">8</ix:nonFraction>%. The Second Amended and Restated Senior Credit Facility includes an interest-only payment period through <em style="font: inherit;"> June 2020 </em>and scheduled monthly principal and interest payments for the subsequent <ix:nonNumeric contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" name="us-gaap:DebtInstrumentTerm" id="c63927959" format="ixt-sec:durmonth">30</ix:nonNumeric> months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility, and the remainder will be used for general corporate purposes. Under the Second Amended and Restated Senior Credit Facility, the Company must maintain a minimum cash balance of $<ix:nonFraction id="c63927960" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="bcrx:LineOfCreditRestrictedCashRequired" scale="3" format="ixt:numdotdecimal" decimals="-6">25,000</ix:nonFraction> of unrestricted cash at all times.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the Company had borrowings of $<ix:nonFraction id="c63927962" contextRef="i_2020-06-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:LineOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction> under the Second Amended and Restated Senior Credit Facility bearing an interest rate of <ix:nonFraction id="c63927963" contextRef="i_2020-06-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="Pure" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" format="ixt:numdotdecimal" decimals="3">8.5</ix:nonFraction>%. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. The remaining scheduled principal repayments of the Second Amended and Restated Senior Credit Facility are as follows:</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="c1621676" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
       <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Principal Payments</b></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927966" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-7">10,000</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927967" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63927968" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
       <td>&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"><ix:nonFraction id="c63927969" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The debt agreement contains <em style="font: inherit;">two</em> provisions that if deemed probable would create the recognition of an embedded feature; however, the Company does <em style="font: inherit;">not</em> believe either provision is probable.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c1621677" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">6</em> - Stockholders&#x2019; Equity</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:26.75pt;">On <em style="font: inherit;"> April 24, 2020, </em>the Company filed a $<ix:nonFraction id="c63927971" contextRef="i_2020-04-24" unitRef="USD" name="bcrx:MaximumAggregateOfferingPrice" scale="3" format="ixt:numdotdecimal" decimals="-8">500,000</ix:nonFraction> shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> May 14, 2020 </em>and allows the Company to sell securities, including common stock, preferred stock, depository shares, purchase contracts, warrants, debt securities and units, from time to time at prices and on terms to be determined at the time of sale. On <em style="font: inherit;"> June 1, 2020, </em>the Company completed an underwritten public offering of <ix:nonFraction id="c63927973" contextRef="d_2020-06-01_2020-06-01" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">22,044,447</ix:nonFraction> shares of its common stock (including shares issued pursuant to the underwriters&#x2019; <em style="font: inherit;">30</em>-day option to purchase additional shares, which was exercised in full), at a purchase price of $<ix:nonFraction id="c63927975" contextRef="i_2020-06-01" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">4.50</ix:nonFraction> per share, and pre-funded warrants to purchase <ix:nonFraction id="c63927976" contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">3,511,111</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction id="c63927977" contextRef="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember" unitRef="USDPerShare" name="bcrx:ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" scale="0" format="ixt:numdotdecimal" decimals="INF">4.49</ix:nonFraction> per pre-funded warrant, for total net proceeds to the Company of $<ix:nonFraction id="c63927978" contextRef="d_2020-06-01_2020-06-01" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">107,665</ix:nonFraction> after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The pre-funded warrants are immediately exercisable and have an exercise price of $<ix:nonFraction id="c63927979" contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction> per share, which is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting the Company&#x2019;s common stock and also upon any distributions of assets to the Company&#x2019;s stockholders.</p>  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="us-gaap:LeasesOfLessorDisclosureTextBlock" id="c1621678" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:justify;"><b>Note <em style="font: inherit;">7</em> &#x2013; Lease Obligations and Other Contingencies</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases at <em style="font: inherit;"> June 30, 2020. </em>Certain operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Renewal options for the Company&#x2019;s leases range from <ix:nonNumeric contextRef="i_2020-06-30_RangeAxis-MinimumMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c63927981" format="ixt-sec:duryear">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i_2020-06-30_RangeAxis-MaximumMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c63927982" format="ixt-sec:duryear">5</ix:nonNumeric> years in length and begin from <em style="font: inherit;">2023</em> through <em style="font: inherit;">2026.</em> At <em style="font: inherit;"> June 30, 2020, </em>the weighted average lease term for the Company&#x2019;s operating leases was <ix:nonNumeric contextRef="i_2020-06-30" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c63927985" format="ixt-sec:duryear">13.6</ix:nonNumeric> years. The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions. The weighted average discount rate for the Company&#x2019;s operating leases was <ix:nonFraction id="c63927986" contextRef="i_2020-06-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">12.7</ix:nonFraction>%.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 16pt 0pt 0pt; text-align: left; text-indent: 30.7pt;">Aggregate lease expense under operating leases was $<ix:nonFraction id="c63927989" contextRef="d_2020-01-01_2020-06-30" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">935</ix:nonFraction> and $<ix:nonFraction id="c63927990" contextRef="d_2019-01-01_2019-06-30" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">706</ix:nonFraction> for the <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019, </em>respectively. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of <em style="font: inherit;">twelve</em> months or less was <em style="font: inherit;">not</em> material.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <table border="0" cellpadding="0" cellspacing="0" style="margin-left:5.5%;width:84.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td colspan="2" style="vertical-align:bottom;width:84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Future lease payments for assets under operating leases as of <em style="font: inherit;"> June 30, 2020, </em>are as follows:</p> </td>
      <td style="vertical-align:bottom;width:0.8%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:10.1%;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
   <p style="margin: 0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-06-30" name="bcrx:LesseeLeaseLiabilityMaturityTableTextBlock" id="c1621679" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><b>Remaining Maturities of Lease Liabilities</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#xa0;</b></td>
      </tr>

      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><b>Year Ending December 31,</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>Operating Leases</b></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927998" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-3">835</ix:nonFraction></td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63927999" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">749</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63928000" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">665</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63928001" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">575</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63928002" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">568</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63928003" contextRef="i_2020-06-30" unitRef="USD" name="bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">7,903</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total lease payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63928004" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:numdotdecimal" decimals="-3">11,295</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c63928005" contextRef="i_2020-06-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">6,365</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c63928006" contextRef="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-4">4,930</ix:nonFraction></td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:36pt;">Of the Company&#x2019;s total lease liability, $<ix:nonFraction id="c63927995" contextRef="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,096</ix:nonFraction> is a current liability and $<ix:nonFraction id="c63927996" contextRef="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,834</ix:nonFraction> is a long-term liability at <em style="font: inherit;"> June 30, 2020. </em>The current and long-term portions of the Company&#x2019;s lease liability are presented within &#x201c;Accrued expenses&#x201d; and &#x201c;Other non-current liabilities&#x201d; on the Consolidated Balance Sheets. The Company&#x2019;s right-of-use asset balance associated with operating leases totaled $<ix:nonFraction id="c63927997" contextRef="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-4">3,720</ix:nonFraction> at <em style="font: inherit;"> June 30, 2020. </em>This amount is presented within &#x201c;Other long-term assets&#x201d; on the Consolidated Balance Sheets.</p>  </ix:nonNumeric>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="p1i2" title="p1i2" href="#"></a>Item 2.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"><i>This Quarterly Report on Form 10-Q contains statements of a forward-looking nature relating to future events or the future financial performance of BioCryst. Such statements are only predictions</i><i>,</i><i> and the actual events or results may differ materially from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include those discussed below and elsewhere in this report, as well as those discussed in other filings made by the Company with the Securities and Exchange Commission, including the Company&#x2019;s </i><i>most recent </i><i>Annual Report on Form 10-K </i><i>and </i><i>subsequent </i><i>Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See &#x201c;Information Regarding Forward-Looking Statements.&#x201d;</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Cautionary Statement</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The discussion herein contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), which are subject to the &#x201c;safe harbor&#x201d; created in Section 21E. Forward looking statements regarding our financial condition and our results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted within the United States (&#x201c;U.S. GAAP&#x201d;), as well as projections for the future. The preparation of these financial statements requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We operate in a highly competitive environment that involves a number of risks, some of which are beyond our control. We are subject to risks common to biotechnology and biopharmaceutical companies, including risks inherent in our drug discovery, drug development and commercialization efforts, clinical trials, uncertainty of regulatory actions and marketing approvals, reliance on collaborative partners, enforcement of patent and proprietary rights, the need for future capital, competition associated with products, potential competition associated with our product candidates and retention of key employees. In order for any of our product candidates to be commercialized, it will be necessary for us, or our collaborative partners, to conduct clinical trials, demonstrate efficacy and safety of the product candidate to the satisfaction of regulatory authorities, obtain marketing approval, enter into manufacturing, distribution and marketing arrangements, and obtain market acceptance and adequate reimbursement from government and private insurers. We cannot provide assurance that we will generate significant revenues or achieve and sustain profitability in the future. In addition, we can provide no assurance that we will have sufficient funding to meet our future capital requirements. Furthermore, the ongoing COVID-19 pandemic could create challenges in all aspects of our business, including without limitation delays, stoppages, difficulties and increased expenses with respect to our and our partners&#x2019; development, regulatory processes and supply chains, could negatively impact our ability to access the capital or credit markets to finance our operations, or could have the effect of heightening many of the risks described in Item 1A. &#x201c;Risk Factors&#x201d; in this Quarterly Report on Form 10-Q.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Statements contained in Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report which are not historical facts are, or may constitute, forward-looking statements. Forward-looking statements involve known and unknown risks that could cause our actual results to differ materially from expected results. The most significant known risks are discussed in the section entitled &#x201c;Risk Factors.&#x201d; Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you not to place undue reliance on any forward-looking statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Our revenues are difficult to predict and depend on numerous factors, including the prevalence and severity of influenza in regions for which peramivir has received regulatory approval, seasonality of influenza, commercialization efforts and resources dedicated to our products by our collaborative partners, ongoing discussions with government agencies regarding future peramivir and/or galidesivir development and stockpiling procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones by us or our collaborative partners.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.05pt;">Our operating expenses are also difficult to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts), drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, and the availability of capital and direction from regulatory agencies, which are difficult to predict. Management may be able to control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">As a result of these factors, we believe that period-to-period comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="text-decoration: underline; "><b>Overview</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We are a biotechnology company that discovers novel, oral, small-molecule medicines. We focus on oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Critical Accounting Policies and Estimates</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public accounting firm. We routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Recent Corporate Highlights</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The outbreak of novel coronavirus (&#x201c;COVID-19&#x201d;) has severely impacted global economic activity and caused significant volatility in financial markets. To date, our financial condition, results of operations, and liquidity have not been materially impacted by the direct effects of the COVID-19 pandemic. However, the COVID-19 pandemic is constantly evolving, and its full impact to our business is uncertain. We are monitoring the COVID-19 pandemic and are making adjustments intended to assist in protecting the safety of our employees and communities while continuing our business activities. We have implemented remote working arrangements where possible and restricted business-related travel. To date, implementation of these measures has not required material expenditures or significantly impacted our ability to operate our business or our internal control over financial reporting and disclosure controls and procedures. We are continuing to monitor developments with respect to the outbreak and its potential impacts on our operations and those of our partners, suppliers, and regulators.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>ORLADEYO</b></i><i><b>&#x2122; (</b></i><i><b>b</b></i><i><b>erotralstat</b></i><i><b>)</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">ORLADEYO is our lead molecule that is being developed as an oral, once-daily therapy for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks. Based on the data from our successful clinical program, including our pivotal Phase 3 clinical trial, APeX-2, and a long-term safety trial, APeX-S, we submitted a new drug application (&#x201c;NDA&#x201d;) to the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in December 2019 for approval of oral, once daily ORLADEYO for the prevention of HAE attacks. In February 2020, the FDA notified us that they had accepted and filed our NDA for review and that our Prescription Drug User Fee Act date for the NDA is December 3, 2020. In the NDA filing acceptance letter, the FDA stated that it is not currently planning to hold an advisory committee meeting to discuss the NDA.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.05pt;">On February 3, 2020, we announced we had submitted a new drug application to the Japanese Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;) for approval of oral, once daily ORLADEYO for the prevention of HAE attacks. In Japan, ORLADEYO is being reviewed under the Sakigake designation. The PMDA has confirmed its regulatory review schedule, and we expect an approval decision in December 2020.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.05pt;">On March 30, 2020, we announced that the European Medicines Agency (&#x201c;EMA&#x201d;) had validated our marketing authorization application (&#x201c;MAA&#x201d;) submission for approval of ORLADEYO for the prevention of HAE attacks. With this validation, the EMA began its formal review of the MAA under the centralized procedure for all member states of the European Union, Norway, Iceland and Liechtenstein. We expect an opinion from the Committee for Medicinal Products for Human Use within approximately 12 months from MAA validation.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 11pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">In anticipation of a commercial launch of ORLADEYO, we are continuing the process of developing our business infrastructure, personnel, partnerships, and marketing strategies to position ORLADEYO for success in the commercial market, which we anticipate&#x2014;based on proprietary market research, including analyses of HAE prevalence in the U.S. and market research studies with HAE patients, physicians, and payors in the U.S.&#x2014;has the potential to reach a global peak of more than $500 million in annual sales. These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance or achievements to be materially different. There can be no assurance that regulatory approval of ORLADEYO will be granted in a timely fashion or at all, that our commercialization methods and strategies will succeed, or that the market for ORLADEYO will develop in line with our current expectations. See the &#x201c;Risk Factors&#x201d; section of this Quarterly Report on Form 10-Q, including the information under &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;We do not have a great deal of experience in commercializing our products or technologies, and our future revenue generation is uncertain&#x201d; for further discussion of these risks.</p>  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On May 5, 2020, we announced that the United States Patent and Trademark Office issued a notice of allowance for a new composition of matter patent which extends patent protection for ORLADEYO in the U.S. market by four years through October 2039.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 11pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><i>APeX-2 Phase 3 Trial: </i>APeX-2 is a Phase 3 double-blind, placebo-controlled, three-arm clinical trial evaluating two dose levels of ORLADEYO<i> </i>administered orally once-daily as a preventive treatment to reduce the frequency of attacks in patients with HAE. APeX-2 tested once-daily ORLADEYO at 110 mg and 150 mg for prevention of angioedema attacks. The trial enrolled patients with Types I and II HAE in the United States, Canada and Europe. The primary efficacy endpoint of APeX-2 was the rate of angioedema attacks over 24 weeks of study drug administration. The trial enrolled and randomized 121 patients. The APeX-2 trial has been amended to extend the duration of dosing to monitor the long-term safety of ORLADEYO. Patients may continue in the trial on open-label ORLADEYO (150 mg).</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">On June 6, 2020, we announced new data from the APeX-2 trial, showing that 31 patients who were randomized to 150 mg oral, once-daily ORLADEYO at the beginning of the study and completed 48 weeks of therapy had a mean baseline attack rate of 2.9 attacks per month, which declined to 1.5 attacks per month after one month and to 1.0 attack per month at 12 months.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><i>APeX-S Long-Term Safety Trial:</i> APeX-S is an open label, long-term safety trial evaluating two dose levels (110 mg and 150 mg) of ORLADEYO administered orally once-daily as a preventive treatment in patients with Types I and II HAE.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">On June 6, 2020, we announced new data from the APeX-S trial, showing that patients completing 48 weeks of treatment on 150 mg of ORLADEYO had a median attack rate of zero attacks per month in 6 of the 12 months, including month 12 (week 48). The low attack rate experienced by HAE patients on 150 mg of oral, once-daily ORLADEYO reduced the burden of disease and translated into clinically meaningful improvements in mean angioedema quality of life (AE-QoL) total score, as measured by the disease-specific AE-QoL questionnaire. This persisted through month 12 (week 48) in the APeX-S trial.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">On June 6, 2020, we announced that an integrated 48-week analysis across both APeX-2 and APeX-S showed no new safety findings. ORLADEYO was safe and generally well tolerated in a total of 342 patients with a total of 232 patient-years of daily oral dosing. The most common adverse event was the common cold, which occurred with similar frequency in ORLADEYO and placebo patients. Gastrointestinal events led to discontinuation of ORLADEYO in 3.2 percent of patients. Drug-related serious adverse events occurred in 3 of 342 subjects (0.9 percent) and resolved after stopping or interrupting ORLADEYO dosing.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;"><i>Expanded Access Program: </i>On June 9, 2020, we announced that we have established an expanded access program with oral, once-daily ORLADEYO for patients with HAE in the United States. Through this program, physicians may be able to request ORLADEYO for HAE patients who do not have access to the program through a clinical trial.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 24.05pt;"><i>Acute Treatment: </i>We have deprioritized the oral berotralstat (750 mg) program for the acute treatment of HAE in light of the market trend toward oral prophylaxis.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:24pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Complement-Mediated Diseases</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 24.05pt;">Discovered by BioCryst, BCX9930 is a novel, oral, potent and selective small molecule inhibitor of Factor D currently in early clinical development for the treatment of complement-mediated diseases. Based on the safety and proof-of-concept data generated to date in PNH patients, we are working closely with key opinion leaders in hematology and nephrology to map the development strategy across a broad set of indications.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24pt;">On June 27, 2019, we announced that we began enrollment of a Phase 1 trial of BCX9930, an oral Factor D inhibitor discovered and developed by us, for the treatment of complement-mediated diseases. The objectives of the trial are to evaluate the safety and tolerability and characterize the pharmacokinetic (&#x201c;PK&#x201d;) and pharmacodynamic (&#x201c;PD&#x201d;) profiles of BCX9930 after single ascending doses (&#x201c;SAD&#x201d;) and multiple ascending doses (&#x201c;MAD&#x201d;) in healthy subjects. In part three of the trial, there is an additional objective to demonstrate proof of concept in paroxysmal nocturnal hemoglobinuria (&#x201c;PNH&#x201d;) patients by evaluating key biomarkers of effectiveness in PNH patients taking BCX9930.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24pt;">On January 12, 2020, we announced that we had completed an additional MAD cohort with 50 mg of oral BCX9930 or placebo administered every 12 hours for 14 days, with vaccination instead of an antibiotic for prophylaxis of bacterial infection. In the additional MAD cohort, a benign rash (similar to prior MAD cohorts) that was self-limited and resolved in four to eight days post-onset was seen in seven healthy volunteers; the protocol allowed two of these healthy volunteers with more limited surface area affected by the rash to continue receiving BCX9930. Both of these healthy volunteers successfully dosed-through benign rash, with rash resolving on-drug, in both patients; biopsies of rashes from multiple subjects confirm the benign nature of the rash. The protocol for part three of the trial in PNH patients allows any patient who develops a clinically benign rash to continue dosing with BCX9930.</p>  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24pt;">Based on the safety, tolerability, PK and PD dose-response results from parts 1 and 2 of the Phase 1 trial, we completed additional MAD dosing cohorts in healthy subjects and advanced to part 3 of the trial, a proof of concept (&#x201c;PoC&#x201d;) study of BCX9930 in treatment-na&#xef;ve PNH patients and in PNH patients who are poor responders to eculizumab or ravulizumab. We have also successfully dosed MAD cohorts of 200 milligrams twice a day and 400 milligrams twice a day in healthy subjects, with no dose-limiting adverse events.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24pt;">On May 6, 2020, we announced that low dose cohort (50 mg and 100 mg twice-daily) data in three treatment-na&#xef;ve PNH patients who completed 28 days of therapy showed that BCX9930 improved biomarkers of hemolysis and was safe and generally well tolerated. These patients were severely ill, with pre-treatment LDH levels from 3.7 to 11 times the upper limit of normal and low hemoglobin of 6.0 to 8.2 g/dL. All patients had dose-dependent reductions in LDH and increases in hemoglobin. No drug-related serious adverse events were observed, and no PNH patients experienced rash. Based on the investigators&#x2019; assessment of clinical benefit, three patients continued on therapy with BCX9930 (100 mg twice-daily) following the 28-day study window and are now receiving BCX9930 therapy at higher (200 mg twice-daily / 400 mg twice-daily) doses.&#xa0; An additional treatment-na&#xef;ve PNH cohort, which starts at the 200 mg (14 days) followed by 400 mg (14 days) twice-daily, has also begun enrollment. We expect to report data from treatment-na&#xef;ve PNH patients receiving 200 mg and 400 mg twice-daily in the third quarter of 2020. In ex-vivo laboratory assays of serum samples from subjects in the 200 mg and 400 mg twice-daily MAD cohorts in healthy volunteers, &gt;98 percent suppression of the alternative pathway was observed beyond 12 hours. Given these data, we expect to achieve our goal of monotherapy for PNH patients receiving 200 mg or 400 mg twice-daily).</p>  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24pt;">We plan to report data from PNH patients who are poor responders to C5 inhibitors receiving 200 mg / 400 mg twice-daily by the end of 2020.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24pt;">On August 3, 2020, we announced that the FDA has granted Fast Track designation for BCX9930 for the treatment of PNH.&#xa0; According to the FDA, the purpose of the Fast Track designation is to get important new drugs to the patient earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:24pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Galidesivir (formerly BCX4430)</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24pt;">Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of COVID-19, Marburg virus disease and Yellow Fever. Phase 1 clinical safety and pharmacokinetics trials of galidesivir by both intravenous and intramuscular routes of administration in healthy subjects have been conducted. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. Galidesivir has also demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including coronaviruses, filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, and flaviviruses. BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:24pt;">In April 2020, we agreed with the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;) to add a group of COVID-19 patients to the ongoing clinical trial in Yellow Fever. On April 9, 2020, we announced that we had opened a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. The trial (NCT03891420) is being funded by NIAID/HHS, part of the National Institutes of Health.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24pt;">In the COVID-19 patients, efficacy measures include qualitative and quantitative changes from baseline, time to clinical improvement, time to hospital discharge, time to undetectable levels (as measured by polymerase chain reaction (&#x201c;PCR&#x201d;) in respiratory specimens) of SARS-CoV-2, the virus that causes COVID-19, and all-cause mortality.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:24pt;">The trial is being conducted in Brazil under a U.S. investigational new drug application, and the protocol also has been approved by the Ag&#xea;ncia Nacional de Vigilancia Sanit&#xe1;ria and the Brazilian National Ethics Committee.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24pt;">Part 1 of the trial is enrolling 24 hospitalized adults diagnosed with moderate to severe COVID-19 confirmed by PCR. Three cohorts of eight patients will be randomized to receive i.v. galidesivir (n=6) or placebo (n=2) every 12 hours for 7 days. Upon completion of part 1 of the trial, an optimized dosing regimen of galidesivir will be selected for part 2 of the trial, based on part 1 results including safety, viral load reduction in respiratory tract secretions, improvement in COVID-19 signs and symptoms and clinical manifestations, and mortality. We expect to provide information from part 1 of our ongoing clinical trial of galidesivir in COVID-19 patients in Brazil by the end of the third quarter.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">In part 2 of the trial, up to 42 hospitalized patients with COVID-19 will be randomized 2:1 to receive i.v. galidesivir or placebo. After treatment, the patients will remain hospitalized until resolution of COVID-19 symptoms allows release. All patients will be followed for mortality through Day 56.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:justify;text-indent:24pt;">The galidesivir development program is substantially funded with federal funds from NIAID/HHS and by the Biomedical Advanced Research and Development Authority (&#x201c;BARDA/HHS&#x201d;). Since September 2013, NIAID/HHS has supported us in developing galidesivir as a therapeutic for Ebola and Marburg viruses. Since March 2015, BARDA/HHS has supported the galidesivir development program for the continued development of galidesivir as a potential treatment for filoviruses.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">We have ongoing studies with NIAID/HHS and academic collaborators to assess the activity of galidesivir against SARS-CoV-2, the virus that causes COVID-19, in both in vitro and animal models. We are also working with NIAID/HHS to increase manufacturing yield and expand the current supply of the drug.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">On June 10, 2020, we announced new data published in <i>Science Translational Medicine</i> show, in a primate model, that galidesivir was safe, provided post-exposure prevention of Zika viral replication across a range of doses, and rapidly reduced viral loads to undetectable levels when dosed up to 72 hours after infection with Zika virus.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:24pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Fibrodysplasia Ossificans Progressiva (&#x201c;FOP&#x201d;)</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 28.7pt;">The goal of the ALK2 inhibitor project program at BioCryst is to discover and develop orally administered kinase inhibitor drug candidates that are able to slow or prevent the progressive formation of bone in soft tissues, also known as heterotopic ossification (&#x201c;HO&#x201d;). Our lead compound, BCX9250, reduced HO in an experimental model of ALK2-driven HO in laboratory rats, with up to 89 percent reduction in volume of HO compared to controls. On November 1, 2019, we announced that we had begun a Phase 1 clinical trial with oral BCX9250 for the treatment of FOP. The Phase 1 trial will evaluate single and multiple ascending doses of oral BCX9250 in healthy volunteers. We expect to report the results from the trial in the second half of 2020.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:19pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>RAPIVAB/ALPIVAB/RAPIACTA/PERAMIFLU (peramivir injection)</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">On March 4, 2020, the International Court of Arbitration of the International Chamber of Commerce (&#x201c;ICC Tribunal&#x201d;) delivered a Partial Arbitration Award (the &#x201c;Partial Arbitration Award&#x201d;) in the arbitration matter between us and SUL with respect to the SUL Agreement for the commercialization of peramivir by SUL. In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to us under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of us terminating the SUL Agreement and restoring all rights to peramivir to us. We have agreed with SUL on a transition process for the product, including a full transition of commercialization of the product in the U.S. to us as of August 1, 2020 and a full transition of commercialization of the product in Australia as of November 1, 2020. The ICC Tribunal also awarded us our attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by us in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to us within 30 days of the approval of peramivir for adult use in the European Union and awarded us $5.0 million (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings for any dispute relating to the return to us of all rights to peramivir in the Territory.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Results of Operations (three months ended </b><b>June 30</b><b>, 2020 compared to the three months ended </b><b>June 30</b><b>, 2019)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">For the three months ended June 30, 2020, total revenues were $2.9 million as compared to $1.4 million for the three months ended June 30, 2019. The increase was primarily due to an increase in collaboration revenue under U.S. government development contracts. Revenues in the second quarter of 2020 included $0.3 million of deferred revenue amortization related to the Torii Agreement and $2.5 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir. Revenues in the second quarter of 2019 included $0.7 million of royalty revenue from Shionogi, Green Cross and SUL associated with sales of peramivir in Japan, Taiwan, Korea and the United States, and $0.8 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Research and development (&#x201c;R&amp;D&#x201d;) expenses decreased to $27.5 million for the second quarter of 2020 from $27.7 million for the second quarter of 2019. During the second quarter of 2020, R&amp;D spending increased on our complement-mediated diseases and galidesivir programs, which was offset by a reduction in spend on the ORLADEYO program as we approach commercial launch.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">Selling, general and administrative (&#x201c;SG&amp;A&#x201d;) expenses for the second quarter of 2020 were $13.9 million compared to $8.7 million in the second quarter of 2019. The increase was primarily due to increased spending on commercial activities and medical affairs to support the U.S. commercial launch of ORLADEYO in 2020.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23pt;margin-top:0pt;text-align:left;text-indent:28.35pt;">Interest and other income was $2.8 million in the second quarter of 2020, compared to $0.5 million in the second quarter of 2019. The increase was primarily due to recognition of income related to our arbitration proceedings.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Interest expense, which is primarily related to our non-recourse notes issued in conjunction with the non-dilutive RAPIACTA royalty monetization transaction in March 2011 and borrowings under our Second Amended and Restated Senior Credit Facility, was $2.9 million in the second quarter of 2020, compared to $3.0 million in the second quarter of 2019.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">A mark to market loss of $0.6 million related to our Currency Hedge Agreement was recognized in the second quarter of 2020, compared to a mark-to-market loss of $1.1 million in the same period in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition, we realized currency exchange gains of $0.6 million and $0.8 million during the second quarters of 2020 and 2019, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><b>Results of Operations (six months ended June 30, 2020 compared to the six months ended June 30, 2019)</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">For the six months ended June 30, 2020, total revenues were $7.7 million as compared to $7.3 million for the six months ended June 30, 2019. The increase was primarily due to increased revenue from galidesivir development under U.S. government contracts and amortization of deferred revenue from the Torii Agreement, partially offset by reduced peramivir product sales by our commercial partner in Korea, Green Cross, and lower royalty revenues. Revenues in the first six months of 2020 included $0.2 million of peramivir product revenue from inventory sales to our commercial partners, $2.0 million of royalty revenue from Shionogi, Green Cross and SUL associated with sales of peramivir in Japan, Taiwan, Korea and the United States, $1.3 million of deferred revenue amortization related to the Torii Agreement and $4.2 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir. Revenues in the first six months of 2019 included $1.7 million of peramivir product revenue from inventory sales to our commercial partners, $3.0 million of royalty revenue from Shionogi, Green Cross and SUL associated with sales of peramivir in Japan, Taiwan, Korea and the United States, and $2.6 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">R&amp;D expenses increased to $57.4 million for the first six months of 2020 from $55.2 million for the first six months of 2019. The increase in 2020 R&amp;D expenses, as compared to 2019, was primarily due to increased spending on our complement-mediated diseases and galidesivir programs, offset by a reduction in spend on the ORLADEYO program as we approach commercial launch.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">The following table summarizes our R&amp;D expenses for the periods indicated (amounts are in thousands).</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months Ended</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>June 30,</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months Ended</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>June 30,</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">R&amp;D expenses by program:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">BCX7353</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,845</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,152</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,390</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,407</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">BCX9930</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,794</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,602</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,443</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,830</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Galidesivir</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,902</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">893</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,360</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,547</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">BCX9250</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">953</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,391</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,522</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Peramivir</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">744</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">590</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,137</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,204</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other research, preclinical and development costs</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,260</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,444</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,644</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,664</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total R&amp;D expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,498</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,681</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,365</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,174</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">SG&amp;A expenses for the six months of 2020 were $29.7 million compared to $14.9 million in the first six months of 2019. The increase was primarily due to increased spending on commercial activities and medical affairs to support the U.S. commercial launch of ORLADEYO in 2020 and contingent legal costs associated with our arbitration proceedings.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23pt;margin-top:0pt;text-align:left;text-indent:28.35pt;">Interest and other income was $9.2 million in the first six months of 2020, compared to $1.1 million in the first six months of 2019. The increase was primarily due to recognition of income related to our arbitration proceedings.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Interest expense, which is primarily related to our non-recourse notes issued in conjunction with the non-dilutive RAPIACTA royalty monetization transaction in March 2011 and borrowings under our Second Amended and Restated Senior Credit Facility, was $6.0 million in the first six months of 2020, compared to $5.8 million in the first six months of 2019.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">A mark-to-market loss of $0.6 million was recognized in the first six months of 2019 related to our foreign currency hedge, compared to a mark-to-market loss of $0.6 million in the same period in the prior year, both resulting from changes in the U.S. dollar/Japanese yen exchange rate in the related time periods. In addition, we realized currency exchange gains of $0.6 million and $0.8 million in the first six months of 2020 and 2019, respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under our foreign currency hedge.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 28.55pt;">Cash expenditures have exceeded revenues since our inception, and we expect our 2020 operating expenses to exceed our 2020 revenues. Our operations have principally been funded through public offerings and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S. Government contracts for RAPIVAB and galidesivir; and to a lesser extent, the PhaRMA Notes financing and the Senior Credit Facility, the Amended and Restated Credit Facility, and the Second Amended and Restated Credit Facility. To date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS galidesivir development contract totaling $43.0 million, which is ongoing, and a BARDA/HHS galidesivir development contract totaling $39.1 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS galidesivir funding obligated under awarded options is $43.0 million and $20.6 million, respectively. We may issue securities through private placement transactions or registered public offerings pursuant to a registration statement filed with the SEC. On June 1, 2020, we issued 22,044,447 shares of common stock to the public at a purchase price of $4.50 per share and pre-funded warrants to purchase 3,511,111 shares of common stock at a purchase of $4.49 per pre-funded warrant, for total net proceeds us of $107.7 million after deducting underwriting discounts and commissions and other offering expenses payable by us.&#xa0; The pre-funded warrants are immediately exercisable and have an exercise price of $0.01 per share, which is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting our common stock and also upon any distributions of assets to our stockholders. In addition to the above, we have previously received funding from other sources, including other collaborative and other research and development agreements; government grants; equipment lease financing; facility leases; research grants; and interest income on our investments.</p>  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 28.55pt;">As of June 30, 2020, we had net working capital of $101.2 million, an increase of approximately $29.2 million from $72.0 million at December 31, 2019. The increase in working capital was principally due to the June 2020 public offering of our common stock and pre-funded warrants to purchase our common stock, partially offset by our normal operating expenses associated with the development of our product candidates. Our principal sources of liquidity at June 30, 2020 were approximately $173.5 million in cash and cash equivalents and approximately $15.9 million in investments considered available-for-sale. We anticipate our cash and investments will fund our operations through the second quarter of 2021.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.55pt;">We intend to contain costs and cash flow requirements by closely managing our third-party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain research and development projects and using consultants. We expect to incur additional expenses, potentially resulting in significant losses, as we continue to pursue our research and development activities and begin to build a commercial infrastructure. We may incur additional expenses related to the filing, prosecution, maintenance, defense and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;">We plan to finance our needs principally from the following:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">lease, royalty or loan financing and future public or private equity or debt financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our existing capital resources and interest earned on that capital;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">payments under existing and executing new contracts with the U.S. Government; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-18pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">payments under current or future collaborative and licensing agreements with corporate partners.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:31.5pt;">As our programs continue to advance, our costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements and additional personnel resources and testing required for the continuing development of our product candidates will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for galidesivir, the amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for the development and or commercialization of our product candidates, the progress and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates, commercialization of our products, and the overall progression of our other programs. The impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors could negatively affect our expenses, revenues and cash utilization rate.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 31.5pt;">With the funds available at June 30, 2020, we believe our financial resources will be sufficient to fund our operations through the second quarter of 2021. We have sustained operating losses for the majority of our corporate history and expect that our 2020 expenses will exceed our 2020 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, our planned operations raise doubt about our ability to continue as a going concern throughout 2021. Our liquidity needs will be largely determined by the success of operations in regard to the progression of our product candidates in the future. We also may consider other plans to fund operations through 2021 including: (1) securing or increasing U.S. Government funding of our programs, including obtaining procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change our overhead structure. We may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings. Our future liquidity needs, and ability to address those needs, will largely be determined by the success of our product candidates, the timing, scope and magnitude of our commercial expenses and key development and regulatory events and our decisions in the future.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 31.5pt;">Our long-term capital requirements and the adequacy of our available funds will depend upon many factors, including:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to perform under our government contracts and receive reimbursement thereunder, and receive stockpiling procurement contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the magnitude of work under our government contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the progress and magnitude of our research, drug discovery and development programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">changes in existing collaborative relationships or government contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:14pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:14pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">our ability to negotiate favorable development and marketing strategic alliances for certain product candidates or a decision to build or expand internal development and commercial capabilities;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">successful commercialization of marketed products by either us or a partner;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to engage sites and enroll subjects in our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the scope of manufacturing of our product candidates to support our preclinical research and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">increases in personnel and related costs to support the development and commercialization of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">competitive and technological advances;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the time and costs involved in obtaining regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">post-approval commitments for RAPIVAB and other products that receive regulatory approval; and</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the costs involved in all aspects of intellectual property strategy and protection including the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors could negatively affect our capital requirements and the availability of funds to finance those requirements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">We expect that we will be required to raise additional capital to complete the development and commercialization of our current product candidates, and we may seek to raise capital in the future. Additional funding, whether through additional sales of equity or debt securities, royalty or other monetization transactions, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale back or eliminate certain of our research and development programs. Our future working capital requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates as well as rate of reimbursement by U.S. Government agencies of our galidesivir expenses and any future decisions regarding the future of the RAPIVAB and galidesivir programs, including those relating to stockpiling procurement. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; the timing, scope and magnitude of commercial spending, and the level of required administrative support for our daily operations.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:32.4pt;">The restrictive covenants contained in the Second Amended and Restated Senior Credit Facility could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&#x2019;s permission or without repaying all Second Amended and Restated Senior Credit Facility obligations. These covenants limit our ability to, among other things, convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property; change the nature of our business; liquidate or dissolve; enter into certain change in control or acquisition transactions; incur or assume certain debt; grant certain types of liens on our assets; modify, liquidate or transfer assets in certain collateral accounts; pay dividends or make certain distributions to our stockholders; make certain investments; enter into material transactions with affiliates; and modify existing debt or collaboration arrangements. A breach of any of these covenants could result in an event of default under the Second Amended and Restated Senior Credit Facility.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Financial Outlook for 2020</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">With the additional capital raised in the second quarter of 2020 and the safety and proof-of-concept data generated to date with BCX9930 in PNH patients, we are investing in accelerated development of BCX9930 and expect full year 2020 net operating cash use to be in the range of $150 to $165 million, and our operating expenses to be in the range of $180 to $195 million. Our operating expense range excludes equity-based compensation expense due to the difficulty in accurately projecting this expense as it is significantly impacted by the volatility and price of our stock, as well as vesting of our outstanding performance-based stock options. Our operating cash forecast excludes any impact of our royalty monetization, hedge collateral posted or returned, and any other non-routine cash outflows or inflows. Our ability to remain within our operating expense and operating cash target ranges is subject to multiple factors, including unanticipated or additional general development and administrative costs and other factors described under the Risk Factors located elsewhere in this report.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">As of June 30, 2020, we do not have any unconsolidated entities or off&#x2013;balance sheet arrangements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Critical Accounting Policies</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">While our significant accounting policies are more fully described in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Inventory</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">Our inventories consist of peramivir finished goods and work in process, which are valued at the lower of cost or net realizable value using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor, overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval of RAPIVAB and other regulatory approvals, we began capitalizing costs associated with the production of peramivir inventories.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accrued Expenses</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">We enter into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to investigative sites in connection with clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance and product candidates; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">professional fees.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Revenue Recognition</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We recognize revenue when we satisfy a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that we expect to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not occur.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We have collaboration and license agreements with a number of third parties as well as research and development agreements with certain government entities. Our primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling price considering market conditions and entity-specific factors. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) we have a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under our contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Under certain of our license agreements, we receive royalty payments based upon our licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Product Sales</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;">Our principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under our procurement contract. We recognize revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Balances</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:25pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="text-decoration: underline; "><i>Contract assets</i></span><i> </i>- Our long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic<i> </i>intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheets.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"><span style="text-decoration: underline; "><i>Contract liabilities</i></span><i> </i>- We often receive cash payments from customers in advance of our performance, resulting in contract liabilities. These contract<i> </i>liabilities are classified as either current or long-term in the Consolidated Balance Sheets based on the timing of when we expect to recognize the revenue.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Costs</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We may incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that we expect to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that we expect to recover are expensed as incurred.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Research and Development Expenses</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">Our research and development costs are charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits; manufacturing costs; clinical, regulatory, and toxicology services performed by CROs; materials and supplies and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Additionally, we have license agreements with third parties, such as the Albert Einstein College of Medicine of Yeshiva University, Industrial Research, Ltd. and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. We expense maintenance payments as incurred.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Deferred collaboration expenses represent sub-license payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We group our R&amp;D expenses into two major categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by active program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to work on non-active product candidates and our discovery research efforts.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Stock-Based Compensation</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred. Significant management judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Currency Hedge Agreement</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">In connection with our issuance of the PhaRMA Notes, we entered into a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Currency Hedge Agreement does not qualify for hedge accounting treatment and therefore mark to market adjustments will be recognized in our Consolidated Statements of Comprehensive Loss. Mark to market adjustments are determined by quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing the Level 2 in the fair value hierarchy as defined by generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). We are also required to post collateral in connection with the mark to market adjustments based on defined thresholds. As of June 30, 2020, no collateral was posted under the agreement.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Tax</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We account for uncertain tax positions in accordance with U.S. GAAP. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Information Regarding Forward-Looking Statements</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.55pt;">This filing contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#x201c;safe harbor&#x201d; created in Section 21E. All statements other than statements of historical facts contained in this filing are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in &#x201c;Business,&#x201d; &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; as well as any amendments we make to those sections in filings with the SEC. These forward-looking statements include, but are not limited to, statements about:</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the impact of the ongoing COVID-19 pandemic on all aspects of our business, including without limitation delays, stoppages, difficulties and increased expenses with respect to our and our partners&#x2019; development, regulatory and supply chain operations, or on our ability to access the capital or credit markets to finance our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the preclinical development, clinical development, commercialization, or post-marketing studies of our product candidates and products, including our HAE programs, BCX9930, BCX9250, peramivir, galidesivir, and early stage discovery programs;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the potential funding from our contracts with NIAID/HHS and BARDA/HHS for the development of galidesivir;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the potential for government stockpiling orders of peramivir and galidesivir, additional regulatory approvals of peramivir, or milestones, royalties or profit from sales of peramivir by us or our partners;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the potential use of peramivir as a treatment for H1N1, H5N1, and H7N9 or other strains of influenza;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to establish and maintain collaborations or out-license rights to our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the outcome, cost and timing of any resolution of disputes and legal proceedings, including but not limited to the dispute with our partner SUL;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">plans, programs, progress and potential success of our collaborations, including Mundipharma for mundesine, Torii for ORLADEYO in Japan and Shionogi and Green Cross for peramivir in their territories;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our and MDCP&#x2019;s ability to satisfy obligations under our Second Amended and Restated Senior Credit Facility;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Royalty Sub&#x2019;s ability to service its payment obligations in respect of the PhaRMA Notes;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the Currency Hedge Agreement entered into by us in connection with the issuance by Royalty Sub of the PhaRMA Notes;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to operate our business without infringing the intellectual property rights of others;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to continue as a going concern;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the timing or likelihood of entering into a U.S. government stockpile order and our ability to execute any such order;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to raise additional capital to fund our operations or repay our recourse debt obligations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to comply with the covenants as set forth in the agreements governing our debt obligations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our financial performance;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">the timing and success of our anticipated commercialization of ORLADEYO in the U.S. and elsewhere; and&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">competitive companies, technologies and our industry.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#x201c;Risk Factors.&#x201d; Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="p1i3" title="p1i3" href="#"></a>Item 3.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Interest Rate Risk</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We are subject to interest rate risk on our investment portfolio and borrowings under our fixed-interest rate PhaRMA Notes and our variable-interest rate Second Amended and Restated Senior Credit Facility. The interest rate applicable to our borrowings under the PhaRMA Notes is fixed at 14.0% and the Second Amended and Restated Senior Credit Facility bears a floating interest rate based on LIBOR. Increases in interest rates could therefore increase the associated interest payments that we are required to make on the Second Amended and Restated Senior Credit Facility. As of June 30, 2020, our Second Amended and Restated Senior Credit Facility had an interest rate of 8.5%.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point increase or decrease in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments, including our borrowings, but may affect our future earnings and cash flows. We generally have the ability to hold our fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#x2019; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Foreign Currency Risk</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The majority of our transactions and the greatest magnitude of these transactions occur in U.S. dollars and we do not have significant operating subsidiaries or significant investments in foreign countries as of June 30, 2020. Therefore, we are not subject to significant foreign currency exchange risk in our normal operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="p1i4" title="p1i4" href="#"></a>Item 4.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to BioCryst Pharmaceuticals, Inc. required to be disclosed in our periodic filings under the Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2020, the Company&#x2019;s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company&#x2019;s management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:28pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b><a id="p2" title="p2" href="#"></a>PART II. OTHER INFORMATION</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="p2i1a" title="p2i1a" href="#"></a>ITEM 1A.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>RISK FACTORS</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><i>An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the Securities and Exchange Commission, before deciding to buy our common stock.</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Risks Relating to Our Business</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:-0.4pt;"><i><b>Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the recent COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, CROs, and others, as well as on the regulatory and government agencies with whom we work.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.3pt;">The COVID-19 pandemic has spread to multiple countries around the world, is affecting the United States and global economies, and may cause significant disruptions to our business, operations, and clinical development or commercialization plans and timelines, as well as the business and operations of third parties with whom we conduct business. For example, quarantines, shelter-in-place and similar government orders have impacted and may continue to impact, among other things: (1) our personnel and those of third parties on whom we rely, including our development partners (such as Torii), manufacturers, CROs, and others; (2) the conduct of our current and future clinical trials; and (3) the operations of the FDA, EMA, PMDA and other health and governmental authorities, which could result in delays of reviews and approvals.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">If our operations or those of third parties with whom we conduct business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be stopped or delayed, or the costs of such development and commercialization activities could increase, any of which could have a material adverse impact on our business. For example, if interruptions related to COVID-19 were to impair our or Torii&#x2019;s ability to perform under the Torii Agreement to complete our regulatory interactions in Japan, including with respect to the pending Japanese NDA with respect to ORLADEYO for the treatment of HAE, then the timing and success of our development and commercialization of ORLADEYO in Japan could be severely impacted.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">Our suppliers or other vendors may be unable to meet their obligations to us or perform their services as expected as a result of the COVID-19 pandemic or other health epidemics. In such circumstances, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Such delays could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">In addition, our clinical trials may be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our inability to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state could adversely impact our clinical trial operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">If global health concerns prevent the FDA, EMA, PMDA or other regulatory authorities from conducting their inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA, EMA, PMDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business and clinical development plans and timelines.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">We have implemented work-from-home policies for our employees, which may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">The spread of COVID-19, which has caused a broad impact globally, may also materially affect our access to capital. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access the equity or debt capital markets or obtain other sources of capital, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">The global pandemic of COVID-19 continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. These effects could be material, and we will continue to monitor the COVID-19 situation closely. We do not yet know the full extent and magnitude of the impacts that COVID-19 has had or will have on our business, on the healthcare system, or on the global economy. In addition, the COVID-19 pandemic could have the effect of heightening many of the other risks described below.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Since our inception, we have not achieved sustained profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts and commercial activities progress. We expect that such losses will fluctuate from quarter to quarter and that losses and fluctuations may be substantial. To become profitable, we, or our collaborative partners, must successfully manufacture and develop product candidates, receive regulatory approval, and successfully commercialize and/or enter into profitable commercialization arrangements with other parties. It could be several years, if ever, before we receive significant revenue from any current or future license agreements or revenues directly from product sales.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Because of the numerous risks and uncertainties associated with developing our product candidates and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:25pt;margin-top:0pt;text-align:left;"><i><b>Our success depends upon our ability to advance our products through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our products.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">To receive the regulatory approvals necessary for the commercial sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. The preclinical and clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy and safety, the occurrence of adverse events that are severe or medically or commercially unacceptable, our or our partners&#x2019; failure to comply with trial protocols, applicable regulatory requirements, and industry standards, or a determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or be approved in accordance with our development plans or at all. We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all, or that the results of such trials will be sufficient to support regulatory approval for our product candidates.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Progression of our product candidates through the clinical development process is dependent upon our trials indicating that our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve any of these endpoints in any of our programs, including ORLADEYO, BCX9930, BCX9250, galidesivir, and our other rare disease product candidates, could result in delays in or modifications to our trials or require the performance of additional unplanned trials. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Product candidates that initially show promise in clinical or preclinical testing could later be found to cause undesirable or unexpected side effects that could result in delays in the development of our product candidates, significant unexpected costs, or the termination of programs. The development plans for our product candidates, including our clinical trials, may not be adequately designed or executed, which could negatively affect the outcome and analysis of study results. Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show favorable results in clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Undesirable or inconclusive data in our pre-clinical studies and clinical trials or side effects in humans could result in the FDA or foreign regulatory authorities (including, e.g., the EMA, the Japanese Ministry of Health, Labor &amp; Welfare (&#x201c;MHLW&#x201d;) or the U.K. Medicines and Healthcare products Regulatory Agency (&#x201c;MHRA&#x201d;) refusing to approve a product candidate for any targeted indications or imposing restrictions or warnings that could impact development or the ultimate commercial viability of a product candidate. In addition, the FDA or foreign regulatory authorities may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and such regulatory authorities may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA, or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Our ability to successfully complete the clinical development process is dependent upon many factors, including but not limited to:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">our or our partners&#x2019; ability to secure suitable clinical sites and investigators and to enroll and maintain an adequate number of patients on a timely basis or at all;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">patients that enroll in a clinical trial may not comply with the clinical trial protocol or maintain contact with investigators to provide complete data during and after treatment;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our product candidates may not prove to be either safe or effective or may produce unfavorable or inconclusive results;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:6pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:6pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">we or our partners may decide, or be required by regulatory authorities, to suspend or terminate clinical research for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, noncompliance with regulatory requirements or their standards of conduct, or findings of undesirable effects caused by a chemically or mechanistically similar product or product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">regulatory authorities may disagree with our or our partners&#x2019; clinical trial protocols or our or their interpretation of data from preclinical studies and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we or our partners enter into agreements for clinical and commercial supplies;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:11pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:11pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the supply or quantity of raw materials or manufactured product candidates or other materials necessary to conduct development activities may be insufficient, inadequate, or unavailable at an acceptable cost, and we or our partners may experience interruptions in supply;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our or our partners&#x2019; development plans may be delayed or changed as a result of changes in development strategy, the impact of new or different regulations, requirements, and guidelines, or other unexpected events or conditions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the cost of pre-clinical studies and clinical trials may be greater than we anticipate;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:8pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">we or our third-party contractors, including those manufacturing our product candidates or components or ingredients thereof, or conducting clinical trials or laboratory testing on our or our partners&#x2019; behalf, may fail to comply with regulatory requirements and industry standards or meet contractual obligations in a timely manner or at all; and&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">the impact of the COVID-19 pandemic on one or more of the foregoing factors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Clinical trials are lengthy and expensive. Many of the factors listed above could result in increased clinical development costs or longer clinical development times for any of our programs. We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner, may not receive regulatory approval for the product candidates, in which case we would be unable to generate any revenues from product sales or licensing arrangements, or any product candidate, if approved, may be subject to restrictions on labeling, marketing, distribution, prescribing, and use, which could adversely impact the sales of such product.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:12pt;margin-top:0pt;text-align:left;"><i><b>If our development collaborations with third parties, such as our development partners, contractors and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;">We rely heavily upon third parties for many important stages of our product candidate development, including but not limited to:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">discovery of natural proteins that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">execution of certain pharmacology preclinical studies and late-stage development for our compounds and product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">management of our Phase 1, 2 and 3 clinical trials, including medical monitoring, laboratory testing, and data management;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">execution of toxicology studies that may be required to obtain approval for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">formulation improvement strategies and methods;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">management of certain regulatory interactions outside of the United States.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations or third-party contractors that conduct our initial or late-stage clinical trials, conduct our toxicology or other studies, manufacture our starting materials, drug substance and product candidates, provide laboratory testing or other services in connection with our clinical trials, or assist with our regulatory function breach their obligations to us, perform their services inconsistent with industry standards, or fail to comply with regulatory requirements, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices, current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) and current Good Clinical Practices, and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could be materially adversely affected.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:57pt;margin-top:0pt;text-align:left;"><i><b>If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our product candidates or continue operations.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">As our programs advance, our costs are likely to increase. Our current and planned discovery, development, approval, and commercialization efforts will require significant capital. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to obtain regulatory approval for and successfully commercialize our product candidates, including ORLADEYO, BCX9930, BCX9250, and galidesivir; our ability to raise additional capital; the amount of funding we receive from partnerships with third parties for the development and commercialization of our product candidates (including, our collaborations with Torii, BARDA/HHS and NIAID/HHS); the commercial success of peramivir achieved by our partners; the amount or profitability of any orders for peramivir or galidesivir by any government agency or other party; the progress and results of our current and proposed clinical trials for our product candidates; and the progress made in the manufacture of our lead products and the progression of our other programs.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In order to continue future operations, progress our drug development programs, and commercialize our current product candidates, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may decide to access the equity or debt markets, incur additional borrowings, or seek other sources to meet liquidity needs at any time. Additional funding, whether through additional sales of securities, additional borrowings, royalty or other monetization transactions, collaborative arrangements with partners, including corporate partners such as Torii and governmental agencies such as BARDA/HHS or NIAID/HHS, or from other sources, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of our currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants than are currently applicable to us under our Second Amended and Restated Senior Credit Facility. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate certain of our research and development programs.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Our ability to raise additional capital when needed or at all may be limited and may greatly depend upon the success of our current drug development programs, including the progress, timeline and ultimate outcome of the development programs for our kallikrein inhibitors such as ORLADEYO (including but not limited to formulation progress, long-term human safety studies, and carcinogenicity, drug-drug interaction, toxicity, or other required studies), BCX9250 for the treatment of FOP, BCX9930 for diseases of the complement system, our broad-spectrum antiviral program, including galidesivir, and other rare disease product candidates, as well as any post-approval studies for RAPIVAB. In addition, constriction and volatility in the equity and debt markets, including as a result of the impacts of COVID-19, may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current economic and political environment, including as a result of the impacts of COVID-19. Any such instability may impact these parties&#x2019; ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development of our product candidates.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We may not be able to continue as a going concern if we do not obtain additional capital.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We have sustained operating losses for the majority of our corporate history and expect that our 2020 expenses will exceed our 2020 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">Our liquidity needs will be largely determined by the success of operations in regard to the progression of our product candidates in the future. Our plans to alleviate the doubt regarding our ability to continue as a going concern primarily include controlling the timing and spending on our research and development programs, raising additional funds through equity financings, and commercializing approved product candidates. We also may consider other plans to fund operations including: (1) securing or increasing U.S. Government funding of our programs, including obtaining additional and delivering on procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments and/or royalties; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (5) reducing spending on research and development programs, including by discontinuing and suspending development; and/or (6) restructuring operations to change our overhead structure.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient additional capital, we may be forced to curtail operations, delay or stop ongoing clinical trials, cease operations altogether or file for bankruptcy.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:36pt;margin-top:0pt;text-align:left;"><i><b>If we or our partners do not obtain and maintain governmental approval for our product candidates, we or our partners will not be able to commercialize and sell these potential products, which would significantly harm our business because we will receive no revenue.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We or our partners must obtain regulatory approval before marketing or selling our products. If the FDA or a comparable foreign regulatory authority delays or denies regulatory approval of one of our product candidates, or revokes approval of a previously approved product, we would be unable to market or sell the product in the applicable jurisdiction and would not receive revenue from sales or licensing arrangements related thereto, which could have a material and adverse impact on our business.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The process of preparing for and obtaining regulatory approval in any jurisdiction may be lengthy and expensive, and approval is never certain. Because of the risks and uncertainties inherent to the development process, including risks and uncertainties related to the impact of COVID-19, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. As discussed under &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;<i>Our success depends upon our ability to advance our products through the various stages of development,</i> <i>especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our products</i>,&#x201d; we or our partners may<i> </i>experience any number of unfavorable outcomes during or as a result of pre-clinical studies and clinical trials that could delay or prevent regulatory approval of our product candidates, or negatively impact our management&#x2019;s credibility, our value and our operating results.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Even if the FDA or foreign regulatory authorities approve a product candidate, the approval may limit the indicated uses for a product candidate, impose other restrictions on the product candidate, and/or may require post-approval studies that could impair the commercial viability of a product candidate. If we receive approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">adverse drug experience reporting regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">product promotion;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">product manufacturing, including good manufacturing practice requirements; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">product changes or modifications.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Our failure to comply with existing or future regulatory requirements for regulatory approval, or our loss of, or changes to, previously obtained approvals, could impair our ability to generate any revenues from product sales or licensing arrangements, which could have a material adverse effect on our business, financial condition, and results of operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We focus on rare diseases, which may create additional risks and challenges.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Because we focus on developing drugs as treatments for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory authorities have broad discretion in determining whether or not to grant such designations. We cannot guarantee that our product candidates will receive orphan drug status from the FDA or equivalent designations from other regulatory authorities. We also cannot guarantee that we will receive breakthrough therapy, fast track, or equivalent designations, which provide certain potential benefits such as more frequent meetings with the applicable regulatory authorities to discuss development plans, intensive guidance on efficient drug development programs, and potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designations for our product candidates, such designations may not lead to faster development or regulatory review or approval and do not increase the likelihood that our product candidates will receive marketing approval. For instance, although BCX9930 for PNH and ORLADEYO for HAE prophylaxis have received Fast Track designation from the FDA, and ORLADEYO has also received Sakigake designation from the PMDA and Promising Innovative Medicine designation from the MHRA, as well as orphan drug status from the FDA, EMA, and the MHLW, we may not experience a faster development, review or approval process compared to the conventional process in the relevant jurisdictions. We may not be able to obtain or maintain these designations for ORLADEYO, BCX9930 or other product candidates that receive them, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><i><b>The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance within the medical community.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If after obtaining regulatory approval of a product we or others discover that it is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:15pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">regulatory authorities may withdraw their approval of, or impose marketing or manufacturing restrictions on, the product, or require us or our partners to create a medication guide outlining the risks of unidentified side effects for distribution to patients;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we or our partners may be required to recall the product, change the way the product is administered, conduct additional clinical trials, or be subject to civil or criminal penalties; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the product may become less competitive and our reputation may suffer.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Even after receiving regulatory approval, any product could fail to gain sufficient, or even any, market acceptance by physicians, patients, third party payors, health authorities and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If an approved product does not achieve an adequate level of market acceptance, it may not generate significant revenues. The occurrence of any of the foregoing could have a material and adverse impact on our business.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><i><b>If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our product candidates could be reduced, delayed or eliminated.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Our business strategy is to increase the asset value of our product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development, regulatory approval, marketing, sales and distribution of our product candidates.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Currently, we have established collaborative relationships with Torii for the commercialization of ORLADEYO in Japan, with each of Shionogi and Green Cross for the development and commercialization of peramivir, and with Mundipharma for the development and commercialization of Mundesine (forodesine). The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory commercial, regulatory or clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">our contracts for collaborative arrangements may expire;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">our partners may choose to pursue alternative technologies, including those of our competitors;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we may have disputes with a partner that could lead to litigation or arbitration, such as the recent arbitration proceeding between us and SUL, which could result in substantial costs and divert the attention of our management;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we do not have day to day control over the activities of our partners and have limited control over their decisions;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:17pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:17pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we or our partners may not devote sufficient capital or resources towards our product candidates; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we or our partners may not comply with applicable government regulatory requirements.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development or commercialization of one or more of our product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, we may not receive any revenues from product sales or licensing arrangements.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>The results of our partnership with Torii may not meet our current expectations.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">We have an agreement with Torii for the development and commercialization of ORLADEYO in Japan (the &#x201c;Torii Agreement&#x201d;). We do not have a history of working with Torii and cannot predict the success of this collaboration. Our ability to realize the expected benefits of this collaboration, including with respect to the receipt or amounts of potential milestone or royalty payments, is subject to a number of risks, including that applicable regulatory agencies may not provide adequate regulatory clearances or reimbursement approvals on a timely basis or at all, the commercial potential of ORLADEYO may not meet our current expectations, we or Torii may fail to comply with our respective obligations under the Torii Agreement, and third parties may fail to perform their obligations to us on a timely basis or at all.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Torii Agreement provides for a potential milestone payment depending on the receipt and timing of regulatory approval and contingent upon receipt of a reimbursement price approval from Japan&#x2019;s National Health Insurance system in excess of the threshold specified in the Torii Agreement, either of which we may not receive on a timely basis or at all. The Torii Agreement also provides that we will be entitled to receive tiered royalty payments, the amounts of which will depend upon the amount of annual net sales of ORLADEYO in Japan during each calendar year, whether ORLADEYO maintains its Sakigake designation, and other factors. We remain responsible for regulatory activities with respect to ORLADEYO in Japan for one year after the first commercial sale. We expect to use third parties to satisfy many of our obligations under the Torii Agreement, including but not limited to our regulatory and other responsibilities in Japan. If our interactions, or those of our third party agents, are unsuccessful, we could fail to meet our obligations under the Torii Agreement, fail to receive regulatory approval of ORLADEYO on a timely basis or at all, receive approval of ORLADEYO on a narrower scope than currently anticipated, or fail to receive reimbursement authorization in excess of the specified threshold, which could negatively impact the commercial success and the partnership, impact the economic benefit expected or require additional development of ORLADEYO.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Torii may terminate the Torii Agreement under certain limited circumstances, including the receipt of notice that certain additional development activities are required for regulatory approval of ORLADEYO, if regulatory approval of ORLADEYO is not received prior to December 31, 2022, or upon one year&#x2019;s written notice after the sixth anniversary of the first commercial sale of ORLADEYO in Japan. If the Torii Agreement is terminated in connection with these provisions, we will no longer be entitled to receive any milestone or royalty payments thereunder, which could have a material adverse impact on our business and results of operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Torii will have sole control over and decision-making authority with respect to commercialization activities for ORLADEYO for the prevention of HAE attacks in Japan, subject to oversight from a joint steering committee. Therefore, our receipt of, and the amounts of, any royalty payments under the Torii Agreement are dependent upon Torii&#x2019;s successful performance of such commercialization activities. In addition, competitive products and variations in patient demand, prescription levels, reimbursement determinations or other factors may limit the commercial potential of ORLADEYO in Japan, which could materially reduce the amount of any royalties we would be entitled to receive under the Torii Agreement.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the Torii Agreement, we will be responsible for supplying Torii with its required amounts of ORLADEYO for commercial sale. If due to the failure of our third-party contract manufacturers to produce sufficient drug product we fail to supply to Torii the required amounts of ORLADEYO, then Torii&#x2019;s ability to successfully commercialize ORLADEYO in Japan could be materially impaired, and we may receive less royalty income under the Torii Agreement, or none at all.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:34pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Any of the foregoing risks could materially adversely impact our ability to obtain regulatory approval of ORLADEYO in Japan, the price of ORLADEYO in Japan, and to perform our obligations under the Torii Agreement, which could materially reduce the economic benefits of the Torii Agreement to us and impair or result in the termination of our collaboration with Torii.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>&#xa0;</b></i></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We do not have a great deal of experience in commercializing our products or technologies, and our future revenue generation is uncertain.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We do not have a great deal of experience in commercializing our product candidates or technologies. We currently have limited sales, marketing and distribution capabilities, and we may be unable to establish or sufficiently increase these capabilities for products we currently, or plan to, commercialize. Our ability to receive revenue from products we or our partners commercialize is subject to several risks, including:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we or our partners may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep regulatory agency marketing approval;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our product candidates;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:18pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:18pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">reimbursement is constantly changing, which could greatly affect usage of our products;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market, distribute and commercialize our approved drugs; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the impact of the COVID-19 pandemic on us or our partners.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left;"><i><b>We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</b></i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">We expect to continue experiencing significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and, if any of our product candidates currently in development receive marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. For example, as we approach the commercial launch of ORLADEYO, we&#x2019;ve expanded our internal commercial team. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. In addition, if a commercial launch for any product or product candidate for which we recruit a commercial team and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p>  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:19.95pt;margin-right:7.95pt;margin-top:0pt;text-align:left;"><i><b>We depend on third-party vendors, including third-party manufacturers and distributors to manufacture and distribute our products, product candidates and the materials for our product candidates. Often, especially early in the development and commercialization process, we have only one or limited sources for a particular product or service, such as manufacturing and/or distribution. If we cannot rely on existing third-party vendors, we will be required to incur significant costs and potential delays in finding new third-party vendors, which could adversely impact the development and commercialization timeframes for our products and product candidates.</b></i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">We depend on these third-party vendors to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party vendors, particularly our third-party manufacturers and distributors, which may be the only vendor we have engaged for a particular product or service, may encounter difficulties with meeting our requirements, including but not limited to problems involving, as applicable:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:67.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:-9.6pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;">insufficient resources being devoted in the manner necessary to satisfy our requirements within expected timeframes;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">inconsistent production yields;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">product liability claims or recalls of commercial product;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">difficulties in scaling production to commercial and validation sizes;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">interruption of the delivery of materials required for the manufacturing process;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">failure to distribute commercial supplies of our products to commercial vendors or end users in a timely manner;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">scheduling of plant time with other vendors or unexpected equipment failure;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">potential catastrophes that could strike their facilities or have an effect on infrastructure;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">poor quality control and assurance or inadequate process controls;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">failure to provide us with accurate or timely information regarding inventories, the number of patients who are using our products, or serious adverse events and/or product complaints regarding our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">inability of third parties to satisfy their financial obligations to us or to others;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">potential breach of the manufacturing or distribution agreement by the third party;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">possible termination or nonrenewal of a critical agreement by the third party at a time that is costly or inconvenient to us; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies or local customs, particularly associated with ORLADEYO, BCX9930, BCX9250, galidesivir, peramivir and our early stage compounds.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">Many additional factors could cause production or distribution interruptions with the manufacture and distribution of any of our products and product candidates, including human error, natural disasters, pandemics, labor disputes, acts of terrorism or war, equipment malfunctions, or raw material shortages.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">In addition, our contract manufacturers may not be able to manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. Our raw materials, drug substances, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#x2019;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or foreign regulatory authorities may at any time implement new standards, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties any of which could be costly to us and could result in a delay or shortage of product.</p>  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">If we are unable to maintain current third-party relationships, or enter into new agreements with additional third parties on commercially reasonable terms, or if there is poor manufacturing or distribution performance or failure to comply with any regulatory agency on the part of any of our third-party vendors, we may not be able to complete development of, obtain timely approval of, or commercialize, our product candidates.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Commercialization of peramivir by our partners is subject to the potential commercialization risks described herein and numerous additional risks.</b></i> <i><b>Any potential revenue benefits to us in the form of milestone payments, royalties or other consideration are highly speculative.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Commercialization success of peramivir is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of peramivir products is subject to further risks and may be negatively impacted by a number of factors, including, but not limited to, the following:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">peramivir may not prove to be adequately safe and effective for market approval in markets other than the United States, Canada, Japan, Korea, Taiwan, Australia and the European Union (&#x201c;EU&#x201d;);</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">necessary funding for post-marketing commitments and further development of peramivir may not be available timely, at all, or in sufficient amounts;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">flu prevention or pandemic treatment concerns may not materialize at all, or in the near future;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">advances in flu vaccines or other antivirals, including competitive i.v. antivirals, could substantially replace potential demand for peramivir;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">a limited number of governmental entities are expected to be the primary potential stockpiling customers for peramivir and if we are not successful at marketing peramivir to these entities for any reason, we will not receive substantial revenues from stockpiling orders;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">government and third-party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for peramivir;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the commercial demand and acceptance for peramivir by healthcare providers and by patients may not be sufficient to result in substantial revenues of peramivir to our partners and may result in little to no milestones or royalties to us;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">effectiveness of marketing and commercialization efforts for peramivir by our partners;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">market satisfaction with existing alternative therapies;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:31pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1433px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">perceived efficacy relative to other available therapies;</p> </td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1433px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1433px;">disease prevalence;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1433px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1433px;">cost of treatment;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1433px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1433px;">pricing and availability of alternative products;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1433px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1433px;">marketing and sales activities of competitors;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1433px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1433px;">shifts in the medical community to new treatment paradigms or standards of care; and</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1433px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 47px;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1433px;">relative convenience and ease of administration.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We face intense competition, and if we are unable to compete effectively, the demand for our products, if any, may be reduced.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced marketing and manufacturing organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the licensing of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. This includes competition with respect to, among other things, galidesivir as a potential treatment for COVID-19. Competition may also arise from, among other things:</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1431px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">other drug development technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 32px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1433px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">methods of preventing or reducing the incidence of disease, including vaccines; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1432px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">new small molecule or other classes of therapeutic agents.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Developments by others may render our product candidates or technologies obsolete or noncompetitive.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">We are performing research on or developing products for the treatment of several rare diseases, including HAE, diseases of the complement system, and FOP, as well as developing broad spectrum antivirals for use as medical countermeasures. We expect to encounter significant competition for any of the pharmaceutical products we are developing and plan to develop. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. There are licensed therapies for HAE (including Berinert<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Haegarda<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Cinryze<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Kalbitor<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Takhzyro<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Firazyr<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> (icatibant) and generic icatibant), therapies for certain complement-mediated diseases such as PNH, aHUS, myasthenia gravis, and neuromyelitis optica spectrum disorder (Soliris<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> and Ultomiris<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>), products for the prevention or treatment of influenza (seasonal flu vaccines, Tamiflu<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> (oseltamivir), generic oseltamivir, Relenza<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, and Inavir<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, favipiravir, and Xofluza&#x2122;), remdesivir as a potential treatment for COVID-19 and a number of additional of products in clinical development in these therapeutic areas and for the treatment of FOP. In addition, various government entities throughout the world may offer incentives, grants and contracts to encourage additional investment into preventative and therapeutic agents against viruses such as influenza, coronavirus, Ebola, and others, which may have the effect of further increasing the number of our competitors and/or providing advantages to certain competitors. See &#x201c;Item 1. Business&#x2014;Competition&#x201d; in our Annual Report on Form 10-K for the year ended December 31, 2019 for further discussion of our competitors, competitive products or programs, and the competitive conditions in these and other therapeutic areas.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If one or more of our competitors&#x2019; products or programs, including potential competitors not currently identified, are successful, the market for our products may be reduced or eliminated.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Compared to us, many of our competitors and potential competitors have substantially greater:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1434px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">capital resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1434px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">research and development resources, including personnel and technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 29px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1436px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">regulatory experience;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 29px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1436px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">preclinical study and clinical testing experience;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 30px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1435px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">manufacturing and marketing experience; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 30px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1435px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">production facilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:12.45pt;">Any of these competitive factors could impede our funding efforts, render technology and product candidates noncompetitive or eliminate or reduce demand for our product candidates.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:11pt;margin-top:0pt;text-align:left;"><i><b>We are subject to various laws and regulations related to our products and product candidates and, if we or our partners do not comply with these laws and regulations, we could face substantial penalties.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Our or our partners&#x2019; activities related to approved products, such as RAPIVAB/ALPIVAB (peramivir), or, following their regulatory approval, any of our product candidates under development, such as ORLADEYO, BCX9930, BCX9250, and galidesivir, are subject to regulatory and law enforcement authorities in the United States (including the FDA, the Federal Trade Commission, the Department of Justice, and state and local governments) and their foreign equivalents (including the EMA, MHLW, MHRA, and others).</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We are responsible for reporting adverse drug experiences, have responsibility for certain post-approval studies, and may have responsibilities and costs related to a recall or withdrawal of RAPIVAB/ALPIVAB from sale in the jurisdictions in which it is approved. We may also incur liability associated with RAPIVAB/ALPIVAB manufacturing contracted by us or in support of any of our partners. We are required to maintain records and provide data and reports to regulatory agencies related to RAPIVAB/ALPIVAB (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial condition. Similar responsibilities would apply upon regulatory approval of any of our other product candidates currently under development.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">In addition, we are subject to the federal physician sunshine act and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various federal and state laws pertaining to health care &#x201c;fraud and abuse,&#x201d; including both federal and state anti-kickback and false claims laws. Outside of the United States, we may be subject to analogous foreign laws and regulations in the various jurisdictions in which we operate. These laws and regulations apply to our or our partners&#x2019; operations, sales and marketing practices, price reporting, and relationships with physicians and other customers and third-party payors. Anti-kickback laws generally prohibit a manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third party payors (including Medicare and Medicaid) claims for reimbursement or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. The sunshine provisions apply to manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government certain payments made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as, ownership and investment interests held by physicians (as defined above) and their immediate family members. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under health care fraud and abuse, anti-kickback, false claims or similar laws. Violations of the physician sunshine act and similar legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to certain regulatory authorities, including the FDA and comparable foreign regulatory authorities. Consequently, the FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator creates a conflict of interest or otherwise affects interpretation of the study. In the event of a conflict of interest with respect to a study, the integrity of the data generated at the applicable clinical trial site may be questioned or the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We have a number of outstanding post-approval commitments to the FDA and EMA that we retain, which we may not complete successfully or on time for any number of reasons, including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators or study subjects. For example, as a condition of the approval of RAPIVAB/ALPIVAB, we were required to complete pediatric patient trials and to submit the final results of these clinical trials to the FDA and EMA. We may be subject to penalties if we fail to comply with post-approval legal and regulatory requirements and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the approval of RAPIVAB/ALPIVAB and any other future product candidates may be subject to requirements for costly post-approval testing and surveillance to monitor its safety or efficacy.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Advertising and promotion are subject to stringent FDA rules and oversight and as an NDA-holder we may be held responsible for any advertising and promotion that is not in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent with the FDA approvals for approved products and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. Adverse event information concerning approved products must be reviewed and as an NDA-holder we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities. In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, state and local governments, and foreign equivalents of the foregoing. All of these activities are also potentially subject to healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition laws.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If our operations with respect to RAPIVAB/ALPIVAB or our other products that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable fraud and abuse laws may be costly.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Our business strategy includes international expansion, including the commercialization of products outside of the United States. We currently conduct clinical studies and regulatory activities and have hired, and expect to continue hiring, employees outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">multiple, conflicting, and changing laws and regulations such as privacy and data regulations, transparency regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">introduction of new health authority requirements and/or changes in health authority expectations;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">failure by us or our partners to obtain and maintain regulatory approvals for the use of our products in various countries;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">complexities and difficulties in obtaining protection for, and enforcing, our intellectual property;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">difficulties in staffing and managing foreign operations;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">limits on our ability to penetrate international markets;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, actual or threatened public health emergencies and outbreak of disease (including for example, the recent coronavirus outbreak), boycotts, adoption or expansion of government trade restrictions, and other business restrictions;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">certain expenses including, among others, expenses for travel, translation, and insurance;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">regulatory and compliance risks that relate to maintaining accurate information and control over commercial operations and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, including its books and records provisions or anti-bribery provisions, or the U.K. Bribery Act and similar foreign laws and regulations; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">regulatory and compliance risks relating to doing business with any entity that is subject to sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:31pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Any of these factors could significantly harm our future international expansion of operations and, consequently, our business and results of operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Additionally, in some countries, such as Japan and the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our partners may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:10pt;margin-top:0pt;text-align:left;"><i><b>Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We are subject to the risk of fraud or other misconduct by our employees and consultants, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee and consultant misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and consultant misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:33pt;margin-top:0pt;text-align:left;"><i><b>We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#x2019; ability to market our products, obtain collaborators and raise capital.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Patient Protection and Affordable Care Act, or PPACA, made extensive changes to the delivery of health care in the U.S. The PPACA included numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which have taken effect over the past several years. For example, the PPACA expanded health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA also imposed substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also required reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We expect that the current presidential administration and U.S. Congress may continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the PPACA or undertake other reforms that impact the pharmaceutical industry. For instance, the Trump administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#x2019;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-staffed FDA could result in delays in the FDA&#x2019;s responsiveness or in its ability to review submissions or applications within the established Prescription Drug User Fee Act time frames, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. There is still significant uncertainty with respect to the impact that the current presidential administration and the U.S. Congress may have on the PPACA specifically and the healthcare industry generally, and any changes will likely take time to unfold. As such, we cannot predict what effect the PPACA or other healthcare reform initiatives that may be adopted in the future will have on our business.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. For example, legislation has been enacted in certain states and at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Adequate coverage and reimbursement in the U.S. and other markets is critical to the commercial success of RAPIVAB or any other product that we might bring to market. Recently in the U.S. there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the third-party payor&#x2019;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of RAPIVAB or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial condition and results of operations.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:28pt;margin-top:0pt;text-align:left;"><i><b>If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#x201c;USPTO&#x201d;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:25pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:25pt;margin-top:0pt;text-align:left;"><i><b>We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any legal proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#x2019; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">the degree and range of protection any patents will afford against competitors with similar products;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">if and when patents will issue;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">if patents do issue, we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="margin: 0pt; text-align: left; text-indent: 24.05pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</p>
  <p style="margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">obtain licenses or redesign our products or processes to avoid infringement;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">stop using the subject matter claimed in those patents; or</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#xa0;</td>
     <td style="vertical-align:top;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;">&#x25cf;</td>
     <td style="vertical-align:top;">pay damages.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any such proceeding may be substantial whether or not we are successful.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates and any such events would significantly impair the value of such product candidates.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:2pt;margin-top:0pt;text-align:left;"><i><b>We face risks related to our government-funded programs; if BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We have completed work under a contract with BARDA/HHS for the development of RAPIVAB and have entered into contracts with BARDA/HHS and NIAID/HHS for the development of galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease, Yellow Fever and Ebola virus disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination. If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government to unilaterally:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1429px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">terminate or reduce the scope of our contract with or without cause;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1429px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1429px;">interpret relevant regulations (federal acquisition regulation clauses);</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1429px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1429px;">require performance under circumstances which may not be favorable to us;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1429px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1429px;">require an in-process review where the U.S. Government will review the project and its options under the contract;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1429px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1429px;">control the timing and amount of funding, which impacts the development progress of our programs; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1429px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 36px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1429px;">audit and object to our contract-related costs and fees, including allocated indirect costs.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits under the active BARDA/HHS and NIAID/HHS galidesivir contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2015; all subsequent fiscal years are still open and auditable. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:7pt;margin-top:0pt;text-align:left;"><i><b>&#xa0;</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:7pt;margin-top:0pt;text-align:left;"><i><b>We face an inherent risk of liability in the event that the use or misuse of our products results in personal injury or death and our product liability insurance coverage may be insufficient.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">If the use or misuse of peramivir, forodesine or any other regulatory body-approved products we or a partner may sell in the future harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates and, therefore, the amount of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us of our product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1431px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1431px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1431px;">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1431px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1431px;">withdrawal of clinical trial volunteers or patients;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1431px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1431px;">damage to our reputation and the reputation of our products, resulting in lower sales;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1431px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1431px;">regulatory investigations that could require costly recalls or product modifications;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1431px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1431px;">litigation costs; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1431px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 34px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1431px;">the diversion of management&#x2019;s attention from managing our business.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>There are risks related to the potential government use or sale of our antivirals.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Government use or sale, in emergency situations or otherwise, of our antivirals&#x2014;including peramivir for the treatment of influenza or galidesivir as a potential treatment for COVID-19&#x2014;may result in risks to us or our collaborative partners. There can be no assurance that government use of our antivirals (whether as indicated or outside of their current indications) will prove to be generally safe, well-tolerated and effective. Any government sale or use (on an emergency basis or otherwise) of our antivirals in any country may create liabilities for us or our partners.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We have entered into a contract with the CDC for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a five-year period. In addition, we have opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. The trial is being funded by NIAID/HHS. We have ongoing studies with NIAID/HHS and academic collaborators to assess the activity of galidesivir against SARS-CoV-2, the virus that causes COVID-19, in both in vitro and animal models. We are also working with NIAID/HHS to increase manufacturing yield and expand the current supply of the drug. There can be no assurance that we or our manufacturers will be able to fully meet the demand for such antivirals with respect to these or future arrangements. Further, we may not receive a favorable purchase price for future orders of our antivirals by governmental entities. Our competitors may develop products that could compete with or replace any antivirals selected for government sale or use. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">There can be no assurance that the non-U.S. partnerships that we have entered into for peramivir will result in any order for peramivir in those countries or that peramivir will be approved for any use or will achieve market approval in additional countries. There can be no assurance that galidesivir will be approved for use in any countries. In the event that any emergency use or market approval is granted in any country, there can be no assurance that any government order or commercialization of the applicable product or product candidate in such countries will be substantial or will be profitable to us.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:32pt;margin-top:0pt;text-align:left;"><i><b>&#xa0;</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:32pt;margin-top:0pt;text-align:left;"><i><b>If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments, or development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions; or fail to pay the minimum annual payments under any of our in-licenses relating to our products or product candidates, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:10pt;margin-top:0pt;text-align:left;"><i><b>Royalties and milestone payments from Shionogi under our license agreement with Shionogi (the "Shionogi Agreement") are required to be used by Royalty Sub to service its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In March 2011, our wholly-owned subsidiary Royalty Sub issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and Taiwan, (ii) rights to certain payments under a Japanese yen/U.S. dollar Currency Hedge Agreement put into place by us in connection with the issuance of the PhaRMA Notes and (iii) the pledge by us of our equity interest in Royalty Sub. Payments from Shionogi to us on non-governmental sales under the Shionogi Agreement will generally not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds have been and will continue to be required to be dedicated to Royalty Sub&#x2019;s debt service and not available to us for product development or other purposes. Since September 1, 2014, payments from Shionogi have been insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in a continuing event of default with respect to the PhaRMA Notes since that time. As a result of the continuing event of default, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The PhaRMA Notes have a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes, together with accrued and unpaid interest, will be due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date would constitute an additional event of default under the PhaRMA Notes. We do not currently expect that Royalty Sub will be able to repay the PhaRMA Notes at final maturity. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing event of default with respect to the PhaRMA Notes or at final maturity if Royalty Sub fails to pay the PhaRMA Notes in full at final maturity. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing event of default on the PhaRMA Notes, or a failure by Royalty Sub to repay the PhaRMA Notes at final maturity, to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result the continuing event of default under the PhaRMA Notes or a failure by Royalty Sub to repay the PhaRMA Notes at maturity.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:3pt;margin-top:0pt;text-align:left;"><i><b>Because a continuing event of default exists under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub. In addition, we do not currently expect that Royalty Sub will be able to repay the PhaRMA Notes at final maturity on December 1, 2020. As a result, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and a continuing event of default exists under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected. In addition, the PhaRMA Notes have a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes, together with accrued and unpaid interest, will be due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date would constitute an additional event of default under the PhaRMA Notes. We do not currently expect that Royalty Sub will be able to repay the PhaRMA Notes at final maturity. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing event of default with respect to the PhaRMA Notes or at final maturity if Royalty Sub fails to pay the PhaRMA Notes in full at final maturity. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing event of default on the PhaRMA Notes, or a failure by Royalty Sub to repay the PhaRMA Notes at final maturity, to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result the continuing event of default under the PhaRMA Notes or a failure by Royalty Sub to repay the PhaRMA Notes at maturity.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:14pt;margin-top:0pt;text-align:left;"><i><b>Our Second Amended and Restated Senior Credit Facility contains restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay the outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:43pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Second Amended and Restated Senior Credit Facility contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1432px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">convey, sell, lease, license, transfer or otherwise dispose of certain parts of our business or property;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1432px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1432px;">change the nature of our business;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1432px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1432px;">liquidate or dissolve;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1432px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1432px;">enter into certain change in control or acquisition transactions;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1432px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1432px;">incur or assume certain debt, including accessing additional tranches of debt under the Second Amended and Restated Senior Credit Facility;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1432px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 33px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1432px;">grant certain types of liens on our assets;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 1434px;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">modify, liquidate or transfer assets in certain collateral accounts;</p> </td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1434px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1434px;">pay dividends or make certain distributions to our stockholders;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1434px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1434px;">make certain investments;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1434px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1434px;">enter into material transactions with affiliates; and</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#xa0;</td>
     <td style="vertical-align: top; width: 1434px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width: 31px; vertical-align: top;">&#x25cf;</td>
     <td style="vertical-align: top; width: 1434px;">modify existing debt or collaboration arrangements.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The restrictive covenants contained in the Second Amended and Restated Senior Credit Facility could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&#x2019;s permission or without repaying all Second Amended and Restated Senior Credit Facility obligations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">A breach of any of these covenants could result in an event of default under the Second Amended and Restated Senior Credit Facility. An event of default will also occur if, among other things, a material adverse change in our business, operations or condition occurs, which could potentially include negative results in clinical trials, or a material impairment of the prospect of our repayment of any portion of the amounts we owe under the Second Amended and Restated Senior Credit Facility occurs. In the case of a continuing event of default under the agreement, the lender could elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we granted to the lender a security interest under the Second Amended and Restated Senior Credit Facility, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Second Amended and Restated Senior Credit Facility are secured by substantially all of our assets and those of our subsidiaries, excluding certain specified assets but including proceeds from those assets.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:12pt;margin-top:0pt;text-align:left;"><i><b>Our actual or perceived failure to comply with European governmental regulations and other legal obligations related to privacy, data protection and information security could harm our business.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">EU member states, Switzerland and other countries have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the General Data Protection Regulation (&#x201c;GDPR&#x201d;) imposes strict requirements on controllers and processors of personal data, including special protections for &#x201c;special category data,&#x201d; which includes health, biometric and genetic information of data subjects located in the EU. Further, GDPR provides a broad right for EU member states to create supplemental national laws, for example relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase and harm our business and financial condition. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the EU to the United States or other regions that have not been deemed to offer &#x201c;adequate&#x201d; privacy protections.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU member states, which may deviate slightly from the GDPR, may result in significant fines of up to 4% of global revenues, or &#x20ac;20.0 million, whichever is greater, and in addition to such fines, our failure to comply with the requirements of GDPR may subject us to litigation and/or adverse publicity, which could have material adverse effect on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the new data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the EU, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We are subject to the supervision of local data protection authorities in those jurisdictions where we undertake clinical trials. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation that will be directly implemented in the laws of each European member state. While this e-Privacy Regulation was originally intended to be adopted on May 25, 2018, it is still going through the European legislative process and the timing of its adoption remains unclear.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:15pt;margin-top:0pt;text-align:left;"><i><b>&#xa0;</b></i></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:15pt;margin-top:0pt;text-align:left;"><i><b>The United Kingdom&#x2019;s decision to withdraw from the EU could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The United Kingdom&#x2019;s exit from the EU, or Brexit, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the EU, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. For instance, preparations for Brexit have resulted in the decision to move the EMA from the United Kingdom to the Netherlands. This transition may cause disruption or delays in granting clinical trial authorization or opinions for marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the EU and/or the United Kingdom. It is possible that there will be increased regulatory complexities, which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the EU and restrict our ability to generate revenues and achieve and sustain profitability.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the EU would have and how such withdrawal would affect us, and the full extent to which our business could be adversely affected.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:10pt;margin-top:0pt;text-align:left;"><i><b>Natural disasters, epidemic or pandemic disease outbreaks, trade wars, political unrest or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">A wide variety of events beyond our control, including natural disasters, epidemic or pandemic disease outbreaks (such as the recent COVID-19 outbreak), trade wars, political unrest or other events could disrupt our business or operations or those of our development partners (such as Torii), manufacturers, regulatory authorities, or other third parties with whom we conduct business. These events may cause businesses and government agencies to be shut down, supply chains to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. If our operations or those of third parties with whom we have business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be impaired or halted, which could have a material adverse impact on our business. See &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the recent COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, CROs, and others, as well as on the regulatory and government agencies with whom we work.&#x201d;</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We are subject to legal proceedings, which could result in losses or unexpected expenditure of time and resources.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">From time to time, we may be involved in disputes, called upon to initiate legal proceedings or to defend ourselves in such legal proceedings relating to our business. Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceedings. An unfavorable outcome in any such proceedings could have an adverse impact on our business, financial condition and results of operations. If our stock price is volatile, we may become involved in securities class action lawsuits in the future. Any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of management&#x2019;s attention and resources that are needed to successfully run our business.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Insurance coverage is increasingly more costly and difficult to obtain or maintain.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">While we currently have insurance for our business, property, directors and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>If our facility incurs damage or power is lost for a significant length of time, our business will suffer.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">We store clinical and stability samples at our facility that could be damaged if our facility incurs physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant delays in our drug development process.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;">In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any system failure could harm our business and operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>A significant disruption in our information technology systems or a cyber-security breach could adversely affect our business.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We are increasingly dependent on information technology systems to operate our business. In addition, the FDA and comparable foreign regulatory authorities regulate, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs damage, or if our vendor data systems fail, suffer damage or are destroyed.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction or interruption of critical information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:8pt;margin-top:0pt;text-align:left;"><i><b>If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates and commercialization of our products and the related expansion of our business will be delayed or stopped.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. This risk has been heightened in the current environment as a result of the ongoing COVID-19 pandemic. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm our business because we rely upon these personnel for many critical functions of our business.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><i><b>If because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result, and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Risks relating to investing in our common stock</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:11pt;margin-top:0pt;text-align:left;"><i><b>Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Several of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own more than 50% of BioCryst and can individually, and as a group, influence our operations based upon their concentrated ownership. These stockholders, if they act together, may be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:24pt;margin-top:0pt;text-align:left;"><i><b>Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended June 30, 2020, the 52-week range of the market price of our stock was from $1.38 to $6.29 per share. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">announcements of technological innovations or new products by us or our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">developments or disputes concerning patents or proprietary rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">additional dilution through sales of our common stock or other derivative securities;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">status of new or existing licensing or collaborative agreements and government contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">announcements relating to the status of our programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">developments and announcements regarding new and virulent strains of influenza;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">we or our partners achieving or failing to achieve development milestones;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">publicity regarding certain public health concerns for which we are or may be developing treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">regulatory developments in both the United States and foreign countries;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">public concern as to the safety of pharmaceutical products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">actual or anticipated fluctuations in our operating results;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">changes in financial estimates or recommendations by securities analysts;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">changes in the structure of healthcare payment systems, including developments in price control legislation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">additions or departures of key personnel or members of our board of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">economic and other external factors or other disasters or crises; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">period-to-period fluctuations in our financial results.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">Future sales of our common stock by current stockholders into the public market could cause the market price of our stock to fall. As of July 31, 2020, there were 176,565,622 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">As of July 31, 2020, there were 18,840,363 stock options outstanding and 10,964,401 shares available for issuance under our Amended and Restated Stock Incentive Plan, 2,975,668 stock options outstanding and 1,424,332 shares available for issuance under our Inducement Equity Incentive Plan and 2,872,764 shares available for issuance under our Amended and Restated Employee Stock Purchase Plan. In addition, we could also make equity grants outside of our Amended and Restated Stock Incentive Plan or Amended and Restated Inducement Equity Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#x2019; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">In March 2017, we entered into a Registration Rights Agreement with entities affiliated with Baker Bros. Advisors LP (the &#x201c;Baker Entities&#x201d;) to provide that, if requested, we will register the shares of our common stock beneficially owned by the Baker Entities for resale under the Securities Act. Our registration obligations pursuant to the Registration Rights Agreement cover all shares then held or thereafter acquired by the Baker Entities, for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. On May 10, 2017, we filed a registration statement on Form S-3 with respect to 11,710,951 shares of common stock held by the Baker Entities. Subsequently, on November 21, 2019, certain of the Baker Entities acquired pre-funded warrants to purchase 11,764,706 shares of our common stock at a price of $1.69 per warrant. In addition, on June 1, 2020, we issued pre-funded warrants to purchase 3,511,111 shares of our common stock at a price of $4.49 per warrant, including pre-funded warrants acquired by certain of the Baker Entities to purchase 3,252,375 shares of our common stock. Each warrant has an exercise price of $0.01 per share. If the Baker Entities, by exercising their underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares, this could adversely affect the market price of our common stock.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Our board of directors has the authority to issue up to 5,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;">In addition, our certificate of incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our certificate also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our by-laws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25pt;">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:12pt;margin-top:0pt;text-align:justify;"><i><b>Our Amended and Restated Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain litigation that may be initiated by our stockholders, which may limit a stockholder&#x2019;s ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.</b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.3pt;">Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated Bylaws or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</p>  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">This exclusive forum provision may limit a stockholder&#x2019;s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely affect our business and financial condition.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><a id="p2i6" title="p2i6" href="#"></a>Item 6.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Exhibits</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:99.6%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:8.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>Number</b></p> </td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.8%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:4.1%;">&#xa0;</td>
     <td colspan="5" style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:8pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>Description</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.8%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:4.1%;">&#xa0;</td>
     <td colspan="5" style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed December</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">22, 2006.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.8%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:4.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:47.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:2.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.3%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p> </td>
     <td colspan="9" style="vertical-align:bottom;width:88.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">Company&#x2019;s Form 8-K filed July 24, 2007.</span></a></p> </td>
     <td colspan="3" style="vertical-align:bottom;width:3.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="4" style="vertical-align:bottom;width:27%;">&#xa0;</td>
     <td colspan="8" style="vertical-align:bottom;width:64.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p> </td>
     <td colspan="10" style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">3.1 to the Company&#x2019;s Form 8-K filed November 4, 2008.</span></a></p> </td>
     <td colspan="2" style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="3" style="vertical-align:bottom;width:26.4%;">&#xa0;</td>
     <td colspan="9" style="vertical-align:bottom;width:65.3%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.4</span></a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">Company&#x2019;s Form 8-K filed May 7, 2014.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="3" style="vertical-align:bottom;width:26.4%;">&#xa0;</td>
     <td colspan="9" style="vertical-align:bottom;width:65.3%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.5</span></a></p> </td>
     <td colspan="10" style="vertical-align:bottom;width:90.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">3.2 to the Company&#x2019;s Form 8-K filed May 7, 2014.</span></a></p> </td>
     <td colspan="2" style="vertical-align:bottom;width:0.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="5" style="vertical-align:bottom;width:32.8%;">&#xa0;</td>
     <td colspan="7" style="vertical-align:bottom;width:58.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm" style="-sec-extract:exhibit;">3.6</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm" style="-sec-extract:exhibit;">Certificate of Elimination of the Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed May 13, 2020.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.7</span></a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Third Restated Certificate of Incorporation</span><span style="text-decoration: underline; ">. Incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Form 8-K filed May 13, 2020.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.8</span></a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Form 8-K&#xa0;</span><span style="text-decoration: underline; ">filed November 4, 2008.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="2" style="vertical-align:bottom;width:15.7%;">&#xa0;</td>
     <td colspan="9" style="vertical-align:bottom;width:75.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.3%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.9</span></a></p> </td>
     <td colspan="8" style="vertical-align:bottom;width:88%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Amended and Restated By-Laws of BioCryst Pharmaceuticals, Inc., dated January 21, 2018. Incorporated by reference to</span><span style="text-decoration: underline; ">&#xa0;</span><span style="text-decoration: underline; ">Exhibit 3.1 to the Company&#x2019;s Form 8-K filed January 22, 2018.</span></a></p> </td>
     <td colspan="4" style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="8" style="vertical-align:bottom;width:88%;">&#xa0;</td>
     <td colspan="4" style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036120012787/nt10011234x7_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.1</span></a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036120012787/nt10011234x7_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Warrant to Purchase Common Stock, dated June 1, 2020. Incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Form 8-K filed June 1, 2020.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_101.htm" style="-sec-extract:exhibit;">10.1</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_101.htm" style="-sec-extract:exhibit;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of March 19, 2020). Incorporated by reference to Exhibit 10.1 to the Company's Form 8-K filed May 13, 2020.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_102.htm" style="-sec-extract:exhibit;">10.2</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_102.htm" style="-sec-extract:exhibit;">BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of March 19, 2020). Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 8-K filed May 13, 2020.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196806.htm" style="-sec-extract:exhibit;">(10.3)*</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196806.htm" style="-sec-extract:exhibit;">Amendment #12 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness Response, dated April 17, 2020.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196626.htm" style="-sec-extract:exhibit;">(31.1)</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196626.htm" style="-sec-extract:exhibit;">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196627.htm" style="-sec-extract:exhibit;">(31.2)</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196627.htm" style="-sec-extract:exhibit;">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196628.htm" style="-sec-extract:exhibit;">(32.1)</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196628.htm" style="-sec-extract:exhibit;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196629.htm" style="-sec-extract:exhibit;">(32.2)</a></p> </td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="ex_196629.htm" style="-sec-extract:exhibit;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; padding: 0px;">(101)</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three and six months ended June 30, 2020, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:8.2%;">&#xa0;</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; padding: 0px; text-align: left;">(104)</td>
     <td colspan="12" style="vertical-align:bottom;width:91.8%;">Cover Page Interactive Data File &#x2013; The cover page from this Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 is formatted in Inline XBRL (contained in Exhibit 101).</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:45pt;vertical-align:top;">( )&#xa0;</td>
     <td style="vertical-align:top;">Filed or furnished herewith.</td>
    </tr>

    <tr>
     <td style="width:45pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">*</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><a id="signatures" title="signatures" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 7th&#xa0;day of August, 2020.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;">BIOCRYST PHARMACEUTICALS, INC.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="text-decoration: underline; ">/s/ Jon P. Stonehouse&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;">Jon P. Stonehouse</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><i>President and Chief Executive Officer</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><i>(Principal Executive Officer)</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="text-decoration: underline; ">/s/ Anthony Doyle&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; &#xa0;&#xa0; </span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;">Anthony Doyle</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Senior Vice President, Chief Financial Officer</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><i>(Principal Financial Officer)</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="text-decoration: underline; ">/s/ Michael L. Jones&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;">Michael L. Jones</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Executive Director, Finance and Principal Accounting Officer</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.1%;margin-right:0pt;margin-top:0pt;text-align:left;"><i>(Principal Accounting Officer)</i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>ex_196806.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<html><head>
	<title>ex_196806.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.3</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><img alt="" src="exh103_1.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div style="text-align: center;"><img alt="" src="exh103_2.jpg"></div>
</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex_196626.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_196626.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b>Exhibit 31.1</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTIFICATIONS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">I, Jon P. Stonehouse, certify that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 1422px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1422px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">2.</td>
			<td style="vertical-align: top; width: 1422px;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1422px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">3.</td>
			<td style="vertical-align: top; width: 1422px;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1422px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">4.</td>
			<td style="vertical-align: top; width: 1422px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:9.45pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and</p>

			<p style="font-family:'Times New Roman', Times, serif;margin-right:9.45pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 1395px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1395px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">b.</td>
			<td style="vertical-align: top; width: 1395px;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1395px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">c.</td>
			<td style="vertical-align: top; width: 1395px;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1395px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">d.</td>
			<td style="vertical-align: top; width: 1395px;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 24px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 1426px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 1395px;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1395px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 89px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">b.</td>
			<td style="vertical-align: top; width: 1395px;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin-left: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: August 7, 2020</p>
			</td>
			<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 29.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Jon P. Stonehouse</p>
			</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 29.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Jon P. Stonehouse</p>
			</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 29.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">President and Chief Executive Officer</p>
			</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 29.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex_196627.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_196627.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b>Exhibit 31.2</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTIFICATIONS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">I, Anthony Doyle, certify that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 1422px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1422px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">2.</td>
			<td style="vertical-align: top; width: 1422px;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1422px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">3.</td>
			<td style="vertical-align: top; width: 1422px;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1422px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 28px; vertical-align: top;">4.</td>
			<td style="vertical-align: top; width: 1422px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:9.45pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and</p>

			<p style="font-family:'Times New Roman', Times, serif;margin-right:9.45pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 1396px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1396px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">b.</td>
			<td style="vertical-align: top; width: 1396px;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1396px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">c.</td>
			<td style="vertical-align: top; width: 1396px;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1396px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">d.</td>
			<td style="vertical-align: top; width: 1396px;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width: 21px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 1429px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 1396px;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1396px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 88px;">&nbsp;</td>
			<td style="width: 29px; vertical-align: top;">b.</td>
			<td style="vertical-align: top; width: 1396px;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin-left: 0pt; width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: August 7, 2020</p>
			</td>
			<td colspan="2" style="vertical-align: bottom; width: 47.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Anthony Doyle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; border-bottom: 1px none rgb(0, 0, 0); width: 29%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Anthony Doyle</p>
			</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: bottom; width: 47.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Senior Vice President, Chief Financial Officer</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 29%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 29%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 18.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex_196628.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_196628.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b>Exhibit 32.1</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:16.2pt;margin-top:0pt;text-align:left;">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u>/s/ Jon P. Stonehouse&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Jon P. Stonehouse</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">President and Chief Executive Officer</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Date: August 7, 2020</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex_196629.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_196629.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b>Exhibit 32.2</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:16.2pt;margin-top:0pt;text-align:left;">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Anthony Doyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">2.</td>
			<td style="vertical-align:top;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u>/s/ Anthony Doyle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Anthony Doyle</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Senior Vice President, Chief Financial Officer</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Date: August 7, 2020</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bcrx-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:15PM UTC 2020-08-07--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bcrx="http://www.biocryst.com/20200630" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20200630">  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20200630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss-unaudited" roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies" roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation" roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization" roleURI="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Royalty Monetization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility" roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Senior Credit Facility</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity" roleURI="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-lease-obligations-and-other-contingencies" roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Lease Obligations and Other Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-tables" roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 2 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-tables" roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 5 - Senior Credit Facility (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-lease-obligations-and-other-contingencies-tables" roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 7 - Lease Obligations and Other Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-summary-of-receivables-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-summary-of-revenues-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-stock-plan-activities-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 2 - Stock-based Compensation - Stock Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-royalty-monetization-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-lease-obligations-and-other-contingencies-details-textual" roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 7 - Lease Obligations and Other Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" name="AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AccruedLiabilitiesCurrentMember" name="AccruedLiabilitiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" name="AdvanceNoticePeriodForTerminationOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_ArbitrationProceedingsOfSulAgreementMember" name="ArbitrationProceedingsOfSulAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" name="AvailableForSaleDebtSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AverageMaturityForPortfolioInvestments" name="AverageMaturityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" name="AverageMaturityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" name="ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractValue" name="CollaborativeAgreementContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" name="CollaborativeAndOtherResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ContractTerm" name="ContractTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentMinimumLibor" name="DebtInstrumentMinimumLibor" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2019Member" name="December2019Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanAndInducementPlanMember" name="IncentivePlanAndInducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_InducementPlanMember" name="InducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestReserve" name="InterestReserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" name="LesseeLeaseLiabilityMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_LineOfCreditRestrictedCashRequired" name="LineOfCreditRestrictedCashRequired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumCustomaryReductionOnRoyaltyRate" name="MaximumCustomaryReductionOnRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_MidCapFinancialServicesLLCMember" name="MidCapFinancialServicesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentReceived" name="MilestonePaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaInternationalHoldingsLimitedMember" name="MundipharmaInternationalHoldingsLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" name="PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" name="PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" name="RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" name="RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" name="RoyaltyRateIfMaintainsSakigakeDesignation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RoyaltyRateOtherwise" name="RoyaltyRateOtherwise" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SecuredCreditFacilityFirstTrancheMember" name="SecuredCreditFacilityFirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SecuredCreditFacilitySecondTrancheMember" name="SecuredCreditFacilitySecondTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SecuredCreditFacilityThirdTrancheMember" name="SecuredCreditFacilityThirdTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeniorCreditFacilityMember" name="SeniorCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeqirusUKLimitedMember" name="SeqirusUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ToriiPharmaceuticalCoMember" name="ToriiPharmaceuticalCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_WarrantsIssuedInPublicOfferingMember" name="WarrantsIssuedInPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" name="statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" name="statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-tables" name="statement-statement-note-1-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" name="statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-tables" name="statement-statement-note-2-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" name="statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" name="statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-senior-credit-facility-tables" name="statement-statement-note-5-senior-credit-facility-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" name="statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" name="statement-statement-note-7-lease-obligations-and-other-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>bcrx-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:15PM UTC 2020-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bcrx-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:15PM UTC 2020-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-document-and-entity-information" xlink:href="bcrx-20200630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20200630.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20200630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20200630.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity" xlink:href="bcrx-20200630.xsd#statement-note-6-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20200630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AverageMaturityForPortfolioInvestments" xlink:label="bcrx_AverageMaturityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyRateOtherwise" xlink:label="bcrx_RoyaltyRateOtherwise" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateOtherwise" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentReceived" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InterestReserve" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LineOfCreditRestrictedCashRequired" xlink:label="bcrx_LineOfCreditRestrictedCashRequired" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LineOfCreditRestrictedCashRequired" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-6-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bcrx-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:15PM UTC 2020-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentMinimumLibor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum LIBOR</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum LIBOR interest that will be added to the basis spread.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentMinimumLibor" xlink:to="bcrx_DebtInstrumentMinimumLibor-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Senior Credit Facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:to="bcrx_statement-statement-note-5-senior-credit-facility-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Lease Obligations and Other Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:to="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Stock-based Compensation - Stock Plan Activities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:to="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:to="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:label="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:to="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbitration Proceedings of SUL Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the arbitration proceedings of several terms under SUL Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</link:label>
    <link:label xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, Restricted stock unit awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, Restricted stock unit awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LinesOfCreditCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LinesOfCreditCurrent</link:label>
    <link:label xlink:label="us-gaap_LinesOfCreditCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentReceived</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of milestone payment received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentReceived" xlink:to="bcrx_MilestonePaymentReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards available, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards available, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards, available, Plan amendment (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seqirus UK Limited [Member]</link:label>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Seqirus UK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeqirusUKLimitedMember" xlink:to="bcrx_SeqirusUKLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Credit Facility, Third Tranche [Member]</link:label>
    <link:label xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the third tranche of a secured credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Credit Facility, Second Tranche [Member]</link:label>
    <link:label xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the second tranche of a secured credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Credit Facility, First Tranche [Member]</link:label>
    <link:label xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the first tranche of a secured credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</link:label>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases of Lessor Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LegalFees</link:label>
    <link:label xlink:label="us-gaap_LegalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Royalty and Milestone Revenue Recognized</link:label>
    <link:label xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue recognition royalty and milestone revenue recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities (Month)</link:label>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment (Month)</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma International Holdings Limited [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma International Holdings Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AverageMaturityForPortfolioInvestments" xlink:label="bcrx_AverageMaturityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AverageMaturityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments (Month)</link:label>
    <link:label xlink:label="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityForPortfolioInvestments" xlink:to="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossRelatedToLitigationSettlement</link:label>
    <link:label xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ServiceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Member]</link:label>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primary financial statement caption encompassing current accrued liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedLiabilitiesCurrentMember" xlink:to="bcrx_AccruedLiabilitiesCurrentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_InterestReserve</link:label>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestReserve" xlink:to="bcrx_InterestReserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance Notice Period for Termination of Agreement (Day)</link:label>
    <link:label xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents advance notice period for termination of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryRawMaterialsNetOfReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryWorkInProcessNetOfReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement (Year)</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement (Year)</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan and Inducement Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the incentive and inducement plans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanAndInducementPlanMember" xlink:to="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2019Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 [Member]</link:label>
    <link:label xlink:label="bcrx_December2019Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2019.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2019Member" xlink:to="bcrx_December2019Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2020</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of potential milestone payments if regulatory approval is granted before December 31, 2020.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumCustomaryReductionOnRoyaltyRate</link:label>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Customary Reduction on Royalty Rate</link:label>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of customary reductions allowed on royalty rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyRateOtherwise" xlink:label="bcrx_RoyaltyRateOtherwise" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyRateOtherwise-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyRateOtherwise</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateOtherwise-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Rate, Otherwise</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateOtherwise-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of net sales that the company will receive otherwise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyRateOtherwise" xlink:to="bcrx_RoyaltyRateOtherwise-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Rate if Maintains Sakigake Designation</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiabilityCurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</link:label>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Payments Receivable, Expiration Term From First Commercial (Year)</link:label>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expiration term of the royalty payments from first commercial date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseRightOfUseAsset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum (Month)</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities (Year)</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value: shares authorized - 450,000; shares issued and outstanding &#8211; 176,429 in 2020 and 154,082 in 2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; shares authorized - 5,000; no shares issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of undiscounted cash flows of both operating and finance lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liabilities recognized in statement of financial position.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromCollaborators-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromCollaborators</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromCollaborators-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ContractTerm</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Term (Year)</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the contract date and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContractTerm" xlink:to="bcrx_ContractTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from collaborations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant</link:label>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)</link:label>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit amount of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:to="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Public Offering [Member]</link:label>
    <link:label xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants issued in public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingStandardsUpdate201602Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfAdoptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MidCap Financial Services, LLC [Member]</link:label>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MidCap Financial Services, LLC entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MidCapFinancialServicesLLCMember" xlink:to="bcrx_MidCapFinancialServicesLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestAndOtherIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeniorCreditFacilityMember" xlink:to="bcrx_SeniorCreditFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label xlink:label="bcrx_InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Inducement Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InducementPlanMember" xlink:to="bcrx_InducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of pre-funded warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</link:label>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RevenueRemainingPerformanceObligation</link:label>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior credit facility</link:label>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Line of Credit, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeMember" xlink:to="us-gaap_OtherIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfSecuredDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CollateralAlreadyPostedAggregateFairValue</link:label>
    <link:label xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]</link:label>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to accrued liabilities, current and other noncurrent liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents potential milestone payments receivable based on possibility of future event payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivable" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and Other Research and Development [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LineOfCreditRestrictedCashRequired" xlink:label="bcrx_LineOfCreditRestrictedCashRequired" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LineOfCreditRestrictedCashRequired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LineOfCreditRestrictedCashRequired</link:label>
    <link:label xlink:label="bcrx_LineOfCreditRestrictedCashRequired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit, Restricted Cash Required</link:label>
    <link:label xlink:label="bcrx_LineOfCreditRestrictedCashRequired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of restricted cash required to be held under the terms of a line of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LineOfCreditRestrictedCashRequired" xlink:to="bcrx_LineOfCreditRestrictedCashRequired-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ToriiPharmaceuticalCoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Torii Pharmaceutical Co. [Member]</link:label>
    <link:label xlink:label="bcrx_ToriiPharmaceuticalCoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Torii Pharmaceutical Co., Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ToriiPharmaceuticalCoMember" xlink:to="bcrx_ToriiPharmaceuticalCoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate (in JPY per USD)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bcrx-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:15PM UTC 2020-08-07--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-document-and-entity-information" xlink:href="bcrx-20200630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20200630.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20200630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization" xlink:href="bcrx-20200630.xsd#statement-note-4-royalty-monetization" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity" xlink:href="bcrx-20200630.xsd#statement-note-6-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20200630.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AverageMaturityForPortfolioInvestments" xlink:label="bcrx_AverageMaturityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized" xlink:label="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CollateralAlreadyPostedAggregateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AdvanceNoticePeriodForTerminationOfAgreement" xlink:label="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyRateOtherwise" xlink:label="bcrx_RoyaltyRateOtherwise-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollaborators-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateOtherwise-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentReceived-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AdvanceNoticePeriodForTerminationOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-4-royalty-monetization-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InterestReserve-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LineOfCreditRestrictedCashRequired" xlink:label="bcrx_LineOfCreditRestrictedCashRequired-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LineOfCreditRestrictedCashRequired-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-6-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:href="bcrx-20200630.xsd#statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:label="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20200630.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncome" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:href="bcrx-20200630.xsd#statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:href="bcrx-20200630.xsd#statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:label="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:href="bcrx-20200630.xsd#statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20200630.xsd#bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:label="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exh103_1.jpg
<TEXT>
begin 644 exh103_1.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 2# WT# 2(  A$! Q$!_\0
M'  !  (# 0$!              4& 00' P((_\0 9Q   0,# P(# P<&!0X*
M!P(/ 0(#!  %$082(1,Q(D%1!Q1A%18R<931TB-6@9&3TS-"4E65)#4V1E1B
M<H.$A9*AL<(7-$53<W2"L\'#)29#1'6RM#=DHJ/4X_ (8V4GI.'Q1\3B_\0
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M 4E0&,*\.TD\#/G6LO7FM&-/V*0[I3=.>>4U-;27<H#>$N**0V=B2LG!!7P
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M7N2"-OJ<X&1ZT%MI7-K1[4K5'T99;I?Y[4J5<>N6Q:X3Z@XEIQ25*2V05@)
M&2KC.<<5N#77OVMM(P;*N-)LE\@R)?7*%!9V %.WD8[G((S]5!?:55]8Z[L.
MD7F&;S(?#[K:G@U'CK>4EI/TG%! .U(]36G=_:;I:U&('YSKJYD(7".F/&==
M+K![* 2D_$X/8 DT%TI5-G^TK2\.VV><J>X^S=DER&F-'<=<<0GZ2MB4E0"?
M/(XK'LEU7)UGI!-WF)CI6N4^TCW=)2@H0LI2<$DY( H+G2E*!2E*!2E*!2E*
M!2E*!2E*!2E*!2E*!7-=2V#4UGU])U5HV+!N7RA$1%FP93Y9.Y!\#B%X([<$
M'_QXZ54#<=7V"W"[F=<V&!:>E[]OR.AU/H9X_C9XQF@YMJ/0VL[O9=.W*Z36
MKEJ"VSGY3D6-+5"2&G1CI-/H 4"G PH]\D9([YL?LXNT5[1\EV)#8=B7>1=+
M@VB6Z_M+B-H.]PE2U\))/ SDUT:;K+3L$R_?+O%9$6.B6\5JP$-+.$*)[>+R
M'<^E:T/V@Z5F6&7>HUZC+ML1:6Y#OB!:4H@)"DD;ADD8R*"DZFTMK1O5>NI>
MEQ$:3?XD41YRI&U;"V4;2C;M/*@5 *\L@_56U>S'5$FU:W0N(VR]?8$5IA,B
MZ+EN!QM>5=1U8R21D\<#M74M>:WB:<LM]<AK9DW>V0A-5#62/ 58!)]":T]5
M>TRQZ=LBES9\1N]KMIG,0EJ/C5TRI*20/""K@9QGRH(.XZ$O$B9[174(CD7R
MSQX4,ESDN(84A6[C@;B.:L%[TS<)GL9<TTR&OE-5H1" *\(Z@;"3XO3([UL2
M=7/M>R;YW"*T9/R2+C[ON.S<6@O;GOCG%0=S]HTN':+C.2S;5KC:?:O C=5?
M5WK'90QC9Y YS\*#18T%>4S-3.J1'Q/TPS:6#U.>NEI22#QPG)'-8LGL]NK=
MTL)G%IJ+'TB;'(6VYE27CC.T>8P#S5UM>M;-)@K<E7",S(BPFILY&X[8J5H"
MAN5V'?@$YQY5 ZF]J5H9]G]XU'I65%NRK<II*VB5(P5N)2-P("APHD''.*"N
M:>T/JMQ[1=JO<6V1+5I1[K)FQI!6N:4I*4 (VC9W\62<UB-[.+VW[)+1IY3<
M7Y1CWA,YX=7P%L2%+[XY.TCBNDO:QL$>#=)<BYL-,6MP,S5*R.@LXPDC&>=P
MQCOFI&\7BWV:TO7.ZRVHD!I(4MYT[0D'M^DD@8[YH.3ZN]G=\ND'VEM1$1BY
M?Y,)V'N=QE+6S=NXX['%1_M&T#K74EWNZ04RX2I$=^ I5S6RRRVC:5-E@#:I
M9(/B5D8[<UTUCVA:4?T](OC5[BFUQW TZ\=P*%GLDI(W9.>!C)KU@ZZTS/M<
M6XQ+O'=ARI:8#3@"AF0KLV01D*^! H.=ZLT/J>;<O:0Q!AQ'(.IH\=4>0N3M
M4VXTA*=BD8\_$<Y\AZ\?=UT9JRVSM3BP0[9<(^IX#$5YR3)+2H3B&2T21M/4
M1@D@#G/^OHT_66GK>FZ&;=&&?DQ;;4L*SEM:QE"<8Y)'8#->+.N],/:=D7U%
MYB_)4=?2>?42GIKX\!21N"N1QC/-!2K-[.+E:+M*#2V9$0:319&GE*PI;R2<
MY'DD\58K'IFX0_8RWIIX-?*:;0N$0%Y1U"V4CQ>F3WJRZ<U!:M2VT3[%.:FQ
M-Q05MY\*AW2H'D'MP1YU&KUYI=&IAI]5ZB"[E8:]WR?IG^)NQMW?WN<_"@I$
M?0FH8ZO9^Y#5%8DV.RRH3SI7N#;ZV$H00,>(!8R:A-)>S[5K>I8MTOT=AYWY
M)DV^2N;<US \ZL<**, (:4>-B.PS745:^TJG4GR ;Y#%VZG1Z&X_PG\C=C;N
M_O<Y^%:TOVEZ-AW)<"7J&"S+0\N.M#BBG8XGNE1(PGS[G!P<9H*9[)]$:CTW
MJ@/NM*M%B1$4V];D7-<QAUXD86TE0RVD<]R3Y>M2^KK'JACVH,:JTW;X%P9:
MLYMZF),GHJ4LNE7A.TXQX3SW&15BB^T+2DJR/7AF]Q3;67Q&=?5N2&W"0 E0
M(R,Y')XK[MFO=+72U7"Y0;W#<A6__C3I44AD>1((!P?(^?EF@Y"W[)-1V*'I
MV3;MMQFQK<_"EQX]S=@!*W'E/!27$8*D K(*3C( _1L7+V4WVV.6F38XC$DI
MLQMDB''NTB&AEPN*<W!85O<:RL@H4<G [>5ZU'[6],VW0T[4MLF-W1J.XEA+
M#2BA:G5=DD*&4\9.2.P.,UXW?VIVZVLWBY=>#+M$.WM36 PXL/NEPE*004X"
M2< '/UB@U-/: GVC5MMEH:B)M\72YM)#3BB$R"]O(3O)5LQG!)S4QH;2$RW^
MQZ-I2[+2S+,%Z(ZME6X(W[QD'SP%5X6WVF6V8_%EKFVYJRN6<W-Q>]Q3S:@]
MTE>';@MI5E)5WR.V.:M;NI[*U-,1VY1T/B%\HJ"E8"8V<=4GL$Y\R:#E]CT1
MJR5(T; OL2V0K=I1"@B5&D%Q<U0;Z:,)VC8,8*LDYK[T?[/+W:F?9<B6W%!T
M\9YG;7,XZR5;-O'BY(S71M*ZQT_JQ,@Z>NC$XQR.JE&4J3GL2% '!\CV-5FY
M^U&U6+7=XLFHY$6WPH<>.ZR^HJ*W5.9R-H!X&!S\>:"NZ:]G=]M[FCS(1& M
M=YG3I&UW.&W=VS'')Y&14<C0>L(VD&+6W;H#K]GU(W>(A]\VB:V''%E/T?R9
M\2>^?/TYZAJ#V@:5T\N(F\7N+'5+:#[/=>YL]E^$'"3Y*/%?=RUUIFV7>+:Y
MMXC-SY1:Z#'*E.=0D((P#D$COVH.42?9AJ%_4-S;?A,2+5>+FFZ/N+O$AMJ/
MNVJ<;,=LI#BTJ'A7\!GX?>I_9]K!RS:MTW:H=LD6N[W8W=N<[**'$[G$++6S
M;](%/TLXQGS-=!1[6-"K.$ZE@D],NCE7('D..5?WH\7PJRV6^VR^65N[6F8U
M*MSB5*2^C.,#(/Q!&#P:"O\ M@T[/U5[.KI9K2&S-D%DH#B]J?"\A9R?J2:U
M8>D9A]HFK;K)Z:+?=;<Q#9<0O+@*4J"^/+N*\=*>UO3-]L-UN[\UF!$M\DL.
M%Y>3M)(;5V[KVDA(R>*MNFM1VC4]O,VPSV9L9*RVI3>04*'=*DG!2?@10<IL
M&@]5J3HVQ7>-;(UHTO,$M-PCR"IR9LW=-(;VC9G=XLDYKTTU[.;Y;[5H&/);
MB]2S7:5,E[7<@(<4LI*>.3XDUM:B]M5OB0M9BTL-/S]/%L);=60) +B&W%<#
M@)4L#OR:O%FUYIB\M7%RWWN&\BW(ZDM6_:EI.,[B3@%/!\0R/C0:/LNT[/TW
M;KXS<@T%R[Q*FM=->[\FXH%.?0_"J /9_JA4"9:7(<+W5.JD7MF3[SGJLEPJ
M4"C'A(&//DD^G/5=*ZOL.K&WUZ>N;$X,$!T(RE2,]B4J .#Y'&#7G-UMIR#J
M)%AE79AN\+6AM,4A6\E2=R?+MCS["@YUK+V=WV[2=?KAHC%-ZE6QV)N=QE+&
MWJ;N..QQZUX:C]G^IGM?2+IIZ.S:7GYS;YND*Y.-H6R,;@_&((6O (\)"3GG
MSKI-@UWIC4,Z3#LUZB2Y$9)6XA"B/"#@J!( 4D'S&16O9_:-I*]7!N!:;[$E
M375+0VTC=E92DJ)''(P#R..#@T$=[8=)S]566UFT*!FVRX-ST,F0J/U@D*!0
M'4\H5A7"AV(JH*]GVH9&A+K:$P(427J&X)5.6[.=F*CQ@1XU+=)ZCV!C(P.Q
MX(JX6SVE65C2EJNFI;I;H[TX.J0(9<>0H(64DI\.[ P,D@ &LW7VH6"!JS3=
MD3(:>%[:ZS<E"\H2E7#6, YWJX'I@YH*I;=!ZD9L>C+/+9@J:TW?4/H?;6$A
M^(D+VK*<<.>(9'GWSG-+I[.[[(EW9QI$;;)U7%O#>7<?U.V!N)X^E\*NS/M.
MT8\S-=;U!#4W";#LA7BPV"K8,\=RKC'?X5L1O:#I238C>6KW%^3!($53ZLI"
M'3V2H$ I/([@4',KSH'64F+K2QQH=J-KU-=U2O?5R2'(K6Y!)*-OBR$C !X.
M?6MO4_LWOLVV>T%F"F,IR[2X,B"''<;TL;-P4<>$G:<59]0>UW2]OT;<[_;)
MK5T1"<2P6&B4*4ZKZ*?$. 0"<XQA)QFI^[ZH81H21J.TR(;C C>\,NR%*0R1
MZJ(!4!^B@B_:/9;QJ_V47&UHBL1KS.8;!CE_<AM86E13OP,@8/.*KMTT%>9+
MWM+6VB.?E^W18L(ESNMM@H5NXX&XBMIKVF.3?:E;M)6\VO:J(B1*=<<<W*6I
M.XML@)P2$X5E6 0?6K9J776F=,2_=;]=X\*3T@^&EA144$D!0 !SRD]O0F@K
M/M-ANV_V 72%(VA^-:$,N;3D;DI2#@_6*J[6C]5:HCB;<XENA)CZ8>M4(,22
MOWIQYO 6KPC8G&/"<D'UKK+6H;'<)$&"W.C27+C',F,V/&'VAC*AY$<BJA?O
M:I9[7<]*%B3$7I^[>]I=G$J :+"1@)&.25>'&/JH*7J?V>:VN-EA69"D2+<B
MP1X"&DW-<9J/)0@!:G$)'Y8''&>.V:F6M*ZST[<GY^GH%KG.W2SQ(+Z9<G8(
M;[+>S=C:>HWSG P3_MM%Q]H<-<G2"M/N1KE;[[-5$,A*C^3"4DG ]<C&#7I;
MO:%:X^E47G4MRMD5MR4[&0J,M;B5J2H@)2"G<58'( XYH*#JWV:ZFE:DN\N.
MS%N;5]C16I1^4WX3#+C;80O>RV?RK9 )"<Y&?UYUC[-M1.ZC<DZ5BLV^441F
MH]XAW-V.I*6TI21(9.[J\# P1D8SFKO=/:+":O.D$6MV--LU\3,6N:A1/32P
MUO) '<Y!!!Y&/6K''U59))LPCW%EPWA*EP G)]X2E.Y1''D.3G%!">UC3=PU
M/I!JVV[I.24S(SRNHK8"E#@4K_4#Q51UA[/+W=6_:B(B(Q5J+W#W'<[C/12D
M+W<<<@XKHVI]7V#2QBC4%TCP52E%+*7,DKQW. "<#(R>PJHZ*]HTG4<;2K[K
M=LC)O#\YM;9=7O(8W;2UP0KME62,#MF@J7M+]G^MM33KU'042X#ONR[>57-;
M+,=+>TK0I@#"UD@X4K( .>^!5SB:1N:-1>TN>MMD-Z@CQVH?C\641E-D*]/$
M:L%AUWIB_P!T7;K1>(\F8E*EAM.X;T@X)02 %@>J2:U8OM%TS<U7&-8[Q$G7
M"(PX]T4$X6$ YVG&%#(Y*2:#FFE_9#>K)IN?8F'VD0K[9NC/*WMQCSD@[5IX
MY;(.T@>E9M7LKOESM=VCWJ,S DJLQM<:0Y=I$Y:UY!)&X[6V24CP 9'K5\M'
MM-LK>AK#?M4S8MJ<NC/40SE2R2.^T %1 XR<<9J7NNO=+VNVP9\R\QA$G)*X
MSC>7>JD?24 @$X'F<<>=!3=+:<U:_K[3]\U#;K; C6VU.6Y2(TKJJ6KC"_HC
M"3Y)YQCD\UUFJQ>-?:6L]L@7"XWN(U#GIWQ7 2OK)QDJ2$@G SR>P\Z^KSKK
M3%ECVY^YWN&PS<$[XJ]^X.IP#N&,^'!'B/'QH*AI.=%8]OVO8;TAM$J3%@*9
M:4K"G EI140//&1GZZZI5.]EE_3K/1]OU+(@QHTR474GI#. AU;8\1YY"15Q
MH-:YS8MMM\B9/?;CQ64%;CKJMJ4)]2?*N>__ *N'/L9T\1_^W_[]RNDNMH=;
M4VZA*T*&"E0R"/JK#+3;#8;9;0VVGLE"0 /T"@@O:#:I-\T-?K5 "#+F0G6&
M@M6U.Y22!D^7>N7'V=:HU&+;#U"U;K9&M%BD6IA^*^73)<=:#>\IVC:D 9(Y
MY[9!X[C2@X'8_95?9]NFP[Y&9@N-V9=KCRE7:1-4MQ0 W)2H[6VC@>#&1Y58
M46WVE2]-3("&;-97X]J3"BNM/=9QYY) WA6T=-!2" ""02#76Z4' X'LQU)*
MCZR$QE$5=[M#<9HR;FN:X'D'_P!HXH9Y[^'@"I.'HW5MUOCMQOEJLK"/FRJR
MHBN2E/MN+WI.7"D)(2KQ?1)*>.2:[32@_/\ ;/97J>58=1VA;J[-:)MN2Q'M
MSMS5-;3*2XE8<02G+;>$[<<G!YSBKA[+-(W>V:@F7F_V]$208:(317=GY[JT
MA6Y65.*VI1D I2!D9//KU"E!R36N@+S>KKK]^+[N&KS:H\6(5N8RXV22%<<#
MXU9;A:KS>O9'.M$N&Q#O4FV.Q.@'PXA*R@H3X\#OP>W&:NU*#@VJ_9OJ.0BT
MN6FWL-W2/:8T-NYPKHY$>8>;0 >J,%+K8/(V@*QQZ5T77FGKK?/95/L+;S<J
M\/P4,*>6=B771MW*/ID@FKI2@XE-]GFIM627_G$W;[4B+85V>,N*^7>NXK'Y
M4C:-J/#]'OSYUO6O1^JKS?K',U)$MMK:L-L?@L>ZR"\9;CK0;*\;1L0 ,A)R
M<_ZNOTH.*Z(T/J>))]G7RQ!AQV],F:R\IN4'.JAQH!"P,#!*LC'D!GSQ5V]E
M>G9^FK1=HUS#0<DW:5,;Z:]PZ;B\IS\<>572E!Q>)[.KXUI*R6]2(OO,358O
M#N'>.@'5*R#CE6".*U+C[.M4O6>[Z,98MQT_<KL;@;N9!#S31=2X4=+;RYE.
M K.,>E=SI04#1UBO5D]HVKI,B+'79;NXW*9EI?\ &E:4)1L+>/\ ".<^0]>*
MSK#V>7RZL^U!,1$8JU"J 86YW&0RE(7NXX['%=EI0<CU/HS5:[UJ^XZ:D,1)
M-PMD2+#=ZFU6YM7Y1/8[<IR ?4^7>J_']F6I'K1[0&G8S<=W4$*,F,B1<ES'
M XUG(<=4,DGOGL,X\J[Y2@X%?O9_JZX7)VZIM;"WKK;&X,J&+T]';C+1E&5E
MK;UFU(P2GODD?7>=(:+EV+7[MQV,"V(L46V,E"R2%-GD842=N .22:Z)2@X%
M!]GFMH&C=+V-*D.PXS,QN;$CW-<0=1UY:FW%.(&Y: E0R@?&IW0F@;Y9Y_L^
M>GMQTHLEOF19>QW=XG%>#;QR"/U5V"E!RKVM:6U7J.\H;M2^O8GK<Y&5&3<5
MPPW(43AUS8"74;<#9V)'->6C-"WJV7_3LR>U'2U TM\CN[70H]<. \?WN!W^
M-=:I0<.TSH+5FDXVB[C;X=OGW*V09%NEPW9722$N.E:7$.;3VSSQG' J]>QW
M3=RTIHM-MO0CB8)3[RO=U91A;A4,?H/:KO2@4I2@4I2@4I2@4I2@4I2@4I2@
M4I2@4H>*^=Z?6@^JXY[4?9S<M3>T"VO0VP=/W)IMF]D.)3PPLK;."059SMX!
MQCG%=BW)]13-!^=[/[,=6)T6Y*ND5F1J./=8,E,1;Z-LJ+#0&VVRH$I&X%2N
M?/&<5O:DT/JG5EOU[=E6A%JF7=B&S$MKDAM2W2PM*RMQ23M!.W Y^O%=ZR*P
M%I/90H.$:ATOK#4\G6=Q>TX8"KI8FH42.J8RM2G$N9*5$*P#W/IC'.<@>M[T
MEJF#,U8U;]/MW9K4MFCQ$O&4TW[FXVP6U)4%')&?$-O&0/K'<\BF1ZB@Y_,T
M[='/80=.HBYO'R"F%[OU$_PP9"=N[.WOQG./C5+NV@]2/M7L-6[<9.CX]J:_
M+MC=)3])OZ7&/Y1X^-=UK!(H/SVW[+M30=":ETE#:ZT6XL1K@Q+>>;W^])*"
M]'<.<G)1X58*1YFL7+0.I;SI36+QLUR:NUQ9B1F&I]S8>=>#;J%J)*0E"0D
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M-S18LS7NJ[V;C\X/>48#75ZF_9G?U<>'M^G'-;4[V?7Y^T7Q@VI"W9>M1=4
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M3<;+9['$8DWB[K=2P9+A;9:2TG<M:RD$G@C '?/>@T%:?UP2<:W: )_FIO\
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M)_3US_L-6>OA+82M2AG*N]!#(8U"!XI5IS\(SGXZ\G&=4[OR4NRX_OXSI_\
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M17;+@KHZO/ZJK'LU_L,@_P"$[_WBJ!\Z)2O[6+\/^PS^]H-420<?->_D_P"
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MAQ*$J*SM4K:M(40#V4<]LS"-1/3(EK5;8C:Y4]"G$H>=VH0A&-RBH Y&2D#
MYW ]J)U#)DLP6X,-LW"3U0IIYTI0UTE;7,J"23A6 ,#G.>*"/N.GY+=RMD>V
M>_L14MRNM,8=;WI<=4A6Y6\Y.2%'@'R\JWK=877;1 8D/S;<[$0IDIAO[4.>
M6_G=G.,C=R,G/-3-EG&Y6UJ2IHLN$J0XV3G8M*BE2<^>%)(SYUJ:HN\BRV_W
MMB 9B$J 6D.I04@D 'GOR:"(O-LDIOML4S%N\J+'B2&U/QY:$+*W%MD E3B2
M>$*^';]&C:K!=UB%%DK?A1(L=X(5^1>*^HX<)=SG*PV$Y4!@E2^?6QR-0Q(
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M"4'O\.<FMUW4,!$2$^CKO>^Y]W:;947%X&3X<9& #G.,=N]!7G]$2W2_BZL
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MB5*7&R(SB5(VA6X[2G/!21C ['TJ1F7V+$1'WMR5O/I*FV&V%*=*1C<2D#(
MR.3CN!W(H-69IY+2FEV;W2($-+87'7&"F'&U$$@H!3@Y'?XG(.:V-+686.V&
M*E3:E*><?46V^F@%:RK"4Y.$C. ,G@5X/ZKMR#"2TF5(<F)664,QEJ)*#A:3
MQX2#P0K&.W>I:VS6;C!9EQ5$LNIW))24GZB#R#\#0;-*AKS<YD.XP(<&)'D+
MDAPE3T@M!&P ^2%9SGX5H-ZEDS%L1($)KY247NNV\\0AGI*"5'<$DJR5)V\#
M(.3C&*"T4K1LLB;)B*5<X:(DA+BD;&W>HE20>% X!P1S@CBO*]OW!E"# ,-I
ML)4MZ3*R4-I3CC:",YYYR ,>?:@DZ55&[]<9\>S-P6H\69/C+E*,A"G$-H1L
M!P 4DY+B<<CC)/I7LB[729:8TIA$&%X7#+=DJ*VV5-G:H  I)!(5XB1@#.#V
MH++2JLU>[C<6+,U :8B3)\5<M9DH4XAM"-@("04DDEQ..1QDD>5?$[4%Q1IR
M'=&(\9*BZAN4VXI2MI+J6U!&,9Y*L$^@XYH+92@[4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H/E7;ZZI^BH2;C[.D0G#A$A$AE7
MU*6L?^-7!9P,U6O9K_8;!_PG?^]505?3>A+Y9KHY<#/@JE.0)&XI2H@3GEI4
MI>,<H\">_/':I>S6B\,7-R0\R"VJ$J/_ %5-+JBYD$>%* D(//8_H%7BF*"C
MV*Q7&W/)6F,A#;,%R.AAR67P%G9M2VM2=R$>$@\\^'CBMBR6BY0).G08L1+,
M&V+AOE#QX6>EC:-G(_)?#Z7PJX4H*S8V;Q'FWMZ7 B(3->]X;")14<AEML)/
M@'<MDY^/:HJ#INXLPK#!4S'9:C6IZWR'6'N4*6EL!2!M&>6\^7)J]TH*%I]<
MI[5UO:=CVX(MMN?BJ7#<4X$JWL@ Y0 @'8<)R3P?2M^U6RZ,VN79G66FHSGO
M(3-;?.\!Q:E)(1M[C=SR,$<9JW4H*<U:KFXJWE<*'%^3F'&TAIX[726]@0/#
MX6^RCGG*4\'&:6.SW&W2M-I5&C)8@VQR$^6W>RR6B"D;1D?DCZ?2JXTH->X(
M<<@/H92E3JFU!(4< G'&3Y535:=N-ZM,2WW9MB$Q%A+C!3+I=4XXIKI;OH@!
M(!)QR22.V.;UFE!#VYV\N2FD38<1AI(/5<0^5[SCC8-HP//GZL'O4G++J8KQ
MC(0X^$$MI6K:E2L< G!P,^>#7K2@JUEM<Y:9HN\=OWF8R42):'MQ/D$(3M\*
M!E6!GXG))-+5;[PV_#<E,14&WP5Q4!#I(D.*V>+Z/@3^3'J?$?3FTTS05>RV
MNX*7)7>8S1E2V2AZ4A_=CT;;3M\*!D^?Q.22:Q8[9=&I-M$]N.VU;8BHR5-N
M;C(4=@W 8&T81V.3E7PR;3FF:"O:<:N#-SN[DNW>ZLRY D)5UTKY#3;>"!YY
M035AIFE I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MYSZUKRM,664VA$BV15A#*(Z?R8!2VE04E (Y "DI('D14Q2@C8UAM<:.VPQ
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M%;5KVX24C9E(R<G.>V.<[@&U:-1LW9F48\28B1'3O,=U*$K6"5 %)W;2"4*
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MG+6WM^47,QU)<#2@[X\##JDHXSR?3)K3>G-LIF&0SJN.8TMN HN7L!/66$*
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M085VJL^S;^PZ#_AO?]ZJK,KM59]FW]AT'_#>_P"]506>JSID#YR:L_ZZU_\
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MD2HDH1FEM[FFUG:@J)R5'"2H@X[[2*#U^>5L_N>]_P!"S/W58.LK;_<M\/\
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M_HF X@+"5*>QO04G^%5W! (JU&JM[-?[$(7^&]_WJZ"U56-.#.I=5_&:S_\
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MG2]]_5'_ 'M8.I9V.-+7PG_)Q_YM!9:56/G+<?S4O?\ I1_WM?0U).QSI:^
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MW_\ T8G[BOGYL7#/]F&H./\ JO[B@MF13(]*JWS<N/YWW[_1B?N*?-JXJ/\
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M '%!9<CU%,CU%5CYM7/SUC?/TM0_W-9^;5R_.Z^_Z$3]Q06;(IN%5KYN7/\
M.^^_Z$/]Q7RK3=R/]M]]_9P_W%!9\BFX>M5<:9N0_MPOOZ&XG[FBM.7!*2I6
ML+Z$@9)*(>!_^(H+1N'J*;A5 +T(HW#VF/A&-V[KV_&/7^!J61IVXK0%(UE?
M%)4,A240\$?L:"TYID8YJK#3ER"A_P"M]]_T(?[BOHZ=N1_MOOO[.'^XH+/E
M.//]5-R?/CZ^*JQTU<C_ &X7[_0A_N:#35Q'?5]^/_8B?N*"T[AZBF1Y9_55
M8^;EQ_.^^_Z$3]Q0Z;N7GJ^_?Z,3]Q06C-8R*JQTW<<9^>%__5$_<5Z#3ER
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M,^(!2N<=L'TH.<WY[6%RLTN,MBZI>?:VN1C'1L0R6$D*#B4C+O5R" ?Y7A
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M"5MA"D$-#.Y.\\*<.#G&0$UT->IK"VE]3EYMJ0PX&G2J4@=-9SA*N>#X5<?
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M7UR4!M:B@+PE6<' /-!4I5\U5#BSC&1=I3:VY"+>MVWCK*< 9+:G$A VC)?
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M0G9HN,9B&A00'Y#[:$*)*@,>+CZ"C@X.!6^K4EH-\8L[4UAVXNA1Z#;B5*0
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ML5QI^,F+U@'\-]-:V4)Y  ='"< J!P.XLR-6:?<:0ZW>[6II;G22M,MLI4O
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M22YM )3CPH3Y9W$5]6[VCS9OR>TFS1FI-Q:CR(P<G'IAMU#RQU%=/*2 PK@
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MI]71G=5P)=96ZC">F 3X"#SQD8)H)YO23C.E[E:(]R6AR9(<?$CI\HW.;MN
MH$C VY!!QV(-0%N]F"HORBI^[J>7-<CN*4&5#9TY1D$ J<4HY)VY))&,Y-%^
MTZ:B,\I>G=CT>+)FO(<E*; 990THE.YH**CU0 "E(R.^"#27[0+E\M11$ML9
M<)\R([+2I6UQQQ$QB,%+\!Z8!6L\;L@^1&*"5LFA7(-ON,.7<O>(\JUM6EOI
M1^DMMEM+@!)W'<O#IYP!QVJ)NGLUN-Q:F!_4#:5RDJ0YTH:VT;2RAH<)>!)
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M6D\+*N$D-#C&03](CBO?5E[N9CZ7^2C+:-S>(=3%2R7MONZW $];P#E(SGG
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MA(=<<#0()P=H2MW:HX.-BN.,4$ S['6&$+;:NB]A6-H4P/ T,$-C!'&2L_\
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M3:+>VV4M08S>5!>4-)20H# 4"!W ) />HK3FD+18(LN/$82XW+4%/!U*3OP
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M-=6ZD5F>AE2V42Y""I*3@+<2C&3ZD#</JS6JU$L[-P,5F/!;FJ;ZW30VD+*
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MUIH+!00#E2%CA1SRGSR#D"MBZ7R^0D7]]"K.MNWVINXMM""M)6IP/;4%75[
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ME':"3D59]#7:WZ<>?C3+G:7S/>#[LQJ>A0"DQVDDKS@Y*T*Y^.?7'3_=F/\
MF6_]$5]=!K&.DC_1%!PB;'1*U2Y+>U+86X#TDJDH1<TX?:]Z:< P$[OX)"DD
M*61E1"0E)KU:B1/?()7?=/2F6)C+K*W+F 8;3<UQ[:VG&%;FE-IQD8V =@*[
M@8D<]V&O] 4$5@=F6Q]210<<U@&+C>IDV#J&QN(<<;7'0]<DI2T4M[<J1@Y&
M<GPE*AW!%2^L9UOO4Q]V'JFU,)%N7'8_J]*"EY2P2K@D#P@IS@D9/%=-]W9_
MYIO_ $13W9C_ )EO_1%!Q:(B%'<CJ^6;(X$XZ*7;MGY//5W;VMB$@Y3@;0$C
MPXR4DU'6ZRE-O4RK5UN:=#2AU3=FU9?#1"70E+:.Z]I)45*(')KO?09_YIO_
M $160RV!@(2!\!0<(1$)NT2=.UC;3)<*7G5,W-L)C.=5:UA.Y"E%.U2$82I&
M0C"N,8D=.3+;8;+J-V1=[$R\[;6FDF)<@ZIUUMMS<X20"%*4H'S/GWKL9B,'
MNTV?K2*^'(,1QI;;L9A;:TE*T*;!"@>X(QR*#@L$VB7"BJ>U#IR-%,=2TQ#=
MTJ+<@QTH2Z2>RBO<3YY /?-;LI<"1(D@ZLT^.L7 Y,1=P'7FUEO:V0.P0$JP
M<GL/Y2JZY\U-/?S#:?L;?W4^:>G?YAM7V1O[J#G>L5V.Y76VRK/>;"6(\3W=
M3:YH0%MA]ESIY /A4EM:?T]B":^+@($K2MH@F]6%<B)<5S.FNX)*&FE*=VH0
MH\G8EQ(&0.$\8XKK+,**PTAMF,RVVA(2E*4 !('  'I7W[LUCZ"?U4'!56:'
M'M$.'#U)96H[+,4/Q6;@VD/.H9<0XK*T+3RI2%9*>=N>"!4[JB5;IMNMD=G4
M]D<=8MZX?4EW4)4S((;VRDJ \:T[5>23XO+)KKGNK//Y-'/PK4FV.TSRCWZV
M0I)1G:7F$KVY[XR..U!PV/+@7>)<G8^J+-;UNR927"N[(#DU'OR5HW)4"$@-
M-J0G(4"'.VTFO9EBVA@J5J^R"2W[I[LIR[H6I@)DNN/ %*4I&6UI2 $@8&WL
M,UV/YJ:=_F&U?8V_NI\T]._S#:OLC?W4'#Y$BUP[(I2=868W5AH-K>;NI)4T
MF &BVD#DY>!5Q@]E#GBI:PS['?\ 15U@LWBU1HTB]-2&(S\_^"CH=94I.%84
MG/3<(&!R?3FNM?-/3N<_(-J^R-_=6W LUKM_4]PMT.+U,;^BPE&[';.!SW/Z
MZ#D(8BL2VDIU%8.BAX&,Y\IX,%M,QQW\F//<TM#9&1C8!R*UK.VV])M#5\U'
M8784%J,PZ@W7J"2&A(W+4" ,DN-G!S]'D\8KN)C,'NRV?K2*^1$C#M'9_P!
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M#OO4N.ZY&9?\ PXE0"RV@JR"0<93]+"N?IR[7?Y.@I5.CN6]4IU#LD2G6TA
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M35$A:XU)%A:?DS@U<U7-4T%B%%2VM(8"@G&]W!Y3N/GCB@Z1_P"L&/H6O/\
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M\)&46W/P<<Q_LHI6H!]%NU'ZW'/NKC^G_:KJ6=JF#:'HL/#EV<;><#9&V&7
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M%86Q&MD%EE;9:4VW'0E*D$DE) '())..W)KT^5[=YSHH^MY/WT^5[;_.$/\
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M=E+:2?4A('-81:+:VVEMNWQ$H24*2D,I !1] @8_B^7IY5\IO5K6<(N,-1]
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MM:'/B30HPY+#X3P2TXE>/U&MF@4I2@4I2@4I2@4I2@4I2@4I2@5I7*UP+DE
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MJ4-/(:?;:Z"<J!4",GWDA/HD9!/-6:9JV=;]'QKK< Q&DSY&(R%M@);;42I
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MX$6X,]&:PV^SN"NFX,I)';(\Z]]HQ@@$?&OJE!@I![@4VC&,<5FE!\A"1C
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M_P Y/?N*&5K'RM5B_I)[]Q4/;=57:7=YT9^,(WNJT(4RF ZZ HQFW2E4@+V
MA2R.W8#UKVTEJ.[356 7?W!:;S;#<&O=65-%D@-$H5N6K</RHPH8[=N> W_>
M]:9_K18OZ1=_<U]B5K#SM=ASZ?*+W[BHE&J+JBV3+\\+>;,R9@]TVK3)PP7
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M[-,H9CK:5$8B*N#;D=*G7RO*E[L'8D(*B1Y)544][5EH8>EHBQC;Q9TRDO\
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M'@@\$CFMOY&OQ[ZHD'_!ALC_ ,*"RTR/6JU\BW[RU3('UPV?NK'R-?OSI?\
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MCB,E.Y$V.1D$@C(7Y$$?HH-M5KN<-<MNT28K<:2ZI[+S2E+96HY64X.% G)
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MW*0XEQT.(47$D)2DA.#@Y"1W['UJ;':JO\X+Y^:,[[7'_'3YP7S\T)_VN/\
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MH3_M<?\ '6?G!??S3F?;8WXZ =-&1J47.6S;4!IPN-JCQMKSAQA)<<)Y ![
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MR9S]=>D+_P"T*[C_ /=L/_O)%6:@JM@M$R'I!%ADK#:FX0CB2TK(W%)!VCN
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M_P#L$?CH+32JP=5.@9.FK_\ 9T?CKX^=ROS=U#]E3^.@M5*JWSL<\M-:@/\
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MNH!_DJ?QT%II56.KG1VTWJ!7^2I'^_0:LD8_L9U!^P1^.@M-*JR=5/9YTUJ
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MAN?<U3%W)AN.I:60UL2ALMC !.3@Y^ND+1:6)\:0Y/<<;:>:EJ;#83O?;8#
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M]/6']U6']@]^.N=3[&N??8I>MRG+(@S3!3<[6_,;;21&P"V"%(RL/%.[^+G
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M+P4EE2HRG0$GTRYN].0<8-97%F^YL^Z1KD-5%R1[^]L="5HV.?QR-JD$EO8
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M;]A:5A""D83QZ8JOC4VM78C09@*;>6XM)=>MK^S<D)*4I2$[PE14?&M*0-I
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MK_ NJ-6P)K2&Y,9R0TCAI15':2%;N0<<J5G/P'\F@M"[O#1=FK:I;@ENI*D
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MC,4]U,+==*"C*N,8V';@  #&.U! P+U.GS5Q(EP0XB3,5T)7122B.&&W< <
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M@H200T&5=8%6X'"L^0VD9H.DTW"G>J/>IR3<[LS<KW(L_12GW(-E*=Z2V"7
M"#U%;RI.WGZ(X\7(7?>*SN%<_NETD-*NKBKE(8N3(!MT/:$^\#II*?R9&5[E
M$@_R>WA(S7E<[B]'=U#/5>9#?N,M@-1^JGIH"DME0(QE0)*T\DXP<8(H.B;Q
MG'GWQ6"O![53I"[?"U@_)FW9R,J5&CAE)?"4/;5NG:D'Z7TAP/Y7QK2O]QBN
M:S^33JAZ EQH=2.V\A*@[E(0E)4DE.=V<#N0/CD+^E63VK.X5S>\Z@?CW_P3
M"Q[O+88<:>F;5ELJ0%KZ ;(*"E1.\J'8D8QBMZXW!*I]S%RODFUR6'@F*PV
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M0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0?"5$K4#V%?=/.E
MI2E I2E I2E I2E H>:4H%*4H%*4H%*4H%*5&W*[Q+<MM$IU0<<!*&VVU.+4
M!C)"4@G R,G&!D4$E2M:W3HUPA-2H;R7H[@REQ/8\X_VBMG(H%*\')3*)+3"
MG$AUT*4A&>5!.,X^K(_77S+EICED%#J^HX&QTVRO!/F<=A\3Q0;-*P%#%8W_
M  H/JE?&^OE]X--*<(40E)40E)42!Z =Z#UI7A;YC%P@1YD16^/(;2ZVH@C*
M5#(.#R.#7O0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
M4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
M4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4KY4L!6,4'U2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!5>EH>MVI'[BJ-(DQI,5J/
MEA&]32D+<5RGOA74'([;>?*K#3.*"DRH:7IXD72QR'(+D<>[1D(#GN[N]942
ME)PE:@4'?Y8(R//1387GW@N^6UV8^W9TH4M0#@4\"HX[^)P @!6/7!KHFX4R
M*"C.P&G(M@N-ULCLU]N&6']T<..H60CZ0/)&4JYYQGXUM:I2I:;,Y'M$MR0R
M^R\E3322IAO<-Z<YXX&"!WJWY%,B@I=VM#-QU(9<VU.R(XMIQO;"AU-V0-N>
M5@9QQQG@BM>(W-::LLJ9;)TI;MI,26UL"E%W\GPL*('.'/$3CGXU?/JI0<O3
M9;HJ#91=H[JV6K6S'++D02RS(1D+. O@J&W"QGZ/<9YD/DM]+;7RW;I]V!A-
MM1BL)4XVL;MP5A1"%GPGJ9\N5#'/0*^2H T$/HN._$TC9HTME;$AB(TTXVL@
ME*DH"2,C@\BMV?)DL/Q$1X3LE#SNQQ:%I2&$X)WJR<D<8P,GFMW(Q3(H(^;(
ME,28;3$)V0AYS8ZXA:4AA."=QR03S@8'/-9FR9$>3#:9AO26WG"EUU"D@,#!
M.Y0)!(R,<9[UOTX\Z .U*#M6"0!S09I6$D$5F@4I2@4I2@4IQYTR*!2E,B@4
MID4R*!2F13(H%*9%,B@4I2@4IY4H%*9 /-*!2E*!2ODK .*RDY-!FE*4"E*4
M"E,BE I3(ID4"E,BF10*4R*9% I3(K!4!09I3(-./.@4H"#G%*!2E,B@4I2@
M4I0'(R*!2E*!2E*!2E*!2E,B@4ID4R*!2F13(H%*9%,B@4ID5@J -!FE8*@!
MF@4#09K! .,^59) %.XR*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!4+K=Y^/HR_OPUK;DM6^0MI;?TDK#:BDCXYQ4U6G=ERT0'E
M6]<=N0!E*Y"2I QWR 0>V?.@Y:G5+]EL27K ];[I-4L!Z.W=Y%T(1TU$N$JY
M;"2-Q 'B (&#BO2;KJ\,Q%/,R+8\ZJ3TEM!A:!";"U@..J4X$X4$HVY4GZ8(
MR*FDZDNRA;RW>].N)G[O=BU&?6'0E022,*[ J R>.:WH=QO\R?,@QKQIUV7#
M*1(:1'=*F]PRG(ZGF*"FS=>:@?B3&HZ[<B<(R=L9AE:WAOB*=ZX)5C:E0'!3
M\,Y(S8=6:KF632=FF1GXKTJ6T%%YQH*:=(:*N/RB "HXP HDYX!K:7)N<"ZR
MV5W;3K,]QGWU]'NS@4IM(V=0_E>PVXS\*PN]7AM]3*[[II+B8AG;2PZ#[N.[
MA_*?1^-!X^SK6,_4<^4S.1&3M92\A$=L_DP3C:M162%8QP4I\R"H<U$6O7=^
MN4B+'B+M3IE/!I;K<5Q289ZJT;%CJ>)12G(Y3V/!!%33NHY[#,9Y_4.G4MR8
MZI;)3%=5U&4I"E+'Y3L 0:V[*W>50BW;)EM:9:) ;<M4AD9)R<;W 2.3R*"N
M?\(=WC1E3I,:+)BQ^F[.:CL.!V&E3BVRTKQ'*P=BNPX"N,$$0\[6FHDVN4U,
M,:US%E2B2AQ96Y^1'1:)7X5#>H]CZX S5R8U!/?C1'V-0Z;4S+D&(PL1W,./
M#/@!ZO?PGZ_TUXR]338KRFG[]8]Z LKV0'UAL(64+*BE9"0% @DX'%!#QO:!
M?7G92)#-MA-)D):6XZDJ]Q275)R\D.>@'?9R<X(K9CW>^R--:*?A3T^]S);P
M??<94MM: R^H91N!QX4X&[T[U,7.\W*T]#Y1O=J;#^.D46Q]P+)[ %+G<^E>
M$K4TF*$EV_6CQ.%D8MDA7Y0?Q#APX5\.]!6Q[2]1.H<<1;[>T?=$O)8<2HKR
M8Z'.I@+W%&]13]$#CZ61BMF?K6_MW.YVZ6U#*8RNF TE;3RL*;VNA*7"L)45
M'R P1XC@@V4W6\"VN3UWFRB(VYT5K$%XD+W[-NWJ9SN.,8[UL1Y5\=@NS%W6
MUL1F@HK7(MCS.T 9)(6XDXQY]J"/T9JRX7!]KY=,)EF5#9E,EMM36Q3CJVPT
M2I1W$X3C&.3VJ#]J.N[G9ILZV6OI#^IMO\'AY*EMK(<0KJ9(20GD((SQG/:8
M5J-V0P"J^VA9#B EIVT/I65')04H+FXYVD@@$':<'BM^;=+S!@-S)=TM33+B
M@A -LD=1:CV2$;]Q/!X SQ05ZWWB\-:%;EN7%3<H7T,N//IW88]\""DYQA.W
MC/IZ5X6/7>I+K*C1^A;H[DF6VPH=)3BHH4EY2DN)2Y](=-(YVG)/A[5/-ZCE
MNQ524:DT^6$M!]2O<G<A!44 XZF<[DE..^1CO7U&U'(D.M,_.&S-2''O=TLO
MVYYESJ%.X)*%NA0)'(R.?*@A86L=2%$*1*%K<;?;@/+;:BNI4$R5K3C=U#RC
M9G.#G.,#O6W9M:3G]#76[RS%5,B+2V%LLY8W*2CL>KA205G)*D8 \020:WEW
MVX!TMM7JV/K\7ACVN0\1M64*SL<.,*2H?6*]&[Y/<G"%\O6<2"\J. ;<\$EQ
M.<H"B[M*A@\9SP:"JVOV@Z@GI>6B/ +,1;8=*6%'KA<LL^ APA/A&[/C&?@:
MEM(ZFNEUN]R=D.LOJ:MB7OD]AM2#'=ZCGY)>5*RYA(&<#ZNU2UWO%PLZ73/O
MEK1TD!UP(MC[A0@YPI02X2!X3R>.#6U;)5\N<-N5"NEL4ROZ)<MCS9/_ &5.
M _ZJ"HR->75J AQN;:9"O=W7^HB(Z$*>2AI28@\?\*HK7V)(VXVYS1_6^H$%
M#CC$)N-(=DH;6J.O^I$,S6XY<=._Q#8X5G&W&WOC-7@1]3$\W2T ?" Y^]KZ
M,?40/]=+2?\ ('/WU!R$:OU"([KZ)B76DN/GK!+H1*2?E(H2GQ^ $LM!.T[N
M4^(X JQ?/N^ M,LM0?>7GQ&,=;#A7#_JIIE#CIW^(+0X5CZ/8<G!-7I3.I,\
M7.T$?]2<_>UYNIU&A385<K3XU;1BWN'G]K05>V:SNRK_ &NWS1""7GWHS@:8
M5U'%-R'FMX27,I00TDY&_&3G (->>N]57J!,O$*W*CLK::4EELLJ4^M)CJ<,
MA)W8VI4-OT2,@Y.2!5DN$VZVQ*57'4%DCA25J&^"L9"!N4?X;R R:W?=]2]T
MW.TG_(7/WU!1-?3[]:+9IV+;KDZVZ]!7O64+677@N/@Y*BK.%.';DG;NYXR/
MM[6NHF+\Q;'&8! DEA3ZD%L2</EO#8*\A02 3C?](' %7KW?4Q']<[2/\A<_
M?5@1]2CO=+3]@<_?4%8U[J2Y0+W&MT5]F,CK6]2$*;47IO4E;7$-JW  )0D;
MN%<+\N#4:QKR[/LLER3:F&EMM.NS5QG>E%<6VZI49:=^2XE2$#.0?&!MR0*O
M)8U+@XN5I^PN?OJ^4,:G)YN-HQ\(+G[V@I$CVC753[<&&U;Q<%3'8ZTN-.'I
M-B0RVTXI&X*&Y+N[!QG'%?-RUYJ6 A"7&+:_U5OH+Z&%-(C]*5T"M96[C"AS
MRI(!(Y(J]F/J,'^N=I^PN?OJ^$LZG!XGV?[$[^]H*,YK?4TJWNNM,P6P.DP.
MDPM:E+=96L.)5OQ@$).,'.2,^=3,G4EZBV"P.V[W>>^]:G9SZNBI9D+:;;4$
M(VJ 25E1&?%]1JP]#4WG<K0/\B=_>U]H8U&?I7.U#ZH#A_\ .H.9.ZSU++]V
MN"#%>1#:E.]&)NZ;ZDH9V[RATC"2ZHD;B"$G(![2(U[J5<"3)88MCR8S'5*F
MVBM+N7NGN"DN[4I0"5*\2@0D\I\KXY'U%_%N5I/^% <'_G5\!G4I 'RC9Q_D
M3G[V@I$37FH9&'0Q;7&&!%+G2;4OW@/2UL>!27"E.$I"N-XSYXKPE^T*]LVV
M(\RNU.O/ +?4IA;:(:^GN]W65N %S=D=PKPGPY(KH'NNI?.YVC[ Y^^KY4QJ
M?L+A:/L+O[V@JVG]2W*Z:WB1I;\=A"43 Y;VT*ZC80IL(6XHJY"@2I/A3P?/
MFM*UZOOBIZVT,QS#8G-,.!QMQ;BP]->9R%E?A"4H2>Q].!BKLF/J?/-RL^/^
MH.?O:S[KJ3SN=I^PN?OJ"E:LU!?+;K*0F&\M4-IV,!&4C*7<QY2NFD^14M#8
MXYSM^HZ<37VI9-J>?:39][$>1*4L-*<2H--(7TP$.D!65$9W$@=T@C!Z$(NI
M,_USM.WU]Q<_?4,74O\ %N=I^P.?OJ"N2[Q=Y>E-2AZ0RQ,M\E+0D1D+:#C6
MQIQ6WE922E:DA0S@X/'EH1[U=U:#*(K<UR=/N#D*WE#O4>#!43O#BR HI;2X
M0I1P<)Y.<FY)BZE_C72T_HMZ_P!]6?=M1CZ-SM9^NWN#_P Z@JT34]RBZ8@(
MF;84UJ<JW39=Q;WI8"4*4EQ80L E8#?(5C+G<]JE]%WNZWR6M4YIB+'1#C.E
MGHK#A<=1N5XBK@#&,;<\\FI$1M2C_E.T_87/WU/=M2^=TM./A <_?4%%D7&X
MQ)<]F]WJ3'MJ;ZXR[-&&>FU[DEQ" <>%/4( ]3QDD\Z]EU3J%Z;:;O<8\]%K
M81%@SE?DTL]1QO\ *NJ22%@I=6T,A. $K_1T41M0XYNML_1;U_OJ\S&U(3CY
M3M)3V_X@O]]016OM6+LMF@3+0_#<][42VZXD.-+2&U+&%=1 YP,8))SP#6C[
M.M8SM27!]J>B,@>[ID)1';/Y,''A6HK)"N>Q0G/<%0YK9T_-O#EIDJ3.LEOB
M6YUV*4F"I+;:6CMR/RH 3@?H%;GRG.]_8@_.2P&:^CJ-,"(K>XG!(4D=?D8!
M/Z#Z4%$@:SU/:M/V],GW>4N0RTX9<AHH]W2I;P/5*G E7\&@ DHY5Y\"MUW7
M&IF[:9A8MK3/O#,92U-*V-;XJ7BXI:G$IVE2M@!QW')/!N<1Z]3DN^Y7VQ/A
MEQ3+A;AJ5L6GNDX>X(\Q7PJ5=4+DH<U#I]*XQ0E\&(K+15C:%?EN,Y&,]\T%
M);UM?F'+@J7(M[!4$OMI>94M#9]T9<2RG"DD]1:W-I//@4 ">![1]4WFV"X2
M);S!<>DR74-2TN>)+:FTHBM#?@+.\X('./HGDBW/7"?&5-]XU)8&O<DI5*WP
MU)Z 4,I*\O\ A!\L]Z^;E=IMM4I,[4M@CK2VETI<AJ2K8I6U*L=;."H@ ^9X
MH*O+UY?HLFWDQ[;TIJW5-!S+04E+_32VE:G!N60"HE*3](>$CFK)JW4,ZWWE
M,%J1%B,K80MOK,+<<E+4M25(:*2,*2 DGA7T@3@ FMFWNWFZ1TR85ZLS[.2
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MV*_?T5"U(1@7JVI'PMBOW]!!ZUU1=+1J>W6^ Q$]W?0A1<D''54IS:4(\0Y
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M2]NN$.Y14R;=+CRXZOHNL.!Q)^HCBMH'-5RX:3M<F2J5 "[7<NRIEO(:</\
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MO;%''6<Z.-O'T?R:N?JKH-*#ES^B+V8QB)G>\)EV]F Y*D.#?$;"D]9M"4I
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M.J%)XX5M^OG->NJ-(3Y]Q9=BR.NAF$ML*DN>)QP267DH5A/T2&BDG' /8UT
M8'E3]%!SV^VF_761#FHM[4,L3.J6X\P-/K1T%H)6X$D9RH  ?Q1W\AJW/2%W
MN"+D]UW6Q(8BH7!<D!2)8;*M[;JPC<-P(&Y)'?D&NF?HI^B@K9C/KULJ0MIP
MM-6T(CK*3L2M3AZ@SVR0EK] -4:YVN^0VH<2,9CON%IZMP5'0X _(0>HA#1[
M**W"=V/XHP<9Q77:4'%U:&U0IIL-[V8VP-KAIG9*G0A*>NI:DD<D+/ *AP>_
M MVK[!>+@8[,,E]H0S'0ZY+4TJ.^2/ZH(2/&0.W8@@X^D<7JE!SN=9+E;M%N
M16FGI=[N<I'O2VWW/$%.[ECJ=T)#>Y(/ ' K0C:-OSA<5(=+;*GF5LQO?%J$
M=KWHNN(!QWV);2"/50!Q74Z4')G](7&'#9EW5I<]H"&_/8:=6ZMUUHO+<6E)
M^EXEM@)'DGMP!5^T9!?MVFH,:8E*)"4%;B <A"E**BG/GC.,_"ILC(Q0<"@4
MI2@4I2@4I2@4I2@4I2@4I2@4I2@5\I"@3N.1Y5]4H!&1BE*4"E*4"E*4"E*4
M"E*4"E*4"E*C;U-G0N@8%K<N"5*(=#3R$*0,<$!9 //Q%!)57M1O"!>=/RR#
ML<D+@K/HEU!(_P#PVVQ^FM9VXZLD\0;';XB3_'GSB5#_ +#2% _Z8K,:QWB=
M,B2=27*(ZU%<#[42#'4V@N $!2U*4I2L9R -HSC.:#[U5JQNQ!YMB&[.DL,&
M4\E!VH8:'\9:L'&<$  $G!XP"1N_+G0TVW=Y\1; Z277F6W$N]-)QD[@<$ '
M)(\@:A!,?T[?+Z_*M=QEQYTAN0R_"8+QP&4-EM21R""V3VQA0YSFM[2-M<1I
MIV+<(Q99D.R%IB+P2TRXXI26SCCA*@,#@=AVH/.ZZJ?9EW%FTVM=P3;4;YCI
M>#24'9OZ:."5KVD'' \0YYJQ6^6U/@1ID96YB0VEUM6.Z5 $']1JN:$L4VRV
M!V->I#<N=(?<>?<1G:K)PGO_ '@2/UULZ']ZB61BU384B.NVI3$2ZXI*D/I2
M,)6@@DD%(!.0""<4'IKRUF]:,O5O1GJOQ'$MX\E[<H/^D!52C:A<UU8[&BUV
MRXH#TJ+*D/2XBVFVFVEI=*DK4-J]Q0$C:3]+/ KI2QE) J(TG:G;)8F;<ZXA
MQ+"W0T4YX:+BBVGZP@I'Z*"8':J=JBTSW-4P;PW;FKQ$BL;&XBG@VIA[<27D
M!7@4HIPGD@C'!Y-66U-3&HFVXR&I$@J)WM,EI.,\#:5*[#SSS7K.=?9AON1&
M!(D(05-LE>SJ* X3N/;/K0<Y7)NJIZY6IM+7VYMMJ)BQVV(:F6.?I;1(45+Q
MQN/;G &3FQ:;U3;I]P7#-MN%HN#^7>C/AEA3^T %25<I60,9P20,>5>J=6?D
M 7K%?FY&/$P(2E%)]-P\!^L*Q4<S%O.IKW;YEWM3=IM5O=6\RR\ZEV3(4IM;
M?C"<I0G:XHXW*)(':@D]2N-1;YIJ6[L1F6Y&*U'&T+8<.,_%3:!6U,U19(LA
M4=VYQC)0VMU;32NHM"$)*E*4E.2!@'D_5WJJZ_TC9(VGS<6K2T^NWOM3%-*2
M7 IM"P7!M.0?!OXQ4W=X;4#1LY>CXC+3K[.YDV]I"20K'C0!@%0221ZD"@C+
M=[3K1=Y)8LL*[W!6PN)4S$PE:00"4J60" 2!QZU,3-4L(L,^<PR_[U%4&3#>
M1L=ZZMO3;(_OBM&",CFHNUQGIYL<:VV>9:;5:E)6EV9A#BPE"D!M* 2K!SXE
M*QV\\Y'PBTSWO:?->>C$68,QY8>)X<D)"T)3CX E7UA%!L6:^2;1;;@-2SU3
MY;$X1D&/&\3BU--KZ;:$#)P5*QYX&2>":@M6:DCW&58'&X\Z'*MUXAO/,S&"
MTH-/%Q@+]""5D<'RI,#[=TOL-=ONWRFW=$W&UR&(JELN$L(2,N$; /IH4%*3
MP>#G&([6*+[#T9?G[K8)4V]S-KG7MBTOL-=)6YE("BEP)21DX2>2HYYP N,[
M4=QMTHW"6U%5ISWHQ%K0%!Z/A73ZJR3A2-X(. "D8//.-C76IWM.18JH< S7
MGE**QOVAII"=SCAP"3M&. ,G-1?LS6YJGV8MF]PE,MW(2"IM9R7&W'%G=\,A
M7_CYUYH9N-EM>DYE^"G7K:MR),=:!<_)*0I"7B!S@E+1/IN.>QH)JP:G]]E3
M85P8;BSHK*)/Y-[JLO,+!VNMKPG*>"#D#!'U$QKU^NUZ]GUJO]C2(SLA#,J0
MT$AU89/+B6\@ K SC(YQCSJJV'2EUN]V>DI2W%L+[;D-"E+4ASW,2WG.DEK'
M"7$EI(42,(!P.15ETT;K95Q],HLKBX<=]P";E*8XB$J4C'.2L92C9CR)[8H)
M/3+MRG26)\:]Q;MIZ3'*T++02[U,C;M* !MQNR",@X^-?%\U<[#?G(M5I?N:
M+<G=.=0ZAI#7AW%"2KZ:]N"0.!D9()JNVCV7R]-7E$S26HEV^(DD+@.QNJRZ
MDDG"\+3DC. K&[ &2?/+FF-9)A.V]]^RS[6^Z^]*90Z[$<DEUQ2RA2]CF$85
MMP "0 -V*#I$*2W,AL26<])YM+B=PP<$9&1Y=Z]JK"FM5S8[:0NTV;(POIA<
MQ:1_>DAM(/UI(^!JQ1&ELQ6FG7W)#B$@*=<"0I9]2$@#]0%!ZTI2@4I2@JEQ
M7[M[2[.X\K:U)MLF,T3VZH<:7M^LI2H_4@^E6K 56C>;7'N\(QY.].%!;;K9
MPMI8^BM!\E#_ /H<@D5#,/:IM[*FGHEONY0<(?0^8SC@_OFRA20?B%8/H.U!
MLWC2ELNTWWJ?[\XO  0F<^VVG'HA*PGGSXYJK>SS1MG^;PD1GKJTX^^^7NE=
M9* M8=4GD!S&X!(&>_'-3,B[ZN<C."+I>(S(*2&U2+DDH2?(J"4$D? ?ZJ^Y
M5CND*;\J:>D1VY+V%3;>]D1I*\<K20"IM?\ ? $'C()YH)NRV6#9FGD6]I:2
M\OJ.N.NK=<<5@#*EK)4HX ')\JB;X[&EZCT\6'VW'H5Q6VZE*@2VI4-XX(\C
M@I/Z:^'=538BMDW2U]#F.\=MI]!^I25]OK /PJKW9BZ2YL_5:+9+MS,;W-Y,
M5[;UWPRMPNK*4$XRTXI(&<G'8<4'4< U!ZW@(G:1NK1\+B8ZW67/-MU W(6/
MB% ']%3$:0U)C-/QW$N,NI"T+2<A22,@@^F*KNOYZV;*NV0B%72[)5#B-CD[
ME A3A_O4))43\,=R*">M;ZI5MBR%@!3K2'"!Y$@&MFO&&PF+$9CH)*&D)0G/
M? &*]J!2E*!04H*#-86,C@UFL*[4%$L5U-FLMZE^[KD@7N0WM0H))WO[0>?(
M%0%3 U4VF-+]X@R6IT=Y$<PP4+6XM8!0$D':<@YR2,8.<8J MMLD7;3=^APN
MCO<O<A1ZJBD83(W'D G)VX_3FI(:3?CH<1;G(\= >1.8"LKZ<CLL$GE2% D=
M\C)QY8#=<U4B)%GJN,%^+*AMH>4QN2O>E9(24J!QC<"#G&,9/&"?)[5$MAF0
M9%DD-.M/1V0"\DH=ZJ@D%*QW )&> :\WK->Y1ESG7H#%P=0TPVR IYA+25[E
MI42 5%8)'88&,?&/D:2GO6V6PB/:V&GY,9SW!"U&.A+2PL_Q.5+P ?"!@#OY
MA-R]3>ZHO2WH#VRUA*EE+B,N)*=Q*<D=AY&O)W5S;4"+)=@26EO2E1%M.*0E
M3*DI4HE9SC&U.>,]Q58U);6K(S/,B19+3:9<AEU2 ZMI2PWC*4A(!W*P/H\U
M79T"]ZG7=8VEK:^U9YBV7!.N[CB25I&U:TI7E9"D83Y#@?&@O[VNXJ(<F:S$
M=DP651\/,+2KJ(>^BI([G@@D<'!\SQ7C(]I5AAW*5#FRFT*:V=,L+$A3^[)&
MU#>5>7F/,55V/99<!;Y#<^\&:MR8V^(K:U18W32I*MI2@%6>"D<X QZ5;]%Z
M-B:8GW)<)F.W%?*"PTVWA3(&2I.X\D94<?  >5!HW'7EP]U4]:-*W-YKJ(:0
M]-4F(A2EJ"4X"CNQDCG;VK5LUUUQJ)]WHILULMZ2 F6A*Y <..0@DIW '^-@
M)]">:M>L;9(N]G3$BHBK5UVG5(DDA"@A87@X![[0/TUY6FUR;2Y.9A>[(@NC
MJQVLJQ'=( *0G&.GD;L C!)XH(P:4O4K'REK&ZG'.(;34<9_0DG'Z:C]2VJV
MV%B,[=;CJ24U(?#)<^4G &QM4HJ("D\ ).< G%7:QBX)M45-Y<C.7$(_+KC)
M4ELJ_O0HD@?76AJBU/70V_I)CK1&D%UQ#^<+26G&RG@'R<_U4%#DVRS=.]2&
M%:@<1;%A"W/E5S\J1D$(!4<^(%.#_&&!4I9],1I]L7*A774D=]"W&E,&XG*'
M$**2GG*>Z>_QKV<T;)2L0HC<9JR]=A1:$ET.*0UN(\8&0K>4JSGNGOS6XSIV
MYP+A(=M<A(C*DHE):D2'72XL-EM06HY(!!2>YP4 X.:"JQ9.I8ZI'N%XN:WD
MR_<F8DYEE[JO!.\IWI5E*0D$E1_1Z';7KS5%E4^S?M.)EN,K0V3;G=RLK!*3
MM/*DG"N4CN",<59&M.S4-"7U6!=A/7<$C!Z(4IOIEOUQL_C?RN<>5:=XTO<K
MJMR3+1 <DO28ZUL*4KI)99*E)0%;<DDJ422!W[<<A]6GVBVZZV!R?&0OWIN0
MF(Y"4M(6VZI02D*.<)2<@Y/;D8R,59[)<)$X24RX+L-Z.YTR%*"D.>$*W(4/
MI)\6,X!R#Q7/K][,77FUKL3\:!,9=W17RDD])0)6PZ.SB-QR-V< X\N=WV/W
M);R+[;[A':@7:)+ DP&4X::\"0%MC^0O:5>7)/UD.C4IFE I2E H:4-!BE*4
M"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4 ]Z5@^5?1H,4I2@4I2@4I2@P
M 1G)K-*4"E*4"E*4"E*4"E*4"M>?,CP(CDF6X&V&QE2R"<<X\JV*\98>,=T1
M2VE_8>F7 2D*QQD#!(S05_Y]:<SQ<@?J9</^[7JUK*PO* 1.)SV)8< _64XJ
ME/ZFO#=JL,QVY-*0(Y<FMM.-MO/J+Z&P4(4A>1](;01RH#=FOK16IKH_>X:;
MI.=7$E,RB2^IC;N;= !2$ *0 ,@[R<\8YH+[\X[5_%DE7^"TM7^P5\JU+;1W
M7)Q\(CQ_W:B=2S)*K\U;Q>%6>*83DH2$!LJ<6E0!'C!&U(.2 ,G(Y&*@)^HY
MZV+K-BWI(7!5&$:,AM"43$N(;5N4% K&]2U)&",8\SF@M_SMLP."^^D^AB/#
M_=KU3J>TJ *7W3D9XCN9_P#EKGUEU+?95RL]LN,QU N,V5T93+:05,H2\.F<
MI("D*0@Y\PH=\&M27J&YV^U6B7,OEQ=1*F3&7=BXK2L,J<2@)4M*4C.T9!Y)
MQV\PZ4K5%K3@E4O!YR(3Y_W*\OGC9L_PLL_5!?/^Y7+Q[2YZH-H=COS)/N;1
ME7)34%:TN)+NT-+4&\(*6PX2H #<@ '&:LVG-0HO[R'U:G=CR'YK\46]MM&0
MCQ]/"2G>A10A+FY7!R>,$8"UIUC9R3A<WCUM\@?[45]2-6VB.PX\^](0TV"I
M:S$>PD#S)VUS:7JB?!APXQO,V3/F7&7'6V'&$.)::==0C!4D)0"4I!6<]CCF
MJY)E7NZR7S=GYUX%OCON-)AJ8+*5-N; ZI*TX=P<\A)/AR .U!U-_P!IED,=
M#MMCW:ZH7RE4*W/*01Z[U)"?]=:G_"@RE>%Z8U*$9 *D0PY@>9PE1/'PR:C;
M;J*Y7"ZP&GKLW&M3I$?WJ,&PAQUMA"U!"E)(PI:UC_%<8YKQT_>+]>M0^Z";
M*D1&6OX>,MIH+2F4\V'5 I.X*2A/"<#CC&:"\P=86B='2]%7+<024G;!?.T@
MX(/@X(/!'D1BO5S5-N:!*TW  ?\ [ND'_P NN5VAR]0]-7J\JERVDS+DUTWD
MNM(2L*?::6<8.U1VJ&3Y?'FI:]7.\Q9L6-!E7:4A,&5(<:BRF''BI"VP#N*<
M' 4?"!GZZ"[JU=:5<$7'T_K9)_=UJV:Z6&V-N,VUBXLLN++G23;Y6Q!.,[4[
M,('G@8&<G&2:J!U-<%VFYS)&H&6YL"WQY$5N/L#4Q2F@HJPI.Y06YN0 ,8QP
M :S8[Y>G-1P3)D36X[]VE1EK>6T8Q0@N!+( &\+X3MS@':><\$.AC44';D-W
M$_YND?@KR=U1;6SEQ-Q3]=MD?@J=3R*8YS05U.J[6K.WWT_7 ?'^Y7NUJ. Z
MUNV3A\#!>!_^2IO I00*M4VMD84F<D#L! ?_  5\?.ZTJ&?ZO^P/_@JPX%".
M,4$(WJ>V*3E'OGZ(+_X*^5:FMR>2FX$?"WOG_<J<"0*S@4%>&K[83]"XCZ[=
M(_!7TG5EM5G:FX'_ #=(_!4_@4P*"".J+<$;BBXX_P#ALC\%?'SNMG\FX_T<
M_P#@JP4H()&J+<OZ(G?48#_X*^EZFMZ!DHN'Z+?(/^Q%3=*"NN:OM;9PI%RR
M>W_HV1^"O8:GMRDI*??3GR$%_P#!4Y2@@G-46]LX4F>#C/\ 6]\\?Z%>7SQM
M?'AN'/K;WQ_N58J4$$C5-M<^C[[]A?\ P5\#5ML4Z\TVN4M;) <2F$\2DD C
M(V>A%6"J9#$GY5UI[D\AB3U6NFZMOJ!!Z">=N1G]=!(G6%K!P??_ $_K>_\
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MFK+:U]-J[?HM,H_[&ZG\4P*"MJUI:DG'0O)^JSR_W=!K*VJQMC7KOYVB4/\
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ML@K !VD$XK$6[7KYP1G+$Y.D6V#[V^MD2C,9FH BY;:=4 3@+<*<D^,%(..
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MN"X,D/0EJCN@^N]!!_6:JFMC<[?;_D.Z/N7!I3C4R%*4D=5Y+#B7'65@8"G
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M7&.];CT2._',=YAIQ@C:6UH!21Z8/%>U*#63 AIC(CIBL!AM)2AL-C:D$8(
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MX,G.'MNP8PG!=3GGD(';L;784:?L]^]\C7>V)A)$A:&VR$X6\IO(P!C"4,I
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MBO2!;(-N3M@0XT9)\F6DH'^H5!6O9Q8[C;H<^X7XH%WND@R7VT'*6?Y* ?/
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M0&W'U+0VD9PE*2< <_[/05.4I0*4I0*&E#08I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E J AVVPHOS\N*Q!%T)4IQ3>WJ GA1P.Q/ )[G
MSJ?KE/S0O+=END]M26+O'D7.3 ;9:0EU2W5NALJ=R=P*5@@<8.W/:@Z-#L]N
MAOAZ)#CL.A!;"VVPDA)45D<>142?K-?"+!:4,*91;8265.H>+882$EQ&-JL8
M[C:G!\L"N>FVZOCWBXM,3+I[B&74QBG:\2@L81XW'AXP[D\ISD8*@GMZ6IO5
M05$,Z->%(;X8#4M"?%UE%2G@M2CM+>W"25D *&<D&@N+.G--M2'VF[;;@\Z"
M'$=-))"B5$8]"4D_';\*DWK5!=N#$]V(PN:P"&GU(!6@$$8"NXX4K]9KC_S<
MO[,VS294*]R$H;AR)2FYX7(Z_0E(=PI:_" IQL820G!X\ZW!"]HJWG2[+>$O
MW/#8;2@M%7NH&"HN !76R<],G..=IX#H;^E].ON%U^UVY:DJ()4TG&5*WD$?
M%2LX/<G/G4JJ%&7+:E*9;,EI"FVW2D;DI405 'R!VIS]0KFCMBN3VC=2,)@W
M8.2KO'E,-O/H5*4TCW;<H+W$9_)KQDYX%-+.ZF&LH]LES'A!RY/6TZZA;S#(
M+B&V7",_3W-+'.?R:^_)H+Q(MM@1?&I$AF BZNG<VI>T.+4!MW 'N<<9[XXK
MZ3:[!(=9B(C6YURW)2AMD)0I4=(*2D ?Q1E"3_V1Z51]3V:Z&=?C'M#<Z9-E
M-OQ7W64NME"6T!+:E;TJ:VK2I6?CD9)(K51:KY;KA,=L5E6B4I,M*5R4M'H+
M=<!2IMY.%.().\I6"0!C(( (=*AVZU0 9,./#CI2E0+C:$H !65*Y'EN))^)
M-1+>F](RHSX:MUH=CNNI4LH;04E?('(\_$1C^^/J:J"=*7N!HC4>G&HK+S#C
M+;D$LD%!4H .((6<YW(WG/!+AK;U1H^Y3DP+5;?<FHK =EN2%1PV@R" AHA+
M>/$C*E GS"?2@N=P@VJ5(@M.N,I?BDEEI*D@[2@I*"GS24GM\ ?*LS;)9Y3+
M;4J!$<V,]!"5('A:!2=H\]N4IX]0*YW\VK],GOW2? ;0'KI#E/Q4(;+^$,,!
M2FGLG 2X@Y3P2E*L$$U)ZGM5QN6K+M#B2&V7ID!@,+=) ]W2XOKMI(Y2HE3>
M3CL4^@P$7[&X%I?L=W@S6(;[:[J\M$=Y*5@[%@I4$G.<$=ZZBVJ!$EJ80N.S
M)E*+Q;W +=. "K'<\ <_"N,Z3T5=+5/L;[EJ2RMDQ5N!H(#8VI4E:E$G>%#<
M3@<'C.:NBK6ZQJ2X.2M/JN<F3<6),682A*66TH;3RLG<G84K.T#Q9X^D<!8R
MUIU;7N^VV*;C*<7T_!AI2]R5G'D5;U@^NX^M?'R#IN5*<G_)ML>?>;VK>Z*%
M%Q&W9@G'(V^'ZN*HENT+<&]'VIA3$=NX>^,..I,5HEM"725%1'\)Q@\GRK8T
M[:)EGU#;8SK&V>N7.=D.M)2EER.4(PI"4_025]#PGG<E??N0\/::BR6V%8+;
M;DP64,75N0Y&;V I\*CO4,_IR:N-PTWIZX1I<A46(VF<G^JI+*4I+Z,I*DJ6
M!RE6T!7J/T&N4>TNR.P[J+BJWRG&7+@IUY;JVUI<R!L2CC(/"N%<#C/E5QB0
M+A ]G\N!\WW+BX9#CL:*]T\*'7"DET!03D%17M'!"2.*#I0=;*4J2H%*AD$=
MC6&7VGP2RM*P#@E)S@^E<H3I74 E:5<89#EMMSZ5="0[T'&U*ZG5<4A&Y!!W
M )2#X0<>9Q9] VB3;+G='%6KY,AOLQRADEH[7$A:5(26S@H2 C"E *.3D\
M+I2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*#.:9K%*#PG1(\Z([%F,-OQW
M4E#C;B0I*TGN"#4!#T-8(DII]N$IQ3*PME#\AUYMDCL4(6HI1CRP!CRJS4H"
M>!6<UBE!G-,UBE!JW2!%ND%Z'/90_%>24.-K&0H&JTG2MWCHZ%OU;<68:>$-
MNL,OK0/3J+22<>JLGU)JWTH*Y9](PH$U%PEO2;I=4IVB;.6'%H'F$  );'^
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-*4"E*4"E*4"E*4'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exh103_2.jpg
<TEXT>
begin 644 exh103_2.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 2# WT# 2(  A$! Q$!_\0
M'  ! 0 " P$!              8%!P$#! ((_\0 9Q   @$# @0"! 0*$1$'
M P,%  $" P01!08'$B$Q$T$4(E%A%3)Q@187(Y&CLK/#T=,D)2<S-38W0E)B
M<W6#H;'!TB8T15158V1E<G2"A)*3E*+"0T96A96DX413M C$U./B\/%V_\0
M% $!                     /_$ !01 0                    #_V@ ,
M P$  A$#$0 _ /U2 @
M                            !Y@>8         !9QU
M                                                   ! X7F<@
M  &4    #(
M          /,        XDLG(
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MJ<W<3YZE1))2E+.98PL)]%A8[(PTMN;QR^3?51+RSI-!A;;WFN^_)/\ \HH
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M;A?>P+L$([KB1!OFTS:E1+RA?W";^O2/CX0XC\R_*#;N/-?"53\6!? A%?\
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M*G25:JI5(KEIOM*77XOO[ 3&Z[R+W%2M=2U>MI6EJPG7IU:=QX"JU5+#S/\
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M@>P#N               /,                            &$,(
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M\2X3[&DL/;=E_P WX2X $*N$FQ%VVS8Y_P!+\(EPFV/+*>W;3&<])37\DBZ
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M4W,_EUNY?_67( @_I6Z)G+O]PR_RM8N/Z1]+ACHT?BWVX(_)K-RO^OY/K%T
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MTZ<:T+N%6"G3>4Z3AS9?R2C%>[F I@%V '5>/%I6?3XDN_;L2?!YYX9;>?\
M@J_E94ZEEZ==)/#\*77&<=&2G!J2EPNVVTL)6D5]9M 68
M           87L      06KNK/:^\+Z-Q55Y&=90\.K*#H^$L02::QVYO],]
M.WIW=ON*I8WE&M;6]Q9^)1IU+V5TIN,DIM.76.%.'3L\^X"T!A-G3J2T2%*K
M.I4=M5JVT:DWEU(TZDH1DWYMJ*,V!Q)96#E+"P !PHI'(
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MVWEG.K.I0K6M.YIQ;RJ;3<))>Q/$7\N29V)^J7Q 6'^?6CS_  + V&   :R
M!U0MZ,$U"G"*;R\12R_:<JE"+;22;[]#L,-NRYK4-,IPM:KHU[FXI6T:J2;I
M\\TG)9\TLX]^ ,KX-+D5/ECR+];A8^L<NG"4U)I.4>B?FB,W#?7U#<'HEO>:
MG"%:G24/1Z-*<*4ISE#FFY0;4>B??VF2N[J[LJFWJLKE5HUJBMKGDQR5'*#:
MFNG[**]V)/W 9WT2@X2@Z5-PFL2CRK#^4.TMW25)T:;I)84'%82^0[UV !))
M878@*<V^.E>'5I:!%K/E^2/+_P#SV%^0$'CCM66.^WX-/_6'G^8"_
M    Z96MO*CX4J%)TLYY'!<N<Y[?*=P Z(6=M"47"WHQ<7E-02QTY?Y$E\AU
M4]+L*5O5MZ5C:PH5>M2G&C%1G\JQAGL?1-D95U'4I;'M]3C>SHW-Q*G<<T:*
MJ.%.K46*:CCKRQFEVRVO,"LMK.VM:<*=M;T:-."<8QIP45%>Q)=CZIVU"EX?
MAT*4/#BXPY8)<B]B]BZ(E=,K:Q=:-J%W1U&I4A*B_17<V\:=2%6$JBES127J
MO$,>??L4VF7<;_3K6[IK$*]*-5+W22?\X'I                      'V(
MB6Q]0;>-[;FBGY*K1Z?8P+<\]_9T;ZW\&YAST^:,\9:Q*,E*+RO--)_,1OT
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M,OS:=23?]A**Q[/JT_PEXR TIYXUZYURUI%MW_6_5)@7X
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MM?NDS8)!Z3'\V3<$GW6E6J2SY.=3\ %X
M                      ,7NB7)MS59-9Q:57CV^HS$;'YOI9Z$X3E"7P51
M:G%)M/PEU6<_R&7W3'FVUJR]MG67_(S$\/J,;SAKM^C5<N2IIE",G"3@\.FE
MT:PU\P&)T_7KRTTU:E5GJ=[:JT52LKFV5+-9\B@J>()M-N6>C2Q]?-:'N&\U
M"O7MJMBH5HTO%IS4:T*;ZXY92G3BT\X[)Y6?9@R=GH=G::;/3X1JU;2:Y94[
MBM.OF.,<N9MO&/+L?%OH%G0=1PE=N4X>&Y3NZLI1CG.(MR;C\V /+HNK:GJM
MG3NIZ;;VU"K3<J?-=N4W+RRE#'*WGKG.,=$WA=.EZG.UVY7NZM.=:O"ZK4O#
M\9U,S\>4%%2:6(Y:2Z=%[<&2LM"L[*RG:6TKN%"45##NZLG%+]BW)N/S8.+;
M;]A;VMQ;1A6G;W":J4ZUQ4JIY;;:YI/#;;>4!CZVX+RP<Z.IV=#TN482H1MZ
MSE"IS3C3PW**Y<2G'KCL\^XZ]&N=3GNZ]HZE"%.*LZ52,*-=U*>7.:RDTG%^
MKA].O\F2I;=T^%*XA.%6MX\8PG.O7G5FU'K%*4FVL/JL/OU[G.G;?L-/U"I?
M6ZN'=U(*G.I5N:M5RBGE)\TGT67CV9?M8'?K6HK3+"=PZ;JRYH4X073FG.2C
M%9\NK77R/#;ZIJ$KBO975I:TKY4/&I*%PYTYK.&G)Q36'^U??YC+7MK1O;>=
M"YASTIK$H]L_@/!;Z!96\+A0E=.I7BH3K3N:DJO*NR4V^9)9?9KNP,9LI:E<
M:?;ZAJE7FG<T(5<1N'.&9>M\5P7+CMT;,MN:K5M] U"O;5I4:U*WJ5(5(I-Q
M<8MIX::\O8?6D:-:Z11\*S=SX2BHQA5N*E5126$HJ3>%\AZ=1LJ.H65:TNE-
MT*T7":A.4&T^ZS%IKYF!&VFOWFGVL[NI4U#4+!4(-SN;54*GCSG&,(0]2&4^
M9Y?*\877K@RFD;BN[Z5W1G8PIW%*EXL'S5%1GUQRN<J<6I+V<KZ-/VXR\=(M
M%ITK"4*E6UDL.-6K.H\?Y4FW\G7H>>AH%M2A6B[F_J.K%0<ZEW4E*,4\XB\]
M/?CJ_/('ET+6=3U;3*5^M-HV]&XH1K4(U+GUFVDTI8BTD\Y33?O2[&)T/4M1
MM=!HZSJ=65>I>TZ/A4(W"E"52JTHI+PX\BS)+N^F<Y:R4=AH=I8Z?Z%;SNU;
MJ$:<4[FHW"*6$HRSE=/8?%#;FFT=+EIT:=>5FXQ@J=2YJ3Y%'XO*Y2;BUA8:
MQV0'12U>]=S>65>TH4[^A1C<0A&X<J52$FTO7Y$T\Q>5R^SOY8U;EU>>EVFH
M+1J%.WNY48THU;W$\U)1C'F2@TEF2?1OHO;T,Q1V]9TJ-S%5;N56Y454N)7$
MG5<8]HJ6<I+KT7M?M9\+;5DK&C:.I>.A0G3J4XNXD^5P:<<//9-+ZP&,T[==
MQ6L;FXOK6VM?#HNK3YKKU98G*&)2<5RYE'IWZ->?0ZH;RJ3TG4KJG9TJM>QE
M34J4*\E&:GC&)2@GGKV:7RF2>T=*=-Q5.XCYQ<;B:<6JGB)KKY3ZKV'S':&G
M>%=0J3OJKNG"5>=2\J-U'%YB_C=.R[870#YGN.O:4[V&I6*IW=O&A)4J%;Q8
MU/&DX02DXQP^9-/*QYGQ>[BOM*L[JXUC3:=&%-4E2G0N?$A4G4GR*.7&+CAM
M9>,8?GV/;5VY9U[J]KW#KU7=TZ=*I&55XQ!MQ<?.+3;>4\Y9R]NVM2E<0NJE
MU<^,HINM7DW'E?-%QPURM22>5URD!TZ!KZU2XNK=PI*K0C&?-0K>+3DI9[2Q
M'JFGE-+R\F9'0[RYOM.IW%]85=/KR<E*WJSC*4,2:67%M=4D^_F?.G:8K)U9
M>DWEQ*HL-UZ[EA>Y=EW[I9]YSH6E4=&TZG96U6YJTH.34KFO*M-\TG)YE)MO
MJP.K<]Q<6VD.5G55&O4K4:$:C2?)XE2,'))],I2;6>F48[3JE]4N]8TFIJ-:
M=2W\*=*ZY(>)&,T^C2BHY3C+#QV:[F<U2QHZE8U+2YBY4JF,X>&FGE--=FFD
M_F/#1T*C2MKJG&O=>-<S52K<*JU5E)))=5C"226.W?IU8'BVM>W,YZG;W]:N
MW:U5R>E\BJJ#@GS2Y/5<6U+#7L:?5'UH4[O5-.O-15W6HPO9N5IA)^%172$E
M&2QF27-U_9+V'W/;-*6FWUJ[NZE4ON57%Q4FI5*D%A./;"3CE=$L9;[]3*7=
MBKBR]&A4JV\%CEE0FX2ACMC'R=GE/LTP,%M^[O;^EJMK5NKFE<4*ZC3E<TJ:
MK1IN$7EQBE'J^?#QV77JF9#:5Y6O-L6-U>5?$KSI<U2H\++\WT27\1]VFB1M
MJ=RXW=U*YN)*52YE*/B/'1)>KRI)>27FWW;/-';<*6@5M)M[V[A;5(*DG*2E
M*$/UT8O"[K*R\]P/+I574=5TR[U"C>>C1O*RE;<\>94K>+PI)/IS2BG++Z>L
MLKH>&&KZA\!7EQ;W3KT:UY1M["\JTXJ4J=25.#J8BDI)2E)Q>$FDNZZNCUC1
M:&J:7Z!4E.E;9CZM+"34>T6FFG'IU36&CKJ:#3N-/KV=[=W5U3JN,E*I**E3
M<<.+ARI)--)Y]J \6F2OZMWJ^F5-0E.K;NE.E=2IP\10FLX:24<IQEAX[-=\
M=?/:W>JW6Q;:YM9U*^IS4'*<(TU*2\1*;2>(YY>;'D96UT*-K2N_"OKMW5W-
M3JW<G!U6TDECU>5))8PE[?-Y/FTT!6NF>@TM0OO#CR^'/GBI4\=DFHI-=.J:
M>?,#G;=\[J%Q2K.]5S;SY:D+R-)3CE)K\[]5K#\LC=NHW.EZ#=7=E156M3CE
M)M877OU[GHTC2:>FRN:BK5KBO<S\2M6K-.4WA)=DDDDDDDD=^JV-+4].N+*X
M<U2K0<).#Q)>]/V@8^ZUFM96=*=S83]*KUO H6U.I&3J2:;[]$NB;>>R3._2
M-5=]7NK:O;RMKNUE%5*<I*2Q)9C*+7=/K[.J9YZN@>/:*E=ZE>UZT*BK4KB7
MAQG1FEA./+%+LVNJ><O)ZM)TFGITZ]7QZ]S<UY*56O7:<I86$O52227DDOXP
M.C=%]7L["E&TFJ=>YN*5M&HX\WA\\DG+'FTLX]^#"UKW5U8:O9VE6K<WUG=T
M:<*\(4_$E2GX<I/E:4>91E/R2Z)E-JVG4M3M'0K2J02G"I&=-XE"49*49+Y&
MD>&CM^%&VKPIWU[&ZKUO2*ETI1524\**RN7E:Y4ER\N,+MGJ V[?.II]QZ77
MN95K:HX5G=PA3G#HI=>3U<8:>5[3QZ15O]1T6YOXW,Z#O*CK6Z\-3=*AT45&
M+_72BN;KG#GVZ8.ZKMJ$]*N[+TRO*5[5C4NZ]3#G6CZJE'HDHIQBH]$L+W]3
M*WED[BWC2I7->T<6G&=#E36/+$DTU[F@,'M^_OM1TF]Y+B5.XHW$J49W=!*J
MHK#^J0BTDWGIVZ.+QU/?H.H2K;7L-1OJM/FG:0KUJG:/6"DW[D?5MHD;:VNH
M4KV[5>YJ>+5N7X;J2>$O./*DHI+"CV1XZFVHK;U#1XWUQ.S@Z4)>*HN4Z,,?
M4_54>C4<-O.4W[0.K3ZNJW>A^F^DPMI7E7QTZT/ZVMWV23_7<J3?-T3D_9@\
MMOK.IUM*MU2JPD[N_P#1K:\E3PYT,.7B<O;.(R2\GT>,=#.Z]HU+6K"G:5KB
MO0I1G&<E1Y?7Q^MDI1:<?/&/)'56T&->Q5O<7]Y5J0K1KTJ[\-3I2CC'+RP4
M<='T:><O('@L[W5+BWU&RC>487-C=JC.\J076DX1J<W*NG-RS2]F5G'D<:??
M:I>;>NZ]&\I.4)S=O>3H85>DEE2Y<I++RD^S24DL/!WW&U+:XTN=E5O;U^+7
M](KULPYZ\NV)KEY7'"2Y<8Q%(]U32ZLK"K;/4KN3J/K5<:7,EC'*DH<J7S9
M[-O752]T'3KJO)2JU[:G5FTL)N44WT^<R!C]%T[X+L*-G&XK5Z5&*A3=513C
M%))+U4O)&0 $!OU?FA</GA?UU=>?]X9?D!OUXXA</L]O2KI9]_@,"_  #
M!]@'V A.'>%NK?B7]U8O[!3+L@>'/Z:M^+"36JQZ9\O!A@O@#[$%PUQ\.[Z]
MOPU+[C3+UD!PSRMP;\4N_P --]_+P:8%^             $/I,4^+VX6TL_!
M=IA_Z=4N")TEKZ;NOKS^"K3[I6_^ +8
M     $               #&[E2EM[4T\X=K573_(9B^&7ZGNV\X_0^AV_P A
M&2W2VMMZJXRY6K2MU]GJ,QG#!YX>;<PO['T?M$!3@
M                                            &O\ B#CZ/>'N%ZWI
MUQC+Z?G$C8!!;_6=]</L_P!O7'_X\P+T     #[ /L! </,O>._L=OA*E]P@
M7Y!</%C=^_LK#>ITW\W@0+T R X:/.YM_)+"6KKI[_!AU+\@.&C_ *J-_1?]
MUD_KTH 7X             0^E23XQ:ZDL8TBU3]_U6J_YRX(/1W^;-N%=/T*
MM7[_ (\P+P                                  $ @
M 8G=RSM76/\ ,JWVC,;PO37#S;F<?UA1^T1D]VY>UM82[NSK?:,QO#''TO-M
M8>4].MWG^#B!3@
M                 $)OYOZ-]@J+Z^G7#Q[O EG^4NR#W[GZ.=@YQR^F7'5^
MWP'C^<"\ 78    #[ /L!!</99WEOW#S^6-+[A O37W#A<N\=_I]'\)4WCY:
M,38( @>&WZ:=^].GPK'K_!0+XA.&N/A_?;\_AEK[#3 NP             @=
M(_5KW!U_L1:_=*A?$#I'3C9N%-/+TBU:^3Q*@%\
M                             ,5NMXVSJS_P2K]HS&\,%CAWMGM^AU#M
M^YQ,GNI*6VM63SUM*O9X_6,QO#1./#_;B:QC3Z'E^T0%,      !-/LP
M                                                    !";\CS;Z
MV!AX?IMSU_U>;_F+L@M]/&_]@>^[N>O^KR O0$    !]@'V U[PZ2^C;B"U_
M=&BOL,381K_AXG]&&_FUC.IT\?[F!L  0W#K"W#OJ*_NOE_/0IER0_#S],F^
MFNSU9?7\"F!<             ! :2OS;M>?F]'MONDR_(71XQ?&3<4LKF6EV
MB[=_7J>?S("Z
M  &*W8W';&K-?VI6^T9XN'24=A;<Y5A?!UO]SB>S=J;VMK&._H=;[1GBX</F
MX?[;?MTZW^YQ HP     )8[
M                     #7^^OU1N'SPL>D7??\ <#8!K_?DOS0N'T5W=U=?
M<0-@ (    #[ /LP(7AY^F;?:;S^6T7]>A3+H@^'513W3OSEES):K!9QY^!#
M*+P 0O#1YUG?"PEC6Y_<J9=$#PQJ1EKN^^7LM;G]RI@7P             1.
MBK'%S<O3H]-L\?[54MB(TA_FO[A2_N7:9_VZH%N
M                             ,3NW]*VL8_M.M]HSQ<-_P!3[;?[W6_W
M.)Z]YX^A'6\]E95ON<CQ\-7S</=MM_W/H?:("D
M                                          -?;[7-Q&X?+L_2;OK\
MEO)_S&P2"WND^(O#_.<*YN_K^C2 O5V0"[     ?9@/L! \-4OHBWY)-_HQR
MM?)1I_A+X@N&R_JCW[US^7&?L%,O0! <,%^7F^WV3UN?3W^' OR X8_H]OO]
M^YO[' "_             "&T6>>,&YHY?JZ;9^7[:K^$N2!T+*XS[J3[/3;)
MKZ]0"^                                   !               PV]
M%G9^N+_ :_W.1Y.&RQP^VVO\7T/M$>S>:YMHZU'VV59?\DCQ<,WGAWME_P"+
MK?[F@*4
M           @=[R:XC;!22_/[OY?SAE\0.^6H\1-@2?]L7:[?WD"^0"[
M   @.&F/HFW]CM\+K[C OS7_  S?]5&_H^S5T\_+1@;  $!PP6-;WU[/AN?W
M.!?D'PRZ:OOA?X\J?<J0%X             $!H+_ #:=U+R^#;+^6J7Y :(\
M<:MSI_KM,LVO]JH!?@
M       #%;L3>U]74>[M*OVC,=PQ>>'.V&WG\K;?[G$R6ZUG;&K)^=I5[?Y#
M,=PSBX\/-M1?=:?07_(@*4
M                          @=]KFW]L%=<J\N7T?]X9?$'OC]4#8#_P +
MNO\ \>8%Y'L NP      -?\ #?'T8<0$L?HG3[?N,38! <.NF\=_K.?RQI/Y
M/J,>A?@"$X;]-?WRL?V:E]QI%V0W#Q-;EWTF\_ELG]>C3 N0
M @-'6.-NX??I-KU_TYE^0>E)_3IUZ6.CTFU6??SU +P
M                                 8S=&/H:U;FZ+T2KG_89X>'<>786
MW5T_K"@^G^0CV;L7-M;6$O.SK+_D9XN'+YM@;;:_N=;_ '.(%$
M                                                      :_WVVN
M(G#]=EZ5=//\ ^G\9L U]OZ2CQ#X?-_VU=+"[Y=$#8* 78      $#PZAC=^
M_I+XKU*G'YU1CG^4OB%X>O\ JJWY'S6J0?UZ%,N@!!\-GS;AWU+KCX9E'+]U
M*!>$)PU7+KN^8YSC6I/Z]*FP+L             (G1L/BWN7VK3K+'^U6+8B
M=)Z<7=P+S>F6C_YZH%L
M         ,9NG]+.K8[^B5?M&8[AKUX>[:_>ZA]S1[]VR<=JZQ)/E:LZSSC.
M/4?D>#AK^I[MOIC\KZ'VB I
M                           #7V_VOI@</E^N],N?K> S8)K_ 'W^J+P^
MZ/\ KJZ[=_ZWE_$!L!=@<1['(     !"</L?1AOUQ;:^$:7U_ ADNR#X=9>Z
M=^M\J_+6*PE_>*?7Y2\ XEV(/AKA;BWVH_%^&7]?P:9>OL:_X8?I@WYV_1J7
M;]R@!L              (G3U^;#K6'T6D6F?E\6M^ MB%TB2EQCW&LK,=+LU
MT7[>J^OUP+H
M 8?>3QM#7'VQ8UW]CD>'ADV^'>VV_/3Z'VB/=O-9VAKB_P !K_<Y'DX;=>'N
MV<K#^#;;I_!1 HP
M                  "#WOA<0]@/&6KF[2^>WD7A!;V?YH^P4EU\:[><^7@@
M7J       !!\.<+=._4O[K1?V"F7AK_AH^;=&_GVC\+I8]ZI0ZFP #(#AETW
M!OM8Z_#4G]B@7[[$%PRS/6M\3_6_#<X^7=4J>?Y@+T!            #[$!H
M;?TZ-SI]GIMFU_M5"_?8U]H+;XT;H33_ $-LL//[:H!L$
M                                   8?>/Z4]:_S*M]HSQ\-,_2\VSG
MO\&V_P!SB>W>&/H3UK.$O0JW5_Y#/)PZ3CL';J?=:?07V.(%$
M                                                     0F].7Z8
MVP7+'Y]>+K[? +L@MZ22XE[ 6/6=:\Z^[T=@7H       (#AI^F;?W[\=OX*
M!?D#PS>=P[]Z/]&I=6O[S3+Y=@#[$-PT7+JN]UC'Y>5']AI%R^Q"<,_T7WMA
M-?EW4[_N=,"[             "!T2..,VZ)?XMLU_P U0OGV(?0XKZ;6Z9<N
M7Z!8KF]G6KT^?^8"X
M       &(W?)0VEK<I?%5E7;_P!W(Z-@?I&V_P!&OR!0[_N<3T;OBI[3UJ+2
M:=E677_(9Y.';YMA;=?MT^A]SB!0@
M                                &O\ >[QQ-X??NUYT]OU V :_WWTX
MC\/I]?ZXNX_7H@;        !"<-TEN#?:_QRW]AIEV0W#WIN??4'_=92^O0I
MER ?8A.&<E+5M[)/.-;J]?X.!=OL0?#-8UG?$7Y:Y4?UZ=,"\
M  'V(G0_U6-T++_K"Q??WUBV(G1_5XM[C7[+3;.7_-50%L
M                                    ,7NK/T+ZQRM*7H=;#;Q^L9X.
M&[SP_P!N/_%]#[G$R&Z&H[9U9R>(JTK9Z?M&8[ALL</]N+V:?0^YH"D
M                                                           (
M#?KQQ X?]>GI=Q]Q9?FO]^I?3"X?-]7Z7<K[!(#8        (/A\W]&&_$_+
M4J;^P0+P@N':;W=OV77'PI!9QT_.8%Z ?9D'PV?]4&^OWY?EC_L:9>2[,@.&
M6%N+?BBVU\,ON_/PH 7X             ^Q$Z8\<7M<Z]]*M']DJEL^Q#Z6E
M]-[7>V?@JT^Z5?\ X N
M         !B-X2<-I:W))-QL:[P_W.1X>&;SP^VX\Y_*^A]HCW;P2EM+6XR[
M.QKI_P"[D8_A@V^'>VVUC\KZ'G^T0%.
M                                   0._(N7$+A[CRO+EY_U>70OB$W
MUA;^V!+S]+N5]@D!=@     !Q+L!"\//TT[[[K\M8]'^X4R[('AUE;LW[%Y>
M-4@^OOH0+X ^Q <,OT?WVO\ ',ON4"_9 <-/TP[[6&ORY;R_/ZE3 OP
M        @M&DWQCW)'KA:;9_;5"](#1NG&C<B]NEVDO^>H@+\
M                                       8G=K2VMK&>WH=;[1F/X8K
M'#O;/?KIMN_L<3W[OZ;5UG_,JWVC/!PSZ</=M+V:=;K['$"F
M               ,                                    !";Z>=][
M"@OC>EW$OF5%Y_E+LA=[I/B!L%/MZ3==/]7D!=      ?8!]@-?\.I*6\=_-
M92^$J:[>RC%&P#7_  V7]5>_G_C:*^PP_";  ,@N&RSN+?=18P]8Y?G5&G^$
MO7V(7ANL:YOGWZU)_8:0%T           !Q)-M-/ ') Z0U].G<*3ZK2+3[I
M5+X@-(C^;1N*7DM*M%G_ $ZGX +\
M  $               #$[M6=KZQEX7H=;K_H,\G#O](FW^_]84._^0CV;L>-
ML:N_99UOM&>3AX^;8FW9/ST^W?V.(%
M                                   0>^'CB)P_QC/I%WT]WH\B\-?;
MZ;7$GAZNG*Z]YG/[C_\ (&P0     /L!+MT @N'&%N3?:6?T8S]@IEZB$X<Y
M^B/?7-C/POG"_<:9=@'V(?ARFM<WOE/#UAX_W-,N&0?#!MZKOC*QC7*BQ_!T
MP+P             (;1TOIM[E?3/P;9+_FK%R1&AR_-9W/'_ !?9/_FK 6X
M       .(14%A>ULY                                         Q.
M[L?0KK.?[2K?:2/'PY_2#MSIC\KK?[G$]>\)<NU-9:66K*MTSC]8_,\G#II[
M"VZX]O@^A]SB!1
M                  &O]^?JB\/O/\D7:Q_ FP#7^^FWQ(X?13Q]7NW]@8&P
M      2[,!@07#>6=R;ZSW^%^_\  P+T@^&G76]\OS^&Y_<J9> </N07"Q\V
MJ;Y>4_R^JK*7][IE\:_X5K&K;[_?ZK]S@!L              (;0YJ7%S<ZR
MO5TZS6/]*J7) [>?YL.[8I8_(%D_E_/ +X
M         $              #"[UZ;0UMO'2QKOK^YR/+PW>=@[=;[_!]#[1
M'KWG%2VCK<9=G8UT_P#=R/#PP?-P\VX_;I]'[1 4X
M                                            !!;W3^F/P^:7_;WB
M?_#R+T@]]^KO[A_/_"[J/U[>0%X     !]@'V @^&N%N#?:7]V6_L-,O"!X;
MIPW1OV+_ +K1E]>C O@#(#A;^C&^DNWPY4?V.!?D!PP>->WW#V:U)_7IP8%^
M             $!M[IQDW8O;I]D_NA?FO]#CR\:=S?M]+M)?\U1 ;
M                            !=@               8C=_Z5=9_S*M]H
MS'<+_P!3O;?[WT/M$9+=WZ5M8S_:=;[1F/X8X^EUMG';X-M_N<0*8
M                                                         @]^
M_IXV#CJU>W#POW"77^,O"#W]E[YV EW]-N']@D!> +L    !]@'V U]PW>=V
M[^R^OPI#SS_V438)K_APOZKM_/\ QI!?8HFP ! <,^NY-^O_ !OW_@8%^0?#
M:+CN#?;Z*+UGHOX&GE@7@             :_T9OZ=NXDWT^";7'^W,V :_T?
MIQMW#CSTFUS_ +<P-@                                    @
M         8K=:SMC5E[;2M]HS'<,UR\/-M+V:=07V-&4W*L[=U18SFUJ]/\
M09C.&K;V#MYR6'Z!1Z?Z" I0
M                           "%WN_ZOM@>STNZ7_MIET06^>F_-@R3Z^F
M7*[]/ZWD!>@     ?9@/L!K_ (<I_1;OUO\ NI#[C$V 07#KINC?B2POA:+^
MO1I_@+T R%X<8^']\X:?Y<?>:9=$)PXZ;AWS%+$5J[?7OETJ>0+L
M     ('2$WQJW WV6DVJ7^\F7Q":/&7TY=PM)<GP5:9;[YYZF/YP+L
M                                            8S=#<=MZK)=U:U7_
M ,C,?PX?-P_VV_\ %UO]SB>_=7Z6=6QW]$K?:,Q_#;]3[;?[W4/N<0*0
M
MU_OYOZ/N'\4\+TRX;^:@_P )L U]O['TPN'W7KZ7<]_W%@;!78!=@    /L
M^S A.'R?T5[[Z]/A.'W"!=D+P[:ENC?<TT_RTA'I[J%,N@!"<-GS:_OIO.5K
M+CU]U&F79!\-7G<&^\+"^&7]QI@7@             1.D].+VX%_BNT?_/5+
M8A]*:?&+7L=UI-JG_O*K N
M            !B]U2Y=LZM+&<6E7IGOZC/!PWZ\/MMYZ_E=0^YH]>\4GM+6D
M^SLJ_7V?4Y'BX9//#O;;_P 7T/M$!2@
M                                  &OM^)RXA</E%)R]+NG\RMY-FP2
M!WPL\1.'[\O2;O\ _'D!?+L NP    'V  @^&_-]$N_.J<?A=8_W-,O""X;Y
M^B7?B;6?A9/[# O0!K_AC^F'?G[]2?V.'X#8#-?\,,K<&_$VW^74G]C@!L
M            (/1I)\9MQI-=-+M,_+S5"\(#1%CC5N;KWTRT?_-,"_
M                            !                P^\_P!*.M],_D*O
MT_@Y'DX;1Y.'NVD_[FV[^O3B>O>/7:6M?YE6^T9Y.&[SP]VR^GZ&6W;]RB!1
M@
M    $'O>2^F!L--=?2;KK_ ,O"$WJG+B'L)9PO'NWV[M4 +M=@$    !]@ -
M?\,L/<N_7'XOPOY]\^%#)L U_P ,EC<N_?WW^]0-@ ""X8OFUG?,O+X<J+ZU
M*F7I"\,\_"^^<]_AVI]QI 70             06C+'&G<G5_H5:/'^G4_ 7I
M Z,\\:MR=LK2K1?\]0"^
M          &'WC^E+6L?VE6^T9Y.&WZGVV\O/Y76_P!S1D-T14MM:M%]G:54
M_P#89C.&/ZG6VOWOH_:("F
M                          (3>K_-$V"O;<7:_P#;R_ 79";X>-^[ ><?
MDRY7U[:8%V@%V      ! <-&GN;?SZY6KI?88%^:^X;+EW?Q BFVOA2#^=T8
MFP0!"\-_T<WQT:7PU)_+]1IET^I!\.7_ %3;ZA[-6S]>C3 O
M  @M'7YM&XGE8^"[3I_I5"](+3.G&O75UP](M6_E\2H!>@
M                                   #'[B_2_J?^;5?M&8SAO\ J?[;
M[?H?0^YHR.YOTN:I_FM7[1F.X;//#[;;7]SJ'W- 48
M                                             !K_ '\\;_X?]LN\
MN5\W@,V :_X@==^\/\=_3;C[BP-@(!=@      0/#E8W;OY>?PG#[C OB%V!
MTWAOU?XQI/[! N@!!\..NX]]/*_1AKH_[S3+PA.'3;W)OM/RUCI_N:8%V
M          $3IB_-?UY_XJM/NE4MB)TUXXPZXO;I-J_LE4"V    ^'*7B84?
M5QGF]_L ^P                                            &.W+^E
MW5/\UJ_:,Q?#3]3W;?[WT/M$9;<.?@'4L+F?HU3I[?59A^&&?I=[:R\M:?16
M?]! 4X
M         !K[?W7B!L"*[^F7#Q\E!FP37^_\K?W#^2S_ %[<+H_;;R V NP.
M(]CD      @^'>7NS?DG++>IP7;V48%X07#N#CNW?K::SJ=/[A O0.)=B"X;
M/.Y-]]<_EQW_ (&F7LNW0@>&WZ9]^>7Y;KHOW& %^             $18O\
M-DU=)Y7P-;?,_&JEN1-ACZ<6L8Z?E/:YZ=WXM4"V
M                              &,W1/P]M:M/..6TJO/^@S%<+GGASMM
MO^T*/VB,GNUXVKK+SC%G6Z_Z#,;PP27#K;6%A?!U!_8T!3@
M                                                  $%OU?U=[ ;
M3:5[<=OW"1>D)OCUM_["CT_KJYE]:@_P@7:[        A.'S?T7[]3><:E3?
MS>! NS7_  WZ[NW_ "PEG5(+HL=J,38 !D!PU_31OWS?PLON4"_9!\-\/<&^
MI<V6]9<>7V8HT_P@7@             06F-_3JUU-M_E1;8Z]OJDR]?8@=*P
M^->OM/MI%I]TJ 7P
M      Q.[GC:FLMY_K.MV_R&>#AG^IWME>S3;=?8XF0W6N;:^L+VV=;[1F-X
M8)KAUMI/RT^@O^1 4X
M                     !#;U_5!V%_G%U]P9<D+O=+Z8&P)>:N[I?7MY 70
M       (#AQGZ+M_+_&D?N42_-?\.>F\N(&'E?"=/[C$V  ?8A.&Z:U_?'3"
M^&7A?P-,NWV(7ATU]$6^4L/\M\Y7[C3 N@            !D!I7ZMNNXZ?E/
M;)^_ZI,OWV('2XKZ=>NR7=Z/;+[),"^
M                     &-W,D]N:JGV=I5^T9B^&77AYMQI8_(%#[1&3W0\
M;:U9YQBTK//^@S'\.'S; VX_;I]#[G$"C
M                                     (+?<L;_ .'\<=[RX>?]7DL?
MQEZ0&_?U0>'W7_ZNYZ?P# OP       07#J.-V;^EC">JQZ?P,"](/A[A;NW
M[UZ_"</N$"\ /L0O#K/T0[X;>?RWQ]AIET^Q!\-4OA_?73K\-2^XTP+P
M         ?8AM*I9XP:]4YLM:5:1P_?.K^ N7V(C2OU7M?\ WJM/+]O5 MP
M                                                !C-T+FVSJ\?;
M9UE_R,QO#-N7#S;;?=Z?0^YHRVX%S:#J2]MM57_*S#<+OU.=M]_T/H]_\A 5
M
M    ! ;_ /T_</O\]N%]@D7Y \0L?1OP_?G\(UDO]Q("^       !!\/GG>&
M_>N?RSI_<(%X06P&OHWW^DL?EA1?E_:\"] ,@N&SSN+?:?=:SG[#3+V79D!P
MWDGNO?RB\_EK!_88 7X             1.G].+^L^_2+5_9:I;$19_JQZG^\
MEO\ =JH%N              !M)98
M   8_<4N3;^IS?ZVUJO_ )&8;A9^ISMS_,*/VB,ON;/T-ZMAX?HE7K_H,P_"
MMYX<[<?^ 4?M4!5
M                   $!Q$S]&O#]KRU&KU_@9%^0F_U_5GL%Y?Z(U>W[A,"
M[       P(+8&?HVW]E+]$*6._\ ]B)>D)L)KZ-]^K/_ -?0?_MX%V ?9D!P
MXZ[KW[^^L>G\# OWV-?\..F[M_\ [Z0^XP V              $+ITU+C)K,
M>GJZ/;?=:GX2Z('37CC7K2Q_8:W?V68%\
M                       ,7NG/T,ZMR]_1*N/]AF)X58^EOMKE::^#Z';_
M "$9G<GZ7]3_ ,UJ_:,PO"C]37;&4E^5U#HO\A 58
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MVW%R\OY7T'C_ $$!2@^9\V%R)-Y\W@^@
M                                  0N_$_HVV$UV5_7[_YO,NB"W_)K
M?&P5CIZ;7>?X"0%Z     !]@'V @.'^/HYW]C^WZ/W&)?D%P]BUO#?N<==2I
M_<(?A+T ^Q"\/(XW1OOIWU2#^P4RZ?9D+PYYGN#?+DTW\+XS[E1IX7U@+H
M           (#3X_FW:O+R^!:'W61?D/IT4^+^M2?QHZ3;)?(ZE3/\B N
M                                               !C-S/&W=4?^"U
M?+/ZQF.X:X?#W;;3S^5UO]S1DMR)O;VJ)?VK5^T9BN&'7AWMK][J'VB IP
M
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MSMIMY?P?1^T0%2
M                  0/$']//#_JL>G5_K^!(OB#W_'.]M@R[8OJ_7^ D!>
M     ?8!@07#W+W?OQM]?A.FNWEX$"](/A]A;OWZEC]$J;Z>^A O !!<-FWN
M;?N7G\MTOL,"](#AJ_ZJ-_)]_A9?<8 7X             1&FRSQBUA9CTT:
MV73O^?5?PEN0.DR_-KUZ/E\#VWG_ 'RH!?
M                        #%[J7-MK58XSFTK+'^@S#\*.O#;;3SG\@4?M
M49S<2SH&I+_!JOVK,!PB?YF>V<]_0*3_ .4"O
M                                         (3B TMX[#;S^B%5?8)%
MV0G$26-U[#77KJ<_N,P+L!     ?9@/L! </6WO7?^6F_A"CV_<(E^0&PI.6
M_=_],)7ENNW]XB7X U_PVZ;JW\NF?A6+Z>^C V 0'#K'T9<0,-?HE2Z?P$.H
M%^             &O],S'CEK2R\2T2W?V6:-@$!9?JYZGY+X!H?/]7G^ "_
M                                                 '@W!^@6H]<?
MD:IU_P!%F!X2K'#3;'3^Q]'[5&>U]9T+45[;>I]JS!<)L?2VVVDTTK&DNG^2
M!6
M      $%Q%6=V;";[+4ZG3'GX$R](7B#A[KV'EX_+.I]PJ 72[(!=@    /L
M !K_ & FM_<0$WG\F6[^PHV 0.PTEO\ X@8>?R5;9_W*+X 07#R.-Y;^?F]1
MI?<(%Z0NPNF\]^I=OA"B_P#V\ +H             ("RZ\<]3;:Z:#127\//
M\)?FO[+IQTU'WZ%2?V=@;
M            'BUKKI%ZEYT)_:LG^$[3X<;<<6FO0:?;Y"AUAXTJ\?\ >9_:
MLGN$\'#AOMQ-8S8TWT]ZR!6@
M                           $%Q!6-V;$DO[IS7UZ,R]('B*\;FV*LK/P
ML^GGCP9Y OEV      ^P &O]B2_-#X@17QO2;5O_ '*-@$!LF..(N_L/*=Q:
M]/?X"+\ 0NPVOHUWZL]?3J#>.W];P+HAMB.+WMOWE>?R=0S\OH\ +D
M       (.T45QNOF\<[T*GCWKQV7A#6\?S:KR2QTT.FG[>M>6/Y&!<@
M                                            #Q:TLZ/>K&?J$^G^
MBS!<*GGAOMK_ #"BO^5&?U=9TJ\7MHS^U9/\*,_2VVUGOZ#2^U JP
M                                                        #7_$
M99W=L%=ORTG]QD; (#B-GZ+M@OIA:G/I_ S OT NR      !"[)C^:!OY^7I
M-K_^.BZ(387Z=]^M_P!N6_W!%V (38/3>>_5T_1"D_L$"[(/A^\[UW_Y+X0H
M]/\ 5X 7@             1-M^K/>K_$5'[O4+8B+5M\9K_*[:)1Q_OI@6X
M                                                 \6MN:T>]\/X
M_@3Y?EY68#A,\\--LO\ P"E]J9S<7Z :E_FU3[5F"X2//#/;+RG^0:7;_) K
M0
M    #7_$5I;PV"WV^$ZB^?P9FP"#XAI?13L232PM5DOL-0"[C\5'(0
M(/83_JZW^L/I>V_7^ B7A!;!;>_.(&4EB\M^G\!'J7H @.';SO3B![?A*DOL
M,2_(#AX\[UW_ )_NC2^XQ OP           #60!!V,L\;-437;1:&'_"S+N$
M>5=V_>R!LF_IYZHNN/@*@_LT_P  %^
M  & P                /!KZSH6HK_!ZGVK,#PDCR\,=L)>>GT7]>*9G]>_
M0/4/\WJ?:LP'"-YX8[8]UA27UHH"M
M                                 (/B&VMU;$2RW\*S>%^X3ZEX07$3
M]-6PVN_PI/M^X5 +V/9 XCV1R      0'#]M[[X@MO/Y-MU]@B7YK_8&5OWB
M"LY7IEN_L"-@ ""X??ISW\_;J-)=O90@7I"[!Z;RWZL_V1I/'RV\ +H
M        (&UPN.FH=\O0*'\5>I^$OF0%GGZ>FH^SX!I?=Y 7X
M                     8#                 \>LQY](O8_LJ$U_RLF^#
M\N;AAMI_X%!%/J?Z'77[E+^0EN#GZE^W,]U:I?6; L@
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M%S^YR_D)KA)'EX:[=3BH_D2#PBDU3]#;O]RG_(R<X3M/AMMMKMZ%3_D K
M
M "!XEM+<&QNG7X9CY_WJH7QK_B7CZ)=B+.'\,+[E,#8"[ (      $#LF#CQ
M*W_)KHZMGA_P/8OB%V7^J+O[]VL_N!= "$V-UWYOV7^&6Z\__L1+L@]BM+?N
M_8K^W+=O_<1 O              B*3_-GN%C*^ J;S[/J\BW(FDOS9[C]XJ?
M_P"1("V                                                  'GU
M!<UC<KVTY?R$QPBDY<,]N-K#]$@5-YCT2OGMR2S]8E>#_P"IEMS_ #2(%@
M
M  0/$SIN'8CZ-?#*6/X*9?$!Q.ZZYL9+XWPU!XQ_>YY OUV 78      $'LF
M7YHN_8^:K6CS\M'_ ."\(/9;;XD[]:SRJI9Q^?P6_P"=%X 9![';^F#O^+\K
MJU>?EMXEX^Q [(DI<1M_8::5Q:+I[?1UD"^             ")AA<:*OM>@P
M_BN'^$MB'CZW&BIV]70HKZ]Q_P# %P
M                    //J+QI]R\M8I2ZKOV);@Z\\,-N?YI%?RE-J_72;W
M'1^!/[5DSP=_4PVWCSLX,"Q
M                           (+B5'.X=BOS6LI?8JA>D+Q'_1W8_[]1^X
MU0+I=@       0>RFGQ(W_C/2O9KM_>$7A![+EGB5O\ 73\^L_E_.%^ O #[
M&O\ 82_-"X@/R]*MET[?G"_C-@,@=B+'$'?_ +?2K9Y_@4!?
M !!4F_IY7,?):!3?_N)?@+T@8+''2NTN^WZ>7_K$P+X
M                                 >75>NF7G[C/[5DQP=ES<+]M/I_6
M<%T*C4WC3KK]RE_(R7X._J8;<[_UI'O\X%B
M                                       0?$;/T3;$Q_=;[S,O"%XB
MI?1%L5OO\+^W^\U +H       &O]BM_3(X@1?E7M']A-@$#LAOZ9._T^WC6G
MW$O@#[$'L5OZ/-_=%CTRW^7\XB7C[$)LC'T>[]ZY?I=M_P#CQ NP
M    !FOZ#_-UNHXZ? $.N?\ "'^$V 0%!?FXW<O9H,%CY:[_   7X
M                                           \VI]--NV^RI3_ )&3
M'""')PRVY%Y_K.#Z^_J5&I=-.NOW*?\ (R;X3)+AMMU+^TZ?\@%8
M                                                        0?$F
M6-P;%6'^C,>O\%,O" XFX6X=AR_QS%?8Y@7X       (+9"?TQM_]?5](M/K
M^ O_ (+T@]EIKB1OY=.5U[-]O/P$7@!]B$V-GZ.]^-QQ^3+;K_J\2[?8A-B=
M-\[\CUQZ;;OO_>(@78             1%&..,EV\)YT.EU\_S^9;D11>.,UR
MLOKH5-_9Y 6X
M  Z;Y<UE<1[9IR7\1+<(Y2EPVV^Y=_18KYEE(J[I9MJR]L'_ "$CP=>>&>W\
M?VLE_&P+(
M             U_Q1Q'6]BU&NVM4U]>$D; -?\5'^6VQU[=<H_:R V
M  "$V:N7B7OV*6/7LI?7HO\  79";1:?%#?:33Z6/GV?A3Z?_P">TNP#[$)L
ME.'$'?L7YW%K/Z]!?@+M]B#V;)_3)W[%]U5L_N %X             $/'IQI
MJ?MM 7\5P_PEP0[_ %:5^\#_ /R$!<
M                    #YJK-*:]L61O!G]3'0/W!_;2+"XER6]67LBW_$1W
M!C'TL=OX_M?_ *F!:@
M                     $!Q4PM1V0_/X>H?:R+\@.*L>;4MCKR^'J/\4)L"
M_       !!;0Q]-3?F$^UCGY?"E^%%Z0>T_U4M]>3_(*^PO\)> 'V('9K_--
MW]_EV7G_ '@OGV-?[(<GQ*W_ ,WE5LTOD\%@;              "'DU].:GW
MZ:#)?^XC^ N"!YL\;^7"6- SGS>;C_X O@
M                       !T7RS97"]M.7\A(<%GS<,- ?]X:_YY%C=K-K6
M7MA+^0C>"?ZEVW\?_8?V\@+<
M                            @N*6?A'9+CCF6NT<973XE0O2$XG==1V7
M'IEZY1?7W0F!=@     ?8!]@(+:,D^*.^DO98OK^XO\  7I ;/GS\4]]M+'*
MK*/R_4I%^!P^_P Q ;(Z<3-_QQ_VED_L+-@$#LR/YIF_9],<]E'Y_!;_ )P+
MX             (&73CG'J^NW_\ ]P7Q /UN.L?;';S?_N?_ ) OP
M                                          !TWKQ:5GY*$OY"0X+K
M'"_;W5O\C_\ 4ROO>MI67[27\A(\&DUPSV\FV_R*GU6.C; M
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M_P"VF!=
M           $#Q67)=;+KIO,-?H1QY>M"HB^(7BLDX[2R^VX+7^28%T
M!]@&!K[:3<.+6^J:^+*%C4^?PFOYC8)K[:R_-=WN\?\ 86/5_P"1(V" (79\
MN3B5OFEY/T*K\[I27UO5+HA-I-/BCOGKEJG8KOV^IS NP             @J
MT^3C=0CA-5=!EU?ERUUV^N7I W:2XX6/5Y>A5/N\0+Y=@%V
M                                    'S4^)+Y"+X-1Y>'FEKV.LOLT
MRUG\5D9P>DY</]-;Z>M66/X:8%H
M                               0?%EXAM/_ /Z"TZ^SJR\(#B[GP]HX
M[O<-GU_TF!?KL @      :_VNOS7=Z]%_6UAU_T9_@-@$'MF7YK.]%_@U@_^
M6H7@ @]H_JI;Z\ER6.5[_"EU+P@]IO\ -5WREV\.Q?V*0%X
M$%=PE+C=8M=$M!JM^_ZO!?SEZ1%QA<:++IWT*LOL],"W79
M                          ZKN56%K5E;0A4KJ+<(3ERJ4L=$WAX6?/!%
M/5.(6,K;FWT_8]5J/[R71KK<=GNE[GN:VFSNI:=6N[2#I1K<JITX\DIU(9?1
M/$XR7GE>P#UK4N(CZ_ &W$L?W3J_BCNI:COY853;^W&_-K5ZT5_^.R6L]+W5
M^0:=I/4J3HUJ=1UKJK+ZI*-&KF%6+J3RG+PU*4<)\R:73)G%I.I7^RM$MM0H
M7<=2J58QN'Z1)3MX2DW4;E%]6HKE3ZX;0'J>K[^QTVOH6<XS\,S?W@^/ACB
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M\71-MKY=1J_BBZPO8 (;TOB.^VD[6C_E:A7_ !1]1K\1GWT[:2]WI]Q^)+<
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M#T  8C4-M:+J.M6FKWVF6EQJ=HDJ%U4IIU*:3;7*_+#;?SF7
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M2\>K5KP4(OQHSKJMR9?;$HXRO)OW-60 16$L@
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M !A)OIW  -)IIK*?D&DUAI->P  ,++>.K  82;:2R^["23;267W  ))9PNX
M        R
M      #>        /: !QY#+  9ZHY  XB\@ #GR.$^P '(
M'V                \@  \@ .!D  VQD !GJ<2;78 #DY
M    80
             #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>bcrx20200630_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcrx="http://www.biocryst.com/20200630"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcrx-20200630.xsd" xlink:type="simple"/>
    <context id="d_2020-01-01_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i_2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i_2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i_2019-06-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-23</instant>
        </period>
    </context>
    <context id="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-31</endDate>
        </period>
    </context>
    <context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-30_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-30_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="d_2015-04-01_2020-06-30_TypeOfArrangementAxis-ASPRBARDAContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_StatementScenarioAxis-ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-11-05</endDate>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-16</startDate>
            <endDate>2015-06-16</endDate>
        </period>
    </context>
    <context id="d_2015-06-16_2020-06-30_CounterpartyNameAxis-CSLLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-16</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-04</startDate>
            <endDate>2020-03-04</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-06-01</startDate>
            <endDate>2006-06-30</endDate>
        </period>
    </context>
    <context id="d_2006-02-28_2006-02-28_TypeOfArrangementAxis-MundipharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-02-28</startDate>
            <endDate>2006-02-28</endDate>
        </period>
    </context>
    <context id="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-11</instant>
        </period>
    </context>
    <context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2000-06-01</startDate>
            <endDate>2000-06-30</endDate>
        </period>
    </context>
    <context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2000-06-30</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-03-01</startDate>
            <endDate>2011-03-09</endDate>
        </period>
    </context>
    <context id="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-03-01</startDate>
            <endDate>2011-03-09</endDate>
        </period>
    </context>
    <context id="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-05</endDate>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilitySecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-05</endDate>
        </period>
    </context>
    <context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-05</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="d_2020-06-01_2020-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i_2020-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i_2020-06-30_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <unit id="JPYPerUSD">
        <divide>
            <unitNumerator>
                <measure>iso4217:JPY</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>iso4217:USD</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2020-01-01_2020-06-30"
      id="thunderdome-EntityCentralIndexKey">0000882796</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2020-01-01_2020-06-30"
      id="thunderdome-EntityRegistrantName">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2020-01-01_2020-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2020-01-01_2020-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2020-01-01_2020-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2020-01-01_2020-06-30">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-06-30"
      decimals="INF"
      id="c63926980"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c63926981"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-06-30"
      decimals="-6"
      id="c63926982"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2019-12-31"
      decimals="-6"
      id="c63926983"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926984"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926985"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926987"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926988"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-06-30"
      decimals="INF"
      id="c63926992"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c63926993"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-06-30"
      decimals="-7"
      id="c63926994"
      unitRef="Share">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2019-12-31"
      decimals="-7"
      id="c63926995"
      unitRef="Share">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926996"
      unitRef="Share">176429000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926998"
      unitRef="Share">176429000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926997"
      unitRef="Share">154082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926999"
      unitRef="Share">154082000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c63927165"
      unitRef="Share">110000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927195"
      unitRef="Share">193000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927205"
      unitRef="Share">22044000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bcrx:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927215"
      unitRef="Share">3511000</bcrx:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c63927255"
      unitRef="Share">160000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927265"
      unitRef="Share">47000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-5"
      id="c63927295"
      unitRef="Share">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <bcrx:MaturityPeriodOfHighQualityMarketablesecurities
      contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember"
      id="c63927396">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      id="c63927423">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"
      id="c63927425">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-06-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      id="c63927426">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927438"
      unitRef="USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927479"
      unitRef="USD">341000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i_2020-06-30_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"
      decimals="-3"
      id="c63927506"
      unitRef="USD">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="i_2019-12-31_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"
      decimals="-3"
      id="c63927507"
      unitRef="USD">0</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      id="c63927695">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="d_2020-01-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927701"
      unitRef="Share">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      id="c63927723">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bcrx:ContractTerm
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      id="c63927844">P5Y</bcrx:ContractTerm>
    <bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
      contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      id="c63927862">P10Y</bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01"
      id="c63927876">P0Y6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <bcrx:RenewablePeriodOfAgreement
      contextRef="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"
      id="c63927906">P5Y</bcrx:RenewablePeriodOfAgreement>
    <dei:DocumentType contextRef="d_2020-01-01_2020-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2020-01-01_2020-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2020-01-01_2020-06-30">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2020-01-01_2020-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2020-01-01_2020-06-30">000-23186</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2020-01-01_2020-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2020-01-01_2020-06-30">62-1413174</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2020-01-01_2020-06-30">4505 Emperor Blvd., Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2020-01-01_2020-06-30">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2020-01-01_2020-06-30">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2020-01-01_2020-06-30">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2020-01-01_2020-06-30">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2020-01-01_2020-06-30">859-1302</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2020-01-01_2020-06-30">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2020-01-01_2020-06-30">BCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2020-01-01_2020-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2020-01-01_2020-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2020-01-01_2020-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2020-01-01_2020-06-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2020-01-01_2020-06-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2020-01-01_2020-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2020-01-01_2020-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2020-07-31" decimals="INF" unitRef="Share">176565622</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926934"
      unitRef="USD">173468000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926935"
      unitRef="USD">114172000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926936"
      unitRef="USD">2188000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926937"
      unitRef="USD">1551000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926938"
      unitRef="USD">15935000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926939"
      unitRef="USD">22054000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926940"
      unitRef="USD">3997000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926941"
      unitRef="USD">22146000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926942"
      unitRef="USD">5233000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926943"
      unitRef="USD">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926944"
      unitRef="USD">3016000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926945"
      unitRef="USD">4422000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926946"
      unitRef="USD">203837000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926947"
      unitRef="USD">164345000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926948"
      unitRef="USD">7149000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926949"
      unitRef="USD">7347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2020-06-30"
      decimals="-4"
      id="c63926950"
      unitRef="USD">3720000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c63926951"
      unitRef="USD">3590000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926952"
      unitRef="USD">214706000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926953"
      unitRef="USD">175282000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926955"
      unitRef="USD">9354000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926956"
      unitRef="USD">13988000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926957"
      unitRef="USD">24843000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926959"
      unitRef="USD">21365000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926960"
      unitRef="USD">17806000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926962"
      unitRef="USD">14904000</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926963"
      unitRef="USD">715000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c63926964"
      unitRef="USD">2120000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926965"
      unitRef="USD">1096000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926966"
      unitRef="USD">1377000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926967"
      unitRef="USD">19056000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c63926968"
      unitRef="USD">9020000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2020-06-30"
      decimals="-4"
      id="c63926969"
      unitRef="USD">29780000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926970"
      unitRef="USD">29561000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-06-30"
      decimals="-4"
      id="c63926971"
      unitRef="USD">102650000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926972"
      unitRef="USD">92335000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926973"
      unitRef="USD">3834000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926974"
      unitRef="USD">3406000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LineOfCredit
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926975"
      unitRef="USD">31715000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926976"
      unitRef="USD">41289000</us-gaap:LineOfCredit>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926978"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926979"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63926989"
      unitRef="USD">1764000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63926991"
      unitRef="USD">1541000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927000"
      unitRef="USD">991574000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2019-12-31"
      decimals="-5"
      id="c63927001"
      unitRef="USD">877300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927002"
      unitRef="USD">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927003"
      unitRef="USD">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927004"
      unitRef="USD">-916834000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927005"
      unitRef="USD">-840628000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927006"
      unitRef="USD">76507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927007"
      unitRef="USD">38252000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927008"
      unitRef="USD">214706000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927009"
      unitRef="USD">175282000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927011"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927012"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927013"
      unitRef="USD">218000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927014"
      unitRef="USD">1679000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927015"
      unitRef="USD">44000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927016"
      unitRef="USD">696000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927017"
      unitRef="USD">1989000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927018"
      unitRef="USD">3018000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927019"
      unitRef="USD">2827000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927020"
      unitRef="USD">752000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927021"
      unitRef="USD">5487000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927022"
      unitRef="USD">2638000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927023"
      unitRef="USD">2871000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927024"
      unitRef="USD">1448000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927025"
      unitRef="USD">7694000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927026"
      unitRef="USD">7335000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927028"
      unitRef="USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927029"
      unitRef="USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927030"
      unitRef="USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927031"
      unitRef="USD">1399000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927032"
      unitRef="USD">27498000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927033"
      unitRef="USD">27681000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927034"
      unitRef="USD">57365000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927035"
      unitRef="USD">55174000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927036"
      unitRef="USD">13883000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927037"
      unitRef="USD">8659000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927038"
      unitRef="USD">29748000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927039"
      unitRef="USD">14897000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927040"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927041"
      unitRef="USD">26000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927042"
      unitRef="USD">69000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927043"
      unitRef="USD">113000</us-gaap:RoyaltyExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927044"
      unitRef="USD">41381000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927045"
      unitRef="USD">36366000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927046"
      unitRef="USD">87182000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927047"
      unitRef="USD">71583000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-4"
      id="c63927048"
      unitRef="USD">-38510000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927049"
      unitRef="USD">-34918000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927050"
      unitRef="USD">-79488000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927051"
      unitRef="USD">-64248000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927052"
      unitRef="USD">2758000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927053"
      unitRef="USD">547000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927054"
      unitRef="USD">9204000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927055"
      unitRef="USD">1143000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927056"
      unitRef="USD">2918000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927057"
      unitRef="USD">3035000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927058"
      unitRef="USD">5965000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927059"
      unitRef="USD">5761000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927060"
      unitRef="USD">63000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927061"
      unitRef="USD">-223000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927062"
      unitRef="USD">43000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927063"
      unitRef="USD">183000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927064"
      unitRef="USD">-38607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927065"
      unitRef="USD">-37629000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927066"
      unitRef="USD">-76206000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927067"
      unitRef="USD">-68683000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927068"
      unitRef="USD">-11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-4"
      id="c63927069"
      unitRef="USD">130000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927070"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927071"
      unitRef="USD">338000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927072"
      unitRef="USD">-38618000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927073"
      unitRef="USD">-37499000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927074"
      unitRef="USD">-76242000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927075"
      unitRef="USD">-68345000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-04-01_2020-06-30"
      decimals="INF"
      id="c63927076"
      unitRef="USDPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-04-01_2019-06-30"
      decimals="INF"
      id="c63927077"
      unitRef="USDPerShare">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-06-30"
      decimals="INF"
      id="c63927078"
      unitRef="USDPerShare">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-01-01_2019-06-30"
      decimals="INF"
      id="c63927079"
      unitRef="USDPerShare">-0.62</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927080"
      unitRef="Share">161569000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927081"
      unitRef="Share">110338000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927082"
      unitRef="Share">157862000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927083"
      unitRef="Share">110253000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927085"
      unitRef="USD">-76206000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927086"
      unitRef="USD">-68683000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927088"
      unitRef="USD">401000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927089"
      unitRef="USD">357000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927090"
      unitRef="USD">6034000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927091"
      unitRef="USD">8702000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927092"
      unitRef="USD">681000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927093"
      unitRef="USD">596000</us-gaap:AmortizationOfFinancingCosts>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927094"
      unitRef="USD">104000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927095"
      unitRef="USD">-17000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-4"
      id="c63927096"
      unitRef="USD">-590000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927097"
      unitRef="USD">-646000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927099"
      unitRef="USD">-18149000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927100"
      unitRef="USD">-691000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927101"
      unitRef="USD">5233000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927102"
      unitRef="USD">-649000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927103"
      unitRef="USD">-817000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927104"
      unitRef="USD">-84000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927106"
      unitRef="USD">-1156000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927108"
      unitRef="USD">2579000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927109"
      unitRef="USD">2902000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927110"
      unitRef="USD">2897000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927111"
      unitRef="USD">-1405000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927112"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927113"
      unitRef="USD">-54322000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927114"
      unitRef="USD">-51499000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927116"
      unitRef="USD">187000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-4"
      id="c63927117"
      unitRef="USD">180000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927118"
      unitRef="USD">15438000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927119"
      unitRef="USD">3018000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927120"
      unitRef="USD">21417000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927121"
      unitRef="USD">41357000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927122"
      unitRef="USD">5792000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927123"
      unitRef="USD">38159000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927125"
      unitRef="USD">92848000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927126"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927127"
      unitRef="USD">14817000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927128"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927129"
      unitRef="USD">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927130"
      unitRef="USD">19477000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927131"
      unitRef="USD">798000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927132"
      unitRef="USD">977000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927133"
      unitRef="USD">108463000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927134"
      unitRef="USD">20454000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927135"
      unitRef="USD">59933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927136"
      unitRef="USD">7114000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927137"
      unitRef="USD">115723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c63927138"
      unitRef="USD">28275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927139"
      unitRef="USD">175656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-06-30"
      decimals="-3"
      id="c63927140"
      unitRef="USD">35389000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927141"
      unitRef="USD">1541000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-5"
      id="c63927142"
      unitRef="USD">877300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927143"
      unitRef="USD">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927144"
      unitRef="USD">-840628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927145"
      unitRef="USD">38252000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927146"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927147"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927148"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927149"
      unitRef="USD">-37599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="-3"
      id="c63927150"
      unitRef="USD">-37599000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927151"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927152"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927153"
      unitRef="USD">-25000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927154"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-03-31"
      decimals="-3"
      id="c63927155"
      unitRef="USD">-25000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927156"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927157"
      unitRef="USD">265000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927158"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927159"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-03-31"
      decimals="-3"
      id="c63927160"
      unitRef="USD">266000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927166"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927167"
      unitRef="USD">2754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927168"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927169"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-03-31"
      decimals="-3"
      id="c63927170"
      unitRef="USD">2754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927171"
      unitRef="USD">1542000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927172"
      unitRef="USD">880319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927173"
      unitRef="USD">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927174"
      unitRef="USD">-878227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-03-31"
      decimals="-3"
      id="c63927175"
      unitRef="USD">3648000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927176"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927177"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927178"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927179"
      unitRef="USD">-38607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927180"
      unitRef="USD">-38607000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927181"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927182"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927183"
      unitRef="USD">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927184"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927185"
      unitRef="USD">-11000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927186"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c63927187"
      unitRef="USD">530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927188"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927189"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927190"
      unitRef="USD">532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c63927196"
      unitRef="USD">220000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927197"
      unitRef="USD">92628000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927198"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927199"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927200"
      unitRef="USD">92848000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927206"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927207"
      unitRef="USD">14817000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927208"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927209"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927210"
      unitRef="USD">14817000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927216"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c63927217"
      unitRef="USD">3280000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927218"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-04-01_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927219"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-4"
      id="c63927220"
      unitRef="USD">3280000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927221"
      unitRef="USD">1764000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927222"
      unitRef="USD">991574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927223"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927224"
      unitRef="USD">-916834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927225"
      unitRef="USD">76507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927226"
      unitRef="USD">1101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-5"
      id="c63927227"
      unitRef="USD">780400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927228"
      unitRef="USD">-297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927229"
      unitRef="USD">-731969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c63927230"
      unitRef="USD">49235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927231"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927232"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927233"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927234"
      unitRef="USD">238000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"
      decimals="-3"
      id="c63927235"
      unitRef="USD">238000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927236"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927237"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927238"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927239"
      unitRef="USD">-31054000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-3"
      id="c63927240"
      unitRef="USD">-31054000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927241"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927242"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927243"
      unitRef="USD">208000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927244"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-3"
      id="c63927245"
      unitRef="USD">208000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927246"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927247"
      unitRef="USD">341000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927248"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927249"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-3"
      id="c63927250"
      unitRef="USD">343000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927256"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c63927257"
      unitRef="USD">220000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927258"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927259"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-4"
      id="c63927260"
      unitRef="USD">220000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927266"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927267"
      unitRef="USD">3317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927268"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927269"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-3"
      id="c63927270"
      unitRef="USD">3317000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927271"
      unitRef="USD">1103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927272"
      unitRef="USD">784278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927273"
      unitRef="USD">-89000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927274"
      unitRef="USD">-762785000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-03-31"
      decimals="-3"
      id="c63927275"
      unitRef="USD">22507000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927276"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927277"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927278"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927279"
      unitRef="USD">-37629000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927280"
      unitRef="USD">-37629000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927281"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927282"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-4"
      id="c63927283"
      unitRef="USD">130000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927284"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-4"
      id="c63927285"
      unitRef="USD">130000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927286"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927287"
      unitRef="USD">413000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927288"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927289"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927290"
      unitRef="USD">414000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927296"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927297"
      unitRef="USD">5385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927298"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-04-01_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927299"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927300"
      unitRef="USD">5385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-06-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c63927301"
      unitRef="USD">1104000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-06-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c63927302"
      unitRef="USD">790076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-06-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c63927303"
      unitRef="USD">41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-06-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c63927304"
      unitRef="USD">-800414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-06-30"
      decimals="-3"
      id="c63927305"
      unitRef="USD">-9193000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621663">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; - Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"&gt;With the funds available at &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company believes these resources will be sufficient to fund its operations through the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; expenses will exceed its &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern through &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the progression of its product candidates in the future. The Company also &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consider other plans to fund operations through &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; including: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) raising additional capital through equity or debt financings or from other sources; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;) reducing spending on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more research and development programs, including by discontinuing development; and/or (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) restructuring operations to change its overhead structure. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"/&gt;   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on &lt;em style="font: inherit;"&gt; March 9, 2011. &lt;/em&gt;See Note &lt;em style="font: inherit;"&gt;4,&lt;/em&gt; Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a $23,000 senior credit facility that the Company closed on &lt;em style="font: inherit;"&gt; September 23, 2016 &lt;/em&gt;and subsequently amended and restated on each of &lt;em style="font: inherit;"&gt; July 20, 2018 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; February 5, 2019. &lt;/em&gt;See Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; for a further description of these transactions. All intercompany transactions and balances have been eliminated.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; adjustments other than normal recurring adjustments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;These financial statements should be read in conjunction with the financial statements for the year ended &lt;em style="font: inherit;"&gt; December 31, 2019 &lt;/em&gt;and the notes thereto included in the Company&#x2019;s &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K. Interim operating results are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of operating results for the full year. The balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2019 &lt;/em&gt;has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Restricted cash as of &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019 &lt;/em&gt;reflects $766 and $134, respectively, in royalty revenue paid by Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;) and $1,422 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;span style="-sec-ix-hidden:c63927396"&gt;three&lt;/span&gt; years and requires an average portfolio maturity of &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 18 months. Some of the securities the Company invests in &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have market risk. This means that a change in prevailing interest rates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; collateralized. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; realized any significant losses from its investments.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company believes that the cost of its investments is recoverable in all material respects.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;June 30&lt;/b&gt;&lt;b&gt;, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Obligations of the U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,991&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,991&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;944&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,929&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,935&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,561&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,742&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,669&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,899&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Collaborations&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;At &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the Company had the following receivables.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;June 30&lt;/b&gt;&lt;b&gt;, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,253&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,272&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Mundipharma International Holdings Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Seqirus UK Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;1,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;2,253&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;3,997&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,353&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,023&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,376&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Green Cross Corporation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,924&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Mundipharma International Holdings Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Seqirus UK Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,091&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;351&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,442&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;6,760&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;15,386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;22,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Product Sales&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;Inventory is stated at the lower of cost and net realizable value, determined under the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&#160; At &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company&#x2019;s inventory consisted of $1,723 of peramivir raw materials and $3,510 of peramivir work-in-process.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"/&gt;   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;span style="-sec-ix-hidden:c63927423"&gt;three&lt;/span&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;span style="-sec-ix-hidden:c63927425"&gt;five&lt;/span&gt; years. Furniture and fixtures are depreciated over a life of &lt;span style="-sec-ix-hidden:c63927426"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Patents and Licenses&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"/&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:30.7pt;"&gt;The Company generally enters into contractual agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;professional fees.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Accumulated Other Comprehensive Loss&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;realized gains of $1 were reclassified out of accumulated other comprehensive loss. &lt;span style="-sec-ix-hidden:c63927438"&gt;No&lt;/span&gt; reclassifications out of accumulated other comprehensive loss were recorded during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2019.&lt;/em&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;em style="font: inherit;"/&gt;&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"&gt;The Company has collaboration and license agreements with a number of &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Arrangements that involve the delivery of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Product Sales&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"&gt;The Company&#x2019;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#x2019;s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;The Company recorded the following revenues for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Three Months&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,018&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Collaborative and other research and development revenues:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,545&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Torii Pharmaceutical Co., Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;282&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total collaborative and other research and development revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,827&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Contract Balances&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contract assets&lt;/i&gt;&lt;/span&gt;&lt;i&gt; &lt;/i&gt;- The Company&#x2019;s long-term contracts, typically the government research and development contracts, are billed as work progresses&lt;i&gt; &lt;/i&gt;in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheet.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/span&gt;&lt;i&gt; &lt;/i&gt;- The Company often receives cash payments from customers in advance of the Company&#x2019;s performance resulting in contract&lt;i&gt; &lt;/i&gt;liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize the revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Contract Costs&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that the Company expects to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that the Company does expect to recover are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:30.7pt;"&gt;Additionally, the Company has license agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Interest Expense and Deferred Financing Costs&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;Interest expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $2,918 and $3,035, respectively, and for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $5,965 and $5,761, respectively, related to the issuance of the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;) and the Second Amended and Restated Senior Credit Facility (defined in Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;). Costs directly associated with the issuance of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was $341 for each of the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively, and $681 and $596 for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively.&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Currency Hedge Agreement&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; resulted in losses of $590 and $646, respectively. Mark to market adjustments are determined by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party pricing model that uses quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of $632 and $830 during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c63927506"&gt;&lt;span style="-sec-ix-hidden:c63927507"&gt;no&lt;/span&gt;&lt;/span&gt; hedge collateral was posted under the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include 14,007 and 1,927, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include 12,963 and 2,528, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Significant Customers and Other Risks&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Significant Customers&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Other than royalty revenues, the Company&#x2019;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly &lt;em style="font: inherit;"&gt;BCX4430&lt;/em&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Centers for Disease Control and Prevention. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:28pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;rely on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assumed credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:33.65pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of&lt;/i&gt; &lt;i&gt;Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;)&lt;i&gt;.&lt;/i&gt;&lt;i&gt; &lt;/i&gt;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires a financial asset (or a group of financial assets) measured at amortized&lt;i&gt; &lt;/i&gt;cost basis to be presented at the net amount expected to be collected. In addition, ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:33.65pt;"&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; as of &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;Given the nature of the Company&#x2019;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2018, &lt;/em&gt;the FASB issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15,&lt;/em&gt; &lt;i&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic&lt;/i&gt; &lt;i&gt;&lt;em style="font: inherit;"&gt;350&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;) &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&#x201d;&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service&lt;i&gt; &lt;/i&gt;contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2019, &lt;/em&gt;with early adoption permitted. The Company elected to adopt this standard early, beginning &lt;em style="font: inherit;"&gt; October 1, 2019 &lt;/em&gt;on a prospective basis. Adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;"/&gt;  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63928935">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"&gt;With the funds available at &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company believes these resources will be sufficient to fund its operations through the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; expenses will exceed its &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern through &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the progression of its product candidates in the future. The Company also &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consider other plans to fund operations through &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; including: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) raising additional capital through equity or debt financings or from other sources; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;) reducing spending on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more research and development programs, including by discontinuing development; and/or (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) restructuring operations to change its overhead structure. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.&lt;/p&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63928938">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (&#x201c;Royalty Sub&#x201d;) and MDCP, LLC (&#x201c;MDCP&#x201d;). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on &lt;em style="font: inherit;"&gt; March 9, 2011. &lt;/em&gt;See Note &lt;em style="font: inherit;"&gt;4,&lt;/em&gt; Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a $23,000 senior credit facility that the Company closed on &lt;em style="font: inherit;"&gt; September 23, 2016 &lt;/em&gt;and subsequently amended and restated on each of &lt;em style="font: inherit;"&gt; July 20, 2018 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; February 5, 2019. &lt;/em&gt;See Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; for a further description of these transactions. All intercompany transactions and balances have been eliminated.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; adjustments other than normal recurring adjustments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;These financial statements should be read in conjunction with the financial statements for the year ended &lt;em style="font: inherit;"&gt; December 31, 2019 &lt;/em&gt;and the notes thereto included in the Company&#x2019;s &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K. Interim operating results are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of operating results for the full year. The balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2019 &lt;/em&gt;has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized
      contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c63927359"
      unitRef="USD">30000000</bcrx:RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized>
    <us-gaap:LineOfCredit
      contextRef="i_2016-09-23_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-6"
      id="c63927365"
      unitRef="USD">23000000</us-gaap:LineOfCredit>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929022">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2020-01-01_2020-06-30" id="c63929023">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Restricted cash as of &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019 &lt;/em&gt;reflects $766 and $134, respectively, in royalty revenue paid by Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;) and $1,422 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"
      decimals="-3"
      id="c63927388"
      unitRef="USD">766000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"
      decimals="-3"
      id="c63927389"
      unitRef="USD">134000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-06-30_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"
      decimals="-3"
      id="c63927392"
      unitRef="USD">1422000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"
      decimals="-3"
      id="c63927393"
      unitRef="USD">1417000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929060">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;span style="-sec-ix-hidden:c63927396"&gt;three&lt;/span&gt; years and requires an average portfolio maturity of &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 18 months. Some of the securities the Company invests in &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have market risk. This means that a change in prevailing interest rates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; collateralized. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; realized any significant losses from its investments.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company believes that the cost of its investments is recoverable in all material respects.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;June 30&lt;/b&gt;&lt;b&gt;, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Obligations of the U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,991&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,991&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;944&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,929&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,935&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,561&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,742&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,669&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,899&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities
      contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember"
      id="c63927399">P18M</bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:MaturityperiodOfShortTermInvestment
      contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember"
      id="c63927407">P12M</bcrx:MaturityperiodOfShortTermInvestment>
    <bcrx:LongtermInvestmentMaturityMinimum
      contextRef="d_2020-01-01_2020-06-30_RangeAxis-MinimumMember"
      id="c63927409">P12M</bcrx:LongtermInvestmentMaturityMinimum>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="d_2020-01-01_2020-06-30"
      id="c6040A63A-B15A-4988-8636-B6988314190C">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;June 30&lt;/b&gt;&lt;b&gt;, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Obligations of the U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,991&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;14,991&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;944&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,929&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,935&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Accrued&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Interest&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Estimated&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,488&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;23&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,561&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,742&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;59&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,669&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,899&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;116&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,054&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927573"
      unitRef="USD">14991000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927574"
      unitRef="USD">0</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927575"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927576"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-06-30_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927577"
      unitRef="USD">14991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927578"
      unitRef="USD">938000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927579"
      unitRef="USD">3000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927580"
      unitRef="USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927581"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-06-30_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927582"
      unitRef="USD">944000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927583"
      unitRef="USD">15929000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927584"
      unitRef="USD">3000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927585"
      unitRef="USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927586"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927587"
      unitRef="USD">15935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927588"
      unitRef="USD">10488000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-4"
      id="c63927589"
      unitRef="USD">50000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927590"
      unitRef="USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927591"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c63927592"
      unitRef="USD">10561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c63927593"
      unitRef="USD">9742000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c63927594"
      unitRef="USD">59000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-4"
      id="c63927595"
      unitRef="USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c63927596"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-4"
      id="c63927597"
      unitRef="USD">9810000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927598"
      unitRef="USD">1669000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927599"
      unitRef="USD">7000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927600"
      unitRef="USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927601"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c63927602"
      unitRef="USD">1683000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927603"
      unitRef="USD">21899000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927604"
      unitRef="USD">116000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c63927605"
      unitRef="USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927606"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927607"
      unitRef="USD">22054000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929083">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Collaborations&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;At &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the Company had the following receivables.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;June 30&lt;/b&gt;&lt;b&gt;, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,253&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,272&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Mundipharma International Holdings Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Seqirus UK Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;1,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;2,253&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;3,997&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,353&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,023&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,376&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Green Cross Corporation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,924&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Mundipharma International Holdings Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Seqirus UK Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,091&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;351&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,442&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;6,760&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;15,386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;22,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b/&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Product Sales&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock
      contextRef="d_2020-01-01_2020-06-30"
      id="c36E0A6AB-F144-45E2-AF5F-E385202D3C7F">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;June 30&lt;/b&gt;&lt;b&gt;, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,253&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,272&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,683&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Mundipharma International Holdings Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Seqirus UK Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;1,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;2,253&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;3,997&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,353&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15,023&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,376&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,336&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,340&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Green Cross Corporation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,924&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Mundipharma International Holdings Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Seqirus UK Limited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,091&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;351&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,442&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;6,760&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;15,386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;22,146&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
   </bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927608"
      unitRef="USD">19000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927609"
      unitRef="USD">2253000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927610"
      unitRef="USD">2272000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c63927611"
      unitRef="USD">1683000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c63927612"
      unitRef="USD">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c63927613"
      unitRef="USD">1683000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c63927614"
      unitRef="USD">35000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c63927615"
      unitRef="USD">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c63927616"
      unitRef="USD">35000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c63927617"
      unitRef="USD">7000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c63927618"
      unitRef="USD">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c63927619"
      unitRef="USD">7000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="-3"
      id="c63927620"
      unitRef="USD">1744000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="-3"
      id="c63927621"
      unitRef="USD">2253000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927622"
      unitRef="USD">3997000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927623"
      unitRef="USD">1353000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927624"
      unitRef="USD">15023000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927625"
      unitRef="USD">16376000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c63927626"
      unitRef="USD">1336000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c63927627"
      unitRef="USD">4000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-4"
      id="c63927628"
      unitRef="USD">1340000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c63927629"
      unitRef="USD">2924000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c63927630"
      unitRef="USD">8000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c63927631"
      unitRef="USD">2932000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c63927632"
      unitRef="USD">56000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c63927633"
      unitRef="USD">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c63927634"
      unitRef="USD">56000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c63927635"
      unitRef="USD">1091000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c63927636"
      unitRef="USD">351000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c63927637"
      unitRef="USD">1442000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="-4"
      id="c63927638"
      unitRef="USD">6760000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="-3"
      id="c63927639"
      unitRef="USD">15386000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c63927640"
      unitRef="USD">22146000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929068">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;Inventory is stated at the lower of cost and net realizable value, determined under the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out (&#x201c;FIFO&#x201d;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&#160; At &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company&#x2019;s inventory consisted of $1,723 of peramivir raw materials and $3,510 of peramivir work-in-process.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927421"
      unitRef="USD">1723000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2020-06-30"
      decimals="-4"
      id="c63927422"
      unitRef="USD">3510000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929069">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;span style="-sec-ix-hidden:c63927423"&gt;three&lt;/span&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;span style="-sec-ix-hidden:c63927425"&gt;five&lt;/span&gt; years. Furniture and fixtures are depreciated over a life of &lt;span style="-sec-ix-hidden:c63927426"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2020-01-01_2020-06-30" id="c63929070">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Patents and Licenses&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929071">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:30.7pt;"&gt;The Company generally enters into contractual agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance and drug products; and&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:12pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width:11pt;vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;&#x2022;&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:top;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"&gt;professional fees.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/p&gt;</bcrx:AccruedExpensesPolicyTextBlock>    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929072">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929073">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Accumulated Other Comprehensive Loss&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;realized gains of $1 were reclassified out of accumulated other comprehensive loss. &lt;span style="-sec-ix-hidden:c63927438"&gt;No&lt;/span&gt; reclassifications out of accumulated other comprehensive loss were recorded during the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2019.&lt;/em&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927437"
      unitRef="USD">1000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929074">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"&gt;The Company has collaboration and license agreements with a number of &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Arrangements that involve the delivery of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Product Sales&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"&gt;The Company&#x2019;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#x2019;s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;The Company recorded the following revenues for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; and &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Three Months&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,018&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Collaborative and other research and development revenues:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,545&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Torii Pharmaceutical Co., Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;282&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total collaborative and other research and development revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,827&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Contract Balances&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contract assets&lt;/i&gt;&lt;/span&gt;&lt;i&gt; &lt;/i&gt;- The Company&#x2019;s long-term contracts, typically the government research and development contracts, are billed as work progresses&lt;i&gt; &lt;/i&gt;in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheet.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;i&gt;Contract liabilities&lt;/i&gt;&lt;/span&gt;&lt;i&gt; &lt;/i&gt;- The Company often receives cash payments from customers in advance of the Company&#x2019;s performance resulting in contract&lt;i&gt; &lt;/i&gt;liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize the revenue.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Contract Costs&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that the Company expects to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that the Company does expect to recover are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621668">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Three Months&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;Six Months&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,018&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Collaborative and other research and development revenues:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,545&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Torii Pharmaceutical Co., Ltd.&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;282&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total collaborative and other research and development revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,827&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;752&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,487&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,638&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,448&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,335&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927641"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927642"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927643"
      unitRef="USD">218000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c63927644"
      unitRef="USD">1679000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927645"
      unitRef="USD">44000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927646"
      unitRef="USD">696000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927647"
      unitRef="USD">1989000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c63927648"
      unitRef="USD">3018000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927650"
      unitRef="USD">2545000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927651"
      unitRef="USD">752000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927652"
      unitRef="USD">4152000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927653"
      unitRef="USD">2638000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927654"
      unitRef="USD">282000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927655"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927656"
      unitRef="USD">1335000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927657"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927658"
      unitRef="USD">2827000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927659"
      unitRef="USD">752000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927660"
      unitRef="USD">5487000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c63927661"
      unitRef="USD">2638000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927662"
      unitRef="USD">2871000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927663"
      unitRef="USD">1448000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927664"
      unitRef="USD">7694000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927665"
      unitRef="USD">7335000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2020-01-01_2020-06-30" id="c63929075">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:30.7pt;"&gt;Additionally, the Company has license agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2020-01-01_2020-06-30" id="c63929076">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929077">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Interest Expense and Deferred Financing Costs&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;Interest expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;30,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $2,918 and $3,035, respectively, and for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $5,965 and $5,761, respectively, related to the issuance of the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;) and the Second Amended and Restated Senior Credit Facility (defined in Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt;). Costs directly associated with the issuance of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was $341 for each of the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively, and $681 and $596 for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively.&lt;/p&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927467"
      unitRef="USD">2918000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c63927469"
      unitRef="USD">3035000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927472"
      unitRef="USD">5965000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927474"
      unitRef="USD">5761000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c63927477"
      unitRef="USD">341000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927482"
      unitRef="USD">681000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927484"
      unitRef="USD">596000</us-gaap:AmortizationOfFinancingCosts>
    <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929078">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Currency Hedge Agreement&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; resulted in losses of $590 and $646, respectively. Mark to market adjustments are determined by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party pricing model that uses quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of $632 and $830 during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c63927506"&gt;&lt;span style="-sec-ix-hidden:c63927507"&gt;no&lt;/span&gt;&lt;/span&gt; hedge collateral was posted under the agreement.&lt;/p&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-4"
      id="c63927492"
      unitRef="USD">590000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c63927494"
      unitRef="USD">646000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c63927499"
      unitRef="USD">632000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-4"
      id="c63927500"
      unitRef="USD">830000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929079">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include 14,007 and 1,927, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include 12,963 and 2,528, respectively, of such potential common shares, as their impact would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-04-01_2020-06-30"
      decimals="INF"
      id="c63927512"
      unitRef="Share">14007</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2019-04-01_2019-06-30"
      decimals="INF"
      id="c63927513"
      unitRef="Share">1927</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927518"
      unitRef="Share">12963000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927519"
      unitRef="Share">2528000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates contextRef="d_2020-01-01_2020-06-30" id="c63929080">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>    <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929081">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Significant Customers and Other Risks&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Significant Customers&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Other than royalty revenues, the Company&#x2019;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly &lt;em style="font: inherit;"&gt;BCX4430&lt;/em&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Centers for Disease Control and Prevention. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:28pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;rely on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assumed credit risk.&lt;/p&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>    <bcrx:AverageMaturityForPortfolioInvestments
      contextRef="d_2020-01-01_2020-06-30_RangeAxis-MaximumMember"
      id="c63927524">P18M</bcrx:AverageMaturityForPortfolioInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-06-30" id="c63929082">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:33.65pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of&lt;/i&gt; &lt;i&gt;Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;)&lt;i&gt;.&lt;/i&gt;&lt;i&gt; &lt;/i&gt;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires a financial asset (or a group of financial assets) measured at amortized&lt;i&gt; &lt;/i&gt;cost basis to be presented at the net amount expected to be collected. In addition, ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:33.65pt;"&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; as of &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;Given the nature of the Company&#x2019;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2018, &lt;/em&gt;the FASB issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15,&lt;/em&gt; &lt;i&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic&lt;/i&gt; &lt;i&gt;&lt;em style="font: inherit;"&gt;350&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;) &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&#x201d;&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service&lt;i&gt; &lt;/i&gt;contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2019, &lt;/em&gt;with early adoption permitted. The Company elected to adopt this standard early, beginning &lt;em style="font: inherit;"&gt; October 1, 2019 &lt;/em&gt;on a prospective basis. Adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621669">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; - Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.55pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company had &lt;em style="font: inherit;"&gt;three&lt;/em&gt; stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the Amended and Restated Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Amended and Restated Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated on &lt;em style="font: inherit;"&gt; March 19, 2020 &lt;/em&gt;and approved by the Company&#x2019;s stockholders on &lt;em style="font: inherit;"&gt; May 12, 2020. &lt;/em&gt;The Inducement Plan was adopted by the Board of Directors on &lt;em style="font: inherit;"&gt; April 24, 2019 &lt;/em&gt;and amended and restated by the Board of Directors in &lt;em style="font: inherit;"&gt; February 2020 &lt;/em&gt;and in &lt;em style="font: inherit;"&gt; July 2020. &lt;/em&gt;The ESPP was amended and restated in &lt;em style="font: inherit;"&gt; March 2020 &lt;/em&gt;and approved by the Company&#x2019;s stockholders in &lt;em style="font: inherit;"&gt; May 2020. &lt;/em&gt;Stock-based compensation expense of $6,034 ($5,205 of expense related to the Incentive Plan, $710 of expense related to the Inducement Plan, and $119 of expense related to the ESPP) was recognized during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; while $8,702 ($8,535 of expense related to the Incentive Plan, $16 of expense related to the Inducement Plan and $151 of expense related to the ESPP) was recognized during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt;&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;There was approximately $22,873 of total unrecognized compensation cost related to non-vested stock option awards granted by the Company as of &lt;em style="font: inherit;"&gt; June 30, 2020. &lt;/em&gt;That cost is expected to be recognized as follows: $5,251 during the remainder of &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; $8,086 in &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; $6,604 in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; $2,668 in &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; and $264 in &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt; In addition, the Company has outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Stock Incentive Plan&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 10pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after &lt;span style="-sec-ix-hidden:c63927695"&gt;four&lt;/span&gt; years. In &lt;em style="font: inherit;"&gt; August 2013, &lt;/em&gt;&lt;em style="font: inherit;"&gt; December 2014 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the Company issued 1,032, 1,250 and 315 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;75% of the &lt;em style="font: inherit;"&gt; August 2013 &lt;/em&gt;grants have vested. As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;85% of the &lt;em style="font: inherit;"&gt; December 2014 &lt;/em&gt;grants have vested. As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c63927701"&gt;none&lt;/span&gt; of the &lt;em style="font: inherit;"&gt; December 2019 &lt;/em&gt;grants have vested. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company recognized $86 of compensation expense related to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; milestone within the &lt;em style="font: inherit;"&gt; December 2019 &lt;/em&gt;grants for which achievement became probable. During &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company recognized $4,998 of stock compensation expense related to &lt;em style="font: inherit;"&gt;two&lt;/em&gt; milestones within the &lt;em style="font: inherit;"&gt; December 2014 &lt;/em&gt;grants for which achievement became probable. Stock option awards granted to non-employee directors of the Company generally vest over &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year. All stock option awards have contractual terms of 10 years. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&lt;/p&gt;   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;


   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.2%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;Related activity under the Incentive Plan is as follows:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:14%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.9%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.7%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;968&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21,050&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Plan amendment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(547&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;547&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.87&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(193&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.76&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,495&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,495&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance June 30, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;10,894&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;18,909&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 18pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"&gt;For stock option awards granted under the Incentive Plan during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $3.35 and $4.69, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/p&gt;   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Inducement Equity Incentive Plan&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:18pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant and generally vest 25% each year until fully vested after &lt;span style="-sec-ix-hidden:c63927723"&gt;four&lt;/span&gt; years. Each stock option has a term of 10 years and is subject to the terms and conditions of the Inducement Plan. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.2%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;Related activity under the Inducement Plan is as follows:&lt;/p&gt; &lt;/td&gt;&lt;td style="vertical-align:bottom;width:14%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:13.9%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.9%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.7%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;171&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,329&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.60&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Plan amendment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,502&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,502&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance June 30, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;514&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;2,686&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;For stock option awards granted under the Inducement Plan during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $3.67 and $3.94, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan and the Inducement Plan during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon government issues with a remaining term equal to the expected term.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"&gt;&lt;b&gt;Employees and Directors under the Plans&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1px solid black;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Life in Years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;81.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Dividend Yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-Free Interest Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;&lt;b&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;The Company has reserved a total of 4,475 shares of common stock to be purchased under the ESPP, of which 3,009 shares remain available for purchase at &lt;em style="font: inherit;"&gt; June 30, 2020. &lt;/em&gt;Eligible employees &lt;em style="font: inherit;"&gt; may &lt;/em&gt;authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month purchase intervals. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; more than 3 shares &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be purchased by any &lt;em style="font: inherit;"&gt;one&lt;/em&gt; employee at the &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month purchase dates, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; employee &lt;em style="font: inherit;"&gt; may &lt;/em&gt;purchase stock having a fair market value at the commencement date of $25 or more in any &lt;em style="font: inherit;"&gt;one&lt;/em&gt; calendar year. The Company issued 110 shares during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.&lt;/p&gt;  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927668"
      unitRef="USD">6034000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927669"
      unitRef="USD">5205000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-4"
      id="c63927670"
      unitRef="USD">710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c63927671"
      unitRef="USD">119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927675"
      unitRef="USD">8702000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927676"
      unitRef="USD">8535000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927677"
      unitRef="USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c63927678"
      unitRef="USD">151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927682"
      unitRef="USD">22873000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927683"
      unitRef="USD">5251000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927685"
      unitRef="USD">8086000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927687"
      unitRef="USD">6604000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927689"
      unitRef="USD">2668000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927691"
      unitRef="USD">264000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c63927694"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-3"
      id="c63927696"
      unitRef="Share">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-4"
      id="c63927697"
      unitRef="Share">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-3"
      id="c63927698"
      unitRef="Share">315000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-06-30_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="2"
      id="c63927699"
      unitRef="Pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-06-30_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="2"
      id="c63927700"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-04-01_2020-06-30_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927703"
      unitRef="USD">86000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927706"
      unitRef="USD">4998000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember"
      id="c63927709">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="d_2020-01-01_2020-06-30"
      id="ACCEC004-2B9B-4339-987E-002BE916D98C">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;968&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21,050&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.96&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Plan amendment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(547&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;547&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.87&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(193&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.76&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,495&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,495&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6.66&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance June 30, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;10,894&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;18,909&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2019&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;171&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,329&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.60&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Plan amendment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,502&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,502&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.34&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance June 30, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;514&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;2,686&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927776"
      unitRef="Share">968000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-4"
      id="c63927777"
      unitRef="Share">21050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927778"
      unitRef="USDPerShare">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-6"
      id="c63927779"
      unitRef="Share">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927782"
      unitRef="Share">22000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927785"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927788"
      unitRef="Share">547000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927789"
      unitRef="Share">547000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927790"
      unitRef="USDPerShare">4.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927792"
      unitRef="Share">193000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927793"
      unitRef="USDPerShare">2.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927794"
      unitRef="Share">2495000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927795"
      unitRef="Share">2495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927796"
      unitRef="USDPerShare">6.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927797"
      unitRef="Share">10894000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c63927798"
      unitRef="Share">18909000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2020-06-30_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927799"
      unitRef="USDPerShare">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927719"
      unitRef="USDPerShare">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c63927720"
      unitRef="USDPerShare">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c63927722"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      id="c63927725">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927806"
      unitRef="Share">171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927807"
      unitRef="Share">1329000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927808"
      unitRef="USDPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-5"
      id="c63927809"
      unitRef="Share">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927812"
      unitRef="Share">1502000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927813"
      unitRef="Share">1502000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927814"
      unitRef="USDPerShare">3.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927816"
      unitRef="Share">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927817"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927818"
      unitRef="Share">145000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927819"
      unitRef="Share">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927820"
      unitRef="USDPerShare">4.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927821"
      unitRef="Share">514000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927822"
      unitRef="Share">2686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2020-06-30_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927823"
      unitRef="USDPerShare">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927738"
      unitRef="USDPerShare">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2019-01-01_2019-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c63927740"
      unitRef="USDPerShare">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c63927747"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621672">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1px solid black;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Life in Years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;83.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;81.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Dividend Yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-Free Interest Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c63927824">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c63927825">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c63927826"
      unitRef="Pure">0.837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="2"
      id="c63927827"
      unitRef="Pure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c63927828"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c63927829"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c63927830"
      unitRef="Pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2019-01-01_2019-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c63927831"
      unitRef="Pure">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c63927751"
      unitRef="Share">4475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c63927752"
      unitRef="Share">3009000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c63927753"
      unitRef="Pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
    <bcrx:PercentageOfCommonStockSharesBeginning
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c63927754"
      unitRef="Pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
    <bcrx:PercentageOfCommonStockSharesEnding
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c63927755"
      unitRef="Pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c63927758"
      unitRef="Share">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount
      contextRef="i_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c63927762"
      unitRef="USD">25000</bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2020-01-01_2020-06-30_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-4"
      id="c63927764"
      unitRef="Share">110000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621673">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; - Collaborative and Other Research and Development Contracts&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; September 2013, &lt;/em&gt;NIAID/HHS contracted with the Company for the&lt;i&gt; &lt;/i&gt;development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&#x201c;i.v.&#x201d;) and intramuscular (&#x201c;i.m.&#x201d;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Yellow Fever and Ebola virus disease, and to conduct an initial Phase &lt;em style="font: inherit;"&gt;1&lt;/em&gt; human clinical trial. In &lt;em style="font: inherit;"&gt; April 2020, &lt;/em&gt;the Company and NIAID/HHS agreed to add a group of COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; patients to the ongoing clinical trial in Yellow Fever. On &lt;em style="font: inherit;"&gt; April 9, 2020, &lt;/em&gt;the Company announced it had opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-&lt;em style="font: inherit;"&gt;19.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program is $43,035. As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;all options have been exercised under this contract.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;U.S. Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;). &lt;/i&gt;On &lt;em style="font: inherit;"&gt; March 31, 2015, &lt;/em&gt;the Company announced that BARDA/HHS had awarded&lt;i&gt; &lt;/i&gt;the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;a total of $20,574 has been awarded under exercised options within this contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;)&lt;/i&gt;. On &lt;em style="font: inherit;"&gt; September 6, 2018, &lt;/em&gt;the Company announced that HHS had awarded the Company a&lt;i&gt; &lt;/i&gt;$34,660 contract for the procurement of up to &lt;em style="font: inherit;"&gt;50,000&lt;/em&gt; doses of RAPIVAB (peramivir injection) over a &lt;span style="-sec-ix-hidden:c63927844"&gt;five&lt;/span&gt;-year period. HHS&#x2019;s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation&#x2019;s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. The Company delivered &lt;em style="font: inherit;"&gt;two&lt;/em&gt; shipments under this contract in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; for a total price of approximately $13,864, and expects to deliver at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; shipment within the award in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; totaling approximately $6,932.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;). &lt;/i&gt;On &lt;em style="font: inherit;"&gt; November 5, 2019, &lt;/em&gt;the Company announced that it had entered into the Torii Agreement, granting&lt;i&gt; &lt;/i&gt;Torii the exclusive right to commercialize ORLADEYO&#x2122; (berotralstat) for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks in Japan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000 and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be eligible to receive an additional milestone payment of either $20,000 if the Japanese Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;) grants regulatory approval on or before &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;or $15,000 if regulatory approval is granted on or before &lt;em style="font: inherit;"&gt; December 31, 2021. &lt;/em&gt;In either case, the regulatory milestone payment is contingent upon receipt of a reimbursement price approval from Japan&#x2019;s National Health Insurance system in excess of the threshold specified in the Torii Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;In addition, the Company will be entitled under the Torii Agreement to receive tiered royalty payments based on the amount of annual net sales of ORLADEYO in Japan during each calendar year. If ORLADEYO maintains its Sakigake designation during the PMDA review, the tiered royalty rate will range from 20% to 40% of net sales; otherwise, the tiered royalty rate will range from 15% to 35% of net sales. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commence upon the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in Japan and expire upon the later of (i) the &lt;span style="-sec-ix-hidden:c63927862"&gt;tenth&lt;/span&gt; anniversary of the date of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in Japan, (ii) the expiration of our patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Under the Torii Agreement, the Company has granted Torii a right of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; negotiation (&#x201c;ROFN&#x201d;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if the Company develops ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party arbitrator.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the &lt;em style="font: inherit;"&gt;$22,000&lt;/em&gt; upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used and an expected cost plus margin approach was utilized for the other performance obligations. The Company recognized $20,101 in revenue in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; including $19,344 associated with the license which was transferred to Torii at the execution of the Agreement and $757 related to the year to date services provided in the performance of the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; approvals. The remaining $1,899 of the &lt;em style="font: inherit;"&gt;$22,000&lt;/em&gt; upfront payment is expected to be recognized as revenue in &lt;span style="-sec-ix-hidden:c63927876"&gt;2020&lt;/span&gt; as the services are delivered.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;Seqirus UK Limited (&#x201c;SUL&#x201d;). &lt;/i&gt;On &lt;em style="font: inherit;"&gt; June 16, 2015, &lt;/em&gt;the Company and SUL, a limited company organized under the laws of the United Kingdom and a&lt;i&gt; &lt;/i&gt;subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#x201c;Territory&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA. Pursuant to rights to sell ALPIVAB in the EU, the Company was also responsible for regulatory filings and interactions with the European Medicines Agency (&#x201c;EMA&#x201d;). In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development. In &lt;em style="font: inherit;"&gt; October 2017, &lt;/em&gt;SUL transferred Canadian registration rights for RAPIVAB to the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;Under the terms of the SUL Agreement, the Company has received an upfront payment of $33,740 and has achieved all development milestones under the contract totaling $12,000. The Company is entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as &lt;em style="font: inherit;"&gt; July 1 - &lt;/em&gt;&lt;em style="font: inherit;"&gt; June 30) &lt;/em&gt;and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstances or events impacting the overall market opportunity. SUL's royalty payment obligations commenced on the date of the SUL Agreement. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company and SUL entered arbitration proceedings that involved many items under the SUL Agreement including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, the EMA approval milestone, which BioCryst maintains is due under the contract as well as appropriately commercializing peramivir in the Territory. On &lt;em style="font: inherit;"&gt; March 4, 2020, &lt;/em&gt;the International Court of Arbitration of the International Chamber of Commerce (&#x201c;ICC Tribunal&#x201d;) delivered a Partial Arbitration Award (the &#x201c;Partial Arbitration Award&#x201d;) in the arbitration matter between the Company and SUL with respect to the SUL Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties have agreed on a transition process for the product, including a full transition of commercialization of the product in the U.S. to the Company as of &lt;em style="font: inherit;"&gt; August 1, 2020 &lt;/em&gt;and a full transition of commercialization of the product in Australia as of &lt;em style="font: inherit;"&gt; November 1, 2020. &lt;/em&gt;The ICC Tribunal also awarded the Company its attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to the Company within &lt;em style="font: inherit;"&gt;30&lt;/em&gt; days of the approval of peramivir for adult use in the European Union and awarded the Company $5,000 (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#x2019; fees and for any dispute relating to the return to the Company of all rights to peramivir in the Territory. The Company recorded the settlement gain of $8,893 in other income and legal fees and other expenses of $5,026 in selling, general and administrative expenses for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020.&lt;/em&gt;&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;i&gt;Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2007, &lt;/em&gt;the Company entered into an exclusive license agreement with Shionogi to develop and&lt;i&gt; &lt;/i&gt;commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In &lt;em style="font: inherit;"&gt; October 2008, &lt;/em&gt;the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2017, &lt;/em&gt;the Company, on behalf of Royalty Sub, instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings have concluded, with the decision that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; sales milestones have been achieved and that the royalties will remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;Green Cross Corporation (&#x201c;Green Cross&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; June 2006, &lt;/em&gt;the Company entered into an agreement with Green Cross to develop and commercialize&lt;i&gt; &lt;/i&gt;peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&lt;i&gt;Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2006, &lt;/em&gt;the Company entered into an exclusive, royalty bearing right&lt;i&gt; &lt;/i&gt;and license agreement with Mundipharma for the development and commercialization of Mundesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology (the &#x201c;Original Agreement&#x201d;). Under the terms of the Original Agreement, Mundipharma obtained rights to Mundesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"&gt;On &lt;em style="font: inherit;"&gt; November 11, 2011, &lt;/em&gt;the Company entered into the Amended and Restated License and Development Agreement (the &#x201c;Amended and Restated Agreement&#x201d;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to Mundesine. Commencing on &lt;em style="font: inherit;"&gt; November 11, 2011, &lt;/em&gt;Mundipharma controls the development and commercialization of Mundesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.35pt;"&gt;&lt;i&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; June 2000, &lt;/em&gt;the&lt;i&gt; &lt;/i&gt;Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately &lt;em style="font: inherit;"&gt;one&lt;/em&gt; quarter of future payments received from other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated by the Company at any time by giving 60 days advance notice or in the event of material uncured breach by the Licensors.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;In &lt;em style="font: inherit;"&gt; May 2010, &lt;/em&gt;the Company amended the license agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-half in the percentage of future payments received from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; apply to (i) any milestone payments the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive in the future under its license agreement dated &lt;em style="font: inherit;"&gt; February 1, 2006 &lt;/em&gt;with Mundipharma and (ii) royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;On &lt;em style="font: inherit;"&gt; November 17, 2011, &lt;/em&gt;the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-half in the percentage of Net Proceeds (as defined in the license agreement) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;On &lt;em style="font: inherit;"&gt; June 19, 2012, &lt;/em&gt;the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be made either in cash, in shares of the Company&#x2019;s common stock, or in a combination of cash and shares.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;On &lt;em style="font: inherit;"&gt; January 6, 2014, &lt;/em&gt;the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#x201c;VUW&#x201d;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;&lt;i&gt;The University of Alabama at Birmingham (&#x201c;UAB&#x201d;). &lt;/i&gt;The Company currently has agreements with UAB for influenza neuraminidase and&lt;i&gt; &lt;/i&gt;complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners. The Company has completed the research under the UAB agreements. These &lt;em style="font: inherit;"&gt;two&lt;/em&gt; agreements each have an initial 25-year term, are automatically renewable for &lt;span style="-sec-ix-hidden:c63927906"&gt;five&lt;/span&gt;-year terms throughout the life of the last patent and are terminable by the Company upon &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently &lt;em style="font: inherit;"&gt;no&lt;/em&gt; activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b/&gt;&lt;/p&gt;
  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="d_2013-09-01_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-6"
      id="c63927833"
      unitRef="USD">5000000</bcrx:CollaborativeAgreementContractValue>
    <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c63927837"
      unitRef="USD">43035000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember"
      decimals="-3"
      id="c63927838"
      unitRef="USD">16265000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember"
      decimals="-3"
      id="c63927839"
      unitRef="USD">22855000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"
      decimals="-4"
      id="c63927840"
      unitRef="USD">39120000</us-gaap:GovernmentContractReceivable>
    <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2015-04-01_2020-06-30_TypeOfArrangementAxis-ASPRBARDAContractMember"
      decimals="-3"
      id="c63927841"
      unitRef="USD">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-4"
      id="c63927842"
      unitRef="USD">34660000</bcrx:CollaborativeAgreementContractValue>
    <us-gaap:ProceedsFromCollaborators
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c63927847"
      unitRef="USD">13864000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_StatementScenarioAxis-ScenarioForecastMember"
      decimals="-3"
      id="c63927850"
      unitRef="USD">6932000</us-gaap:ProceedsFromCollaborators>
    <bcrx:UpfrontPaymentsReceivableAmount
      contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-6"
      id="c63927851"
      unitRef="USD">22000000</bcrx:UpfrontPaymentsReceivableAmount>
    <bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-7"
      id="c63927852"
      unitRef="USD">20000000</bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020>
    <bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-6"
      id="c63927853"
      unitRef="USD">15000000</bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c63927855"
      unitRef="Pure">0.20</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"
      decimals="1"
      id="c63927856"
      unitRef="Pure">0.40</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:RoyaltyRateOtherwise
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c63927857"
      unitRef="Pure">0.15</bcrx:RoyaltyRateOtherwise>
    <bcrx:RoyaltyRateOtherwise
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c63927858"
      unitRef="Pure">0.35</bcrx:RoyaltyRateOtherwise>
    <bcrx:MaximumCustomaryReductionOnRoyaltyRate
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="1"
      id="c63927860"
      unitRef="Pure">0.50</bcrx:MaximumCustomaryReductionOnRoyaltyRate>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-3"
      id="c63927869"
      unitRef="USD">20101000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c63927871"
      unitRef="USD">19344000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember"
      decimals="-3"
      id="c63927872"
      unitRef="USD">757000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01"
      decimals="-3"
      id="c63927874"
      unitRef="USD">1899000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember"
      decimals="-4"
      id="c63927877"
      unitRef="USD">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
    <bcrx:MilestonePaymentReceived
      contextRef="d_2015-06-16_2020-06-30_CounterpartyNameAxis-CSLLimitedMember"
      decimals="-6"
      id="c63927878"
      unitRef="USD">12000000</bcrx:MilestonePaymentReceived>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"
      decimals="-6"
      id="c63927882"
      unitRef="USD">5000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"
      decimals="-3"
      id="c63927883"
      unitRef="USD">8893000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LegalFees
      contextRef="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"
      decimals="-3"
      id="c63927884"
      unitRef="USD">5026000</us-gaap:LegalFees>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember"
      decimals="-4"
      id="c63927888"
      unitRef="USD">250000</us-gaap:ProceedsFromLicenseFeesReceived>
    <bcrx:UpfrontPaymentsReceivableAmount
      contextRef="d_2006-02-28_2006-02-28_TypeOfArrangementAxis-MundipharmaMember"
      decimals="-7"
      id="c63927889"
      unitRef="USD">10000000</bcrx:UpfrontPaymentsReceivableAmount>
    <bcrx:PotentialMilestonePaymentsReceivable
      contextRef="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember"
      decimals="-6"
      id="c63927890"
      unitRef="USD">15000000</bcrx:PotentialMilestonePaymentsReceivable>
    <bcrx:MilestonePaymentMinimum
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-5"
      id="c63927891"
      unitRef="USD">1400000</bcrx:MilestonePaymentMinimum>
    <bcrx:MilestonePaymentMaximum
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-6"
      id="c63927892"
      unitRef="USD">4000000</bcrx:MilestonePaymentMaximum>
    <bcrx:AnnualLicenseFeeMinimum
      contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-4"
      id="c63927895"
      unitRef="USD">150000</bcrx:AnnualLicenseFeeMinimum>
    <bcrx:AnnualLicenseFeeMaximum
      contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-5"
      id="c63927896"
      unitRef="USD">500000</bcrx:AnnualLicenseFeeMaximum>
    <bcrx:AdvanceNoticePeriodForTerminationOfAgreement
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      id="c63927897">P60D</bcrx:AdvanceNoticePeriodForTerminationOfAgreement>
    <bcrx:PeriodOfAgreement
      contextRef="d_2020-01-01_2020-06-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"
      id="c63927905">P25Y</bcrx:PeriodOfAgreement>
    <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621674">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; - Royalty Monetization&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;i&gt;Overview&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;On &lt;em style="font: inherit;"&gt; March 9, 2011, &lt;/em&gt;the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the &lt;em style="font: inherit;"&gt; September 2012 &lt;/em&gt;interest payment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of &lt;em style="font: inherit;"&gt; March 9, 2011 &lt;/em&gt;with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen, and milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impacted as a result of this transaction.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;Non-Recourse Notes Payable&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;On &lt;em style="font: inherit;"&gt; March 9, 2011, &lt;/em&gt;Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; (the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of &lt;em style="font: inherit;"&gt; March 9, 2011 (&lt;/em&gt;the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on &lt;em style="font: inherit;"&gt; September &lt;/em&gt;&lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;but is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to, make capital contributions to a capital account that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be used to redeem, or on up to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:30.7pt;"&gt;In &lt;em style="font: inherit;"&gt; September 2014, &lt;/em&gt;Royalty Sub was unable to pay the accrued interest obligation due &lt;em style="font: inherit;"&gt; September 3, 2013. &lt;/em&gt;Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in &lt;em style="font: inherit;"&gt; September 2013 &lt;/em&gt;by the next succeeding Payment Date for the PhaRMA Notes, which was &lt;em style="font: inherit;"&gt; September 1, 2014, &lt;/em&gt;constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the &lt;em style="font: inherit;"&gt; December 31, 2014 &lt;/em&gt;balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes &lt;em style="font: inherit;"&gt; may &lt;/em&gt;pursue acceleration of the PhaRMA Notes, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;incur costs associated with liquidating the related Currency Hedge Agreement, which would &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the PhaRMA Notes remain in default.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:36pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Indenture does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the aggregate fair value of the PhaRMA Notes was estimated to be approximately 3% of the PhaRMA Notes carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;i&gt;Currency Hedge Agreement&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The Currency Hedge Agreement does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#x2019;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; resulted in losses of $590 and $646 respectively.&lt;/p&gt;
  </bcrx:RoyaltyMonetizationTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-7"
      id="c63927912"
      unitRef="USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-3"
      id="c63927913"
      unitRef="USD">22691000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <bcrx:TransactionCosts
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-3"
      id="c63927914"
      unitRef="USD">4309000</bcrx:TransactionCosts>
    <bcrx:InterestReserve
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-6"
      id="c63927915"
      unitRef="USD">3000000</bcrx:InterestReserve>
    <bcrx:PrivatePlacementOfSeniorSecuredNotes
      contextRef="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c63927917"
      unitRef="USD">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c63927918"
      unitRef="Pure">0.140</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c63927920"
      unitRef="Pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1
      contextRef="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c63927929"
      unitRef="Pure">0.03</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c63927930"
      unitRef="USD">30000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"
      decimals="INF"
      id="c63927932"
      unitRef="JPYPerUSD">100</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-4"
      id="c63927936"
      unitRef="USD">590000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2019-01-01_2019-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c63927937"
      unitRef="USD">646000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621675">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; - Senior Credit Facility&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;On &lt;em style="font: inherit;"&gt; February 5, 2019, &lt;/em&gt;the Company entered into a $100,000 Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#x201c;Second Amended and Restated Senior Credit Facility&#x201d;). Borrowings under the Second Amended and Restated Senior Credit Facility will be available in &lt;em style="font: inherit;"&gt;three&lt;/em&gt; tranches, with (i) the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; tranche comprised of $50,000 funded at closing, which included $30,000 of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#x2019;s prior credit agreement, (ii) the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche to be comprised of $30,000, and (iii) the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; tranche to be comprised of $20,000, with the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; tranches to be funded upon the completion of certain contingencies related to the Company&#x2019;s development activities of its product candidates and the establishment of certain financial covenants. On &lt;em style="font: inherit;"&gt; September 10, 2019 &lt;/em&gt;the Company executed the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche to &lt;em style="font: inherit;"&gt; November 30, 2019. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 30, 2019, &lt;/em&gt;the Company&#x2019;s access to the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche expired.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of &lt;em style="font: inherit;"&gt; July 20, 2018 (&lt;/em&gt;the &#x201c;Amended and Restated Senior Credit Facility&#x201d;). The Second Amended and Restated Senior Credit Facility bears a variable interest rate of LIBOR (which shall &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be less than 0.5%) plus 8%. The Second Amended and Restated Senior Credit Facility includes an interest-only payment period through &lt;em style="font: inherit;"&gt; June 2020 &lt;/em&gt;and scheduled monthly principal and interest payments for the subsequent 30 months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility, and the remainder will be used for general corporate purposes. Under the Second Amended and Restated Senior Credit Facility, the Company must maintain a minimum cash balance of $25,000 of unrestricted cash at all times.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the Company had borrowings of $50,000 under the Second Amended and Restated Senior Credit Facility bearing an interest rate of 8.5%. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. The remaining scheduled principal repayments of the Second Amended and Restated Senior Credit Facility are as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Principal Payments&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 80.3%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;50,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"&gt;The debt agreement contains &lt;em style="font: inherit;"&gt;two&lt;/em&gt; provisions that if deemed probable would create the recognition of an embedded feature; however, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe either provision is probable.&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-8"
      id="c63927942"
      unitRef="USD">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c63927945"
      unitRef="USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c63927946"
      unitRef="USD">30000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c63927948"
      unitRef="USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c63927950"
      unitRef="USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <bcrx:DebtInstrumentMinimumLibor
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="3"
      id="c63927957"
      unitRef="Pure">0.005</bcrx:DebtInstrumentMinimumLibor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="2"
      id="c63927958"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      id="c63927959">P30M</us-gaap:DebtInstrumentTerm>
    <bcrx:LineOfCreditRestrictedCashRequired
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-6"
      id="c63927960"
      unitRef="USD">25000000</bcrx:LineOfCreditRestrictedCashRequired>
    <us-gaap:LineOfCredit
      contextRef="i_2020-06-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c63927962"
      unitRef="USD">50000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i_2020-06-30_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="3"
      id="c63927963"
      unitRef="Pure">0.085</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621676">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;Principal Payments&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 80.3%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;20,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
       &lt;td&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;50,000&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i_2020-06-30"
      decimals="-7"
      id="c63927966"
      unitRef="USD">10000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i_2020-06-30"
      decimals="-7"
      id="c63927967"
      unitRef="USD">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i_2020-06-30"
      decimals="-7"
      id="c63927968"
      unitRef="USD">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt
      contextRef="i_2020-06-30"
      decimals="-7"
      id="c63927969"
      unitRef="USD">50000000</us-gaap:LongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621677">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; - Stockholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:26.75pt;"&gt;On &lt;em style="font: inherit;"&gt; April 24, 2020, &lt;/em&gt;the Company filed a $500,000 shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; with the SEC. This shelf registration statement became effective on &lt;em style="font: inherit;"&gt; May 14, 2020 &lt;/em&gt;and allows the Company to sell securities, including common stock, preferred stock, depository shares, purchase contracts, warrants, debt securities and units, from time to time at prices and on terms to be determined at the time of sale. On &lt;em style="font: inherit;"&gt; June 1, 2020, &lt;/em&gt;the Company completed an underwritten public offering of 22,044,447 shares of its common stock (including shares issued pursuant to the underwriters&#x2019; &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day option to purchase additional shares, which was exercised in full), at a purchase price of $4.50 per share, and pre-funded warrants to purchase 3,511,111 shares of common stock, at a purchase price of $4.49 per pre-funded warrant, for total net proceeds to the Company of $107,665 after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The pre-funded warrants are immediately exercisable and have an exercise price of $0.01 per share, which is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting the Company&#x2019;s common stock and also upon any distributions of assets to the Company&#x2019;s stockholders.&lt;/p&gt;  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bcrx:MaximumAggregateOfferingPrice
      contextRef="i_2020-04-24"
      decimals="-8"
      id="c63927971"
      unitRef="USD">500000000</bcrx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-06-01_2020-06-01"
      decimals="INF"
      id="c63927973"
      unitRef="Share">22044447</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-06-01"
      decimals="INF"
      id="c63927975"
      unitRef="USDPerShare">4.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"
      decimals="INF"
      id="c63927976"
      unitRef="Share">3511111</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <bcrx:ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant
      contextRef="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"
      decimals="INF"
      id="c63927977"
      unitRef="USDPerShare">4.49</bcrx:ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2020-06-01_2020-06-01"
      decimals="-3"
      id="c63927978"
      unitRef="USD">107665000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"
      decimals="INF"
      id="c63927979"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LeasesOfLessorDisclosureTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621678">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:justify;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &#x2013; Lease Obligations and Other Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases at &lt;em style="font: inherit;"&gt; June 30, 2020. &lt;/em&gt;Certain operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Renewal options for the Company&#x2019;s leases range from 1 to 5 years in length and begin from &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; At &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;the weighted average lease term for the Company&#x2019;s operating leases was 13.6 years. The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions. The weighted average discount rate for the Company&#x2019;s operating leases was 12.7%.&lt;/p&gt;   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:30.7pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; made any residual value guarantees related to its operating leases; therefore, the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; corresponding liability recorded on its Consolidated Balance Sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 16pt 0pt 0pt; text-align: left; text-indent: 30.7pt;"&gt;Aggregate lease expense under operating leases was $935 and $706 for the &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; June 30, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; June 30, 2019, &lt;/em&gt;respectively. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months or less was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:30.7pt;"&gt;&#160;&lt;/p&gt;


   &lt;table border="0" cellpadding="0" cellspacing="0" style="margin-left:5.5%;width:84.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;
    &lt;tbody&gt;
     &lt;tr&gt;
      &lt;td colspan="2" style="vertical-align:bottom;width:84%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;Future lease payments for assets under operating leases as of &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;are as follows:&lt;/p&gt; &lt;/td&gt;
      &lt;td style="vertical-align:bottom;width:0.8%;"&gt;&#160;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;width:5%;"&gt;&#160;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;width:10.1%;"&gt;&#160;&lt;/td&gt;
     &lt;/tr&gt;

    &lt;/tbody&gt;
   &lt;/table&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;b&gt;Remaining Maturities of Lease Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;835&lt;/td&gt;
       &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;749&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;575&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;568&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,903&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,295&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less imputed interest&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,365&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,930&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:36pt;"&gt;Of the Company&#x2019;s total lease liability, $1,096 is a current liability and $3,834 is a long-term liability at &lt;em style="font: inherit;"&gt; June 30, 2020. &lt;/em&gt;The current and long-term portions of the Company&#x2019;s lease liability are presented within &#x201c;Accrued expenses&#x201d; and &#x201c;Other non-current liabilities&#x201d; on the Consolidated Balance Sheets. The Company&#x2019;s right-of-use asset balance associated with operating leases totaled $3,720 at &lt;em style="font: inherit;"&gt; June 30, 2020. &lt;/em&gt;This amount is presented within &#x201c;Other long-term assets&#x201d; on the Consolidated Balance Sheets.&lt;/p&gt;
  </us-gaap:LeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2020-06-30_RangeAxis-MinimumMember"
      id="c63927981">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2020-06-30_RangeAxis-MaximumMember"
      id="c63927982">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2020-06-30" id="c63927985">P13Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2020-06-30"
      decimals="3"
      id="c63927986"
      unitRef="Pure">0.127</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2020-01-01_2020-06-30"
      decimals="-3"
      id="c63927989"
      unitRef="USD">935000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2019-01-01_2019-06-30"
      decimals="-3"
      id="c63927990"
      unitRef="USD">706000</us-gaap:OperatingLeaseExpense>
    <bcrx:LesseeLeaseLiabilityMaturityTableTextBlock contextRef="d_2020-01-01_2020-06-30" id="c1621679">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;b&gt;Remaining Maturities of Lease Liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;835&lt;/td&gt;
       &lt;td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;749&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;665&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;575&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;568&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;7,903&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,295&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less imputed interest&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,365&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,930&lt;/td&gt;
       &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </bcrx:LesseeLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927998"
      unitRef="USD">835000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63927999"
      unitRef="USD">749000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63928000"
      unitRef="USD">665000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63928001"
      unitRef="USD">575000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63928002"
      unitRef="USD">568000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63928003"
      unitRef="USD">7903000</bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63928004"
      unitRef="USD">11295000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2020-06-30"
      decimals="-3"
      id="c63928005"
      unitRef="USD">6365000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember"
      decimals="-4"
      id="c63928006"
      unitRef="USD">4930000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2020-06-30_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember"
      decimals="-3"
      id="c63927995"
      unitRef="USD">1096000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-3"
      id="c63927996"
      unitRef="USD">3834000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2020-06-30_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-4"
      id="c63927997"
      unitRef="USD">3720000</us-gaap:OperatingLeaseRightOfUseAsset>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831693868360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1413174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4505 Emperor Blvd., Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-1302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,565,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831693584744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 173,468<span></span>
</td>
<td class="nump">$ 114,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">15,935<span></span>
</td>
<td class="nump">22,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables from collaborations</a></td>
<td class="nump">3,997<span></span>
</td>
<td class="nump">22,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,016<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">203,837<span></span>
</td>
<td class="nump">164,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,149<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,720<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">214,706<span></span>
</td>
<td class="nump">175,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,354<span></span>
</td>
<td class="nump">13,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">24,843<span></span>
</td>
<td class="nump">21,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">17,806<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease financing obligation</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Senior credit facility</a></td>
<td class="nump">19,056<span></span>
</td>
<td class="nump">9,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">29,780<span></span>
</td>
<td class="nump">29,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">102,650<span></span>
</td>
<td class="nump">92,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease financing obligation</a></td>
<td class="nump">3,834<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Senior credit facility</a></td>
<td class="nump">31,715<span></span>
</td>
<td class="nump">41,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; shares authorized - 5,000; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value: shares authorized - 450,000; shares issued and outstanding &#8211; 176,429 in 2020 and 154,082 in 2019</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">991,574<span></span>
</td>
<td class="nump">877,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(916,834)<span></span>
</td>
<td class="num">(840,628)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">76,507<span></span>
</td>
<td class="nump">38,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 214,706<span></span>
</td>
<td class="nump">$ 175,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831705128520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">176,429<span></span>
</td>
<td class="nump">154,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">176,429<span></span>
</td>
<td class="nump">154,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831624805528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 7,694<span></span>
</td>
<td class="nump">$ 7,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">27,498<span></span>
</td>
<td class="nump">27,681<span></span>
</td>
<td class="nump">57,365<span></span>
</td>
<td class="nump">55,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,883<span></span>
</td>
<td class="nump">8,659<span></span>
</td>
<td class="nump">29,748<span></span>
</td>
<td class="nump">14,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">41,381<span></span>
</td>
<td class="nump">36,366<span></span>
</td>
<td class="nump">87,182<span></span>
</td>
<td class="nump">71,583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,510)<span></span>
</td>
<td class="num">(34,918)<span></span>
</td>
<td class="num">(79,488)<span></span>
</td>
<td class="num">(64,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">2,758<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">9,204<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,918)<span></span>
</td>
<td class="num">(3,035)<span></span>
</td>
<td class="num">(5,965)<span></span>
</td>
<td class="num">(5,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative</a></td>
<td class="nump">63<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,607)<span></span>
</td>
<td class="num">(37,629)<span></span>
</td>
<td class="num">(76,206)<span></span>
</td>
<td class="num">(68,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available for sale investments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (38,618)<span></span>
</td>
<td class="num">$ (37,499)<span></span>
</td>
<td class="num">$ (76,242)<span></span>
</td>
<td class="num">$ (68,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">161,569<span></span>
</td>
<td class="nump">110,338<span></span>
</td>
<td class="nump">157,862<span></span>
</td>
<td class="nump">110,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">3,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,827<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
<td class="nump">$ 5,487<span></span>
</td>
<td class="nump">$ 2,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831694050648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (76,206)<span></span>
</td>
<td class="num">$ (68,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="nump">104<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">590<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">18,149<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(5,233)<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">817<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,156)<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">2,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,405)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(54,322)<span></span>
</td>
<td class="num">(51,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(15,438)<span></span>
</td>
<td class="num">(3,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">21,417<span></span>
</td>
<td class="nump">41,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">5,792<span></span>
</td>
<td class="nump">38,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="nump">92,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Sale of pre-funded warrants</a></td>
<td class="nump">14,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from senior credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">108,463<span></span>
</td>
<td class="nump">20,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">59,933<span></span>
</td>
<td class="nump">7,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">115,723<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 175,656<span></span>
</td>
<td class="nump">$ 35,389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831619078168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment [Member] </div>
<div>AOCI Attributable to Parent [Member]</div>
</th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance (Accounting Standards Update 2016-02 [Member]) at Dec. 31, 2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,101<span></span>
</td>
<td class="nump">$ 780,400<span></span>
</td>
<td class="num">$ (297)<span></span>
</td>
<td class="num">$ (731,969)<span></span>
</td>
<td class="nump">$ 49,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,054)<span></span>
</td>
<td class="num">(31,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">784,278<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(762,785)<span></span>
</td>
<td class="nump">22,507<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance (Accounting Standards Update 2016-02 [Member]) at Dec. 31, 2018</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">780,400<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="num">(731,969)<span></span>
</td>
<td class="nump">49,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,683)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">790,076<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(800,414)<span></span>
</td>
<td class="num">(9,193)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">784,278<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="num">(762,785)<span></span>
</td>
<td class="nump">22,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,629)<span></span>
</td>
<td class="num">(37,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">790,076<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="num">(800,414)<span></span>
</td>
<td class="num">(9,193)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">877,300<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(840,628)<span></span>
</td>
<td class="nump">38,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,599)<span></span>
</td>
<td class="num">(37,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,754<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">880,319<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(878,227)<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">877,300<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(840,628)<span></span>
</td>
<td class="nump">38,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,206)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">991,574<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(916,834)<span></span>
</td>
<td class="nump">76,507<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">880,319<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(878,227)<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(38,607)<span></span>
</td>
<td class="num">(38,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">92,628<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">92,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,817<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 991,574<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (916,834)<span></span>
</td>
<td class="nump">$ 76,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831619699816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) - shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares (in shares)</a></td>
<td class="nump">22,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Warrants issued (in shares)</a></td>
<td class="nump">3,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831617151816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">1</em> - Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>The Company</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in <em style="font: inherit;">1986,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">With the funds available at <em style="font: inherit;"> June 30, 2020, </em>the Company believes these resources will be sufficient to fund its operations through the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2021.</em> The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2020</em> expenses will exceed its <em style="font: inherit;">2020</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern through <em style="font: inherit;">2021.</em> The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the progression of its product candidates in the future. The Company also <em style="font: inherit;"> may </em>consider other plans to fund operations through <em style="font: inherit;">2021</em> including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"/>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Basis of Presentation</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;) and MDCP, LLC (&#8220;MDCP&#8221;). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on <em style="font: inherit;"> March 9, 2011. </em>See Note <em style="font: inherit;">4,</em> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a $23,000 senior credit facility that the Company closed on <em style="font: inherit;"> September 23, 2016 </em>and subsequently amended and restated on each of <em style="font: inherit;"> July 20, 2018 </em>and <em style="font: inherit;"> February 5, 2019. </em>See Note <em style="font: inherit;">5</em> for a further description of these transactions. All intercompany transactions and balances have been eliminated.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form <em style="font: inherit;">10</em>-Q and do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">These financial statements should be read in conjunction with the financial statements for the year ended <em style="font: inherit;"> December 31, 2019 </em>and the notes thereto included in the Company&#8217;s <em style="font: inherit;">2019</em> Annual Report on Form <em style="font: inherit;">10</em>-K. Interim operating results are <em style="font: inherit;">not</em> necessarily indicative of operating results for the full year. The balance sheet as of <em style="font: inherit;"> December 31, 2019 </em>has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Cash and Cash Equivalents</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Restricted Cash</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Restricted cash as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019 </em>reflects $766 and $134, respectively, in royalty revenue paid by Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">4</em>) and $1,422 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Investments</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c63927396">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than 18 months. Some of the securities the Company invests in <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> June 30, 2020, </em>the Company believes that the cost of its investments is recoverable in all material respects.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of the U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,742</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,899</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Receivables from Collaborations</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#8220;Green Cross&#8221;), Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;) and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">At <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the Company had the following receivables.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,253</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,272</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">3,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,353</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,023</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,376</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Green Cross Corporation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,924</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">351</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">6,760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">15,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">22,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Receivables from Product Sales</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Inventory</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Inventory is stated at the lower of cost and net realizable value, determined under the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&#160; At <em style="font: inherit;"> June 30, 2020, </em>the Company&#8217;s inventory consisted of $1,723 of peramivir raw materials and $3,510 of peramivir work-in-process.</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"/>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Property and Equipment</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c63927423">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c63927425">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c63927426">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Patents and Licenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"/>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accrued Expenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to investigative sites in connection with clinical trials;</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance and drug products; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">professional fees.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Income Taxes</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accumulated Other Comprehensive Loss</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>realized gains of $1 were reclassified out of accumulated other comprehensive loss. <span style="-sec-ix-hidden:c63927438">No</span> reclassifications out of accumulated other comprehensive loss were recorded during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2019.</em></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><em style="font: inherit;"/></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Revenue Recognition</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Product Sales</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">The Company&#8217;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#8217;s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">The Company recorded the following revenues for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Torii Pharmaceutical Co., Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,448</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Balances</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="text-decoration: underline; "><i>Contract assets</i></span><i> </i>- The Company&#8217;s long-term contracts, typically the government research and development contracts, are billed as work progresses<i> </i>in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheet.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="text-decoration: underline; "><i>Contract liabilities</i></span><i> </i>- The Company often receives cash payments from customers in advance of the Company&#8217;s performance resulting in contract<i> </i>liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize the revenue.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Costs</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company <em style="font: inherit;"> may </em>incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that the Company expects to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that the Company does expect to recover are expensed as incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Advertising</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Research and Development Expenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Stock-Based Compensation</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Interest Expense and Deferred Financing Costs</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Interest expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $2,918 and $3,035, respectively, and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> was $5,965 and $5,761, respectively, related to the issuance of the PhaRMA Notes (defined in Note <em style="font: inherit;">4</em>) and the Second Amended and Restated Senior Credit Facility (defined in Note <em style="font: inherit;">5</em>). Costs directly associated with the issuance of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was $341 for each of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and $681 and $596 for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;">2019,</em> respectively.</p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Currency Hedge Agreement</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> resulted in losses of $590 and $646, respectively. Mark to market adjustments are determined by a <em style="font: inherit;">third</em>-party pricing model that uses quoted prices in markets that are <em style="font: inherit;">not</em> actively traded and for which significant inputs are observable directly or indirectly, representing Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of $632 and $830 during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em><span style="-sec-ix-hidden:c63927506"><span style="-sec-ix-hidden:c63927507">no</span></span> hedge collateral was posted under the agreement.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Net Loss Per Share</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> does <em style="font: inherit;">not</em> include 14,007 and 1,927, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> does <em style="font: inherit;">not</em> include 12,963 and 2,528, respectively, of such potential common shares, as their impact would be anti-dilutive.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Use of Estimates</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Significant Customers and Other Risks</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Significant Customers</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Other than royalty revenues, the Company&#8217;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Centers for Disease Control and Prevention. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:28pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company <em style="font: inherit;"> may </em>rely on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#8217;s product candidates in development.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Credit Risk</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"/>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Recent Accounting Pronouncements</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:33.65pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of</i> <i>Credit Losses on Financial Instruments </i>(&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>)<i>.</i><i> </i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires a financial asset (or a group of financial assets) measured at amortized<i> </i>cost basis to be presented at the net amount expected to be collected. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:33.65pt;">The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> as of <em style="font: inherit;"> January 1, 2020. </em>Given the nature of the Company&#8217;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic</i> <i><em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>) </i>(&#8220;ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15&#8221;</em>). ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service<i> </i>contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2019, </em>with early adoption permitted. The Company elected to adopt this standard early, beginning <em style="font: inherit;"> October 1, 2019 </em>on a prospective basis. Adoption did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;"/>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623150472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">2</em> - Stock-Based Compensation</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.55pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the Company had <em style="font: inherit;">three</em> stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the Amended and Restated Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Amended and Restated Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was amended and restated on <em style="font: inherit;"> March 19, 2020 </em>and approved by the Company&#8217;s stockholders on <em style="font: inherit;"> May 12, 2020. </em>The Inducement Plan was adopted by the Board of Directors on <em style="font: inherit;"> April 24, 2019 </em>and amended and restated by the Board of Directors in <em style="font: inherit;"> February 2020 </em>and in <em style="font: inherit;"> July 2020. </em>The ESPP was amended and restated in <em style="font: inherit;"> March 2020 </em>and approved by the Company&#8217;s stockholders in <em style="font: inherit;"> May 2020. </em>Stock-based compensation expense of $6,034 ($5,205 of expense related to the Incentive Plan, $710 of expense related to the Inducement Plan, and $119 of expense related to the ESPP) was recognized during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020,</em> while $8,702 ($8,535 of expense related to the Incentive Plan, $16 of expense related to the Inducement Plan and $151 of expense related to the ESPP) was recognized during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2019.</em></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">There was approximately $22,873 of total unrecognized compensation cost related to non-vested stock option awards granted by the Company as of <em style="font: inherit;"> June 30, 2020. </em>That cost is expected to be recognized as follows: $5,251 during the remainder of <em style="font: inherit;">2020,</em> $8,086 in <em style="font: inherit;">2021,</em> $6,604 in <em style="font: inherit;">2022,</em> $2,668 in <em style="font: inherit;">2023</em> and $264 in <em style="font: inherit;">2024.</em> In addition, the Company has outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; has occurred and the award vests.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Stock Incentive Plan</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 10pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after <span style="-sec-ix-hidden:c63927695">four</span> years. In <em style="font: inherit;"> August 2013, </em><em style="font: inherit;"> December 2014 </em>and <em style="font: inherit;"> December 2019, </em>the Company issued 1,032, 1,250 and 315 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of <em style="font: inherit;"> June 30, 2020, </em>75% of the <em style="font: inherit;"> August 2013 </em>grants have vested. As of <em style="font: inherit;"> June 30, 2020, </em>85% of the <em style="font: inherit;"> December 2014 </em>grants have vested. As of <em style="font: inherit;"> June 30, 2020, </em><span style="-sec-ix-hidden:c63927701">none</span> of the <em style="font: inherit;"> December 2019 </em>grants have vested. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020, </em>the Company recognized $86 of compensation expense related to <em style="font: inherit;">one</em> milestone within the <em style="font: inherit;"> December 2019 </em>grants for which achievement became probable. During <em style="font: inherit;">2019,</em> the Company recognized $4,998 of stock compensation expense related to <em style="font: inherit;">two</em> milestones within the <em style="font: inherit;"> December 2014 </em>grants for which achievement became probable. Stock option awards granted to non-employee directors of the Company generally vest over <em style="font: inherit;">one</em> year. All stock option awards have contractual terms of 10 years. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</p>   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>


   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="vertical-align:bottom;width:56.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">Related activity under the Incentive Plan is as follows:</p> </td><td style="vertical-align:bottom;width:14%;">&#160;</td><td style="vertical-align:bottom;width:13.9%;">&#160;</td><td style="vertical-align:bottom;width:2.1%;">&#160;</td><td style="vertical-align:bottom;width:11.7%;">&#160;</td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2019</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">968</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,050</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.96</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Plan amendment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Restricted stock unit awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(547</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">547</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(193</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,495</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,495</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">18,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 18pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">For stock option awards granted under the Incentive Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $3.35 and $4.69, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i><b>Inducement Equity Incentive Plan</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:18pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees are granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant and generally vest 25% each year until fully vested after <span style="-sec-ix-hidden:c63927723">four</span> years. Each stock option has a term of 10 years and is subject to the terms and conditions of the Inducement Plan. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="vertical-align:bottom;width:56.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">Related activity under the Inducement Plan is as follows:</p> </td><td style="vertical-align:bottom;width:14%;">&#160;</td><td style="vertical-align:bottom;width:1.1%;">&#160;</td><td style="vertical-align:bottom;width:13.9%;">&#160;</td><td style="vertical-align:bottom;width:0.9%;">&#160;</td><td style="vertical-align:bottom;width:2.1%;">&#160;</td><td style="vertical-align:bottom;width:11.7%;">&#160;</td></tr>
</tbody></table>
   <p style="margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2019</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">171</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,329</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.60</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Plan amendment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,502</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,502</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">For stock option awards granted under the Inducement Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value per share of the awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $3.67 and $3.94, respectively.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under the Incentive Plan and the Inducement Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <em style="font: inherit;">not</em> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will <em style="font: inherit;">not</em> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <em style="font: inherit;">zero</em>-coupon government issues with a remaining term equal to the expected term.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><b>&#160;</b></p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>Weighted Average Assumptions for Stock Option Awards Granted to</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><b>Employees and Directors under the Plans</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: center; border-bottom: 1px solid black;"><b><b>2020</b></b></td><td style="border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Life in Years</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Dividend Yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free Interest Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company has reserved a total of 4,475 shares of common stock to be purchased under the ESPP, of which 3,009 shares remain available for purchase at <em style="font: inherit;"> June 30, 2020. </em>Eligible employees <em style="font: inherit;"> may </em>authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during <em style="font: inherit;">six</em>-month purchase intervals. <em style="font: inherit;">No</em> more than 3 shares <em style="font: inherit;"> may </em>be purchased by any <em style="font: inherit;">one</em> employee at the <em style="font: inherit;">six</em>-month purchase dates, and <em style="font: inherit;">no</em> employee <em style="font: inherit;"> may </em>purchase stock having a fair market value at the commencement date of $25 or more in any <em style="font: inherit;">one</em> calendar year. The Company issued 110 shares during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> under the ESPP. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</p>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831617290648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">3</em> - Collaborative and Other Research and Development Contracts</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;). </i>In <em style="font: inherit;"> September 2013, </em>NIAID/HHS contracted with the Company for the<i> </i>development of galidesivir as a treatment for Marburg virus disease. NIAID/HHS, part of the National Institutes of Health, made an initial award of $5,000 to the Company. The goals of this contract, including amendments, are to file IND applications for intravenous (&#8220;i.v.&#8221;) and intramuscular (&#8220;i.m.&#8221;) galidesivir for the treatment of Marburg virus disease and other hemorrhagic fever virus diseases, including Yellow Fever and Ebola virus disease, and to conduct an initial Phase <em style="font: inherit;">1</em> human clinical trial. In <em style="font: inherit;"> April 2020, </em>the Company and NIAID/HHS agreed to add a group of COVID-<em style="font: inherit;">19</em> patients to the ongoing clinical trial in Yellow Fever. On <em style="font: inherit;"> April 9, 2020, </em>the Company announced it had opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-<em style="font: inherit;">19.</em> As of <em style="font: inherit;"> June 30, 2020, </em>the total NIAID/HHS contract amount to advance the program through the completion of the Phase I clinical program is $43,035. As of <em style="font: inherit;"> June 30, 2020, </em>all options have been exercised under this contract.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>U.S. Department of Health and Human Services (&#8220;BARDA/HHS&#8221;). </i>On <em style="font: inherit;"> March 31, 2015, </em>the Company announced that BARDA/HHS had awarded<i> </i>the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of <em style="font: inherit;"> June 30, 2020, </em>a total of $20,574 has been awarded under exercised options within this contract.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>U.S. Department of Health and Human Services (&#8220;HHS&#8221;)</i>. On <em style="font: inherit;"> September 6, 2018, </em>the Company announced that HHS had awarded the Company a<i> </i>$34,660 contract for the procurement of up to <em style="font: inherit;">50,000</em> doses of RAPIVAB (peramivir injection) over a <span style="-sec-ix-hidden:c63927844">five</span>-year period. HHS&#8217;s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation&#8217;s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. The Company delivered <em style="font: inherit;">two</em> shipments under this contract in <em style="font: inherit;">2019</em> for a total price of approximately $13,864, and expects to deliver at least <em style="font: inherit;">one</em> shipment within the award in <em style="font: inherit;">2020,</em> totaling approximately $6,932.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Torii Pharmaceutical Co., Ltd. (&#8220;Torii&#8221;). </i>On <em style="font: inherit;"> November 5, 2019, </em>the Company announced that it had entered into the Torii Agreement, granting<i> </i>Torii the exclusive right to commercialize ORLADEYO&#8482; (berotralstat) for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks in Japan.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000 and <em style="font: inherit;"> may </em>be eligible to receive an additional milestone payment of either $20,000 if the Japanese Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) grants regulatory approval on or before <em style="font: inherit;"> December 31, 2020, </em>or $15,000 if regulatory approval is granted on or before <em style="font: inherit;"> December 31, 2021. </em>In either case, the regulatory milestone payment is contingent upon receipt of a reimbursement price approval from Japan&#8217;s National Health Insurance system in excess of the threshold specified in the Torii Agreement.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In addition, the Company will be entitled under the Torii Agreement to receive tiered royalty payments based on the amount of annual net sales of ORLADEYO in Japan during each calendar year. If ORLADEYO maintains its Sakigake designation during the PMDA review, the tiered royalty rate will range from 20% to 40% of net sales; otherwise, the tiered royalty rate will range from 15% to 35% of net sales. Torii&#8217;s royalty payment obligations are subject to customary reductions in certain circumstances, but <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#8217;s royalty payment obligations commence upon the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:c63927862">tenth</span> anniversary of the date of <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan, (ii) the expiration of our patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the Torii Agreement, the Company has granted Torii a right of <em style="font: inherit;">first</em> negotiation (&#8220;ROFN&#8221;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if the Company develops ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that the Company <em style="font: inherit;"> may </em>develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do <em style="font: inherit;">not</em> agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a <em style="font: inherit;">third</em>-party arbitrator.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the <em style="font: inherit;">$22,000</em> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC <em style="font: inherit;">606.</em> Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used and an expected cost plus margin approach was utilized for the other performance obligations. The Company recognized $20,101 in revenue in <em style="font: inherit;">2019</em> including $19,344 associated with the license which was transferred to Torii at the execution of the Agreement and $757 related to the year to date services provided in the performance of the <em style="font: inherit;">two</em> approvals. The remaining $1,899 of the <em style="font: inherit;">$22,000</em> upfront payment is expected to be recognized as revenue in <span style="-sec-ix-hidden:c63927876">2020</span> as the services are delivered.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Seqirus UK Limited (&#8220;SUL&#8221;). </i>On <em style="font: inherit;"> June 16, 2015, </em>the Company and SUL, a limited company organized under the laws of the United Kingdom and a<i> </i>subsidiary of CSL Limited, a company organized under the laws of Australia, entered into a License Agreement (the &#8220;SUL Agreement&#8221;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#8220;Territory&#8221;).</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the terms of the SUL Agreement, the Company is responsible for fulfilling all post-marketing approval commitments in connection with the FDA's approval of the NDA. Pursuant to rights to sell ALPIVAB in the EU, the Company was also responsible for regulatory filings and interactions with the European Medicines Agency (&#8220;EMA&#8221;). In accordance with the SUL Agreement, the Company and SUL formed a joint steering committee, composed of an equal number of representatives from each party, to oversee, review and coordinate the conduct and progress of the commercialization of RAPIVAB in the Territory and any additional development. In <em style="font: inherit;"> October 2017, </em>SUL transferred Canadian registration rights for RAPIVAB to the Company.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under the terms of the SUL Agreement, the Company has received an upfront payment of $33,740 and has achieved all development milestones under the contract totaling $12,000. The Company is entitled under the SUL Agreement to receive tiered royalties at a percentage rate beginning in the mid-teens contingent upon meeting minimum thresholds of net sales, as well as a low-thirties percentage of the gross profit from government stockpiling purchases made outside the U.S. Specifically, the Company receives tiered royalties at a percentage rate in the mid-teens to low-forties on net sales in the U.S. during a Contract Year (defined as <em style="font: inherit;"> July 1 - </em><em style="font: inherit;"> June 30) </em>and tiered royalties at a percentage rate in the mid-teens to mid-twenties on net sales in the Territory, other than in the U.S., during a Calendar Year, each subject to certain downward adjustments for circumstances or events impacting the overall market opportunity. SUL's royalty payment obligations commenced on the date of the SUL Agreement. The Company developed peramivir under a license from UAB and will owe sublicense payments to them on any future milestone payments and/or royalties received by the Company from SUL.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company and SUL entered arbitration proceedings that involved many items under the SUL Agreement including, but <em style="font: inherit;">not</em> limited to, the EMA approval milestone, which BioCryst maintains is due under the contract as well as appropriately commercializing peramivir in the Territory. On <em style="font: inherit;"> March 4, 2020, </em>the International Court of Arbitration of the International Chamber of Commerce (&#8220;ICC Tribunal&#8221;) delivered a Partial Arbitration Award (the &#8220;Partial Arbitration Award&#8221;) in the arbitration matter between the Company and SUL with respect to the SUL Agreement.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties have agreed on a transition process for the product, including a full transition of commercialization of the product in the U.S. to the Company as of <em style="font: inherit;"> August 1, 2020 </em>and a full transition of commercialization of the product in Australia as of <em style="font: inherit;"> November 1, 2020. </em>The ICC Tribunal also awarded the Company its attorneys&#8217; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to the Company within <em style="font: inherit;">30</em> days of the approval of peramivir for adult use in the European Union and awarded the Company $5,000 (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#8217; fees and for any dispute relating to the return to the Company of all rights to peramivir in the Territory. The Company recorded the settlement gain of $8,893 in other income and legal fees and other expenses of $5,026 in selling, general and administrative expenses for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020.</em></p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><i>Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;). </i>In <em style="font: inherit;"> February 2007, </em>the Company entered into an exclusive license agreement with Shionogi to develop and<i> </i>commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In <em style="font: inherit;"> October 2008, </em>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">In <em style="font: inherit;"> December 2017, </em>the Company, on behalf of Royalty Sub, instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings have concluded, with the decision that <em style="font: inherit;">no</em> sales milestones have been achieved and that the royalties will remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Green Cross Corporation (&#8220;Green Cross&#8221;). </i>In <em style="font: inherit;"> June 2006, </em>the Company entered into an agreement with Green Cross to develop and commercialize<i> </i>peramivir in Korea. Under the terms of the agreement, Green Cross will be responsible for all development, regulatory, and commercialization costs in Korea. The Company received a <em style="font: inherit;">one</em>-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;). </i>In <em style="font: inherit;"> February 2006, </em>the Company entered into an exclusive, royalty bearing right<i> </i>and license agreement with Mundipharma for the development and commercialization of Mundesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology (the &#8220;Original Agreement&#8221;). Under the terms of the Original Agreement, Mundipharma obtained rights to Mundesine in markets across Europe, Asia, and Australasia in exchange for a $10,000 up-front payment.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> November 11, 2011, </em>the Company entered into the Amended and Restated License and Development Agreement (the &#8220;Amended and Restated Agreement&#8221;) with Mundipharma, amending and restating the Original Agreement. Under the terms of the Amended and Restated Agreement, Mundipharma obtained worldwide rights to Mundesine. Commencing on <em style="font: inherit;"> November 11, 2011, </em>Mundipharma controls the development and commercialization of Mundesine and assumes all future development and commercialization costs. The Amended and Restated Agreement provides for the possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. These royalties are subject to downward adjustments based on the then-existing patent coverage and/or the availability of generic compounds in each country.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.35pt;"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively). </i>In <em style="font: inherit;"> June 2000, </em>the<i> </i>Company licensed a series of potent inhibitors of PNP from AECOM and IRL, (collectively, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration are forodesine and ulodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. The Company agreed to use commercially reasonable efforts to develop these drugs. In addition, the Company has agreed to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development of these inhibitors, single digit royalties on net sales of any resulting product made by the Company, and to share approximately <em style="font: inherit;">one</em> quarter of future payments received from other <em style="font: inherit;">third</em>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. This agreement <em style="font: inherit;"> may </em>be terminated by the Company at any time by giving 60 days advance notice or in the event of material uncured breach by the Licensors.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">In <em style="font: inherit;"> May 2010, </em>the Company amended the license agreement through which the Company obtained worldwide exclusive rights to develop and ultimately distribute any product candidates that might arise from research on a series of PNP inhibitors, including forodesine and ulodesine. Under the terms of the amendment, the Licensors agreed to accept a reduction of <em style="font: inherit;">one</em>-half in the percentage of future payments received from <em style="font: inherit;">third</em>-party sub licensees of the licensed PNP inhibitors that must be paid to the Licensors. This reduction does <em style="font: inherit;">not</em> apply to (i) any milestone payments the Company <em style="font: inherit;"> may </em>receive in the future under its license agreement dated <em style="font: inherit;"> February 1, 2006 </em>with Mundipharma and (ii) royalties received from its sub licensees in connection with the sale of licensed products, for which the original payment rate will remain in effect. The rate of royalty payments to the Licensors based on net sales of any resulting product made by the Company remains unchanged.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> November 17, 2011, </em>the Company further amended its agreements with the Licensors whereby the Licensors agreed to accept a reduction of <em style="font: inherit;">one</em>-half in the percentage of Net Proceeds (as defined in the license agreement) received by the Company under its Amended and Restated Agreement with Mundipharma that will be paid to AECOM/IRL.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> June 19, 2012, </em>the Company further amended its agreements with AECOM/IRL whereby the parties clarified the definition of the field with respect to PNP inhibition and AECOM/IRL agreed to exclusive worldwide license of galidesivir to BioCryst for any antiviral use.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">At its sole option and subject to certain agreed upon conditions, any future non-royalty payments due to be paid by the Company to AECOM/IRL under the license agreement <em style="font: inherit;"> may </em>be made either in cash, in shares of the Company&#8217;s common stock, or in a combination of cash and shares.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> January 6, 2014, </em>the Carbohydrate Chemistry Research Team from Callaghan Innovation Research Limited, formerly Industrial Research Limited, transferred to Victoria University of Wellington (&#8220;VUW&#8221;) to establish the Ferrier Research Institute. The intellectual property rights relating to this research team, and the contracts relating to that intellectual property were transferred to a wholly owned subsidiary of VUW, including the contracts to which BioCryst is a party. The parties executed novation agreements in order to effectuate the transfer. Except for a substitution of parties, the terms and conditions of the contracts are substantially the same.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;). </i>The Company currently has agreements with UAB for influenza neuraminidase and<i> </i>complement inhibitors. Under the terms of these agreements, UAB performed specific research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <em style="font: inherit;">third</em>-party partners. The Company has completed the research under the UAB agreements. These <em style="font: inherit;">two</em> agreements each have an initial 25-year term, are automatically renewable for <span style="-sec-ix-hidden:c63927906">five</span>-year terms throughout the life of the last patent and are terminable by the Company upon <em style="font: inherit;">three</em> months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <em style="font: inherit;">no</em> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts it receives.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b/></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831619322568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">4</em> - Royalty Monetization</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Overview</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">On <em style="font: inherit;"> March 9, 2011, </em>the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <em style="font: inherit;"> September 2012 </em>interest payment.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">As part of the transaction, the Company entered into a purchase and sale agreement dated as of <em style="font: inherit;"> March 9, 2011 </em>with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments will be paid by Shionogi in Japanese yen, and milestone payments will be paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was <em style="font: inherit;">not</em> impacted as a result of this transaction.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Non-Recourse Notes Payable</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">On <em style="font: inherit;"> March 9, 2011, </em>Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due <em style="font: inherit;">2020</em> (the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <em style="font: inherit;"> March 9, 2011 (</em>the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on <em style="font: inherit;"> September </em><em style="font: inherit;">1st</em> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, make capital contributions to a capital account that <em style="font: inherit;"> may </em>be used to redeem, or on up to <em style="font: inherit;">one</em> occasion pay any interest shortfall on, the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:30.7pt;">In <em style="font: inherit;"> September 2014, </em>Royalty Sub was unable to pay the accrued interest obligation due <em style="font: inherit;"> September 3, 2013. </em>Under the terms of the Indenture, Royalty Sub&#8217;s inability to pay the full amount of interest payable in <em style="font: inherit;"> September 2013 </em>by the next succeeding Payment Date for the PhaRMA Notes, which was <em style="font: inherit;"> September 1, 2014, </em>constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <em style="font: inherit;"> December 31, 2014 </em>balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <em style="font: inherit;"> may </em>pursue acceleration of the PhaRMA Notes, <em style="font: inherit;"> may </em>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential acceleration or foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. In addition, the Company <em style="font: inherit;"> may </em>incur costs associated with liquidating the related Currency Hedge Agreement, which would <em style="font: inherit;">no</em> longer be required in the event of foreclosure, or if the PhaRMA Notes cease to be outstanding. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is <em style="font: inherit;">not</em> expected to have a significant impact on the Company&#8217;s future results of operations or cash flows. As of <em style="font: inherit;"> June 30, 2020, </em>the PhaRMA Notes remain in default.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:36pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Indenture does <em style="font: inherit;">not</em> contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the aggregate fair value of the PhaRMA Notes was estimated to be approximately 3% of the PhaRMA Notes carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level <em style="font: inherit;">3</em> in the fair value hierarchy as defined in U.S. GAAP.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The PhaRMA Notes are redeemable at the option of Royalty Sub at any time at a redemption price equal to the outstanding principal balance of the PhaRMA Notes being redeemed plus accrued and unpaid interest through the redemption date on the PhaRMA Notes being redeemed.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Currency Hedge Agreement</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company has the right to purchase dollars and sell yen at a rate of 100 yen per dollar.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Currency Hedge Agreement does <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#8217;s Consolidated Statement of Comprehensive Loss. Cumulative mark to market adjustments for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> resulted in losses of $590 and $646 respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623351608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">5</em> - Senior Credit Facility</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">On <em style="font: inherit;"> February 5, 2019, </em>the Company entered into a $100,000 Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#8220;Second Amended and Restated Senior Credit Facility&#8221;). Borrowings under the Second Amended and Restated Senior Credit Facility will be available in <em style="font: inherit;">three</em> tranches, with (i) the <em style="font: inherit;">first</em> tranche comprised of $50,000 funded at closing, which included $30,000 of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#8217;s prior credit agreement, (ii) the <em style="font: inherit;">second</em> tranche to be comprised of $30,000, and (iii) the <em style="font: inherit;">third</em> tranche to be comprised of $20,000, with the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> tranches to be funded upon the completion of certain contingencies related to the Company&#8217;s development activities of its product candidates and the establishment of certain financial covenants. On <em style="font: inherit;"> September 10, 2019 </em>the Company executed the <em style="font: inherit;">first</em> amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the <em style="font: inherit;">second</em> tranche to <em style="font: inherit;"> November 30, 2019. </em>On <em style="font: inherit;"> November 30, 2019, </em>the Company&#8217;s access to the <em style="font: inherit;">second</em> tranche expired.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of <em style="font: inherit;"> July 20, 2018 (</em>the &#8220;Amended and Restated Senior Credit Facility&#8221;). The Second Amended and Restated Senior Credit Facility bears a variable interest rate of LIBOR (which shall <em style="font: inherit;">not</em> be less than 0.5%) plus 8%. The Second Amended and Restated Senior Credit Facility includes an interest-only payment period through <em style="font: inherit;"> June 2020 </em>and scheduled monthly principal and interest payments for the subsequent 30 months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility, and the remainder will be used for general corporate purposes. Under the Second Amended and Restated Senior Credit Facility, the Company must maintain a minimum cash balance of $25,000 of unrestricted cash at all times.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">As of <em style="font: inherit;"> June 30, 2020, </em>the Company had borrowings of $50,000 under the Second Amended and Restated Senior Credit Facility bearing an interest rate of 8.5%. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date. The remaining scheduled principal repayments of the Second Amended and Restated Senior Credit Facility are as follows:</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
       <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Principal Payments</b></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">50,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The debt agreement contains <em style="font: inherit;">two</em> provisions that if deemed probable would create the recognition of an embedded feature; however, the Company does <em style="font: inherit;">not</em> believe either provision is probable.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831617265032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Note <em style="font: inherit;">6</em> - Stockholders&#8217; Equity</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:26.75pt;">On <em style="font: inherit;"> April 24, 2020, </em>the Company filed a $500,000 shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> May 14, 2020 </em>and allows the Company to sell securities, including common stock, preferred stock, depository shares, purchase contracts, warrants, debt securities and units, from time to time at prices and on terms to be determined at the time of sale. On <em style="font: inherit;"> June 1, 2020, </em>the Company completed an underwritten public offering of 22,044,447 shares of its common stock (including shares issued pursuant to the underwriters&#8217; <em style="font: inherit;">30</em>-day option to purchase additional shares, which was exercised in full), at a purchase price of $4.50 per share, and pre-funded warrants to purchase 3,511,111 shares of common stock, at a purchase price of $4.49 per pre-funded warrant, for total net proceeds to the Company of $107,665 after deducting underwriting discounts and commissions and other offering expenses payable by the Company. The pre-funded warrants are immediately exercisable and have an exercise price of $0.01 per share, which is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting the Company&#8217;s common stock and also upon any distributions of assets to the Company&#8217;s stockholders.</p>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623399512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Lease Obligations and Other Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLessorDisclosureTextBlock', window );">Leases of Lessor Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:justify;"><b>Note <em style="font: inherit;">7</em> &#8211; Lease Obligations and Other Contingencies</b></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases at <em style="font: inherit;"> June 30, 2020. </em>Certain operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheets represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Renewal options for the Company&#8217;s leases range from 1 to 5 years in length and begin from <em style="font: inherit;">2023</em> through <em style="font: inherit;">2026.</em> At <em style="font: inherit;"> June 30, 2020, </em>the weighted average lease term for the Company&#8217;s operating leases was 13.6 years. The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions. The weighted average discount rate for the Company&#8217;s operating leases was 12.7%.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 16pt 0pt 0pt; text-align: left; text-indent: 30.7pt;">Aggregate lease expense under operating leases was $935 and $706 for the <em style="font: inherit;">six</em>-month periods ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> June 30, 2019, </em>respectively. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of <em style="font: inherit;">twelve</em> months or less was <em style="font: inherit;">not</em> material.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">&#160;</p>


   <table border="0" cellpadding="0" cellspacing="0" style="margin-left:5.5%;width:84.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td colspan="2" style="vertical-align:bottom;width:84%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Future lease payments for assets under operating leases as of <em style="font: inherit;"> June 30, 2020, </em>are as follows:</p> </td>
      <td style="vertical-align:bottom;width:0.8%;">&#160;</td>
      <td style="vertical-align:bottom;width:5%;">&#160;</td>
      <td style="vertical-align:bottom;width:10.1%;">&#160;</td>
     </tr>

    </tbody>
   </table>
   <p style="margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><b>Remaining Maturities of Lease Liabilities</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      </tr>

      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><b>Year Ending December 31,</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>Operating Leases</b></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">835</td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">749</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">575</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">568</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,903</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total lease payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,295</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,365</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,930</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:36pt;">Of the Company&#8217;s total lease liability, $1,096 is a current liability and $3,834 is a long-term liability at <em style="font: inherit;"> June 30, 2020. </em>The current and long-term portions of the Company&#8217;s lease liability are presented within &#8220;Accrued expenses&#8221; and &#8220;Other non-current liabilities&#8221; on the Consolidated Balance Sheets. The Company&#8217;s right-of-use asset balance associated with operating leases totaled $3,720 at <em style="font: inherit;"> June 30, 2020. </em>This amount is presented within &#8220;Other long-term assets&#8221; on the Consolidated Balance Sheets.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831624765720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>The Company</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was incorporated in Delaware in <em style="font: inherit;">1986,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. BioCryst has incurred losses and negative cash flows from operations since inception.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">With the funds available at <em style="font: inherit;"> June 30, 2020, </em>the Company believes these resources will be sufficient to fund its operations through the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2021.</em> The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2020</em> expenses will exceed its <em style="font: inherit;">2020</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Accordingly, its planned operations raise doubt about its ability to continue as a going concern through <em style="font: inherit;">2021.</em> The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the progression of its product candidates in the future. The Company also <em style="font: inherit;"> may </em>consider other plans to fund operations through <em style="font: inherit;">2021</em> including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.</p><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Basis of Presentation</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including JPR Royalty Sub LLC (&#8220;Royalty Sub&#8221;) and MDCP, LLC (&#8220;MDCP&#8221;). Both of these subsidiaries were formed to facilitate financing transactions for the Company. Royalty Sub was formed in connection with a $30,000 financing transaction the Company completed on <em style="font: inherit;"> March 9, 2011. </em>See Note <em style="font: inherit;">4,</em> Royalty Monetization, for a further description of this transaction. MDCP was formed in connection with a $23,000 senior credit facility that the Company closed on <em style="font: inherit;"> September 23, 2016 </em>and subsequently amended and restated on each of <em style="font: inherit;"> July 20, 2018 </em>and <em style="font: inherit;"> February 5, 2019. </em>See Note <em style="font: inherit;">5</em> for a further description of these transactions. All intercompany transactions and balances have been eliminated.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form <em style="font: inherit;">10</em>-Q and do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">These financial statements should be read in conjunction with the financial statements for the year ended <em style="font: inherit;"> December 31, 2019 </em>and the notes thereto included in the Company&#8217;s <em style="font: inherit;">2019</em> Annual Report on Form <em style="font: inherit;">10</em>-K. Interim operating results are <em style="font: inherit;">not</em> necessarily indicative of operating results for the full year. The balance sheet as of <em style="font: inherit;"> December 31, 2019 </em>has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Cash and Cash Equivalents</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Restricted Cash</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Restricted cash as of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019 </em>reflects $766 and $134, respectively, in royalty revenue paid by Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">4</em>) and $1,422 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its Birmingham research facilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Investments</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c63927396">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than 18 months. Some of the securities the Company invests in <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> June 30, 2020, </em>the Company believes that the cost of its investments is recoverable in all material respects.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of the U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,742</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,899</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Receivables from Collaborations</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#8220;Green Cross&#8221;), Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;) and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">At <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the Company had the following receivables.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,253</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,272</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">3,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,353</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,023</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,376</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Green Cross Corporation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,924</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">351</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">6,760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">15,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">22,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b/></i></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Receivables from Product Sales</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Receivables from product sales are recorded for amounts due to the Company related to sales of RAPIVAB. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Inventory</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Inventory is stated at the lower of cost and net realizable value, determined under the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (&#8220;FIFO&#8221;) method, or market. The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company will capitalize subsequent costs related to the production of inventories.&#160; At <em style="font: inherit;"> June 30, 2020, </em>the Company&#8217;s inventory consisted of $1,723 of peramivir raw materials and $3,510 of peramivir work-in-process.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Property and Equipment</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c63927423">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c63927425">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c63927426">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Patents and Licenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 19pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accrued Expenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to investigative sites in connection with clinical trials;</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance and drug products; and</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;"><tbody><tr><td style="width:12pt;">&#160;</td><td style="width:11pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#8226;</p> </td><td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">professional fees.</p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</p><span></span></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Income Taxes</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Accumulated Other Comprehensive Loss</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. During the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>realized gains of $1 were reclassified out of accumulated other comprehensive loss. <span style="-sec-ix-hidden:c63927438">No</span> reclassifications out of accumulated other comprehensive loss were recorded during the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2019.</em></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Revenue Recognition</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will <em style="font: inherit;">not</em> occur.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Product Sales</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:28.7pt;">The Company&#8217;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#8217;s procurement contract. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">The Company recorded the following revenues for the <em style="font: inherit;">three</em> and <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019:</em></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Torii Pharmaceutical Co., Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,448</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Balances</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="text-decoration: underline; "><i>Contract assets</i></span><i> </i>- The Company&#8217;s long-term contracts, typically the government research and development contracts, are billed as work progresses<i> </i>in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheet.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="text-decoration: underline; "><i>Contract liabilities</i></span><i> </i>- The Company often receives cash payments from customers in advance of the Company&#8217;s performance resulting in contract<i> </i>liabilities. These contract liabilities are classified as either current or long-term in the Consolidated Balance Sheet based on the timing of when the Company expects to recognize the revenue.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Contract Costs</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company <em style="font: inherit;"> may </em>incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that the Company expects to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that the Company does expect to recover are expensed as incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Advertising</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed as the costs are incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Research and Development Expenses</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:30.7pt;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Stock-Based Compensation</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Interest Expense and Deferred Financing Costs</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 28.7pt;">Interest expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June&#160;</em><em style="font: inherit;">30,</em> <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $2,918 and $3,035, respectively, and for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> was $5,965 and $5,761, respectively, related to the issuance of the PhaRMA Notes (defined in Note <em style="font: inherit;">4</em>) and the Second Amended and Restated Senior Credit Facility (defined in Note <em style="font: inherit;">5</em>). Costs directly associated with the issuance of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Second Amended and Restated Senior Credit Facility using the effective interest rate method. Amortization of deferred financing costs and original issue discount included in interest expense was $341 for each of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019,</em> respectively, and $681 and $596 for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020, </em>and <em style="font: inherit;">2019,</em> respectively.</p><span></span></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Currency Hedge Agreement</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The Currency Hedge Agreement does <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore, mark to market adjustments are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark to market adjustments for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> resulted in losses of $590 and $646, respectively. Mark to market adjustments are determined by a <em style="font: inherit;">third</em>-party pricing model that uses quoted prices in markets that are <em style="font: inherit;">not</em> actively traded and for which significant inputs are observable directly or indirectly, representing Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined by U.S. GAAP. In addition, the Company realized currency exchange gains of $632 and $830 during the <em style="font: inherit;">first</em> <em style="font: inherit;">six</em> months of <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively, associated with the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. The Company is also required to post collateral in connection with the mark to market adjustments based on thresholds defined in the Currency Hedge Agreement. As of <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em><span style="-sec-ix-hidden:c63927506"><span style="-sec-ix-hidden:c63927507">no</span></span> hedge collateral was posted under the agreement.</p><span></span></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Net Loss Per Share</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> does <em style="font: inherit;">not</em> include 14,007 and 1,927, respectively, of such potential common shares, as their impact would be anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2020 </em>and <em style="font: inherit;">2019</em> does <em style="font: inherit;">not</em> include 12,963 and 2,528, respectively, of such potential common shares, as their impact would be anti-dilutive.</p><span></span></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Use of Estimates</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Significant Customers and Other Risks</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Significant Customers</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">Other than royalty revenues, the Company&#8217;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Centers for Disease Control and Prevention. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:28pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">The Company <em style="font: inherit;"> may </em>rely on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#8217;s product candidates in development.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:21pt;margin-right:0pt;margin-top:0pt;text-align:left;"><i>Credit Risk</i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:28.7pt;">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</p><span></span></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Recent Accounting Pronouncements</b></i></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:33.65pt;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of</i> <i>Credit Losses on Financial Instruments </i>(&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>)<i>.</i><i> </i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires a financial asset (or a group of financial assets) measured at amortized<i> </i>cost basis to be presented at the net amount expected to be collected. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates.</p>   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:33.65pt;">The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> as of <em style="font: inherit;"> January 1, 2020. </em>Given the nature of the Company&#8217;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:32.4pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic</i> <i><em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>) </i>(&#8220;ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15&#8221;</em>). ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service<i> </i>contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2019, </em>with early adoption permitted. The Company elected to adopt this standard early, beginning <em style="font: inherit;"> October 1, 2019 </em>on a prospective basis. Adoption did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</p><span></span></td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623116120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of the U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,935</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Amortized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Accrued</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Interest</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gains</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Gross</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Unrealized</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Losses</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Estimated</b></b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,488</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,742</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">59</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,899</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">116</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,054</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:center;"><b><b>June 30</b><b>, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,253</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,272</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">3,997</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td></tr></tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:center;"><b><b>December 31, 2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><b><b>Billed</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Unbilled</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,353</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,023</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,376</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shionogi &amp; Co. Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Green Cross Corporation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,924</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mundipharma International Holdings Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Seqirus UK Limited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">351</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">6,760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">15,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">22,146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td></tr></tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Three Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>Six Months</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,018</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,545</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Torii Pharmaceutical Co., Ltd.</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">752</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,487</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,638</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,448</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr></tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831619333928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2019</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">968</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,050</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.96</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Plan amendment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Restricted stock unit awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(547</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">547</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.87</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(193</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,495</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,495</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.66</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,894</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">18,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr></tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2019</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">171</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,329</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.60</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Plan amendment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,502</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,502</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance June 30, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">514</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr></tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2" style="text-align: center; border-bottom: 1px solid black;"><b><b>2020</b></b></td><td style="border-bottom: 1px solid black;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>2019</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Life in Years</p> </td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">81.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Dividend Yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free Interest Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr></tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831693452152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
       <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><b>Principal Payments</b></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80.3%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
       <td>&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">50,000</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831617247192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Lease Obligations and Other Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LesseeLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><b>Remaining Maturities of Lease Liabilities</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
       <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      </tr>

      <tr style="vertical-align: bottom;">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt;"><b>Year Ending December 31,</b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><b>Operating Leases</b></b></p> </td>
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p> </td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 16%; border-bottom: 1px none rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">835</td>
       <td style="width: 1%; border-bottom: 1px none rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">749</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">665</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">575</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">568</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,903</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total lease payments</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,295</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,365</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Total</p> </td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,930</td>
       <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of both operating and finance lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liabilities recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831615467432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 23, 2016</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit, Total</a></td>
<td class="nump">$ 31,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, Raw Materials, Net of Reserves</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Inventory, Work in Process, Net of Reserves</a></td>
<td class="nump">3,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">5,965<span></span>
</td>
<td class="nump">5,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">14,007<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">12,963,000<span></span>
</td>
<td class="nump">2,528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="nump">$ 830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember', window );">Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral Already Posted, Aggregate Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member] | MidCap Financial Services, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit, Total</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized', window );">Revenue Recognition Royalty and Milestone Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition royalty and milestone revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831694035784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 15,929<span></span>
</td>
<td class="nump">$ 21,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">15,935<span></span>
</td>
<td class="nump">22,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,991<span></span>
</td>
<td class="nump">10,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,991<span></span>
</td>
<td class="nump">10,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleDebtSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831622860120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 3,997<span></span>
</td>
<td class="nump">$ 22,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,253<span></span>
</td>
<td class="nump">15,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">16,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,253<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831619556424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 7,694<span></span>
</td>
<td class="nump">$ 7,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">1,989<span></span>
</td>
<td class="nump">3,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="nump">5,487<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member] | US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="nump">4,152<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member] | Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,335<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831613324664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,034<span></span>
</td>
<td class="nump">$ 8,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,873<span></span>
</td>
<td class="nump">22,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,251<span></span>
</td>
<td class="nump">5,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,086<span></span>
</td>
<td class="nump">8,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,604<span></span>
</td>
<td class="nump">6,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,205<span></span>
</td>
<td class="nump">$ 8,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,894<span></span>
</td>
<td class="nump">10,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | December 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623913144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation - Stock Plan Activities (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Awards, available, Plan amendment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, Restricted stock unit awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards available, Restricted stock unit awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(547)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">10,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">18,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">$ 5.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Awards, available, Plan amendment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">2,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831619460136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details) - Incentive Plan and Inducement Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">83.70%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831609651320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
<th class="th" colspan="1">63 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2020</div></th>
<th class="th"><div>Nov. 05, 2019</div></th>
<th class="th"><div>Sep. 06, 2018</div></th>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Feb. 28, 2006</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Jun. 30, 2000</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Nov. 11, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 7,694<span></span>
</td>
<td class="nump">$ 7,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember', window );">Arbitration Proceedings of SUL Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Litigation Settlement, Amount Awarded from Other Party</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember', window );">Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember', window );">Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020', window );">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021', window );">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate', window );">Maximum Customary Reduction on Royalty Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial', window );">Royalty Payments Receivable, Expiration Term From First Commercial (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty Rate if Maintains Sakigake Designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateOtherwise', window );">Royalty Rate, Otherwise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty Rate if Maintains Sakigake Designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateOtherwise', window );">Royalty Rate, Otherwise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentReceived', window );">Milestone Payment Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivable', window );">Potential Milestone Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement', window );">Advance Notice Period for Termination of Agreement (Day)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AdvanceNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents advance notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AdvanceNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the contract date and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of customary reductions allowed on royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumCustomaryReductionOnRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents potential milestone payments receivable based on possibility of future event payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments if regulatory approval is granted before December 31, 2020.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration term of the royalty payments from first commercial date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRateOtherwise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales that the company will receive otherwise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRateOtherwise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118261985&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831705497800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual) - Torii Pharmaceutical Co. [Member] - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="nump">$ 1,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831693542392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Royalty Monetization (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>&#165; / $</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate (in JPY per USD) | &#165; / $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt</a></td>
<td class="nump">22,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestReserve', window );">Interest Reserve</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623940024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 05, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 23, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,715<span></span>
</td>
<td class="nump">$ 41,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentMinimumLibor', window );">Debt Instrument, Minimum LIBOR</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Month)</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LineOfCreditRestrictedCashRequired', window );">Line of Credit, Restricted Cash Required</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Line of Credit Facility, Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | Secured Credit Facility, First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt, Total</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | Secured Credit Facility, Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | Secured Credit Facility, Third Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentMinimumLibor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum LIBOR interest that will be added to the basis spread.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentMinimumLibor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LineOfCreditRestrictedCashRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash required to be held under the terms of a line of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LineOfCreditRestrictedCashRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilitySecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilitySecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831618738184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831697623224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">22,044,447<span></span>
</td>
<td class="nump">22,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 107,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bcrx_WarrantsIssuedInPublicOfferingMember', window );">Warrants Issued in Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">3,511,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant', window );">Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)</a></td>
<td class="nump">$ 4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bcrx_WarrantsIssuedInPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bcrx_WarrantsIssuedInPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831624869816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Lease Obligations and Other Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">13 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">12.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentMember', window );">Accrued Liabilities, Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">3,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 3,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139831623225976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">7,903<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">11,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember', window );">Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 4,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MFNCJ@M5]@>&^_AYM(3,-/>OO:'OT)6E19*.1XV)L=:M@N+W; D[A'[OC*+C
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MK-#GEG65 ,,WZ!A]OKM!KU^]0:^0:-&GM>PT:RM]OC0@RH9>EH. MUL!=$;
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M3?$K"+03X/I**;L;N(.V^:Z:_P-02P,$%     @ EI8'4=O[FOH5!@  3!D
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MH#8YJ$U:M<F$VJ]0W)747H=W*[-VI:W@^_/Y,B-1=KJX/_:#1RS+LSP^B+T
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M<<*J1B!^7Y8E_W'0O$^Z>Y?[_#]02P,$%     @ EI8'49V!3#O5 @  "@@
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M<LG,SVM]V(X"88M^,KO 8,.N=V[J1\*C!UL-("_Z1<6@ _.0:W,4SS25)..
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MD&EC/14SVH(,IX FSCZ[R+9KDKXZ0@D&#64O$DR,K H@@C:/P0DLH:D(;Y?
M#:ZB4V=XUC]\(/[!*/P1,D8(+G1WI5T/AH]\R/*T_=<@ /)/?*(FA%J(NE_<
M&BJR^7,U= *E;%PJ4MDO>K4"H^[KVCY8[I]C1.2F2'T+2N!( W9+7G^KEMD<
MM$=RV(V<*ABN(@YA$?)/PE<; 4+@Q3[4##N96-G*W4LB'-?HDGS95U&SX/3W
M&6#O5?<:MYZ9[IB/E([V\!S#MQ] D>[Z\ZCW>,A_;!^)/MWVMNT[3FW'DQ>]
M3Y/Q!5?7S\XOVT-F03ZSF3J[/,/-RXM+-4WHQ-<^4A08>]![A^7]\&T[/4E.
M9Z?J_'2B9LD8/R?)V?1"?8#+M#MG0JGDGTC-?W(Q:5=&]?_3]IO4X-._RSRF
MOYB<,SNGR>SBO&5'*OO^(>J$7)R/69RS&8GU/#F[G/%O8N8F9+C7.I<:'(,[
MNR8UV,=:DBQ3SX0A"==DZ#P,K<+X,VC@'/D_ETA\<Z4]0-75DNE<AK\;%YB?
M=QDWIYC?^^7['#=P0Q=;)@3:$C(:QH8=S2A7_7XPN_%"4/=TX)M+K#UNNN]Q
MUMM>O.$X$IL7X2C$76H=L_>)[YEBJ7T1E,%8[ELU&=4%[;QI :M$J2.(%79,
MT28BR#Z"H'O)B7I;NH\G]85+>H0#[D"=4LO!WJ% >! M#!48NRK7EX%3=%S&
M\]$O?^Y,'1-IH5HX@TM!:"BR[\\<@3N!PMT#!X(\%4'@&6T9!QWD)!GK3#4*
MP*H+[N0T![(H@N&<I\R-5(!*LO)"3A_1F$7#,/>@[/@5B[BBXZU"K'!C:ZE-
MC-0]5\A]F6 ?M/?$34L.0A&FA39'"V$R?J1=#CWE,<(W[55"C)%OD4H#,#&
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M 198H)@H40H#EM760084K.K?OYBD1!0IO")>#0ME( YR*DAJ=/B5M@D33=L
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MKD<#SS:/#CKN%Q'Y"0=@2DZ@>'@3D.@&BGHQ6U!W?]F>Q<57#!'B1:*6S-V
MXV.5;7!&VVU.0R^'S%R7J2*6H UVH;T--0"$8@5Z(";A$X<N'DQ&*99S;F#6
M=$]F!7I%5M'>T)6I6X;CV7XSNET$/ZY1Q'2\CGJ:H[6T24#TXN1$?+%Z45&9
M+3%E)6S+J#_X4%6-6'\.-*VF>-1C-I</_BSPMR%$:) "D:&A50QM?7)J\.C<
M.44.<"*>+2D,F+@!9H-K'8.!R]1LOU?:JO9P]#,JDML!VCV/NOU(?MGVM1E!
M))3B9&(#LW^KDK3&%R>=!V,;/8T#S<FEP69+/["PQ :V:6]=\T%2RIS/BD-,
M@FW$M8372M+E$ GDX5<*Q Q-J$L8E!9U(Q* 9Z+<49<,= *MH+6W"?8_2K\]
M 0.@M@(F&>FH2C$IBOI8T!U0ZA=T-22<_C&\$4 !KZ#,I%K\+O/R[2,'GV9!
MUPD_J(6M:""=3Z>@]H[HIZ\YI=L#2:#^PHA_ JM"G##IG!A;FCK)&QV][UN#
M#=VKCOBT=HF\U"4?TZ $,2Z:6YUSD"%7Z/:<U-ORN/40?57TH K7)OC[D5=1
MAF>4 HXB7B$:='VE J,V P3]_@IRU@\2#8^.YHY.ZN&"*4%TJ"[;R\0MG*.S
MDZO+VDS>4K^_N&F&/1YW%-_@9IL>0-, 4)C$:2Y'#"XE.3@;?"("HL\M NS;
M]'"(P:O&8=J(+V&^Y*LLM$<1>>8/9U"\I@R7RC"V?V"I#R9UA7 3H\F#<YWO
M*3"=59YN]_C<NWVJ3"I5#]REU$ESF] 6MQ&,U 2X]*BJ.3[(ML[)4S)?%NQK
M&)#WPQ58+SA\$0AN1%:!WH\U44>ZDGD;E[OHN$N> "3-ZN$Z ;V8O'CL-G32
MNX]&::=\ZT[$BU-RN)INW[87^U&XS^Z6A_\50-=(Z02<J26V3L>O#G8":34/
MWI1\N[TP'F=%_KE2Z->6%N#[TAC?/)""]K\[WO\?4$L#!!0    ( ):6!U&6
M]RA'1P0  !P*   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;'U6;6_;
M. S^*X0/.-R'+._;NET:(.UN6 =T*YKV[L/A/B@V$PN5)4^2FV:__DC:<9TN
MS8<VDDP^?'E(2K.M\P\A1XSP5!@;SI,\QO+C8!#2' L5^JY$2U_6SA<JTM9O
M!J'TJ#)1*LQ@/!R^&Q1*VV0^D[,;/Y^Y*AIM\<9#J(I"^=T%&K<]3T;)_N!6
M;_+(!X/YK%0;7&*\+V\\[08M2J8+M$$["Q[7Y\EB]/%BRO(B\+?&;>BL@2-9
M.?? FZOL/!FR0V@PC8R@Z.<1+]$8!B(W?C2826N2%;OK/?IGB9UB6:F E\[\
MH[.8GR=G"62X5I6)MV[[!9MXWC)>ZDR0_["M92?3!-(J1%<TRN1!H6W]JYZ:
M/'04SH:O*(P;A;'X71L2+S^IJ.8S[[;@69K0>"&ABC8YIRV3LHR>OFK2B_-O
M+B),X0W<NITR<0?7SF+4/Q7G;#:(9((%!VD#=U'#C5^!>\?Z,0_PE\TP.]0?
MD&NM?^.]?Q?CDX!?*]N'R; 'X^%X> )OTL8[$;S)B7@#1 >?M54VU<K ,JJ(
M5&<QG,"?MOA3P9^^@G\LC?#O'3Y%N# N??CO6$Y/0S84?7]$_\AE_MW"M?)I
M#A\X*Z-1#Y984@0K]+P?PR) J7P$MX:8(T2O;%#2!#TYN'1%J>P.*&3TF(&V
ME \%946@5."@; 9!&5IL/$IF(*,49: "8QX8!^LB?'/VS2VFKO*D76?X1NW4
MBB!^=9:)?('Q1R>"48AM+2ZKU>^_G8U'[_\DPRNC-Y).H:]4.RB])@9+HI ]
MUA(-:5/".<J;7-U>+QIWE,<#A. ,FAU'T[$E,"RYU3&G 49#IXF)\T,)<X3K
MH40?.)5DW%29MIMN4GN 3RD%PRI\3,1S_AHJ&J$VJ-)@MD'^JF, _%%I\F0?
M2*#5@7NT#559NF=JNS'VX:[#;:'(%>:&%I01A"M[6";3;ME,A(A)_U!DTJ6E
MURA]PK31:8[$POYO;]$Z65+W8MN]/7'PB@:#C15E.7-$#$LMI*Q>R$Y$^A<2
MJ5ZI)*6T5)0<N%)Z["6541B+=('(6A2+6I3J)D7.-E5.0Q.Q'2+1SVP^E]5*
M&9H1>"S;L$*6K=VAUBA-10ZFJ:^X3ZB.*ELJW:G*F'M7;7(!ZOC"C76T8@_Q
M^W!9>8\VW<$7*9E%VYI$;.JL;6XY+ET!TR%4XOQJ=Y"8([&<G JOVJ6ON1RE
MZ"/=_N!U>* <A.!HK/*X$%]HI-@-2BVSE4=EJC:A7Q591.JO'?(-;Q3?T'M*
M[OO+/M6(,<KWX9ZJQM=NON+/81 TQ^I,\Z4L\V(_W&K$4 \Y>@R([;I"A(HU
MC(9#.:0^;^W?G;#\7,A!/QV6,3?(AV.WRJ!S8Q?H-_(N"41D96-]>;>G[=-G
M4=_XS^+UNXE&Z4;32#.X)M5A__W;I Y[OXFNE/M_Y2*])F29T_,-/0O0][6C
M(F@V;*!]$,[_!U!+ P04    " "6E@=11[Y1#K@"   1!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6R55=]OVC 0?N]?<8KZL =&0BA=5P$2M*NV
M2NU0Z;:':0\F.8A5Q\[L2RG__<Y.8%0K2'LA=^?[/M\O'\.UL4^N0"1X*95V
MHZ@@JB[CV&4%EL)U386:3Y;&EH)8M:O8519%'D"EBM,D.8]+(74T'@;;S(Z'
MIB8E-<XLN+HLA=U,49GU*.I%6\.#7!7D#?%X6(D5SI&^53/+6KQCR66)VDFC
MP>)R%$UZE],S[Q\<ODM<NST9?"8+8YZ\\B4?18D/"!5FY!D$?Y[Q"I7R1!S&
M[Y8SVEWI@?OREOTFY,ZY+(3#*Z-^R)R*470108Y+42MZ,.O/V.8S\'R942[\
MPKKQ[:<19+4C4[9@CJ"4NOF*E[8.>X"+Y  @;0%IB+NY*$1Y+4B,A]:LP7IO
M9O-"2#6@.3BI?5/F9/E4,H[&]X80!O >YJBEL7!E,9<$-R*32M)F&!-?XEWC
MK"6<-H3I <)SN#.:"@>?=([Y:WS,P>TB3+<13M.CA+>U[D(_Z4":I,D1OOXN
MXW[@ZQ_)V $9N)%:Z$P*!7,2A#QIY([PG^WXSP+_V0'^:UP07$N7*>-JB_#S
M$5\(ILID3[_>*N=QMK8_7S7<X,+6_&Y@X$O1^]@!*BPB+*5U! XSHW,V29N_
M5N98<7(+M-!+&N1KR+UY;H[[[7'W7U-GZ_Q8(!,&<<(%XPZ#8/D!G2]A?F"*
M_.L-Q6[=+59*>(68[G]X\G H')@EW-9JP\&% "_@'6A#;-,8Y@0FK0_KV]GI
MG,RLY(97W/&9V(1^GP3G4U^:)$F\UO.<K9QNY4=###J%05!#%7+?9K'B#G@B
MX)(0KT >K+7QH;PU2/'>,RW1KL(R<@RM-34O=F?=[;M)\\S_NC?+\D[8E;]-
MX9*A2??#( +;+*!&(5.%1[\PQ"LDB 7O;+3>@<^7A@>K5?P%NW^!\1]02P,$
M%     @ EI8'415V7# ; @  I00  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL?53;CILP$/V5$2]]V09"+EVM"%*R%[65TD:;7AZJ/C@P"5:,S=I#
M2?Z^MB$TE9*\@,>><^:<84S2*+TW!2+!H132S(*"J'H(0Y,56#(S4!5*>[)5
MNF1D0[T+3:61Y1Y4BC".HFE8,BZ#-/%[*YTFJB;!):XTF+HLF3XN4*AF%@R#
MT\8KWQ7D-L(TJ=@.UTC?JY6V4=BSY+Q$:;B2H'$["^;#A\78Y?N$'QP;<[8&
MYV2CU-X%G_)9$#E!*# CQ\#LZP\^HA".R,IXZSB#OJ0#GJ]/["_>N_6R808?
ME?C)<RIFP7T .6Y9+>A5-1^Q\S-Q?)D2QC^A:7,G40!9;4B5'=@J*+ELW^S0
M]>$<<'\%$'> V.MN"WF53XQ8FFC5@';9ELTMO%6/MN*X=!]E3=J><HNC](LB
MA"F\AS6I;%\HD:,V[^#YK>9T3$*R)5QBF'5TBY8NOD(WA:625!AXECGF_^-#
M*ZW7%Y_T+>*;A)]K.8!1= =Q%$<W^$:]WY'G&]WP:X 4O'#)9,:9L,X9H9TS
M,C?XQSW_V/./K_!?:B/X)C]QDPEE:HWPZQL>"!;"IOZ^U./;);I/]E7"O-)<
M0#QNNW,'(UBR(PR[&&SO$(;]X<7VA6>C4Z+>^0MB(%.UI':*^MW^#L[;T?N7
MWE[@)=,[+@T(W%IH-/@P"4"WEZ(-2%5^$#>*[%C[96'_(ZA=@CW?*NNL"UR!
M_L^4_@502P,$%     @ EI8'40'\\G6- P  IP<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL?55+;^,V$+[[5PRT1D]:2Y;\3&T#<=*@+3:;($E;
M%$4/M#R2B%"BEJ1B^]]W2,E:>YOX((I#SGSS'BYV4KWJ'-' OA"E7GJY,=55
M$.@DQX+I@:RPI)M4JH(9(E46Z$HAVSJA0@11&$Z"@O'26RW<V:-:+61M!"_Q
M48&NBX*IPQJ%W"V]H7<\>.)9;NQ!L%I4+,-G-']4CXJHH$/9\@)+S64)"M.E
M=SV\6H\LOV/XD^-.G^S!>K*1\M42OVV77F@-0H&)L0B,?F]X@T)8(#+C6XOI
M=2JMX.G^B'[G?"=?-DSCC11_\:W)E][,@RVFK!;F2>Y^Q=:?L<5+I-!NA5W#
M.R:-2:V-+%IAH@M>-G^V;^-P(C +/Q"(6H'(V=TH<E;>,L-6"R5WH"PWH=F-
M<]5)DW&\M$EY-HIN.<F9U5=I$*;P&;X@^08/&\$S9N.E@95;># Y*KB1I>%E
MAF7"42\"0WJM=)"T.M:-CN@#'1.X)X!<PR_E%K?G\@'9VQD='8U>1Q<!?Z_+
M <2A#U$8A1?PXBX(L<.++P1!@Y%PQTM&3C(!SX89I.(S^@+^J,,?.?S1!_@N
MMAID2E'66BJXY3H14M<*X9\7W!M8"YF\_OM>:"\BVY:]TA5+<.E13VI4;^@=
M<_J2(V6NJ%AY -%8D* RU*C M$:CH:9\** &5\SFM^7R89?S)(=*<>I3+@Z0
M4#EP;7!K7:#6%X#:QJ<3$&PC"4.J ^"WFE<V<$>=MHQDFO($W[DS0+G$+I<#
MN\9VF0S.;_PS=W*FH92&/KC.,H599PS@GN85_=_W#78DV9_'8V=6?QI.@ 8;
M4)6#YOMSE:?4<.Z#V:%X0ZNW=U<;F[M&8\4.KE <TL7(TJV-X+ECO2>TP]-R
MW3."Y88?:\6B?^%LPX4[[/V-3-DFLKRWF&"Q(27QT(>'3E%3:CUG?Q]F\=AN
MAS =S>TF@LG$G<0PGKK-",:368]B2VE-#<%-_7D8]UZDH2S_X-]PZ$?S<<_6
M,/"BJFU!\)*$J!I@XL<$W<CU8>3/XQ >4A?9-FL_?9I%P^G/MM&^@XO6O8,/
M_:$?SB? *4PT^91R=7*\;O(5^[-XU' (66:?27=QRO._<OJ!?*^7@Y/A6:#*
MW!-!K2+KTC1SM#OM7J'K9OA^9V^>L'NF,DZ34V!*HN%@.O9 -<]"0QA9N5&\
MD88&N]OF])*BL@QTGTIJW9:P"KJW>?4?4$L#!!0    ( ):6!U%3U)[.<1D
M /%1   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;,5<>6_;2++_*@V_
MP2(#T(HNR_;D &QG9N+9'(:=S#Y@L7^TR);4$QZ:;M*RYM._.KK)ID31=MX
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M6_]H-[!4<D.!=A_ ].3H\X16Q"KUS6)2D$)C!O.?'/7**92BV>(B3YPY4H0
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M/JE3I24F(1M,&L:8.>4" L%Z%+/[",#P*M!8+E773+M(.5<KF2Z8!$TX&R&
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M,0)%XA&XPFZ:(;EYX['KE1=]6Z:I>A[UERG7=>8.L#@@X_;I+_6Y5 :<3]U
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M@T(0^R"HP]#3.<J".,\.0!''&23NC7R[THQ)N/":VY+?G><$E9Y X=XQ^1'
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M!6/B1W6=LEL8N7/=Z58:ZG5NNJ4?%ZBL )VO)3W2_<(:&'ZNS/\#4$L#!!0
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M-A,+E25/DIOVWX^2'2\#VEPL2N)[?"1-S79*/YH"T<)S*:29!X6UU5D4F:S
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M ;F]&=R^:+%,[IDF0FL1)H\+&/.8- 3P^TP(O7LQ K+[V:O_ 5!+ P04
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M..K?(_CA!C]L@.;(MNH-_J:0W8*LJ/15HC_4OPP![3"HFX B11O0WFD#3UK
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M+&JW@=9GBFIO.7$?J#IW_Q=02P,$%     @ EI8'45X2""R0"   3RH  !D
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M9WS);($U,)'"K5FA@JD4AHLEBH2CAI-K-(QG&K[@UA0L.R7TX\,UG+P[A7?
M!7Q9R4(36@]]0Q1M(C^IZ%R5=*(#='HPHUPK#1]%BNF/>)^DU?JB%WU746O
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MI^J'HNX863IQ7DB#4N^:.3ZNH.P$'%])%.BF8_6^?:YG?P!02P,$%     @
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "6E@=10+ BVCD#  "O%P
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M\@?U(',$,H\(N6@@FC]8HE=DKNN-!SE&(,?[@V2V\B G".1D;Y +IPL/<HI
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MH01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M (6N*0M84A:PI"EE3%+*F_TG6#ZV7?_T/L%V36JKFX,^Z
M'ZVS+U!+ 0(4 Q0    ( ):6!U$'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ EI8'44;6M!/O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ EI8'49E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "6E@=18MS:33,%  !Y%0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ EI8'43403<GH!0  %1<  !@              ("!=PT  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ):6!U'I?3PVR0(  &,)
M   8              " @943  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "6E@=1V_N:^A4&  !,&0  &               @(&4%@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ EI8'41*2+&,L
M!@  MQ<  !@              ("!WQP  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( ):6!U&12XNSVP<  -<M   8              "
M@4$C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "6E@=1
MG8%,.]4"   *"   &               @(%2*P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ EI8'4=),UWO %P  D40  !@
M     ("!72X  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M ):6!U'7NF81, 8  -\0   8              " @5-&  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "6E@=1NLI>]5X*  #Z&   &0
M            @(&Y3   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( ):6!U&6]RA'1P0  !P*   9              " @4Y7  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ EI8'44>^40ZX @
M$08  !D              ("!S%L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "6E@=1%79<,!L"  "E!   &0              @(&[
M7@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ):6!U$!
M_/)UC0,  *<'   9              " @0UA  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ EI8'45/4GLYQ&0  \5$  !D
M     ("!T60  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ):6!U&5C#M_1 <  *L=   9              "
M@=F,  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ EI8'
M479%&'@)!   KQ   !D              ("!5)0  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "6E@=1Z*=H16$$  #Z%0  &0
M        @(&4F   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( ):6!U'#A=D5T ,  *0.   9              " @2R=  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ EI8'45=8,4 0"   N"X
M !D              ("!,Z$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "6E@=1=<,G=CL%  !;'   &0              @(%ZJ0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ):6!U'EHF9A
MT@(  ,4'   9              " @>RN  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ EI8'45X2""R0"   3RH  !D
M ("!];$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "6
ME@=1Z:#DHW "   I!0  &0              @(&\N@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ):6!U%N]RAN]P,  'X,   9
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M970S,RYX;6Q02P$"% ,4    " "6E@=1JV2WSL "  "Z!P  &0
M    @($.SP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M ):6!U&*ACY/,P(  -L)   -              "  072  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ EI8'49>*NQS     $P(   L              ( !
M8]0  %]R96QS+RYR96QS4$L! A0#%     @ EI8'44"P(MHY P  KQ<   \
M             ( !3-4  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ):6
M!U&,WU^M;@$  -T4   :              "  ;+8  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ):6!U$&5T)WCP$  ' 5   3
M          "  5C:  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     J "H
*70L  !C<      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>211</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies</Role>
      <ShortName>Note 1 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation</Role>
      <ShortName>Note 2 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Royalty Monetization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization</Role>
      <ShortName>Note 4 - Royalty Monetization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Senior Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility</Role>
      <ShortName>Note 5 - Senior Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity</Role>
      <ShortName>Note 6 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Lease Obligations and Other Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies</Role>
      <ShortName>Note 7 - Lease Obligations and Other Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 1 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 2 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables</Role>
      <ShortName>Note 2 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 5 - Senior Credit Facility (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables</Role>
      <ShortName>Note 5 - Senior Credit Facility (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 7 - Lease Obligations and Other Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables</Role>
      <ShortName>Note 7 - Lease Obligations and Other Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual</Role>
      <ShortName>Note 2 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 2 - Stock-based Compensation - Stock Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details</Role>
      <ShortName>Note 2 - Stock-based Compensation - Stock Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details</Role>
      <ShortName>Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual</Role>
      <ShortName>Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 4 - Royalty Monetization (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual</Role>
      <ShortName>Note 4 - Royalty Monetization (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual</Role>
      <ShortName>Note 5 - Senior Credit Facility (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details</Role>
      <ShortName>Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual</Role>
      <ShortName>Note 6 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 7 - Lease Obligations and Other Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual</Role>
      <ShortName>Note 7 - Lease Obligations and Other Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx20200630_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details</Role>
      <ShortName>Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bcrx20200630_10q.htm">bcrx20200630_10q.htm</File>
    <File>bcrx-20200630.xsd</File>
    <File>bcrx-20200630_cal.xml</File>
    <File>bcrx-20200630_def.xml</File>
    <File>bcrx-20200630_lab.xml</File>
    <File>bcrx-20200630_pre.xml</File>
    <File>ex_196626.htm</File>
    <File>ex_196627.htm</File>
    <File>ex_196628.htm</File>
    <File>ex_196629.htm</File>
    <File>ex_196806.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bcrx20200630_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 211,
   "dts": {
    "calculationLink": {
     "local": [
      "bcrx-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcrx-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bcrx20200630_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcrx-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcrx-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bcrx-20200630.xsd"
     ],
     "remote": [
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 444,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 33,
    "http://www.biocryst.com/20200630": 5,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 44
   },
   "keyCustom": 57,
   "keyStandard": 284,
   "memberCustom": 40,
   "memberStandard": 31,
   "nsprefix": "bcrx",
   "nsuri": "http://www.biocryst.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.biocryst.com/20200630/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts",
     "role": "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
     "shortName": "Note 3 - Collaborative and Other Research and Development Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 4 - Royalty Monetization",
     "role": "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
     "shortName": "Note 4 - Royalty Monetization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 5 - Senior Credit Facility",
     "role": "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
     "shortName": "Note 5 - Senior Credit Facility",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 6 - Stockholders' Equity",
     "role": "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
     "shortName": "Note 6 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 7 - Lease Obligations and Other Contingencies",
     "role": "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
     "shortName": "Note 7 - Lease Obligations and Other Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 1 - Significant Accounting Policies (Tables)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables",
     "shortName": "Note 1 - Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 2 - Stock-based Compensation (Tables)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables",
     "shortName": "Note 2 - Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 5 - Senior Credit Facility (Tables)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables",
     "shortName": "Note 5 - Senior Credit Facility (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 7 - Lease Obligations and Other Contingencies (Tables)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables",
     "shortName": "Note 7 - Lease Obligations and Other Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)",
     "role": "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
     "shortName": "Consolidated Balance Sheets (Current Period Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
     "shortName": "Note 1 - Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details",
     "shortName": "Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Receivables (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
     "shortName": "Note 1 - Significant Accounting Policies - Summary of Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-04-01_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 1 - Significant Accounting Policies - Summary of Revenues (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
     "shortName": "Note 1 - Significant Accounting Policies - Summary of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-04-01_2020-06-30_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 2 - Stock-based Compensation (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
     "shortName": "Note 2 - Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2019-12-31_PlanNameAxis-IncentivePlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 2 - Stock-based Compensation - Stock Plan Activities (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
     "shortName": "Note 2 - Stock-based Compensation - Stock Plan Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2019-12-31_PlanNameAxis-IncentivePlanMember",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
     "shortName": "Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30_PlanNameAxis-IncentivePlanAndInducementPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-04-01_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
     "shortName": "Note 3 - Collaborative and Other Research and Development Contracts 1 (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual",
     "shortName": "Note 3 - Collaborative and Other Research and Development Contracts 2 (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2020-07-01",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "bcrx:CurrencyHedgeAgreementPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLossOnDerivative",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 4 - Royalty Monetization (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
     "shortName": "Note 4 - Royalty Monetization (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DerivativeForwardExchangeRate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "JPYPerUSD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "role": "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual",
     "shortName": "Note 5 - Senior Credit Facility (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details",
     "shortName": "Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-04-24",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 6 - Stockholders' Equity (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual",
     "shortName": "Note 6 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-04-24",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 7 - Lease Obligations and Other Contingencies (Details Textual)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
     "shortName": "Note 7 - Lease Obligations and Other Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)",
     "role": "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
     "shortName": "Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-04-01_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-04-01_2020-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2019-01-01_2019-03-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)",
     "role": "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 1 - Significant Accounting Policies",
     "role": "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
     "shortName": "Note 1 - Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 2 - Stock-based Compensation",
     "role": "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
     "shortName": "Note 2 - Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20200630_10q.htm",
      "contextRef": "d_2020-01-01_2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "bcrx_AECOMAndIRLMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AECOM and IRL",
        "label": "AECOM and IRL [Member]"
       }
      }
     },
     "localname": "AECOMAndIRLMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ASPRBARDAContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The potential value of the ASPR/BARDA Contract.",
        "label": "ASPRBARDA Contract [Member]"
       }
      }
     },
     "localname": "ASPRBARDAContractMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AccruedExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents accrued expenses policy.",
        "label": "Accrued Expenses [Policy Text Block]"
       }
      }
     },
     "localname": "AccruedExpensesPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to accrued liabilities, current and other noncurrent liabilities.",
        "label": "Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AccruedLiabilitiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing current accrued liabilities.",
        "label": "Accrued Liabilities, Current [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AdditionalDevelopmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The additional development options that can be exercised by the Government.",
        "label": "Additional Development Options [Member]"
       }
      }
     },
     "localname": "AdditionalDevelopmentOptionsMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AdvanceNoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents advance notice period for termination of agreement.",
        "label": "bcrx_AdvanceNoticePeriodForTerminationOfAgreement",
        "terseLabel": "Advance Notice Period for Termination of Agreement (Day)"
       }
      }
     },
     "localname": "AdvanceNoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_AmortizationOfDiscountAndPremiumOnInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to the discount and premium on investments.",
        "label": "Amortization of premium/discount on investments"
       }
      }
     },
     "localname": "AmortizationOfDiscountAndPremiumOnInvestments",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents annual maximum license fee.",
        "label": "bcrx_AnnualLicenseFeeMaximum",
        "terseLabel": "Annual License Fee Maximum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMaximum",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent minimum annual license fee.",
        "label": "bcrx_AnnualLicenseFeeMinimum",
        "terseLabel": "Annual License Fee Minimum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMinimum",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ArbitrationProceedingsOfSulAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the arbitration proceedings of several terms under SUL Agreement.",
        "label": "Arbitration Proceedings of SUL Agreement [Member]"
       }
      }
     },
     "localname": "ArbitrationProceedingsOfSulAgreementMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_August2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents award date of August 2013.",
        "label": "August 2013 [Member]"
       }
      }
     },
     "localname": "August2013Member",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AvailableForSaleDebtSecuritiesAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accrued Interest"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccruedInterest",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AverageMaturityForPortfolioInvestments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average maturity for portfolio investments during the period.",
        "label": "bcrx_AverageMaturityForPortfolioInvestments",
        "terseLabel": "Average Maturity for Portfolio Investments (Month)"
       }
      }
     },
     "localname": "AverageMaturityForPortfolioInvestments",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average maturity period of high quality marketable securities.",
        "label": "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities",
        "terseLabel": "Average Maturity Period of High Quality Marketable Securities (Month)"
       }
      }
     },
     "localname": "AverageMaturityPeriodOfHighQualityMarketableSecurities",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_BaseContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.",
        "label": "Base Contract [Member]"
       }
      }
     },
     "localname": "BaseContractMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CSLLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents CSL Limited which is a company organized under the laws of Australia.",
        "label": "CSL Limited [Member"
       }
      }
     },
     "localname": "CSLLimitedMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of warrants issued.",
        "label": "bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant",
        "terseLabel": "Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "bcrx_CollaborativeAgreementContractValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents collaborative agreement contract value.",
        "label": "bcrx_CollaborativeAgreementContractValue",
        "terseLabel": "Collaborative Agreement Contract Value"
       }
      }
     },
     "localname": "CollaborativeAgreementContractValue",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAndOtherResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to Collaborative and other research and development.",
        "label": "Collaborative and Other Research and Development [Member]"
       }
      }
     },
     "localname": "CollaborativeAndOtherResearchAndDevelopmentMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollateralForCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.",
        "label": "Collateral for Credit [Member]"
       }
      }
     },
     "localname": "CollateralForCreditMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ConcentrationOfMarketRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents concentration of market risk policy.",
        "label": "Concentration of Market Risk [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationOfMarketRiskPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_ContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between the contract date and its expiration.",
        "label": "bcrx_ContractTerm",
        "terseLabel": "Contract Term (Year)"
       }
      }
     },
     "localname": "ContractTerm",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_CurrencyHedgeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.",
        "label": "Currency Hedge Agreement [Member]"
       }
      }
     },
     "localname": "CurrencyHedgeAgreementMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CurrencyHedgeAgreementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents currency hedge agreement policy.",
        "label": "Currency Hedge Agreement [Policy Text Block]"
       }
      }
     },
     "localname": "CurrencyHedgeAgreementPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_DebtInstrumentMinimumLibor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum LIBOR interest that will be added to the basis spread.",
        "label": "bcrx_DebtInstrumentMinimumLibor",
        "terseLabel": "Debt Instrument, Minimum LIBOR"
       }
      }
     },
     "localname": "DebtInstrumentMinimumLibor",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_December2014Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents award date of December 2014.",
        "label": "December 2014 [Member]"
       }
      }
     },
     "localname": "December2014Member",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_December2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents award date of December 2019.",
        "label": "December 2019 [Member]"
       }
      }
     },
     "localname": "December2019Member",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_DescriptionOfCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The description of company policy.",
        "label": "Description of Company [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfCompanyPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear",
        "terseLabel": "Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year five.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Five"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee stock purchase plan, (ESPP).",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents expected receivable from awards for research and development contracts.",
        "label": "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
        "terseLabel": "Expected Receivable From Awards for Research and Development Contracts"
       }
      }
     },
     "localname": "ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_GreenCrossCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents Green Cross Corporation.",
        "label": "Green Cross Corporation [Member]"
       }
      }
     },
     "localname": "GreenCrossCorporationMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the incentive and inducement plans.",
        "label": "Incentive Plan and Inducement Plan [Member]"
       }
      }
     },
     "localname": "IncentivePlanAndInducementPlanMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents Incentive Plan.",
        "label": "Incentive Plan [Member]"
       }
      }
     },
     "localname": "IncentivePlanMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related to the Inducement Plan.",
        "label": "Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents interest expense and deferred financing costs.",
        "label": "Interest Expense and Deferred Financing Costs [Policy Text Block]"
       }
      }
     },
     "localname": "InterestExpenseAndDeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestReserve": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents interest reserve established as part of the royalty monetization.",
        "label": "bcrx_InterestReserve",
        "terseLabel": "Interest Reserve"
       }
      }
     },
     "localname": "InterestReserve",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_JPRRoyaltySubLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents JPR Royalty Sub LLC.",
        "label": "JPR Royalty Sub LLC [Member]"
       }
      }
     },
     "localname": "JPRRoyaltySubLLCMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to laboratory equipment, office equipment and software.",
        "label": "Laboratory Equipment, Office Equipment and Software [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentOfficeEquipmentAndSoftwareMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LesseeLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of both operating and finance lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liabilities recognized in statement of financial position.",
        "label": "Lessee, Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_LineOfCreditRestrictedCashRequired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of restricted cash required to be held under the terms of a line of credit.",
        "label": "bcrx_LineOfCreditRestrictedCashRequired",
        "terseLabel": "Line of Credit, Restricted Cash Required"
       }
      }
     },
     "localname": "LineOfCreditRestrictedCashRequired",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_LongtermInvestmentMaturityMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents long term investment maturity minimum.",
        "label": "bcrx_LongtermInvestmentMaturityMinimum",
        "terseLabel": "Long-term Investment Maturity, Minimum (Month)"
       }
      }
     },
     "localname": "LongtermInvestmentMaturityMinimum",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityPeriodOfHighQualityMarketablesecurities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents maturity period of high quality marketable securities.",
        "label": "bcrx_MaturityPeriodOfHighQualityMarketablesecurities",
        "terseLabel": "Maturity Period of High Quality Marketable Securities (Year)"
       }
      }
     },
     "localname": "MaturityPeriodOfHighQualityMarketablesecurities",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityperiodOfShortTermInvestment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maturity period of short term investment.",
        "label": "bcrx_MaturityperiodOfShortTermInvestment",
        "terseLabel": "Maturity Period of Short Term Investment (Month)"
       }
      }
     },
     "localname": "MaturityperiodOfShortTermInvestment",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.",
        "label": "bcrx_MaximumAggregateOfferingPrice",
        "terseLabel": "Maximum Aggregate Offering Price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MaximumCustomaryReductionOnRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum percentage of customary reductions allowed on royalty rate.",
        "label": "bcrx_MaximumCustomaryReductionOnRoyaltyRate",
        "terseLabel": "Maximum Customary Reduction on Royalty Rate"
       }
      }
     },
     "localname": "MaximumCustomaryReductionOnRoyaltyRate",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_MidCapFinancialServicesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents MidCap Financial Services, LLC entity.",
        "label": "MidCap Financial Services, LLC [Member]"
       }
      }
     },
     "localname": "MidCapFinancialServicesLLCMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_MilestonePaymentMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents milestone payment maximum.",
        "label": "bcrx_MilestonePaymentMaximum",
        "terseLabel": "Milestone Payment Maximum"
       }
      }
     },
     "localname": "MilestonePaymentMaximum",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestonePaymentMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents milestone payment minimum.",
        "label": "bcrx_MilestonePaymentMinimum",
        "terseLabel": "Milestone Payment Minimum"
       }
      }
     },
     "localname": "MilestonePaymentMinimum",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of milestone payment received.",
        "label": "bcrx_MilestonePaymentReceived",
        "terseLabel": "Milestone Payment Received"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MundipharmaInternationalHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to Mundipharma International Holdings Limited.",
        "label": "Mundipharma International Holdings Limited [Member]"
       }
      }
     },
     "localname": "MundipharmaInternationalHoldingsLimitedMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_MundipharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to Mundipharma.",
        "label": "Mundipharma [Member]"
       }
      }
     },
     "localname": "MundipharmaMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents National Institute of Allergy and Infectious Diseases.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_PercentageOfCarryingAmountInExcessOfFairValue1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the percentage of carrying amount in excess of fair value.",
        "label": "bcrx_PercentageOfCarryingAmountInExcessOfFairValue1",
        "terseLabel": "Percentage of Carrying Amount in Excess of Fair Value"
       }
      }
     },
     "localname": "PercentageOfCarryingAmountInExcessOfFairValue1",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfCommonStockSharesBeginning": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents percentage of common stock shares beginning.",
        "label": "bcrx_PercentageOfCommonStockSharesBeginning",
        "terseLabel": "Percentage of Common Stock Shares, Beginning"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesBeginning",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfCommonStockSharesEnding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents percentage of common stock shares ending.",
        "label": "bcrx_PercentageOfCommonStockSharesEnding",
        "terseLabel": "Percentage of Common Stock Shares, Ending"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesEnding",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents percentage of salary to purchase common stock maximum.",
        "label": "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum",
        "terseLabel": "Percentage of Salary to Purchase Common Stock, Maximum"
       }
      }
     },
     "localname": "PercentageOfSalaryToPurchaseCommonStockMaximum",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents period of agreement.",
        "label": "bcrx_PeriodOfAgreement",
        "terseLabel": "Period of Agreement (Year)"
       }
      }
     },
     "localname": "PeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_PhaRMANotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents PhaRMA notes.",
        "label": "PhaRMA Notes Member]"
       }
      }
     },
     "localname": "PhaRMANotesMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents potential milestone payments receivable based on possibility of future event payments.",
        "label": "bcrx_PotentialMilestonePaymentsReceivable",
        "terseLabel": "Potential Milestone Payments Receivable"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivable",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of potential milestone payments if regulatory approval is granted before December 31, 2020.",
        "label": "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020",
        "terseLabel": "Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2020"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312020",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.",
        "label": "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021",
        "terseLabel": "Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PrivatePlacementOfSeniorSecuredNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents private placement of senior secured notes.",
        "label": "bcrx_PrivatePlacementOfSeniorSecuredNotes",
        "terseLabel": "Private Placement of Senior Secured Notes"
       }
      }
     },
     "localname": "PrivatePlacementOfSeniorSecuredNotes",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents proceeds from awards for research and development contracts.",
        "label": "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts",
        "terseLabel": "Proceeds from awards for Research and Development Contracts"
       }
      }
     },
     "localname": "ProceedsFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RenewablePeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents renewable period of agreement.",
        "label": "bcrx_RenewablePeriodOfAgreement",
        "terseLabel": "Renewable Period of Agreement (Year)"
       }
      }
     },
     "localname": "RenewablePeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue recognition royalty and milestone revenue recognized.",
        "label": "bcrx_RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized",
        "terseLabel": "Revenue Recognition Royalty and Milestone Revenue Recognized"
       }
      }
     },
     "localname": "RevenueRecognitionRoyaltyAndMilestoneRevenueRecognized",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyMonetizationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the royalty monetization transaction.",
        "label": "Royalty Monetization [Member]"
       }
      }
     },
     "localname": "RoyaltyMonetizationMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RoyaltyMonetizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty monetization.",
        "label": "Royalty Monetization [Text Block]"
       }
      }
     },
     "localname": "RoyaltyMonetizationTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expiration term of the royalty payments from first commercial date.",
        "label": "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
        "terseLabel": "Royalty Payments Receivable, Expiration Term From First Commercial (Year)"
       }
      }
     },
     "localname": "RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.",
        "label": "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation",
        "terseLabel": "Royalty Rate if Maintains Sakigake Designation"
       }
      }
     },
     "localname": "RoyaltyRateIfMaintainsSakigakeDesignation",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyRateOtherwise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of net sales that the company will receive otherwise.",
        "label": "bcrx_RoyaltyRateOtherwise",
        "terseLabel": "Royalty Rate, Otherwise"
       }
      }
     },
     "localname": "RoyaltyRateOtherwise",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents royalty receivable.",
        "label": "Royalty Receivable [Member]"
       }
      }
     },
     "localname": "RoyaltyReceivableMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure representing receivables from collaborations.",
        "label": "Schedule of Receivables from Collaborations [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfReceivablesFromCollaborationsTableTextBlock",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_SecuredCreditFacilityFirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the first tranche of a secured credit facility.",
        "label": "Secured Credit Facility, First Tranche [Member]"
       }
      }
     },
     "localname": "SecuredCreditFacilityFirstTrancheMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SecuredCreditFacilitySecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the second tranche of a secured credit facility.",
        "label": "Secured Credit Facility, Second Tranche [Member]"
       }
      }
     },
     "localname": "SecuredCreditFacilitySecondTrancheMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SecuredCreditFacilityThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represent the third tranche of a secured credit facility.",
        "label": "Secured Credit Facility, Third Tranche [Member]"
       }
      }
     },
     "localname": "SecuredCreditFacilityThirdTrancheMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SeniorCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Senior Credit Facility [Member]"
       }
      }
     },
     "localname": "SeniorCreditFacilityMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SeqirusUKLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to Seqirus UK Limited.",
        "label": "Seqirus UK Limited [Member]"
       }
      }
     },
     "localname": "SeqirusUKLimitedMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents share based compensation arrangement by share based payment award options grants in period awards available.",
        "label": "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
        "negatedLabel": "Awards available, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.",
        "label": "bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeitures in period awards available.",
        "label": "Awards available, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShionogiAndCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shionogi &amp; Co. Ltd.",
        "label": "Shionogi and Co. Ltd [Member]"
       }
      }
     },
     "localname": "ShionogiAndCoLtdMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ToriiPharmaceuticalCoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to Torii Pharmaceutical Co., Ltd.",
        "label": "Torii Pharmaceutical Co. [Member]"
       }
      }
     },
     "localname": "ToriiPharmaceuticalCoMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents transaction costs associated with royalty monetization.",
        "label": "bcrx_TransactionCosts",
        "terseLabel": "Transaction Costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_UABMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "UAB",
        "label": "UAB [Member]"
       }
      }
     },
     "localname": "UABMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_USDepartmentOfHealthAndHumanServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "United States department of health and human services.",
        "label": "US Department of Health and Human Services [Member]"
       }
      }
     },
     "localname": "USDepartmentOfHealthAndHumanServicesMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_UpfrontPaymentsReceivableAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents upfront payments receivable.",
        "label": "bcrx_UpfrontPaymentsReceivableAmount",
        "terseLabel": "Upfront Payments Receivable Amount"
       }
      }
     },
     "localname": "UpfrontPaymentsReceivableAmount",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_Vest25PercentEachYearUntilFullyVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents vest 25% each year until fully vested.",
        "label": "Vest 25% Each Year Until Fully Vested [Member]"
       }
      }
     },
     "localname": "Vest25PercentEachYearUntilFullyVestedMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents vesting upon successful completion of specific development milestones.",
        "label": "Vest Upon Successful Completion of Specific Development Milestones [Member]"
       }
      }
     },
     "localname": "VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_WarrantsIssuedInPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents warrants issued in public offering.",
        "label": "Warrants Issued in Public Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInPublicOfferingMember",
     "nsuri": "http://www.biocryst.com/20200630",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies - Fair Value of the Company's Investments by Type (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies - Summary of Receivables (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-summary-of-receivables-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies - Summary of Revenues (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-summary-of-revenues-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-tables",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-stockbased-compensation-stock-plan-activities-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 2 - Stock-based Compensation - Stock Plan Activities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-stockbased-compensation-stock-plan-activities-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 2 - Stock-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-2-stockbased-compensation-tables",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 2 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 5 - Senior Credit Facility - Scheduled Principal Repayments of the Credit Facility (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-5-senior-credit-facility-tables": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 5 - Senior Credit Facility"
       }
      }
     },
     "localname": "statement-statement-note-5-senior-credit-facility-tables",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 7 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-7-lease-obligations-and-other-contingencies-tables": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 7 - Lease Obligations and Other Contingencies"
       }
      }
     },
     "localname": "statement-statement-note-7-lease-obligations-and-other-contingencies-tables",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.biocryst.com/20200630",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r101",
      "r108",
      "r167",
      "r252",
      "r253",
      "r254",
      "r272",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r101",
      "r108",
      "r167",
      "r252",
      "r253",
      "r254",
      "r272",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r101",
      "r108",
      "r167",
      "r252",
      "r253",
      "r254",
      "r272",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r214",
      "r216",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r386",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r214",
      "r216",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r386",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r142",
      "r203",
      "r204",
      "r356",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r142",
      "r203",
      "r204",
      "r356",
      "r385",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r205",
      "r214",
      "r216",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r386",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r205",
      "r214",
      "r216",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r351",
      "r386",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r189",
      "r215",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by billing status of receivables.",
        "label": "Billing Status, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r17",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Receivables from collaborations"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r50",
      "r51",
      "r52",
      "r376",
      "r396",
      "r400"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r98",
      "r99",
      "r100",
      "r280",
      "r391",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r255"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r358",
      "r359",
      "r360",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r217",
      "r219",
      "r258",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r191",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Issuance of pre-funded warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r219",
      "r244",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r66",
      "r83",
      "r308"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of debt issuance costs",
        "terseLabel": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r132",
      "r135",
      "r140",
      "r163",
      "r278",
      "r281",
      "r297",
      "r362",
      "r374"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r46",
      "r92",
      "r163",
      "r278",
      "r281",
      "r297"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r155",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r152",
      "r156",
      "r175",
      "r366"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r154",
      "r175"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r220",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r220",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r284",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.",
        "label": "Billed Revenues [Member]"
       }
      }
     },
     "localname": "BilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r30",
      "r85"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r86",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r86",
      "r88",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r79",
      "r85",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r298"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r198",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r274",
      "r275",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "us-gaap_CollateralAlreadyPostedAggregateFairValue",
        "terseLabel": "Collateral Already Posted, Aggregate Fair Value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.01 par value: shares authorized - 450,000; shares issued and outstanding \u2013 176,429 in 2020 and 154,082 in 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r65",
      "r369",
      "r383"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r213",
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68",
      "r356"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r363",
      "r364",
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r307",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Month)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred collaboration revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r83",
      "r131"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeForwardExchangeRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual rate at which a foreign currency can be purchased or sold.",
        "label": "us-gaap_DerivativeForwardExchangeRate1",
        "terseLabel": "Derivative, Forward Exchange Rate (in JPY per USD)"
       }
      }
     },
     "localname": "DerivativeForwardExchangeRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "us-gaap_DerivativeGainOnDerivative",
        "terseLabel": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r285",
      "r287",
      "r290",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "us-gaap_DerivativeLossOnDerivative",
        "terseLabel": "Derivative, Loss on Derivative"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r117",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r103",
      "r110",
      "r112",
      "r120",
      "r167",
      "r195",
      "r197",
      "r252",
      "r253",
      "r254",
      "r272",
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r296",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r212",
      "r213",
      "r296",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Lease financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "us-gaap_FinanceLeaseLiabilityNoncurrent",
        "terseLabel": "Lease financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r206",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r285",
      "r289"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (loss) on foreign currency derivative"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "us-gaap_GainLossRelatedToLitigationSettlement",
        "terseLabel": "Gain (Loss) Related to Litigation Settlement, Total"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractReceivable": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of receivables that are derived from government contracts.",
        "label": "us-gaap_GovernmentContractReceivable",
        "terseLabel": "Government Contract Receivable"
       }
      }
     },
     "localname": "GovernmentContractReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r283",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r88",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "us-gaap_IncreaseDecreaseInDerivativeAssets",
        "negatedLabel": "Change in fair value of foreign currency derivative"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "us-gaap_IncreaseDecreaseInInterestPayableNet",
        "verboseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInReceivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r88",
      "r184",
      "r353",
      "r354",
      "r355",
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and other income"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r130",
      "r306",
      "r308",
      "r370"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r71",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r38"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r44"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r45",
      "r88",
      "r119",
      "r180",
      "r181",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "us-gaap_InventoryRawMaterialsNetOfReserves",
        "terseLabel": "Inventory, Raw Materials, Net of Reserves"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "us-gaap_InventoryWorkInProcessNetOfReserves",
        "terseLabel": "Inventory, Work in Process, Net of Reserves"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.",
        "label": "Leases of Lessor Disclosure [Text Block]"
       }
      }
     },
     "localname": "LeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "us-gaap_LegalFees",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r92",
      "r163",
      "r297",
      "r365",
      "r378"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r92",
      "r163",
      "r279",
      "r281",
      "r282",
      "r297"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r14",
      "r364",
      "r373"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",        "label": "Senior credit facility",
        "terseLabel": "Long-term Line of Credit, Total"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r35",
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd",
        "terseLabel": "Line of Credit Facility, Interest Rate at Period End"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r12",
      "r363"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",        "label": "us-gaap_LinesOfCreditCurrent",
        "terseLabel": "Senior credit facility"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "us-gaap_LitigationSettlementAmountAwardedFromOtherParty",
        "terseLabel": "Litigation Settlement, Amount Awarded from Other Party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r192",
      "r364",
      "r375"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "us-gaap_LongTermDebt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r96",
      "r190"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r96",
      "r190"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r57",
      "r63",
      "r84",
      "r92",
      "r102",
      "r106",
      "r107",
      "r108",
      "r109",
      "r111",
      "r112",
      "r114",
      "r132",
      "r134",
      "r136",
      "r139",
      "r141",
      "r163",
      "r297",
      "r367",
      "r381"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Non-recourse notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "us-gaap_NotesPayableFairValueDisclosure",
        "terseLabel": "Notes Payable, Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r132",
      "r134",
      "r136",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "us-gaap_OperatingLeaseLiabilityCurrent",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "us-gaap_OperatingLeaseLiabilityNoncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "us-gaap_OperatingLeaseRightOfUseAsset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r317",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r55",
      "r58",
      "r61",
      "r64",
      "r195",
      "r299",
      "r304",
      "r305",
      "r368",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized (loss) gain on available for sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r72",
      "r74",
      "r153"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "us-gaap_PaymentsToAcquireProductiveAssets",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r220",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.001 par value; shares authorized - 5,000; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "us-gaap_ProceedsFromCollaborators",
        "terseLabel": "Proceeds from Collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Sale of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "us-gaap_ProceedsFromIssuanceOfSecuredDebt",
        "terseLabel": "Proceeds from Issuance of Secured Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Sale of pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "us-gaap_ProceedsFromLicenseFeesReceived",
        "terseLabel": "Proceeds from License Fees Received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r77",
      "r95"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from senior credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r72",
      "r73",
      "r153"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r247"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Net proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r186",
      "r380"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r88",
      "r186",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.",
        "label": "Receivables Billing Status [Domain]"
       }
      }
     },
     "localname": "ReceivablesBillingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r17",
      "r24",
      "r379",
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r147",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r52",
      "r53",
      "r299",
      "r303",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
        "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "terseLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r261",
      "r406"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r88",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r9",
      "r85",
      "r87"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash",
        "terseLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r197",
      "r255",
      "r377",
      "r395",
      "r400"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r103",
      "r110",
      "r112",
      "r167",
      "r252",
      "r253",
      "r254",
      "r272",
      "r273",
      "r391",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r128",
      "r129",
      "r133",
      "r137",
      "r138",
      "r142",
      "r143",
      "r144",
      "r202",
      "r203",
      "r356"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenues",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "us-gaap_RevenueRemainingPerformanceObligation",
        "terseLabel": "Revenue, Remaining Performance Obligation, Amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r233",
      "r235",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Awards available, Restricted stock unit awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
        "negatedLabel": "Awards available, Restricted stock unit awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected Dividend Yield",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Awards, available, Plan amendment (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "periodEndLabel": "Awards available, ending balance (in shares)",
        "periodStartLabel": "Awards available, beginning balance (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedLabel": "Options outstanding, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted average exercise price, stock option awards cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Options outstanding, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r227",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r218",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, stock option awards exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, stock option awards granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r88",
      "r220",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r239",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected Life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r98",
      "r99",
      "r100",
      "r103",
      "r110",
      "r112",
      "r120",
      "r167",
      "r195",
      "r197",
      "r252",
      "r253",
      "r254",
      "r272",
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r120",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-revenues-details",
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-2-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization",
      "http://www.biocryst.com/20200630/role/statement-note-4-royalty-monetization-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-scheduled-principal-repayments-of-the-credit-facility-details",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Employee stock purchase plan sales, shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r195",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock, shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r195",
      "r197",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options, shares (in shares)",
        "negatedLabel": "Options outstanding, stock option awards exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Employee stock purchase plan sales"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r195",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r21",
      "r22",
      "r92",
      "r148",
      "r163",
      "r297"
     ],
     "calculation": {
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r197",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-6-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-tables",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-tables",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-tables",
      "http://www.biocryst.com/20200630/role/statement-note-7-lease-obligations-and-other-contingencies-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r270",
      "r271",
      "r272",
      "r273",
      "r358",
      "r359",
      "r360",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-stockholders-equity-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20200630/role/statement-note-3-collaborative-and-other-research-and-development-contracts-1-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.",
        "label": "Unbilled Revenues [Member]"
       }
      }
     },
     "localname": "UnbilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-1-significant-accounting-policies-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20200630/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation",
      "http://www.biocryst.com/20200630/role/statement-note-2-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r113",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20200630/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=118261985&loc=d3e55295-109406"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r407": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r409": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r411": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r412": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001171843-20-005753-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-20-005753-xbrl.zip
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M Y&<NB#QH>HB@?'N7FKRUI&1.ZFO"1%;ZZ\+"1]+KQT<(; Y;:\) =NJKPL
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M=JH-0PC#\GXK^=X6MF4\B)ND&&W39J$I6^7;HKS*F8:*O(UMBQ'V\)-0+7=
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M:IXA9SB<&3*??WN-PL8,A*2<73?/S]K-!C"?!Y2-KYO/CU[GL7MWUVS(F+"
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MKDL,)6X 7'ZA?@RQ:WSR/U!+ P04    " "6E@=1,(*K!()*  !TQP4 %0
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MJ-US1!%<%BV2JV_!4NC?RE+G1G/<0Q$:I&A/1E).G*YXCGHP!N*5NTPWO+<
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M[B*;MX*_XA;0#&V#&/DMH!G: C'E5G]1.P\TU@8Y.5?7UUP=6?GR[2T=9(&
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M(&&":F(,H[5,3AC1JCDZM629QXC<KHY'6]60,*V?WO=$C5R!;K%9['G0@I'
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MB@AC^<"NB58&Z*J&]H[P[N.*SR -_<)/H_1^S8@?3I/??18)/4F=QFDVO6N
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MFC,DY'29D-,6L94MU0LYX6JUCNF&D&+,7<Z")9<W[F)?FL[5Y%FXH+]H)F\
M5=*('@LTDT3#VL_I"/+6%O:\E7@5ILJ![HE^X&\\F!J4MXQJ:.\(-Y&RD.?O
MU;/MH?&+U[#G04$KK;2.%T#?>LCH&P*7 $_3%(O=?AK8;M#L>A!3I8T,J*@V
M>+-O1^LP<[<!'Q;WMX$JA&X_JZTQ%&QM0KEY81^&UC+PH(O0 G]) R\!NA@L
M.,AZ'AYT85=@P!";DN,]"VH:VLH%@Q^V'=:$%V>[ K+=NV>H#M)N2+C.?H+N
ME@%'NC>L[H$M_]G<Q8(N0-=@1S:S.Z.+Q:U1P*7U2 %TT;7-MX>]J'5L?=!J
M>"B 2']&AK1A,(C#$.>$9L3[4(;M%B?2"XZ.I/=UVT32\\LNDI[/R5V5F].;
M4U9.]$K1R?._"C.4MQ"X^)R,>F3+ZU+/3T(OC!B7N"@3+=;X=_/X;>"M.>-+
MN0;,E8MXOY;Z>&F<=+L(OL:,O%&+/"X*<'Q<)A!WX2CA)R7,2]5,_*+2H6,\
M#U/S.8PT#0WQ%*5Q^6ZZ]5=$$;-2-:0[0I6A9M6#>D%L]P%QU?7A1N)"7Q2<
MYV)S&++-YQ\)5GOM1ZR0=T8'KBP*WX@DJ<M()&0EH<@DDZR#L_>>R9+^3H6I
M1U1/<;VHU6_N^;+.HO3+-2-D5ZC'U:*JWMO1DK[07E]">S39+\^ZT%>M9:LO
M',(HA[KFR.N:P[P>E0(8A4D];O%8# ^02YWHH@$DZT]KJW*=N:1480%FNQ"#
M^W_H&C!T#3A#OZ CP:FG_D7GBD]/O9:.M>Z^NCS=:GRN?20_>"E)(LJ\H"BF
MY<W]H-CE7AHL29C')/36+$J":.W'GJALO-G71!%&\]-9]1P>[1+AS'OA @:\
MJ,Q@XQ]L_#LF-J')0ESPBOZ?54.Z)71;"34BZ6Q_5J;SN]T)NDEN^6%X^$KB
M)_*)RYI+F:G%RC.1+\4_B<\>OE(;*W#R*-3 9T2<?"XWB(8M:>#'@OCFBZ!\
M[&!4'(R*R(V*@]EC,'N<G]G#+@/OJ7'#HC#34[-%<V&FIY8(N83NT&CPK$;J
MHQ^+2N1>NB2$Z[%!SI@8LR[B7P]U4>'6@"9/=UXAMA9]@_X^Z.^U2Y+N&FB-
MRZTF$:K5@[LC_M ,3]3J!D%03>D$"+\ PEWK*G[K:%&HQZ,L  LH*5?S*6B*
MP<I@J4=W0/ZS[E"GU%:TCG)/W&DQ_4HBJSO6N"=6<URKQG1 JK(MUN$G#9AZ
M3^F@:FO95.&DE<(H&_N,;:)DH2K?:S2WTX*T2A228>X)WO4LG9$GDN0:,4,]
MV#WQ9:</,A%M3/;=)=40(%.0 +FE26".Y>4L]W!.VI^JOXAZ<!?$EVV,-T==
M6U^0_')(!TZ3@Y#).2*X1"-T&CY &L'#='JG -5G I/^( Q4IXW77I#[<D@W
MA.Y;Q.G65SZT@Z+D-",P/5\QLJ,"Y:4$K;VJE&,[2-5C6TE&*ZDI1G9"MN@S
M7]E?7KUQ#&9V 8NN"<LV(I@\X[0)=KT6QE?Y#0R9TD5E^Y.^<;54G)I/Z;Z0
M_Y&-Z+)LE"9%")TX1%Z<:57\OA43-Y9&F\F?0\S+$/,RQ+R\RI@7E?T<71:D
MA%C:R&"+[L/I43:2V=#%)>GQ-O(UH(M" N %>Z?111KIP<G-F4 P[BHWZL$8
M:[I C.X*+P)V8V,T[@HJ0KX85)<'@G-70U$/#F#X J+Z!1&JJD $=+<8,,2R
MEM< G2!F#*/B<E,9EM')9 T!0Z*TT.WH)I@A;E9T@ED3P)!@!73"6A/ \- &
M=&)=$]@3K2\/G837!*[6!8A. FSV<:VP:'<2H?4#W!NIL>D9K@X@0'<EU>WC
MT1,YTNR[:;WCZ,1&,WSJ.$UT\J&A% R)?4=X_@PE_?II"^BD0S/LIEYV=%*A
M&5Q+K9-<-EBI*0D!PC8/8-VFA^Y_790X"HY/F\>7,VV<(6K^ N=)HG5);-1R
M8DSCV'^DK.@'M[-ZSTA*^$X0_JA+K@7'M#"KROM/U'X(IJ12C#2]HD37E&5'
M437\I].(&M&Z\([1, ^R*=LVR*J@43?,*:$%RRUI2"L_.&ALCTCNOC%%A:2F
M25$%S.@"1LI)^$AI>+S(]_SFEJ+03>@&A*!FZU25143*AG5/L"963S?</8"=
MS'Y'V*[4:!2(&SB*\R/!X00'<)9[.!\Y2Q%ZUC2YIHQ$BZ0TY@6;2\*BIT+<
MN$GXFN>%V'1+LTN2\E%"G!JEOY%PP5$=#9# ;^DMW>7/[42PDIE)4*L'=T?\
M]C!IJ#X9U4'R355KVM.T&WG[6J<)-VLB1'.Q234$*T9VE"=4<3E_3ACQX^A/
M$O[&;S=.[.'\'@+(1BQ*^9^.NVQJQ("V7]=)?HR0TBKU-N683C)@*I1%-2L
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M$F:DS_K9_E[\C^ %_#?_'U!+ P04    " "6E@=1",^9P"1E  !QA@4 %0
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MO?8 =RU0".L]1_#KP!*+[09[F-0DY[S>5(T';($#/R/'= )F 1%U!W\1N @
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MW7I:4YHR'"UU(LD'6ETF1,QTY19RO?D8K>DY@\ 6I57GN+F5M6?7K><5:$&
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M_$0,M,,J2X]4^U1E2%3^%.66E564_;_IYHPEPV;E6&-3==GKU+?&2.*$4R=
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MBB@ON;7%Q7K&ROX;S:$VF+EYV)>727E(5%N/S5$CIF&'* D%VWC>51TF8L!
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MI>VU?T?!>9U?EC_)FM+D8:_B=,A,9AW)JRSL0^*<B28"N-$"/QI?VM;$'86
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MB<PPBO@OM*P^;?BNN(TA'G"YS2#H)J/RK;Y[61,B/N< ,K:!J*X/:<8_8?G
M&<9NIYA88V/BKE42 !) 2'80R0ZC6&-KE*0#D^QPXC,= PC'.&"W>5MO"R(K
M=R*+]T16-B)+.B);M^@#!._:FP7,S>@9+AWG-!:=OGOS]G?#:\%P*\SD/N[-
M_08B*<*#+;_#3SP;P(UG4O0Y*A(BJN3S&;/'68#Y,:(93%%JGF- TQP"Z47E
MVJ$8T)XFV!C03E>>BC$?U"M&18$:H4:<62#6\H1_MR9 6F2V".(A:__U:@%3
M$9+ADGRZ?=J6%9\MOQU>D(?:8);CP[Z<YY(*>K!@_1:_%)N#MKP0=[@*L P/
MZ@-3DI>%\\>[W]>)2A=1O(+PN4]YE6:7VRQ[@3_39/RDH?DY]DRA2,;+Z>'=
M[_\? C (X" ""!%(B(1B=D!PQJF5HX!@7A2\?P'FMX+YI6#^6: +9.KKJB$S
ME;AG!U):1D]/!94.]IME[9-XB!XS.O6XGM:W6/>2"@WGAX4]$+"VUS#(+P)(
M\*?W]$:"&8G7]UWG)GH1;V/=+!62M:::H^\?^[OU%Y#73Q\7@V>+%U3874,<
M9M'.R < (4W[2;UAN@+T7BMDL^62A 1+Z2*:J!@RUAI?-Z2O5P_50P19TM(-
M7D-D5+A,4V*>%2DJ5Z=Y O\!5,]1!HJN]MBNUK=8)5.AX5SE.'7Q\IGXH8-C
M=F_RZ@T),Y*S7T5]'V40''*_HK2Z!BWB]LM(.--4<Z0Z#G7K6@-KND00)@WE
MD"%"DP)FNE(+KT^C<</3'UC4*3]1PT-:%3)D6$',$YH5/F"X?S&]HV55I!#/
M-K;8:NVU>EU:W8+52 ?<F7< R6O?OS6'>7);QXR=S@PJFRE4TOC[)_;\0T)3
M+HJW/\(/)_!#9]+P7_W/>>U1_*]M5'#[.'OA9RY6'![Z%5IJJOA(C\Y]3#59
MTM(EDK!7O5,1*=.0DV]G44RYSCYF5/'$,OT!VF$TU+'[X/.&\FP6,04I,WW1
M.5V +L3KZ/ Z=+&I@PM% ;0S2 4M7LY8<OC(M^97B(5)H7?G9<<$!+*'0>0H
M5.*9OAH) 2C>ERT=X3.D1#W7FXYC  +9$# 1TLF7^:8_P%::'NS8>6A 2YDT
MI/DIMR8>J,+TM)29ON@\%^9,GW((*HSRZAC@U*ZI]S&V5*<2$><15#L4I%<5
M0^^MFF/!S 3LQ>A_***\%"79)ZW^H:8&9O]AE][L_AWAT(;_H%29CJA\N^_*
MM+Q9'FCRB]HQ0.]CM%M/A8A[%Q]'(:+36ARS<WIH#@<SD['GC9=FO,^GGVA.
MBR@[S9/39)WF*5@$5?I,F[=]1Z]O47U@MV$=6N[CF068!:GA"!_>/B#2( I[
M"8P;(F9%[EX.QA4%$Y8C.8^JJ#_M4+6YP5&XKUMO9^"6.*3G1Z0F'^S<.RIB
MIBLWITI4Y]2^7'R)5URT]&.T[G.GC#5#*$U?=^Y7+$F3-$0)4/6N(Z.29*KB
M\:(3;]\]/J15-J8/ATT,=*'IRK4>"")@=KU]]^WC=TVR_40JCD-%.!(A4Y%+
M@#)+X)Q;T^FZ2GWM3 HI=?OS4SE)4IQ!I:1>41Z61AJ63Q ?:?F15;2\9OQ
MRFVERS2/\IB;3YV[A/<O[U-A4H&'=UL^<)0CX4*VNC7SMZ+).S]%2J)$4ET0
MH!LR^,C:<!T[;BV-0;"+T#ULHP%-:A^97XCV=.[O4K0D^[H;-KA)4>3]MZ.3
M<O2K<Y_RQQ0*Y-0I).,NC/'&2!WK[]2U;C54FYR@P)Z'"<DR/7%Y=N*J*]!8
M4ZR#-H#RO)^3ZHS*E.D(RJ_:]+\E+HXR-!E)%E/^#JE0D_W[2A^;!(+)(W/
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M'[=_$R\C?[H_#_,NLJ)Z,9QL#^=7E\5K_A/_9?,K_C_@+.:_^?\!4$L#!!0
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M^_C^_0_O=J/?;H>+7X-D/^%X\$_O\A_W0U\]^OF';.R'3Y\^O<M^W0]E8=%
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M;YN2&-63'.**,%AR@4&#SL P]:7LFO2(@@>JNG(VF9K4#0(NP1#UI32==-E
M@A]=63!P7YXV"LZ5NPNZAPQ30<'P=+0'%7S_G$N1"4C^P#$L)0*X#E"UE>S^
M,:_6^(@X=!X?O<8QR]ZV(PR8Y*Y]3HO)[4!:*B6UC])%RI*/[S_\(,]!E8VI
M(1GV$OO9(_G#?Y03(!]5+PF?0"1\JIT$:<T6.3W *340=Q/[?$7R:T5-D&)8
M+40$J9]M#1T5\G'GD>O^!^9;]:<[3,7GN$+^\A\8T:_\RT37:11MQ,^2O(&R
MTVLB^NN:Q/>I[V/&YFG6$#/"XK";SN_7V!<WT"5^PA')C1!AQ*>06)+05.]#
MAPS[(<-^2&-O.*1]](QH<,D/1D462>$8BZ0J$WPDHRR1JTFR*AQC,XMX.A\?
M";PS+#QVP9BPA&55R"Z$3'R'-MDMJDM!J>FI/4^J=H0-F[GA+X3NO&"@,MU+
M.]Y"PB*F61]N+JWGY?R4#&A&6R"?2_6W:*7,%RT88H]0=0YHX2 +Z63[P^_X
M>!R)\H:+7%&YV+PZ(+,KXW!OQ &(Y29?-20/NE>R7RAQ8;Q0[/>"$=;(5"[]
MPC%#.N:0CGD*QY".N4-D2,=T-XFI6)DG0 7:*114X3'-"TRN0%DD"!#0]>L*
M H6J#X'I&ZY@ (@ E2J(KD3'R-8!S%'G2D",!@6=H]"9L$P5#$9N9%>VA_Z(
M4)C#70%!*W@ C9>NG!;Z12$U-+BR)"0"5+6X %?6AW:_@&SEKJ"A6RHUQEVX
M<@\#;YUB][8K1XQ4Z0<$&KJR=]08Z&(=7=D.8!0*PRW!* S)N=UCOO'DW-XF
MJ=97C*?W27!#-D:AJZS66*;VTS1^\'Q1?2'+F V?L(?BP"/)$E-/O)G3L\S^
M%!R$0SXA3^XS;5=8QZM:3/:HC]QJ^2!7X^F741S<S":*A!#9H!I"P4?W=[.+
MT>QRI.R\ 1E:!S%!$(I/C*(C=67;*59!%WA6'232QS"AV4*\H\3'..!Z&>-Z
M5AH!6D*:SZZ!9'$TZ;^N?%0-)(SO)Y-P%2I3(61C:GC]9PYM/*:$L3&A:Y)_
M #DE@.$U$/4EC8-PS>^.%5(TEI0-JB.[!N6[1N2OADF:\"MN%$68+C;BK(GG
MV.>_IXQ?@9BO#<4&K/2@\T@3>B T#.^R[^CC- E]%(V)'%' \!J(^CJZD)/P
MZL<Z7GA_B;F(EN1%.W['*$I$%:G?TQ6*=R7<%!09SQXRB;J72306*<V8B@^Y
MD806ZX:U0^B$"Q6+[&0;\U-+0J9\D TB7Q>ZEI(JJXE]QHED'6[5RH7%(/63
M*=V><Y+5J!K6*J%,U&#:'LG2!:D=.^0/MI8_"",+K[<A"WMEY?28EGYLX[GM
ML'3OXQC1D(@*1SYBQ?J1?F"[Q'Z-6>[5PX$4;^W8EDC>"=4[>B0;33G.0@[G
M4;PG/YYNN79S^,L#_R^&?+E5HN)3VF=W?&P*.Z*ZP%@J8;7$$WJ>&.D(&S;S
M.V]BGZSPP?,@7JUN. N8T1DVE,E)H#GMLS+A0EC,BD4/Y9CV29T*8WT.HY)<
MZ;CV29YM/0O\+CBR5!^=EON&160;W<2EC8Q^IFW;6NNS>P6-5.EMY-D6\D=Q
MQ)^Y^(QC44.=,S$*5EP394E^V5Y]%TY)36)YJ6?88#53 S6L%(P94I'=2T46
M>V\Z/]JFBM-/.7;(^1UR?D_A&')^=X@,.;_NY?QJ;<'$R +K AP*1PTQ\8^X
M@(72MT8JV6O[#H^)H8&44N==04@M<I&:K*"NH%6O>DX:56[[CKG>GT",?"1]
MQP,>!-Z $:GOR1.-;>"Z(N=< 5B_.@%*OBM@:"]74,BN*QE\,#1,P\!=R>P#
MH@,)WG=EP:C3_/2AA7T_1B!*7J606E?VCGJA ()27%@I1K*R*OZI[\<'>-N
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MLGV_6TJB4B%8S15-!&;M E?C<D5FA<&BJ=[DRAT-M(BJJYZZ<L0TX[B2%+X
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M'DZ;O^O3;5HAHYVDG!99J92Z<UH6\V4QS&T)H9V8MWOO<=I.J0>8A"=("#]
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M.K4=UF-XGLFB2BEX6G4I):8ZC6XAN,M_]HX5(ID@XE&Z FTT"FN VQ>,)Y&
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MTAZ3C)DB8QZ1%7LT3'KH]K9DV#09]CB]E&-AWL/RIR2GILBIT@O-D"TEAQT
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MBWT*7LTI^/DBW99F\QJ:0,'2D&KL=4H]_#&2;SO]NSL8MK![@S: ?[G[:2Y
ML4F,(W:7'MU7Q<\IN5X"2THF3<D4J@E5BJ5J^..=[OA"J(-MOWHE'>@.Y=?
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M1 2,$!.RC/%24B7C9_3O&-BV>\-_8Y;L[/3HD_XR\KQ$_Y+=M6V7:%WST1T
MRW(MHYLO@LO&5:/RY52<L:4IJQ*AXPH^EB3-A*0BR2JV4^-PZH1F7[,SK;2M
M RK!F7TYS+0F_0LV6%FF_HB0Q6H#;56EP/IWX"XQNU0GMI?HX;1-C:?%/UBF
MZET)/2,FR0*IMVJPP8:U/89\[%0_3L(>%>V.CRL7MN$</_,M#;-MV\0Y-MJ%
M!R44V3Y?Z&^7E-B62U5B Q79]Q'!&N^0IK]>H;\@])E]@'\1^G]_?<.E3_S:
MXMW/$V0[4P-(,817%X=XK!O3R[\_P^39Z('\0D_6&)M_+R!^I8!LZ,_P$W_6
MUO]'+I72Q/DTQO1%-R_91]:[(C;T%_.2';]+Z*>S*Z_QSQ<3:)8U&K2HZ?;$
MP--+9%HF@>?^@CX/9@\/V*"\KL[[&'H[FKT>?O3]H?M\<XWZS^WGF_[G 447
M5ZA_T_G^U'WNWO11^^$:W?Q?YUO[X>L-ZO3N[[O]?K?WX#_X;VR/P$UP++.
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MZ=KO9VPKA</JRGH??1/XC$OVQ_;3,]\9T7UH/W2Z[3O4?6 GR[>?N[V'R(T
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M,,6:A9I2$DTPK&"IOR\U\/>E=\]?S=_LO?B2?0SA@)<T.;OZ*!E%5$9)H@!
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M5=B1_"+YQ>>7)"JC),@O=;#'Q*N/(I=@A7<#OYN4P(3\CVC^0JPG#5[8RBQ
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MA=_59X$DCL)."(1/K&JLK3ND3^BKKA)/=#T1U7HQ^5NX%#LH/9O(R3V2%8^
M%?,.8^3%ENMMB$(C\C!S49 H&?/X&5.D0(O4G9)%)8N^8]'< D&2'R4_2GY<
MYL=&$H$J:8^FP%PGGA2S517->TS5D5]"TS]4Y?B"7^].)!%#"FTJE-.(J)J9
M8DI+,E4SA:VK(\&<+Y@C"F5FE+:R/[";S5*AHLC*@1+:D=".J(V90VI* O([
MRNJ3"#\1A*_;!]"(*(>9=NI)DN4P&\U"N=P0"=VR'.:1L],Z;HJH@+E%8DL"
M%3 +]:I0Q6'3RUT)CIG\>OO'G]7B=?<!'AX7J?92=$;P4T(UT+%%U=!!8!4I
ML2V7J@0<*)L=S<Z_%$?.V"@2@XNXX@C 8S  $>WH0@.RN*88.7"-%1DKU7EH
ML5ZLE&1QS1.S'0\)PBLR/;:#L"RN*1;&3A?.*_(CMH2S+*XIH2W<'O_&BL2"
M[;"==W'-9J%>BG+PC]6YEZ5?\N:;YHH$@"6^D2R0!0O(-7]97%-0&;).A*PH
MKIFJHR\K1TEDIX_L%<4U,_/_)<HERC.P 5<4U\PE+I!^G35%F(I$TL,Z$NY:
MQUPKBFNF'YB0RD/".P/EL:*XYE8!!"GT18TI''D1C9LW0E7=)L@:^O4UK0D#
M1[R:FBU64[-5D34UQ=.Z>20?K"O8P^_U/&P%H--VV]@DBB 3!7FG"_*\TQ,R
M 'SU[*I6*4G(2\A[D!<IA2$Q^$MO2\(_'OQSRW*06)=8SQ;KK20R$[(QR6L5
M(8WR$T\GV.#Z,U3P @+@^JO<T?,B '$\_W()//]RN5"J5J7S+Y[D$,WYA^'R
M.SOD1E49SJ3_(Z'M0UMDEW\/F(,2;94+]7+4?CZ)])-$^J%X^AM1+ST>"?EX
MD!?2NY?XEOA.!-_E4MH>_=X&2#.RH$#N:)5K^'$=>5#NQ2&KB*#%<N.5&BLC
M46/)(9X7_PM3BD&22A<^9U&1APL?IX[IOSV > )(:D0)\_U@GK<[GQCD-Y1D
M*S0583;UB0+%TT6]2*Z]%/H2_AG#/S<W7V)=8CU;K"M)N/RG;J3(=7QY#N;B
MS)SL@25E1=3 @#P[2)X==&*L> C!BVS/':JR<'*YF4^^CF1,R9@>8QY:?$7J
M3LFB)\:B0L> )#]*?CPM?BQG%:>2]FBVYV >>N[+5N=@_N&:!%5*1WT,YF;^
MKP#0-,L=&.2= !A<_4VD(W:VZODZZ;7BC,V4=KDD<<9FHY[?,6TQ9_UDU+[D
MJ/<<M>*@SPPVU^S/7:V64J@U)'])_A*7OU:<-IKQEIX$#J&37":Y+->>KRG.
M6"ZO./$TS6U$"9YXVE+JA69%H/-\XQ-&GHR:/V<<+D^O8^D5QZ[&W#FUO\9K
MU NUR!-:#DKM>6&E"V=@:5/V#<,;KM!?$'"0IK]ZG]+C8!7$+*&?WIW\._$:
MAAX$)[X^?OWRC[/E^2R5?HM"F'^%0YE?.N.O6WK?[?/3[(5A#O#[A$*-^+]?
M>,%H6*36K^#.\BV5& 9Z_/KP_7YM&^^HN@"/I1F&:?+:0J@:M#HCTL+G\,<1
M11=1P_]V'3U\+E03&/QSKW.GFS_G??;H&[?CF^"'-N%OE2CR,;(\Y#E73-(&
MO:^V,FMO,Y/YD\^9/Z#C4#>?V?=HIEL/W"WD&N^G;FK01T:9-W;&,\#'GF 5
MK*W?STK>]PG6M."[)_G81Y"QGMS:&!9/*> =;0&D]G[58A-C<CVU2:IDO,0T
M,+#Z,V5[+PQD+UX[M_>R:96;#BN-3$GW]"DPCRIF37L6Q2QV,X><'S;-$71E
MX4"7H8\9)@6#WSSHMNAO9M8#'NO+J>V%$&-.??C SL+XB+P YUJ?7Y!T$,F@
MI\6@UV2HJ[HCH2FAN0B,9VNFQS,'93CFY64:MC[EU!4OY(8^^'RR/FZ;*Z.(
MGW(5Q&DJRF\"I5]=$Y4ODD"W6 J6TCR9L+QXX?:-8?3Z^S"ZTBPJY6)%$31E
M2BE%G6&6TTK8J2PB'R"R&SLC.^?4I=K95:-9*E1+4?G*$N>GB/.UR0W-W8$N
M4@[1/-^AW,IO736?DRI/,8?A$%FMM3.KB9!'U "#O%5O2=Z2O"6<N58IK6:M
M3!R+:JM0KM1$X@U9^RAN_*$[G@"YD&,AZHM91'PYBX;4&B.L>><9L]K([7X'
M-:OE(Y0#HNU(7;O5M!*Q66NF2T-;2&\M"AT!2Q5 [; ZY]0RX:/*5>W,C/5O
M@@XV-4PU^_M$ VT,;ZR7RIZJ_='Q3%VP;&^&0Z(ZWN;2WK#M8\,+:FQZ:-8Q
M_ZTYQ4B$W$9^(E[C8;%9Q ZNHV.S3 (VDN4DR\5CN8A-7<?'<EF'CB3[2?:+
MQWX1F[V.COWR"R==E2M"'@XD>2T/7HO8A75XO';*;"-^DDN>@:4'XB##LN4Y
M6'G+F8ARUTJK6%*\NF3L8R7QC!4@OF?(LI1C:99*".\'X8@RT=M#>(](AX2S
MA'."<(XHKKP#G).)(DAH2VAO.<OKTCPJ$56)M\?V+BYZ+"#'2_:H*(52+:IF
MS+'F>7R41GK.?%.-J!X<P3>2!;)@ 9DQLLZQY]8&/R=K9FX@W=]3*J5(GH9E
M5<G!U5]E?#(9! *I-WS&;]*NE,C>#]GEG", $N42Y>FCO")08& ?Q*]?S2D)
MN9HC$9\'XJMYA0ND0)?P3A_>M02\^E,3Q">^K+[AK.J;-T)5W29L.X;-?#3D
M)6; BS^SPC%!MXHV48OZ6W&D:QHQ+WU UFIG5TJ]]/F"/7J%;':4%/S2)([T
MW7,6%7DLT_,'O0/OKUW*DHMXN@\_*HS?ZWG8"D"G[29G1)0R$N1Y@#SOA?QL
M %^I1I59D9 _2<B+M-B?&/RE!R3A'P_^N>4#2*Q+K&>+]5H2:_A962A1IX[E
M#ML37WC?Y/J/)X8U)<3W^R<N54?8)FAB,+<?,! O!E"OG5U5&S($()[\$"T$
M$ "./_/HP^T1T"95I83Z?E 7.1"P->Q7J]KJV56Y'%6+4L+^)&%_*,$ *?DE
M"Z3$ D(&!"3>)=[3P7L][:# 25@K,B=@76" D[XX +IK/"\?+ ',<4C>V.=C
MS,O?\_B>O$1%[&ZODRAYA E"!4F>K15^5Y^%DC@*.R$0/A%HWM8=TB?T55>)
M)[J>B&J]F/PM7(H=E)Z-1\134<>GS(IYAS'R8LOUBPN%BA)U"H$H2)2,>?R,
M*5*@1>I.R:*21=^Q:&Z!(,F/DA\E/R[S8R.)0)6T1U-@KA//BMGJ -5[3-51
M<'IJZT@/+>*##EH[G'.*&E''EJ27U)+,@:E1>7)"'&LDP9POF*,.!\DF;65_
M8#>:U4*Y$;7[4T+[1*"]KAA9(^H4CNQS4Q(\OK$I3VZ41I @S!5UQD;*62])
M'H1:+Q<:3:$.>Y3L=.3LM(Z;HD[1B)]3D\#9%.5"K234F=LR;T8>42%<A')]
MZ'%%1DMU'GJL%RLE>43%B7E/AP3A%9D@VT%8'E$A%L9.%\XK\B>VA+,\HD)"
M6[A2^XT5B0?;83OO(RH:A7HY*JAUK!ZX/*(B;[YIKD@06.(;R0)9L(#,"9!'
M5 @K1=8)D15'5*3JZLM:SQ+9Z2-[Q1$5F44 ),HERM-'^8HC*G()#*13&;UZ
M=J54A-P%+1&?!^)7'%&1?KA "G0)[_3AO>*(BJV\^E,3Q">^K)[J$14M=D1%
M21Y1(:"HR&.9/IMZN+)>OP2Y#_*\%_*S 7Q5$;( M(1\'I 7:;%?ENV7\,\8
M_KGE TBL2ZQGB_56$FOX65DH51%A>^(+[[(2Y;N9.=V2(:T\ @*R>H^LWB-9
M\1TKYAVV$++R3ZU0B=RJ*@H2)6,>/V.*%%R1NE.RJ&31=RR:6P!(\J/D1\F/
M2_Q8*241I)+VJ'B5* \][V6K2I1_N"9!E=)1%Z+<S/\5 )IFN0.#O!, @ZN_
MB51I9JN>KY->*ZI<II0:DTR5RZA0>S8%;&+.^LFH?<E1[SEJ1:G-#/)P$BBU
MV2H52HVZY"_)7\+RUXIRGQDG_>S/:]6H-$[)9I+-LNOYF@(*E=**RI]I9A<E
M64.W5"I$)V7D5.HP/F%DA=#\.>-(>7I%_=&8650)LF>KH+0$.JS@0)C3BVA=
M. -+F[)O&#IXA?Z"X+:FOWJ?TNN>"@*>T! 33])NT9^0S-J;C;!/",(JRPG#
MYA14&#(M!][N6(Q]>"B2&9%HJ)O85'5L0(]\A6B?YS8O  &D&M@&7GO\^N4?
M9\L<5"K]%@5]_PJ78OS2&7_=TOMNGY]F+PP+/W_*4*@1__<++Q@-B]3Z%=Q9
MOJ42PT"/7Q^^WZ]MXQT?+PB$I8F%^?':0J@6M#KCDH7/X8\CBBZBAO_M.GKX
MG!()#/ZYU[G3S9_S/GNTC=OQ3?R/-L%NE8ST,;(\Y!1Y,I#!H2L<K*'O++*]
MBG-96+O;ZSS]V7]&C]_:3_?MSLWWYVZG?=<OH.Y#YWPF4D7K]F?,5?5,IOS@
M,N<,.;K#>SB3-?[U$66Z^J_PVPM\]=![OND#BE"G]]#OW76OV\\WU^BV^]!^
MZ'3;=ZC_#!?N;QZ>^\*._T/71,[(<FUL:M 6>5/)Q$$30KU=M0B/+1?DZT=Q
M!_#=Q*ZF@V)(JX^Q]8 G1N8R)"0?/)/KP1U#,^J[E<MR:7:&'OOH&89+IB"T
MK ]U%9M.&U0DT(0EU8-.5'5B/\/+OAA@*YYY=J=2+ROU.EA^!*S%"1.>U"6!
M@LG"DGH 9D&?R3C<U"72S1&\C#VB?+X@XRM41*%AH?FX4#"P,$4S)VD64Z5S
M&<1'J?.1[HZ4@4K?+J^!XE3G>RMZPXYG2?')G"YCA/DFS5:EM@R2K ;]/"+(
M[V!X_ =/Z1@2S3/ZJFM%'.\G_ZZ;&HB[RW+UO%3CWOP7W>K0J>V@1Y#08ZP2
MER^P0[>ZIGJ./C@PLUZ6COK)GV'OJ_;I(])MA-% !_Y41Z9E6"]3Y!O<H :P
M@S3=5JU7\#=!X;T2HX LBN%O&[Q)HSBV#**ZX)Z-B0;\:1+['(7H".:,ZMHP
M8Q;3*00YE&">7L&J/%"F3>#M!+,G=!/]&NGJB/NF@0!PS3%QO'<SA4N(9H-"
MTF&DH)S@?T3,_TW'!$T,/+5Y"S_)%%'H%'L?^PX#@R'QGT^P,_J%IZQI=L=O
M>;&_O[#-:S[2"8R2N1;PFFMBX%^LK_!YG01K->L%3XJQSNF.C48$:_]U,778
M[,$\ [/-7NK2$1X7T(-%G1'J8.@S&!:+G=&!TU]8-^R@PZH^,=@DLS%X(YL6
MD,I(#\2PX-G)""[XM( AJR,RAMFB4]XE1E87^H+&ED8,)E7!D0K(RY_0"%#8
MFGC$13/B3A9A!;VAEOLRXKV:4$LEMHU^FM8O$\'T07.NZKB4%%]<78/1:M1]
M@3<SNIZC&51'WDR[E,(C[#P-&!7K@DE>L,-*;ZK8'J&A8?VRT9!:8V2!"<)3
M;: )G:5+L+^X7#L734PD$!3A!C\"B<#_C33^_2N^-$!S<?!OW?%H,W3!A$/X
M%>L&"U&P!),U  XGGY3A;XYE)X3' 8 & ,+1:!-$B6VY%(@/?A>@94"0[0Z'
M3$L#YP*R6.N<#4*4"R-G35=L FI.\YC)9R &^36_@"XKY]X/PBS$4&:[MA<'
M#SH"P/<!-[0H[\H8_\>"]W#9P'H\$P!H!.QC^?S#MJ.ICNV)1?;8^OZ4O.[X
MF]C\66+F--'B_YK"A)ONLEB=]80'0F!$+F&?.3^]'^4JMF*FE3%K 3Y@$+\8
ML 5"8(F6MCN!"0&Q;;Y8[,USDIYS*XUJ<-4 V<,&!M+8#$TWHSO%K+0/"^6!
MZ!Y8KC=_>* ;;-;#P\!,'7F-P#654',&FJW)[RFYUB>0O/I_01BQMCPE$B#6
M &8CQA3$$T!LS$$RF')(V*[*Y1H@(C0.D-P49I)JK,^^^'L!1K!9A-<'#US2
M0 +"3)L:#U#9@3(:NDPN+I(2Y*FUEBO'H++XR%C("P0J$)@7*F:S;,_X+(+'
M-DR7-UL &<-EQ+M$'S::YQ]!:*E\\RX8 >RG !F;??M^WC]'7YD:,;EV9UWB
M3\UF!'33&(3>K#ED#1A3LD],@\"T\!\R&+ HM/UI;7?*?G< 2$4P9=G*,;R(
M6U$>4Q#*WKY$$9OU^CUU"FCB4MO%'M(](R0L]GY9KJ$!V54RXQ^0\@3D FCB
M]?VL^/UD\&<]Q+/,$G@/3RJ948OP:#[KH4: 2?PP@_G".^TI0$YV7^:N;[<:
MS,]LDD,MOYL!!FFV',_EW 1NOW+;T9L);_0OQ"34>Y1+BT)H"CS;(A KZSM6
M"R:$0!=8OVP0CAX>UAI7T(Z'5XM9+Y0K'\)/[0Z9+1Q!45@#EN9F#A<Q[$+H
M!Y_8&R[@M>NZ79]U.[!N%H4@Q]P(FR_$4WC ",SVF]M"BSP?B]UUME?>9SA'
M)PL#4GG.GU<G#>!+R9!P.\J_H)&)90.Z@)Y!)32 .'009/",PX# F%) O5WP
M(#=OBD\J6X:"6P$^)U1_90  L:-ZO JO,6UOQ8B#%% $RI*P?DS< ; EL!_T
MBV-XM0"<RVCOYK*H+GBF_EQ3 )*9P&4Q*AB._PR7YX$P![F^5IY'"VD8J@Z_
M> '+3 7*\F;'F&5ONQJ9&P;C,:M/@(VY7F</,K<CC$)V+<15C&D<>^87L,4X
M.] GH7GA[O[%@K^_POO.V<+<9/_N&N;>E"Q]T.&8('#W!72FW1LN!>W6!V6:
M>05E>&<9^A^9Q#4=+N].,SQ3V3(\TSQO<- R8;=QN=(7[H2+ ^Q!PPY"%3-;
MT9<?OT:684R+X' SF>\.P"S4,5W2$7\\/L$L3+$!8K/O#M#=70=]"*) H1OS
M2!![_?UUY[&P^"R[-'L(/'BP0_R.V62A=?0+A#]/0B#</AYBE4EMIC5FYLRB
MU@C\+W^ YPL=9K$8_V4@)F$&3>)E4OQB_BU&?UN385%K1618*.R$UU+KQQU8
M\,8-L)XSY7E2,%-^N] L#'U=GA2/J3YY1E!H=X__^[:IW0=VT>)#_]NEH$T#
M+,A2H51Z7\XV>D(7P,*B/09A>%MO6J%[;D>U^)X3Y=PS/MC"^Z:0?=6/=@4T
MNX=!._K_N(0H<-)B4&R46ZW:/ KM80>$2JCCYQQW>U&\'I534P=R%\N5'QTP
M2G3GUL.C1_0^,76++M[P"/_C#NR&WC#B-_>ZUL&3VX!]_:U>]@;(!'(__-KM
ML5 'KZ<2C06;#P6I_,T!U_G1VP5$&):]&0Y],G'X:!"TQS!1]R#!I /C=G!4
M0&"!F06#,UE\S[-UN"CC+^=AA/71&O2'"R\H>_N<FO/WK_O)+1E0EYFT-6]W
MU!9(];R.39!DXBPLG<Y1&XQ*%H2ELX!X6'BQ#@^\K5LV&F'P#0>$P/ -9D:R
MR1 N+IFN?BSOH1_?.0.;%>9\QL'_F6#J"0W,@U%\.YTG-.9+B.#!F"R #C/@
MN;,& ['*@LC>;QFO?#?9PC'BB;7V7 =Z 8YV>ZX(.9HX./1QJ(/0%8ORYA@\
MV!MUT_," S_Q%MA][3J"%_DK_M-S;=<&ATS+"8=QP'( Q/I&@VYZ@H7AF[UI
M:%F.ESY%6:R!>J[1;&!\/('.B,ZH JT,G!U)#/! #9#5O'T\WT3KR2"@#3-,
MP*0W\0O_P9S.UD0WN;X 40_N&>-OF*.)9VR"+-,ICRJ:_,TP&A@XGV6;!T +
M8?FV$3S<*>:-P>]=PUD*[A46 QE>R!4,&F[5K"6"O^H3&K<7JX'1F\AD5&!=
M9FL=7BAF]IR4$'$EA!V-262/>'QJP")".# ;_N.:(;N!.]A1OPVLSRG!%'FZ
M;)T"N@:$<KU843P---=;["U^:B*#C!>*9PPYDROO,+HV.LOV_C)(M4W3A3X_
M$3_X'EMX_.,<=7W9-%\."%"/-^'9%RH!2P(PX#9;@^4K"'.F";TSF,NA"WS*
M)M0+\OCZ$<A$B,-B^QOL@A5SS)9QN*C7X,%7QM0L(,I=)2_3)[Z#M9HB8\MV
M>)B799[L/O'Q@SAB,MM1B*0,PSD=4!C@][%_6$;^*YCU +?5T9Q6J5S.*YK#
M.LFU'/\0ZNY1171V,CU#-F&PT&9[Q@"93Q.S30:>E<5OC8CAZYQ96%@=$?4G
M5_-^$*? 5Z-X1HOC96[XX?D"2!R33%FD\R<3CK.@#[,K7TE@2NBF%Y[W[$CO
M&M=K8 T%\?KU4M494>(OGT"+SH@W8;!@N.\@.C"E[!W!(H$GNU5,*4^Z?V6E
M2]A]-8#/NWGART9O^I@/D5EM_H\T;V&:!^!'($J++"P/#,0C_3.O"R3XV$Y;
M<$H)F*T$?&)K9;H*^GB=A%P4C.\25+.:D'EGN6@\*G$8VV)0=K080I/G28B-
M9MY"IE&\\,\*R]!W/.VUL<'ELRKT$)A_;,)I]%5O@ZT7^7SBJ0$LPRI.&'!3
M>VVGXPO>W4M&->KO:T=PP;UVEJ)BYJVB4BY6E*.<):7R?E]R(8@M@)OA1QZH
M']_V4Q_0!.O_'WMOVIPXDBT,?W]^A<)S^[E5$4"QVU3UK0B\57NF%K^V:^X[
MGR8$2HRZA,1HL4W_^N><DXM20HC%8(2MB9YNVR!EYLFSK^0ZN1W# ]Z];?Q?
M<S+]!'I$K6)\#:U:[#62WXB=1CP-DALITG\$)Y7YL==C\^9;G_R9@?'.8B.*
M8,,>EOKB18+"LCON971%V08EG'D.]G, _>E2.M4+<\N5=K.Y/C7TLOM;/)L:
MB@VIQO%2BM C"K;F3 0U;V("0F/>E8D^.'E.X7=W6"C2.$6@P@P"#U1FI 7E
MIW$P)=M@3VP8*<?E(+(=JXHY@R()X]3&U([[L3F)TX!$U .4X<(8X)N*TSTJ
M'0 T]D1NDHSRR8V*3_,*,%^H_%2NEL<_>8*7VI=6Y[FHZ)-J5,7;KOM?+JJG
M-Q?]?U3[EW<7-Q_!0GPT9X&L9_]H "JR!'P^@>W(*WV;TZ=/AFAX^+<Z_2^K
M%Z+XZ$C6Q3ZW,';MBYDKC4W6QJX$-"++!(;I*">Q<>X[!VD572D;/L\7U*WO
MR^2)]_>ZO#\[X\\J^RU9HX-0)"_-&-XJ9=M_(I-B\"E'3CHZ:=.?Y5>,*2&*
MS+RU Z$N"N%JN_8$SLK3SKT@L$5.)$A%3/3G3AMO\"<7U:G<H=C-/;<>+@3O
M9VZ 3AERU9@C%O)T(XK$^0^F#)/SIU%]C:@\V,2L'PSZ!4KZ4^6!2N),UA%,
M, R@0FQ2>1#A11VNE&8:$("P9"(0OCB"6A:@8Y<_^LGL,!(A/=TS1Z^F+"D\
MV7V<KF[>,Q>+2_&*B&'C5C&,S]UCO.)9I8#RA=D3W $ELUYEWZN\S)2^1(4X
M%"!"0/*P*/K_Z._I/%P*GZY>'!#0)M/)^%F'G242BY-^2,Q[C4(,?_ *GAB%
MX9N@HP[M*7S&"\IDF0P/?I&VYA%>:'"?FE-17@;R!!;@*=SA/6RDBG(.<]BT
MS0"T,;<: VG!@DSA>106B(0(0_%CF>V,J%*5.*(!6H.QR"V:F$_V))I0H.O!
MMO#XPL%*%+9\!G6KUU6N5CZ%&L-@@4B/$=N#=YAP$W!T R-+(]B]EUQG>9R9
M\M\IM+R^D/KW#2:I\V0F?F!I?&CI;7V^PV]B6[R5]8_1'P#+_X^#\IN"Y*T"
MY%'">NHE[ X$V$<K\LG]#(;&25H_%X[IFG'K313K2A!")LM=B30H440@MV\'
MOQ"I@! GC.IG*$%!)>]3,@G6RR$34]8YK\%<C0[-*! LFJ>;(*DH_L'S,A3R
M8HZD@P4"\'[858+'HVD%FTWRCV X9E;D",:H"Y=T1(#.-?1P"Y9@2KQHC&DI
M#C)[/AQ'6";HV90X2L%LQH4.\#H&QP9<TVG.QW0SY&%A$".O18=(%(/I6[>\
M?!"JJ+.H,D1*'E,QF,KZD"R7LT_M;@A2ANGS(AN*#:?@ PQ1AG<6Y(SHP%PU
M0![;N)C?69NK/%SE'3[C3QMTOUKMLRQ1S#K-VU+4CK>AJ)$U [!%)LR3I-(D
M9&JELE5@7M7 = "C?[KJBNY!N^$,75R.Y\[AC:_R?45@,&YM2D]5C,CEL3<7
M?E*OQH]0/9"Q1TY^ Z9G$H5L@N+6YVY)KB0.3<%NLMXUQH(8>I%>KYE0LXBW
M8U6W0PY.FSW.\Q;TWV1M ]U'O!P=MJ,%_8""@;<,,9UB0.4#"+%'  +#.G-1
M"X/99L1TZ>FA[0^C21#R9$J1;,+B%%85BXQY*8I2TB=6XLNK<1ZZ/91^ R=5
MLJ77/NLZ0@KLE%TGL]<R  6L<\(3:GCB3,RO$OQ,0*9FW"Q$/8YK%/S@J*;>
M@%_BUV53+]TXX45+D;F-$V, EHD.O,97+^!+48.&N)(J"J1X0'\@\BD0^? *
M'MM& V'"PK$GW7EZKBS"U;=X?K )3"$,'5Y$1O6'A"6H2*?DF0?T3WT,-,%F
MBF>T<#5<SLS+#Q_-A\ Y3B()37@TV@Q56'R7RI74JJ9"J[K%L/@=@#@^O:Y)
MM>O'N9I4<X$F%6=()5.P"'9XKXH?6N2MQ3X,;IAQ!V8LX268GP48U' R ?,5
MU/XP 0<)*O%,$BSY"N:6P.+ GBAE 12;K?5.D"S-"\(L,60'.A=:F/KZQG2
MQKK-<?04'S"S0"(1\T*88DN(";)AX4S11-=RITE !:5 OEP^P%\IZ\72WI*N
MV])*7.TG8M:"+2<UAR3J?:4N#$MKX%4%:7R&L0VH YQQAJ_18H@JU9MV#FP3
MOR[JEW%]/H 9W3P#<OF00P*LUB$7*2CTZ!?;G4;H"XAE&9:=8M6OC]4P>/@
MK!C']"O&(,HEFSA_G>3($!L+Z7E.Y#(C;Q:WWTAM2*Y&853Y-'XLUDZ_1[Y
M9J2OM"V^N(27?L/X!EY=+[-1$?&PF%U82+RZ750("4D3A39*\S7N%B'].BA]
M]0C4\]SNYVP0QDZ)OE3H+SW_%M3Y._QYSA-?;]?[W5:_>MKH]*OMWLE)]:3;
MZE9/N_!CJ]%N].IG*2^]ZE=B]4$ G9[T3GK-]D6UU6F=PPLNZM7^:>.TVF@W
M3_OUT[/N:;NK&I)R!Y0(K@!QTI:RF\3F1[K6* %/E''7IT^?X #,<8*IB6CZ
M/T=U_OL4NT2(WWGD"G_\_+MH=+QTA->.AG-E-RL_V/<//02\^S]'C9/E<<[]
MSMM[D2;/O,^V4* H%#7XS/6HW+[X6P//)C,35YQI5Q+$6@31+.E!T4,?8R1H
M^B>)X,76/P/SI+CT5V+EGK!R. 3U9U\X>25<7"5>EGB9Q(POOA<$>\+*.$"P
MIPU\0=]P21,E390TH3;PE:(D)5&41)'$BPOIK]T37EZB#Y%2](N+FSL8V)Z!
MB]O#^QT.;]?;#\[U*#SZ_&, $!$N=.'SS\J^HU['(L?P3<SX.\+!?<48VG>4
M,\2V<YQ1Y*."EJK/UY6*)% (\^=M?+U]<:M)K_,J!3UISW3*;RVM?S3#J0?C
M9A4][4JOES7?=B\X\39FUAX,[F<,EMTQ[HOLTES$YPX&:>DOPOJ_F.]99C!.
M(WRUQ/42US-P/:,Y9#'X?#P*G<RUV&Y"H_Z4 <ZS._.I)(.2#+9!!MV#(P.T
MXS<E@WC,<4D/)3UDT<-Q8>@A?CKYKE>F]C_3M=#ID%?A+;@6SK*;AKU&]\'S
M_*?[XBPK;SN/ >4U)EK$@'3,^#$ZYWA1&)=#KW6R%\:SVFV\&9G\AFDJHXW5
M]FEJ>ZZ,7&IJE;14TM+^:.FD7B#Y]#Q724EF)9D5ELP:AT!FA^R**4FM)#5.
M:GD-,'=.:EOU\O3:\^U+BX,\._8$O:$DDSLOI+966KNVU^<#6DKL+4 SG!_N
ML#2U%\;7O/J6\QA43DI* =P[C4ZEU^P5@>\L@NZ;$>(ER4B2R<ED*;TW)9V4
M="+H)"<+IO3,E"14DM!R$LK)H"F]+B49E62T&AGE)-[L,V\&C)M6YY!)A7M5
M/HB&+1^HUXS6>E]OB+:W_CZB=8ZID*)LG_.:NH64[6VRZO[FQI<=?/G?*\/6
MLDBV[#U3EFX7&BO+WC,E7A80+]]TGXVR]TQ)$R5-E+UG2J(H>\^\H/&Y3EK0
MMH\E?$SM^F]%ZCU3]IV9'D[A:=9 >C5<^C7TG:E7VB?[J0-[L[&D@\']C/JL
M'>/^2Z3[M(\^=^HEQI<8/X_QO8PJJF)P^QTF[C3WD[E3$D/1B2&CUJG@Q'#(
M*3@E/12='C(*DO9$#]O-I:E7.MVWTH/FD*J-E LAR\]P]/E,S71/#:-_A0Z$
MHA4XYC.*C,*@I8Q"W69!'06]RG&[640F4:+X/E \HY!G%RC^0N4_G?W4R968
M74#,SBB]V2/SWI7=WT:]KT3ZMX3T[_*P/J-:IHA8OY*!GV_M% 7I7R"E_WUI
M">Q9F&14S[PD66W/3]!&"^"DF"*C^)D(>W43E.UI7W^SI-XF:0K%;D_;J'2[
MA6A?4K8@>[-4M4D"1%$;U!Z7M%32TMYHJ5O?)+7B !O4EF16DMD^R6R3I(VR
M06U):B6IK4UJF^2#%+-!+=A:)X7HW[6?%K6O/%&D;$O[ACHV=>LYV2<%<.LT
M&Y637B'\.F63LY)D!,GD9+/LU6?3:'1+2BDII4"4DI,=4TB/3/OH<WL_0<N2
MAMXR#>4DVW3K.<DV9=K,EBZ@3*\IR?1YHBXG=V>/KIIFLU+O%&*<T(XZW^I-
M9U^^]VVZ^>[NUXX[[NY^*9OZRU [&9L6WLN:"0@G:,P2W:4;\$^BT722P&[8
MD-D/B#?!M>?8P]D=O.#4\8:_CF(*[M5Q0 \#$IO"HR'88D<O=EQM@\;(]R;&
MF>< 1\"L/NP"HT-C3]V=M[>@Y ?:7XCRM=^)X7]LQ'] AV76/O7VS<UVK=XA
MYC$'S6$"FH;I P=B0^1.%C)2PYQXD1L&AA4Q(_2,<,S@ B93TYW!]T@_PC_[
MS)X,(C^@-M5@HC/3'XZI&X_%'ICC3:D[S] +0K$LOH>:]YRSJ>F3*Q43ZOX
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M):>"Y \7"+_?+BEEE.'M1A/>(\JW28*TZT5$^[)0)T^=73"%NE1G]\TV,DH
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MBY,TL<KRG?V>,U:U'/85YFG_H? YNJ9J/Y?QYN33CRN6WBHWX2+536DD5&@
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MVA,<^^>-LF9D5XR![3CP.1\D.32#,87 :3JPB\,<@\@) YR4C%_$X:[#(6:
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M&\WU6'ZK+EA^W^(><(1>)7'S8^ N(.J)NYCW/F.<(9)1N!(:&HB&1'(!\;#
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MO+ B"HEX#B1FCX'VCLTP>-TI^G^U9J3XW717/Y"W09AP-<=[7Q34&NI!K4S
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MVN&8]B#V5#-R2HS4'HRY/?A,?8E>">J0-JD>-&N#_2?BF\+5 '2_6"@^$6Q
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MS81(',P,U#QR'O1<QF]'\F;).39 !ZSL \5I23&DZZ467.E8:A'.WL;F ^\
M0 7YH)7]P@I *C 5^T=NR%Q1*"J[!^057'=WH K\O#W?:*+67"+/,DSK3[QH
M0V6@F:%Q 8<D:D4U8$7\P85=R_0-3!=*UCQ295ENN6-WMR)H_4$#"]\=K _C
M-LCRQKS;6%)U$>J7DZISS="QD\K]W("K@6+/BY1NT!T=DU?YT-]BUF '0\10
M59TKC43'\WY5T3<M+459=PEZ"SS&L,30=G&AE5M^J(K$+*/\I<U.+"/CY6)Q
MJ5A<#?;\6IXSSP$EW<..I ],8R3G '#'"T#9R"[4:646ZKR  V$ ^D"8B^HM
MCI-5(W$VPIP?@#J^<0-&M F(Q:NTV -SO"FQ^3./5WOONT)K'UV&-JZ#M3]_
M)SHW'>/*#4([C+BL[#L.\^]G!.0K=X1-"[PH, "Q&%!T$/MYOE_UK\X__/''
MK7+VH-UG?[[*+44V;MDT)$8-IF*C5>%B7KU+5>XSBY<DZ\TD1%DU;)T6LC04
MP!9!<&:+!?8#: 98;6^$/C-#^A0?_&;Z@\B_-^#C" O"Z3@U0ZU<,::FK[H6
MS,.&N.H?S'3"<04T#PLQ$\YEAS9\BYHB+-$T3EH9QFJC5:WWA)N7?@1I)_&\
M[UH:EFM$+O$=;$_FHS"Z]'PBD>!TIIH"R!.H _P8B:LE9[&\6'FO2W68),>Y
M]UEB*\FN+2O+R.[1YTZEGC$W7$H2<?5<L;CWX"E^0W:@,*4"MX ELR0G8$\6
M#5(!?13-#L\8V0XSKKZ?&^9TZMA#,RY7M?'Y!^8B>BNLMFL/-8701 3TM4D4
M#",PO?4O3K0OZL@GJ_]C_(,M9Z(?O=\CYC9FH'GY8_,>Y,&(VA,DOAGHI_P7
MP[XLQB5]#5]Q,? <,_D U\?A_  F*QJ&.K9>DVS.*PKGK'@< ;\RA@X\APTQ
M0A\>KAE+Z+L/0MDA-Y"@;9V"<4\QK9N(1;1)TT+7*,:IIPBLLQ__O#JOYFU0
M]*^:PG7RWAT<73SWWD,()??,JZ-BF-6,'ZN<H5=9? Q &C R #E"L$G@#D%5
M@M^8ZP.5\+8*+A[+ )JUO EZ1BNBO61U 'N#WZ:@T+"!5R4T]G X2WK7^((
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MK(6E%P;ZK)@P@7=%<8&5;ZFSM$)E*[?T[]L0]H+?NQTRUP3"I1?(7T#19T,
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MTMG,;K._)O:XZSJ=M?G7/:[V7*KOY25O7L.]MS+2T>D:+>E3N&FG^RVF%Z
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M*O(A/A9O-/:E80<[=,J3?3V?;'GT3&TPZNMF.H4V&,.4[^G7%L#L9&A%E+P
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M2<G>2+0;R=$EOX!I$.V!;#^HL:,$ !H-EV.2ZK06).]=0Z-!N/+/0H S?$B
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M.A/7R4!+BE6@8+4??OG9R^9JDMST%:"8'ME&%NQH^S4U.*@33B7-.R978.8
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MM4&[#"IK)XT"1R"P'0<F"PLKO!'KVUE'SZ-'^X_IYMF.<^Q8MT@)@98.M*P
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MU6CG'GW4?*D[MV6W+;MMV:W[$SP$$%>)%R0N.0\-KY:S>.56HVU9;"/Z[&^
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M'6H8UAP@.2_S<YDOY'JKNMJGMHRU9:PM8W5_PI1X:<=BI/!\AYE#X_#GREA
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MBG88-[51."10FL)8#CJ(RU)WR0<**"89(BN6IQZOKU1#^+,!V3R@7>@,,B$
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M[3/GW\X"/KX]2#VJ7O:"(#1;3KW1 NL05^%&C,\9WU 6Q0Z(<6,VDI4]HHB
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M5J(;Z_9V]<GLB7ZSAK@%%@!<- VS O]DJ:.JS'-:YW)E.?@5HDLP5/AJ.!?
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M@KTU"B\KFW%H"]W*_$URN>.W'3A^NJ%*Q_"73+=29VP<L0\V="M5E UGYN3
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MB[9:Q_#-&H^0^\GL 6VGA_W0,_@CPN-I>%*2@62J1+T(Y0ZWFS;EM"FG37G
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MM\-SG? TW]\='N<^I\9 *:U6]AO!LRJ?CQC0)(Q(QTN"&_]PE]TZ2K^9[7#
M5C"A_8XKF;0M_>9J_?7,]W_4N;CSY[L<#;:>'3$L9EP<Q ',=15896LLPNBG
MW80N_/;0A7^=T(5'B"Z\OY\4[S?P.[/5;L0[?8\H*+1=%%67"*1N*RIUD']I
MR>CH6 LX- _F+P6L-I13E4^'(%32!T,0/Y]T36PN5O']F&<+\!F)38RCV;^[
M!=Z A[W@A":<@ UB>VSETB.PD87*^ZE]P+Q$[2&>S9ORC*MNI&3*D#?*-Z%(
MP6+WC3FXGSDT?7B +F^,LNI2\G4B3TJ8B%)]7!*\O/%\D/*/UF,O'K:E:#H6
MT1!)HLSCY]7UB0_RN(*'%#,1=@]S@$2ZI!5L]8**4H_^6QE,7QN+,,"#N6GK
M9A^(:>X0:QFX"KGNSL&&]6G)T&#T@6!:M$5#2-8!Z:4=FX^:/5!J#QIZ#+2B
MA1N/O<C^P9HH/Z +:+Z54E\(2D;GNUY,DHP01O+;ZJM&#:P2XYDBZV_@W-5+
M4V/@"\:DEK18V9^^A&J28>INR;S8R#5JB1\/SR'Z#J]I9QRP,][S%'O86.5@
M[2HFG^I5/G@96IYD;G?Q4M#:YQ!-+H?,X>M(''<>*N4GL\=B^:18(2AGK&46
M\AG*>F?%FLL_DJ?HQ#$+*C>:B&WD,G[)E1WAD5#;V@O4;M(/G;8(V&S"UZL-
M 6=C%D:%$22Q5FI? 8['F>5).9F=UA2&M34BXAC6H'#[M_!JB%K ,A3_[GOZ
M73U[2VT?F!LI*27S6#:&?@I.U-=$!<R9(*Y)2\&EDY<10&P<S&LDC2.GZO2!
M-]*B7O&<FL'M'-9,&5INO]S7W^7Y2[F-XA"&W &*8/NL^ ")-B6,"$;]#9\1
M/F<;7F!I%^UFCH[::K@\M/2YF$ZI[6"Y#.G#'&SI&SL1QH^"O@0C?C@T/FOM
MKN:J$$\QKW*X>,N>3!FE=*4H<ZOLZ??7M:?:960\@CU.0.8/;1<HK2W'LARY
M//-H'KCPQ:*VR&V&UJO58L#@)9#4%0VJ0"1B4N9!BHI$,SD64S2,0#"+%Y=;
MUMN-YYE%%/?OI7&:;O)@'8,W@JM]T*'F&$H\DZ@_GY.CTMN%T1TV^:@W;>L7
M<6\43"F?4V,=N(3KJ]TL%LVH\,)+^"TX,YHDX\ C08 UV@?!6&*"<:+$G>@S
M_I#T&>IO$QC+')/@,Y958US$259MVDC31AI_!3T%X;^;$G?+M%FFS3)MEOV;
M)2)KBR"VV%;>52/G+N[(3YO8T::--FVTRS>::O02.<B2\EH&=C6)B_5RKP<,
M_T&<9Y8!RG=.E1Y-/Z;9N"JKH411HDDNA.3-5&=2YE:DO+0^P$E>M[3 DRBJ
M[^0#;T)8:F]V7R(-[4.+,_N#U!;).+?%,6>N/A7INRH74E@W'2E^=@BF1CJ^
MME >LNFPG'+,\[O;RASQ.!1J_4A*YIO@41 IU\3CHWU'LET[@\V  V[KK;98
M%\!O)L0]]\&DRJMTNV/.N+I!H-GBPPR;B\X*01:,U[5'LV3:"@2;GEK.[.5<
M7KL+0GK(MR_**E^>S%ZO&E<D8PE-VLS4(T5%B\HQ4W7A4:A$N;#V  @L&*)-
MJ4AX"ALQ[$,09E)4!,_:%#_D7$ QC\F$:3[1#"<6)YI6S)3)SXZ]O0$!#K]I
M@',./U^W>C\TFXF9RV3/T^B.5/8HKT_C$Z-SL,DK8M&25CUN#*Z8Y(BZPPG>
MJ!Q)MI0[,I/81,IEI[C AI">A/*KG"P]:V'HJ3Y$!"8"K;FDES\\N8-=IFUB
MM#L$TXOG$VQ<JH=D7#/G7T5D7KB5#*P(4:<!;ZFM/0?NDF3@T]H+0601",^%
M^7*Q!EY\ (?']LEL@EHR2$6I8V@*B%$F6V, <_"*#HB$4!]\3NEN)M%,$%^T
MIC5F>QO?_/R"'L,W<.(O7YP^(Z:-]2Y/P>'@K2LW6LZ>X\I\W[4RT?Y)XFNN
ML0B&&\)?XUWZ(3O#*NG@%=Z\@BV(5W@#OV'([DO82>?<-_ *U5NPEW7PNZ]>
MO#V-^B0OV>K)[-FKT]"4]^K%3[]ZRXL3$Q'=]2<Y&9I7K9PSY",4DJF?OPA(
M7_J0V-#*Y>X<39TMF@?*NP[,2! J5(P12!-#C'HKND>88_A7!DC(<;GIDH(/
M;1)?^<.7@05&;;_X1/((([=EVM-!()5Q\$PMTKB1,KPCU!YCK%7X=$+U)EWT
M_GFMW]*3"KV<':T<Z4";0,G?'BCYT01*_N.#DOO1RX,#*N\:OKS?5VHN^JBW
MP'&()H-.'-1@6,4XMQH& ZPUAYYL'>%489 .];2F5&]'%$Z=,1J$:.+Y"[6Z
M?L(7:8)LH4C-B*F1 W_ND&*"+BUW"[^'TEDJ>Y4HF>'[8NOO[I@"KB^0:D$:
MS14>Z?OQ;!%(07!">(36GM"/YS<;72AFPE'OFIC7\-BZB543$8'F.?'FA%S)
M.867O,;+Q:*M)J#!'RL3??^'RU?WMYZ*OJ%W& E(T:]#H[BLT@OQ/,W6);,J
M<*<(MQT7ASH8J,2:?X%3>QJE+DX0L[22#Q.33(XC!L $"LS9M 3H*N$&PQZ.
M-[UPSL#3S%LEG=O"%:E:M2?;/LD@?[KP]3 (M,<5Z%">.EXATK](^;!TUW4>
MTB5FN#!Z9 (,%LNP;48#.A0Q"FV1G6="W$%D71!"ND+;6ZF&.2V*S[,H[%P:
M+IY<8WP,,PFE**%RY;9MDWK4N^BT'&EY^8^D@$#Y07;X.,DQXO!Y]GP3'RB'
M]UG<*LC96;INL4L&O/4Y7&B]J^'3E!Y50YX8\N =-JY3GF+M,$L7 X&5'<RG
MBOI./V7ZW,<4><D2<SO*@I:8EL?\$KR+=-/7<%IZ\1I](DZ+^0HC9Z+Q">CM
MI(GR(D[2*M%D\':5MK)@PHY0X*#(7HA)<(P\IU<8$WE4&+R<">HD;Z8E#M%<
M<+L.Q6.3?E!\K:13+^(7;8M<R%7Q?</P5(X"1>S2HP\R2"2P$OA[6>,?!D_&
M9\F8825CK%RVF;?@>WNU]_Z8"H%_/Q9=EG!!4A20\ \_M(2[XW!X*8C>*B.B
M*\T3^C*L)0@/I"T8'U,@4#DA(1U4$I@:K#Z]K*K=TL-J /N(T&'1$-%;5J\[
M+*-6MJ7NMYP.<VQT^T$R$71B'V?&!3C-I?H4A&I88?G(LK9QJU%Z5CG+STNJ
M5[YZ$Y?_KR5VP?1CRT15+R*BTN6MS'0\V'_T[>_.?VU[B86]>H?.J9$NX!)@
M78-UX<:?L7F:(;A[5>99234*26K,2!$GPU;ENHDXYEEYAEH(8;W[ZRDQ<&":
MOHP&.N;<3Z539EMEU#9R6DNGOUV+5NLNWCY2AA#FH"V<!^J&1S6>X=\..@X^
MPDP$ZT*GDHWF;B7U7&\E']#=/[R*G^BQ;WA U502%^&XL0SJ"0,=@L8P^<(E
MV-'_2K=I(93;1$L&?W^WA@^69\PN_G>P@L7L285PJBLI0'CE!*ZQT1U>(3W3
M%CO_TZM=[!6G$ LWNP/?*_G?=_FP-XV\?J347\J4RI:/_/&QRVIB5\T6;=XP
MG_ ]9*IJ/;=65IR7^7G,0V[Z:G=6->0++KP)0_OEXN1>VH2@2Y0O*<"K;(CO
MK33NAGCD [NT]6YU6]3PQYJU9ZR?%!G@TBAY2K'6@L&Q33'D!/TG\6)9(\C#
M5%,X*%[7/2;-GU$CN!2AL< QC?PS]5=,:AQ[#H8A"$(S1[;Q$O)]]W$+$=LT
M(U]NMR_6)>;8,7! YCX7R2AZY>,.UW:L21$P&]/$?<X<-TX7N4[@F6Y;!I-A
MWBE$A*&#6Q%NR"E^EBHB)JWF6<- F,1C"QG(M"!/)?R='1#'S(&NN4!_J67'
M^-TO/\6((&%*H!0;R3^+W'#=J">-K\112M,PF$I73Z SF!;/YUP\5G)SF3)D
M*]W%ZILT09@1Y"2FQCR6?Y^^K^(0W2]G%6DCU=ETJG[16O,!TI;??*WY9MYA
MK+=%VFZ8B<42S@:V6<&(1UQTED9'2M1T<0%4AVP?T3"S @IQ)&',E2YV>Q-Z
MHWQE_&#C4")BI)%\M\29L!G#X_?5]*;Z\]>H/VO*&#-=KB*RZXS"J20 @(DQ
M;N6D!HDP_#QW++G!7\/L%Z7;B"2ELE!_YLN48A3>D&5"/>)V6V6N08G0K,",
M<*J]&WSP4\$[E3PB6'QG?07C2?SFRBTR?'."VQ:1X&NHB,.B1.-WI%H* 3E8
MRRJD^')%^4V'Q9=>F^@+@.THL> 4&%2-T CX=%Z.\()DL_<H=4[3]Q6FS[:8
MFOX?(UPY1GQTI*"&"6 _ K#__CN][02P_^,"['O5F&L3VPTS+ZN[HO)?HK6Q
M16D+[_4BE24+$Z++412(!#&LW:IX-2R$'E%TDH-A=++WEY!]]ID!]YEBNF:%
MPS()^AR87F0/ QG,-RY^>/Z[B6X9I<T(:TP'7Z#P%O>[8JZ#LR+1!>)X>)B5
M/(0$$77UOB)-&>F "A.Z3?>H_N>,(:9&@)EUOSKMB\-E^X)%Z<IJ+P$Q@02(
M";5_%3-VTMY87A2J.L3LYQBVF/2A>A!!GIT5VOAM!!AUT-./]%(R 3?)E7DE
MVTYOF-)O9Z-7D<R(UZZV=*8#7+3L'*4,)M+H[))M85H3/3GB==D6CKG@_$D,
M".]YQUH5>BNJ:^K(.A>DLFT5 ;DSR#<*'@U4Y1I:90AA4ZS04 W^H )WKR8_
MNX/?5;YCON*IWD9)?>\2.,4F+%.O?@87O2@K0@Z:AV*]G$+:;; /MRN,11"7
MZ+QA;2LK"^P8C$4L"M(B%CKQ!Z]A:R+T.!71(GLJ:]KL6[)KZ0:52YF8VP?
M003)ZQ[M?'HJP?*]@9*GAK^8&A+BBDS:C+$ J'BZ+GOE'? 01?/A1>Y2$O\0
M.V=1D2$_51IS-T_KK+;&KL,:&][6+HB#MJ *.(1=JSZ*C7W43U$L:P_SA@_4
M66K:.VY125'*1D!TG/0;$#\='X!CML_])K[KNJ#O^W.BZ]+S'P]L$]D;DID5
M%2R[TVA:63N.4+W]MD V5H2=P2M1;M?OTQ7Q?MM%SV*N@:0<3VHR98%]^V?A
M)9Z]8" XRKZS@ XK3:/U0SE&M41H8F#!KLN<Q.T6W$TD[E!OH;J,R55604ZM
MZTOL6XVSH9$F7@<_W!'!";C4..I-[B+"=M@AB*3NVRBJ&07;)L^(5^H*H_.G
M&+I<8(*S<-[9&3HJA(Z=7"W4O2^6:37;@7D*=-'&G+"C71/L=8BHPBIV,RR%
M>1HJM^$TO+CZ(N!C5T[P>[LVOO_0Q$<""Q6?4YH6"*&=57739;;O2'&V!.2T
M%@GAQ@2CV;%2MG@U!UJXO:+N;#3#.P8U\X&(CUZ-XAU-4HMT.^.2(S2 ;9#
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MF3U&!157U_S[[W\T>6KE,5'6H-.B:&'XWCKT%="I>X[T4?>_N_<//]L[) U
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M!_5H ZN_'K@!NH/W/F2+#W/=ARMX.FQF2+,-N[/(8M*@]J3V3W3$VV0_QG+
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M/\"C\J2MFNX]RJ-@-2I;T?1+UU[2%7'V!R1]E.K1\=JRQ"&4;]'>\7PW -W
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M85M![+1@/!75)B/05X2UC/^2?E0OY"-5H2GJV] _?:*:/LF;F_P^_L)(+<
M_V,OV&A=P:$#FU8^*@3(UQ<&OXGU?!7)SI%O?.''O8(\)W\'S&QH=02+BEH
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M^"5S?!&QO]*DFTBS+:CNJ&5.Y&T'[PW;ED?TH"5(\NPEU8$K00T5*\$\8B"
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M^^9YI]]T3 75#*!*PUD&)\V8V4W+,_12"%VE<PS@3S_.HD\_'P>_%+5R?MH
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M+O13F*8@UNG$IVE4E( )W5X@K5[/#%QK"5TP@O&R17XBC(8V""G0^85%;#7
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M,$Z+>8+C-)! X#MYPH\G'4Z!,.M6@66WIWEZ_[N#J8H3H?RX6/(Z+HLHYB.
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M7T2D+IY$..<2UB638,3(]M$G-XO9LN(0EQ$@K_N2? I.4\54KX7")<UBU,W
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MT=9_2>7@NV22L,'!2[[Y1^@6O.Q]N[M8<K>#%O-**1M.C.'$N,[]A]M[UYS
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M._:U1],YXT9XW *'DD@<\,6$)4(G[8!&4+<,89M"-UW'TD:IM@7&44 W.@T
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MX3.5]_[*];\8?(B/ELHJ^L%P$IR?G@_\X'QT >/+R?32OP@@&'TI%8^$QSV
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M4$L! A0#%     @ EI8'49%*$,Q3"@  >(8  !4              ( !7A(
M &)C<G@M,C R,# V,S!?8V%L+GAM;%!+ 0(4 Q0    ( ):6!U$P@JL$@DH
M '3'!0 5              "  >0<  !B8W)X+3(P,C P-C,P7V1E9BYX;6Q0
M2P$"% ,4    " "6E@=1",^9P"1E  !QA@4 %0              @ &99P
M8F-R>"TR,#(P,#8S,%]L86(N>&UL4$L! A0#%     @ EI8'48D3.2*U2@
MB/H% !4              ( !\,P  &)C<G@M,C R,# V,S!?<')E+GAM;%!+
M 0(4 Q0    ( ):6!U'X4&U43AL"  *P%  4              "  =@7 0!B
M8W)X,C R,# V,S!?,3!Q+FAT;5!+ 0(4 Q0    ( ):6!U']COG/$@@  !8S
M   -              "  5@S P!E>%\Q.38V,C8N:'1M4$L! A0#%     @
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52P4&      L "P"T @  !4\#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
